[ { "date": "2026-04-27", "title": "Ibogaine cardiac safety concerns will materially slow or condition U.S. regulatory pathways, requiring mandatory cardiac monitoring protocols that will significantly increase deployment costs and complexity", "confidence": 76, "category": "regulation", "geography": "USA", "resolve_date": "2026-07-26", "tags": [ "ibogaine", "FDA", "REMS", "cardiac" ], "status": "pending", "priority": "high", "plain_title": "", "plain_what": "" }, { "date": "2026-04-27", "title": "Ibogaine will become the central contested exhibit in the 2026-2027 psychedelic safety culture war, simultaneously weaponized by pro-regulation and anti-prohibition advocates", "confidence": 78, "category": "culture", "geography": "Global", "resolve_date": "2027-06-30", "tags": [ "ibogaine", "media", "policy", "culture-war" ], "status": "pending", "priority": "high", "plain_title": "", "plain_what": "" }, { "date": "2026-04-27", "title": "Psilocybin will be the first classic psychedelic to receive FDA NDA acceptance for review for treatment-resistant MDD, with acceptance by Q2 2028", "confidence": 74, "category": "regulation", "geography": "USA", "resolve_date": "2028-06-30", "tags": [ "psilocybin", "FDA", "MDD", "EPISODE" ], "status": "pending", "priority": "high", "plain_title": "", "plain_what": "" }, { "date": "2026-04-27", "title": "Fluoxetine-psychedelic interaction data will be incorporated into FDA guidance requiring standardized SSRI washout criteria for psychedelic NDA submissions within 24 months", "confidence": 72, "category": "regulation", "geography": "USA", "resolve_date": "2028-04-30", "tags": [ "FDA", "SSRI", "fluoxetine", "drug-interaction", "psilocybin" ], "status": "pending", "priority": "medium", "plain_title": "", "plain_what": "" }, { "date": "2026-04-28", "title": "No psychedelic substance is rescheduled from Schedule I to Schedule II or III in the United States before January 1, 2029", "confidence": 77, "category": "regulation", "geography": "USA", "resolve_date": "2029-01-01", "tags": [ "Schedule I", "rescheduling", "DEA", "psychedelics" ], "status": "pending", "priority": "high", "plain_title": "", "plain_what": "" }, { "date": "2026-04-28", "title": "Oxa-noribogaine enters a human Phase 1 clinical trial before October 31, 2027", "confidence": 62, "category": "research", "geography": "Global", "resolve_date": "2027-10-31", "tags": [ "ibogaine", "oxa-noribogaine", "Phase 1", "cardiac safety" ], "status": "pending", "priority": "high", "plain_title": "", "plain_what": "" }, { "date": "2026-04-28", "title": "Ibogaine's cardiac safety profile causes at least one major clinical trial sponsor to publicly pause or redesign an ibogaine IND before December 31, 2027", "confidence": 70, "category": "regulation", "geography": "USA", "resolve_date": "2027-12-31", "tags": [ "ibogaine", "cardiac safety", "IND", "clinical hold" ], "status": "pending", "priority": "high", "plain_title": "", "plain_what": "" }, { "date": "2026-04-28", "title": "FDA issues a formal guidance document specifically addressing psychedelic-SSRI pharmacodynamic interactions and washout requirements for psychedelic clinical trials before December 31, 2027", "confidence": 38, "category": "regulation", "geography": "USA", "resolve_date": "2027-12-31", "tags": [ "FDA", "SSRI", "washout", "psychedelics", "guidance" ], "status": "pending", "priority": "medium", "plain_title": "", "plain_what": "" }, { "date": "2026-04-28", "title": "CMPS (Compass Pathways) closes below $7.00 on at least one trading day before June 30, 2026", "confidence": 45, "category": "markets", "geography": "USA", "resolve_date": "2026-06-30", "tags": [ "CMPS", "Compass Pathways", "stock price", "psychedelic biotech" ], "status": "pending", "priority": "medium", "plain_title": "", "plain_what": "" }, { "date": "2026-04-29", "title": "No ibogaine product achieves FDA approval before 2030", "confidence": 84, "category": "regulation", "geography": "USA", "resolve_date": "2030-01-01", "tags": [ "ibogaine", "FDA" ], "status": "pending", "priority": "high", "plain_title": "No ibogaine product gets FDA approval before 2030", "plain_what": "Ibogaine is a plant compound that some people use to treat addiction, but it can damage your heart in serious ways \u2014 causing dangerous irregular heartbeats. The FDA (the US drug regulator) won't approve it as medicine until someone runs long, careful studies proving it's safe for the heart. Those studies don't exist yet and probably won't be done by 2030." }, { "date": "2026-04-29", "title": "No federal ibogaine approval pathway is established before 2029", "confidence": 76, "category": "regulation", "geography": "USA", "resolve_date": "2029-01-01", "tags": [ "ibogaine", "FDA", "DEA" ], "status": "pending", "priority": "high", "plain_title": "No federal ibogaine approval pathway established by 2029", "plain_what": "An approval pathway means the government has a clear set of rules and steps for how ibogaine could become legal medicine. Right now it doesn't. The FDA needs cardiac safety data, the DEA (which controls what drugs are illegal) won't change ibogaine's legal status without the FDA moving first, and Congress hasn't written any special laws to speed this up. None of those things will happen by 2029." }, { "date": "2026-04-29", "title": "Fluoxetine-psychedelic drug-drug interaction research generates at least five independent replication studies published in peer-reviewed journals by 2028-04-29", "confidence": 58, "category": "research", "geography": "USA", "resolve_date": "2028-04-29", "tags": [ "SSRI", "drug-drug interaction", "psychedelics", "clinical trials" ], "status": "pending", "priority": "medium", "plain_title": "Five independent studies replicate fluoxetine-psychedelic interaction by April 2028", "plain_what": "Fluoxetine is Prozac, one of the most common antidepressants. Early research suggests it might interact badly with psychedelics, making them less effective or more dangerous. Scientists want to confirm this is real, but they need five separate research teams to run the same experiment and get the same results. That's hard to do in two years \u2014 it takes time to recruit people, run the study, and publish the results." }, { "date": "2026-04-29", "title": "Fluoxetine-psychedelic drug-drug interaction becomes a required screening criterion in federally funded psychedelic trials by 2028-04-29", "confidence": 52, "category": "research", "geography": "USA", "resolve_date": "2028-04-29", "tags": [ "SSRI", "drug-drug interaction", "psychedelics", "FDA", "clinical trials" ], "status": "pending", "priority": "medium", "plain_title": "Fluoxetine-psychedelic screening becomes required in federal psychedelic trials by April 2028", "plain_what": "This means the FDA (the US drug regulator) would make it official rule: if you're running a federally funded psychedelic study, you must screen people to see if they take fluoxetine. If that interaction is real and dangerous, the FDA will probably make this a rule \u2014 but that takes time, and it won't happen until the evidence is really solid." }, { "date": "2026-04-29", "title": "DEA completes its Schedule I review process for psychedelics without rescheduling any substance to Schedule II or III before 2028-01-01", "confidence": 77, "category": "regulation", "geography": "USA", "resolve_date": "2028-01-01", "tags": [ "DEA", "Schedule I", "rescheduling" ], "status": "pending", "priority": "high", "plain_title": "DEA keeps all psychedelics in Schedule I without rescheduling by 2028", "plain_what": "Schedule I means the government treats a drug as having no medical value and high abuse risk \u2014 the harshest legal category. The DEA (which controls drug scheduling) almost never moves drugs to easier schedules on its own. Instead, it creates special exemptions letting researchers access Schedule I drugs for studies while keeping them illegal everywhere else. That's probably what will happen with psychedelics \u2014 not actual legalization, but research carve-outs." }, { "date": "2026-04-29", "title": "At least three additional U.S. states pass veteran-specific ibogaine access legislation by end of 2027", "confidence": 62, "category": "legislation", "geography": "USA", "resolve_date": "2027-12-31", "tags": [ "ibogaine", "legislation", "veteran", "state law" ], "status": "pending", "priority": "high", "plain_title": "Three more states pass ibogaine access laws for veterans by end of 2027", "plain_what": "Texas already passed a law letting veterans use ibogaine outside clinical trials. Veterans are a sympathetic group, and states are willing to pass right-to-try laws giving people access to unproven treatments. But ibogaine causes serious heart problems, and state legislators will worry about liability \u2014 if someone dies from a heart attack after ibogaine their state approved, who gets sued? That worry will slow things down. Probably only three more states will do this by 2027." }, { "date": "2026-04-29", "title": "FDA issues formal protocol amendment guidance affecting active psychedelic clinical trials based on fluoxetine-psychedelic interaction data by Q2 2027", "confidence": 45, "category": "research", "geography": "USA", "resolve_date": "2027-06-30", "tags": [ "FDA", "SSRI", "drug-drug interaction", "psychedelics", "clinical trials" ], "status": "pending", "priority": "medium", "plain_title": "FDA issues protocol guidance on fluoxetine-psychedelic data by Q2 2027", "plain_what": "If scientists publish solid evidence that fluoxetine and psychedelics don't mix well, the FDA might put out official written guidance telling researchers how to handle this in clinical trials. But FDA guidance takes 18-36 months to write after the data comes out. For that to happen by mid-2027, the science would already need to be published and in FDA's hands by mid-2025. That timeline is tight and probably won't happen." }, { "date": "2026-04-30", "title": "MAPS or Compass Pathways publishes Phase 3 psilocybin trial enrollment or safety data update", "confidence": 80, "category": "research", "geography": "USA", "resolve_date": "2026-10-30", "tags": [], "status": "pending", "priority": "high", "plain_title": "MAPS or Compass publishes psilocybin trial safety or enrollment update", "plain_what": "Two major psychedelic companies running government-approved depression trials must publicly share how their studies are going. This matters because it tells patients, doctors, and investors whether magic mushroom therapy actually works and is safe." }, { "date": "2026-04-30", "title": "DEA maintains Schedule I status for psilocybin and MDMA through October 2026 with no approved rescheduling petition", "confidence": 88, "category": "legislation", "geography": "USA", "resolve_date": "2026-10-30", "tags": [], "status": "pending", "priority": "high", "plain_title": "DEA keeps psilocybin and MDMA illegal through October 2026", "plain_what": "The DEA (US drug enforcement agency) almost certainly will not change the legal status of magic mushrooms or MDMA in the next six months. That's because no approved medicine using these drugs exists yet, and rescheduling requires years of bureaucratic work." }, { "date": "2026-04-30", "title": "A bipartisan psychedelic research bill is introduced in the U.S. Congress", "confidence": 62, "category": "legislation", "geography": "USA", "resolve_date": "2026-10-30", "tags": [], "status": "pending", "priority": "medium", "plain_title": "Congress introduces a bipartisan bill supporting psychedelic research", "plain_what": "At least one member of Congress from each major party will sponsor a bill aimed at expanding research funding or removing regulatory barriers for psychedelics. Introducing a bill is easy; passing it is hard. This matters because it signals that politicians see this research as legitimate." }, { "date": "2026-04-30", "title": "At least one U.S. state legislature passes a psychedelic decriminalization or regulated therapeutic access bill", "confidence": 38, "category": "legislation", "geography": "USA", "resolve_date": "2026-10-30", "tags": [], "status": "pending", "priority": "medium", "plain_title": "One US state passes a psychedelic therapy or decriminalization law", "plain_what": "A state legislature will vote and pass a bill allowing either regulated psilocybin therapy (like Oregon and Colorado did) or decriminalizing possession of psychedelics. This matters because it creates legal markets and proves the model works elsewhere. However, this is harder than just introducing a bill\u2014the law must actually pass both chambers and be signed." }, { "date": "2026-04-30", "title": "A U.S. insurer, CMS, or federal agency issues formal guidance or announces a pilot program for psychedelic-assisted therapy reimbursement", "confidence": 8, "category": "market", "geography": "USA", "resolve_date": "2026-10-30", "tags": [], "status": "pending", "priority": "medium", "plain_title": "US insurer or Medicare announces psychedelic therapy reimbursement guidance", "plain_what": "CMS (Centers for Medicare and Medicaid Services, which runs Medicare) or a major insurance company announces they will pay for psilocybin or MDMA therapy. This would be huge for patients and companies. But it almost won't happen in six months because the FDA hasn't approved any psychedelic medicine yet, and insurers won't pay for unapproved drugs." }, { "date": "2026-04-30", "title": "A U.S. federal or state bill specifically addressing indigenous ceremonial plant medicine access or sovereignty is formally introduced", "confidence": 42, "category": "legislation", "geography": "USA", "resolve_date": "2026-10-30", "tags": [], "status": "pending", "priority": "medium", "plain_title": "Congress introduces bill protecting Indigenous plant medicine and sovereignty rights", "plain_what": "A legislator will formally introduce a bill that protects Indigenous peoples' ability to use traditional plant medicines like peyote, ayahuasca, or psilocybin in ceremonies, and recognizes tribal sovereignty over these practices. This matters because it validates Indigenous knowledge and potentially carves out legal space for traditional healing. But federal bills on this are rare." }, { "date": "2026-04-30", "title": "MAPS or Compass Pathways publicly announces Phase 3 psilocybin efficacy data or a formal FDA pre-approval meeting", "confidence": 55, "category": "research", "geography": "USA", "resolve_date": "2026-10-30", "tags": [], "status": "pending", "priority": "high", "plain_title": "Compass or MAPS announces Phase 3 results or FDA pre-approval meeting", "plain_what": "One of the two leading companies will announce new data showing how well their psilocybin therapy works, or announce a formal meeting with the FDA to discuss approval. Compass already reported results; MAPS is earlier. Either company sharing next-step news matters because it moves closer to actual FDA approval." }, { "date": "2026-05-01", "title": "FDA will issue formal guidance requiring mandatory cardiac screening protocols (ECG, QTc thresholds) for any ibogaine IND by Q3 2026, effectively gatekeeping clinical access without blocking analog development.", "confidence": 62, "category": "regulation", "geography": "USA", "resolve_date": "2026-09-30", "tags": [ "ibogaine", "FDA" ], "status": "pending", "priority": "high", "plain_title": "FDA requires heart screening tests for ibogaine drug trials", "plain_what": "The FDA (the US drug regulator) will publish official rules saying anyone testing ibogaine in humans must do EKG heart tests first and check for dangerous heart rhythms. This matters because ibogaine can affect your heart, and regulators need to protect trial volunteers\u2014but the new rules won't stop companies from developing safer versions of ibogaine." }, { "date": "2026-05-01", "title": "At least two Phase 3 psychedelic trials will formally adopt standardized fluoxetine washout protocols (documented in trial registry or protocol amendment) by Q4 2026.", "confidence": 52, "category": "research", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "FDA", "Phase 3", "fluoxetine", "washout" ], "status": "pending", "priority": "high", "plain_title": "Two major psilocybin trials will require patients to stop antidepressants", "plain_what": "Researchers running big psilocybin studies will update their rules to require people taking fluoxetine (Prozac) to stop the drug before the trial, and they'll document this in public trial databases. This matters because fluoxetine might interfere with psilocybin's effects, and trials need to show clean results." }, { "date": "2026-05-01", "title": "Oxa-noribogaine developers will achieve a sustained public market or disclosed private valuation premium of 40%+ over comparable raw ibogaine-focused companies within 12 months of 2026-05-01.", "confidence": 48, "category": "market", "geography": "Global", "resolve_date": "2027-05-01", "tags": [ "ibogaine", "oxa-noribogaine", "valuation" ], "status": "pending", "priority": "high", "plain_title": "Safer ibogaine versions will be worth much more than original", "plain_what": "Companies developing oxa-noribogaine (a safer chemical cousin of ibogaine) will be valued at least 40% higher than companies focusing only on raw ibogaine, within one year of May 2026. This matters to investors because it signals which version of the drug the market thinks will actually work and get approved." }, { "date": "2026-05-01", "title": "Fluoxetine washout standardization will be documented as adopted protocol practice across at least two Phase 3 psychedelic trials by 2026-07-30.", "confidence": 28, "category": "research", "geography": "USA", "resolve_date": "2026-07-30", "tags": [ "FDA", "Phase 3", "fluoxetine", "washout" ], "status": "pending", "priority": "high", "plain_title": "Psilocybin trials will require antidepressant washout by July 2026", "plain_what": "At least two major psilocybin studies will update their trial rules to require fluoxetine washout and publish this change publicly by July 30, 2026. This is a tighter deadline than the previous prediction and matters because protocol changes usually take months to approve through review boards." }, { "date": "2026-05-01", "title": "FDA will formally request endpoint renegotiation or place a clinical hold on at least one active psilocybin or ibogaine addiction trial citing mismatch between extinction-enhancement mechanism and relapse-prevention primary endpoint by Q2 2027.", "confidence": 38, "category": "research", "geography": "USA", "resolve_date": "2027-06-30", "tags": [ "psilocybin", "ibogaine", "addiction", "FDA", "endpoints" ], "status": "pending", "priority": "high", "plain_title": "FDA may halt a psilocybin trial over treatment endpoint mismatch", "plain_what": "The FDA (US drug regulator) might put a clinical hold on or ask researchers to redesign at least one big psilocybin or ibogaine addiction trial because the main goal (stopping relapse) doesn't match how the drug actually works (helping people forget trauma). This matters because if the FDA thinks a trial is measuring the wrong thing, it can freeze the study until researchers fix it." }, { "date": "2026-05-02", "title": "Psychedelic biotech sector aggregate market cap will not recover to 2024 highs before 2026-09-30, absent an FDA approval or clear NDA acceptance for a psychedelic compound.", "confidence": 80, "category": "market", "geography": "USA", "resolve_date": "2026-09-30", "tags": [ "FDA", "biotech", "market" ], "status": "pending", "priority": "high", "plain_title": "Psychedelic biotech stocks won't recover to 2024 peaks by September 2026", "plain_what": "Psychedelic drug companies' stock prices fell sharply from their 2024 highs and haven't bounced back. Without an actual FDA approval or a clear sign that one is coming, investors see no reason to pour money back in. The sector needs real regulatory wins to recover." }, { "date": "2026-05-02", "title": "FDA will issue formal written guidance requiring cardiac monitoring protocols (including QT-interval surveillance) as a prerequisite for any ibogaine or ibogaine-analog IND submission, before 2027-01-15.", "confidence": 79, "category": "regulation", "geography": "USA", "resolve_date": "2027-01-15", "tags": [ "ibogaine", "FDA", "cardiac-safety" ], "status": "pending", "priority": "high", "plain_title": "FDA will mandate cardiac monitoring for ibogaine drug trials by January 2027", "plain_what": "Ibogaine, a plant medicine some people use for addiction, can affect the heart's electrical rhythm. The FDA (the US drug regulator) has seen enough published research showing this risk that it will issue formal written guidance requiring anyone testing ibogaine to monitor patients' hearts closely. This is standard FDA practice when a drug shows a consistent safety signal." }, { "date": "2026-05-02", "title": "No psychedelic compound will receive FDA approval or be federally rescheduled before 2026-12-31.", "confidence": 82, "category": "regulation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "MDMA", "psilocybin", "ibogaine", "FDA", "rescheduling" ], "status": "pending", "priority": "high", "plain_title": "No psychedelic drug will be approved or rescheduled by end of 2026", "plain_what": "MDMA (the active ingredient in ecstasy) got rejected by the FDA in 2024 and needs more data before resubmission. Psilocybin (magic mushrooms' active compound) is years away from even applying for approval. Congress hasn't passed any bills to reschedule these drugs federally. Every pathway to approval or rescheduling hits a wall before 2027." }, { "date": "2026-05-02", "title": "Ibogaine cardiac safety literature will constitute a recognized regulatory signal sufficient to require mandatory cardiac monitoring protocols in any new IND submission for ibogaine or close analogs, delaying direct ibogaine clinical development timelines materially into 2027.", "confidence": 72, "category": "regulation", "geography": "Global", "resolve_date": "2026-07-31", "tags": [ "ibogaine", "cardiac-safety", "FDA", "clinical-trials" ], "status": "pending", "priority": "high", "plain_title": "Ibogaine heart risk will force FDA to delay trials into 2027", "plain_what": "Ibogaine's risk to heart rhythm is now documented clearly enough in published research that the FDA will treat it as an official safety signal. This means anyone wanting to run an ibogaine trial will face mandatory cardiac monitoring requirements, which will delay trial startup and add costs. FDA precedent shows they respond this way to cardiac risks in new brain drugs." }, { "date": "2026-05-02", "title": "Psychedelic biotech equities will remain below 2024 high-water marks through 2026-09-30, with no sector-wide recovery absent a positive FDA binary event.", "confidence": 78, "category": "market", "geography": "USA", "resolve_date": "2026-09-30", "tags": [ "FDA", "biotech", "market" ], "status": "pending", "priority": "high", "plain_title": "Psychedelic biotech stocks will stay depressed through September 2026", "plain_what": "Multiple industry experts agree: psychedelic drug company stocks are down and won't recover until the FDA actually approves a drug or gives clear signals it will. Without real regulatory progress, the sector will languish. This prediction captures broad expert consensus on market dynamics." }, { "date": "2026-05-03", "title": "FDA will issue formal guidance requiring cardiac screening protocols as a precondition for ibogaine IND approval by Q1 2027.", "confidence": 52, "category": "regulation", "geography": "USA", "resolve_date": "2027-03-01", "tags": [ "ibogaine", "FDA" ], "status": "pending", "priority": "high", "plain_title": "FDA issues formal cardiac screening rules for ibogaine trials", "plain_what": "The FDA (the US drug regulator) will publish official written guidance saying that anyone testing ibogaine\u2014a plant-based psychedelic being studied for addiction\u2014must first get heart tests to check for dangerous electrical abnormalities. This matters because ibogaine can affect your heart rhythm, and the FDA needs to protect patients in clinical trials." }, { "date": "2026-05-03", "title": "Cardiac screening will be included as a mandatory requirement in at least one enacted or advanced federal ibogaine access bill or FDA guidance document by August 2026.", "confidence": 44, "category": "regulation", "geography": "USA", "resolve_date": "2026-08-01", "tags": [ "ibogaine", "legislation", "FDA" ], "status": "pending", "priority": "high", "plain_title": "Cardiac screening becomes mandatory in one federal ibogaine bill or guidance", "plain_what": "At least one official pathway to legal ibogaine\u2014either a law passed by Congress or an FDA (US drug regulator) rule\u2014will require heart screening before anyone can use it. This is a lower bar than FDA guidance alone: it could be a bill text, a proposed FDA rule, or a condition letter from the FDA to a specific company." }, { "date": "2026-05-03", "title": "Any federal ibogaine access legislation that passes both chambers will include mandatory cardiac screening as a statutory floor requirement.", "confidence": 71, "category": "legislation", "geography": "USA", "resolve_date": "2027-06-01", "tags": [ "ibogaine", "legislation" ], "status": "pending", "priority": "medium", "plain_title": "Any federal ibogaine law will require cardiac screening if it passes", "plain_what": "If Congress actually passes a law allowing ibogaine access\u2014something that hasn't happened yet and faces long odds\u2014that law almost certainly will require heart screening first. The logic is political: any law that didn't screen for cardiac risk would face fierce opposition, so any bill that survives both chambers will include it." }, { "date": "2026-05-03", "title": "MMED (Mind Medicine) share price will remain below its Q1 2026 high through September 30, 2026, absent a confirmed FDA catalyst event.", "confidence": 68, "category": "market", "geography": "USA", "resolve_date": "2026-09-30", "tags": [ "FDA", "biotech", "MMED" ], "status": "pending", "priority": "high", "plain_title": "Mind Medicine stock stays flat or down through September 2026", "plain_what": "Mind Medicine (ticker: MMED), a psychedelic drug company, will not recover to its highest price in early 2026 between now and the end of September 2026\u2014unless the FDA (the US drug regulator) approves one of their drugs or they announce successful late-stage trial results. Without good news from the FDA, the stock is likely to stay weak." }, { "date": "2026-05-03", "title": "The psychedelic biotech sector (as proxied by PSYK ETF or equivalent index) will show no positive return from May 2026 levels through June 2, 2026, absent a confirmed FDA approval or Phase 3 trial success announcement.", "confidence": 61, "category": "market", "geography": "USA", "resolve_date": "2026-06-02", "tags": [ "FDA", "biotech" ], "status": "pending", "priority": "medium", "plain_title": "Psychedelic biotech sector flat or down by early June 2026", "plain_what": "The psychedelic biotech sector\u2014tracked by the PSYK ETF (an exchange-traded fund that holds psychedelic drug companies)\u2014will show no gain from May through early June 2026 unless the FDA (the US drug regulator) approves a psychedelic drug or a company announces success in a late-stage trial. Over just 30 days, the sector is likely to stay stuck without major good news." }, { "date": "2026-05-03", "title": "Glutamatergic mPFC modulation will be cited as the primary mechanistic hypothesis for ibogaine-class therapeutic effects in the majority of new ibogaine/noribogaine preclinical publications by end of 2028.", "confidence": 48, "category": "research", "geography": "Global", "resolve_date": "2028-01-01", "tags": [ "ibogaine", "neuroscience", "mechanism" ], "status": "pending", "priority": "medium", "plain_title": "Ibogaine research shifts focus to brain chemistry pathway by 2028", "plain_what": "By the end of 2028, most new scientific papers studying how ibogaine works will focus on a specific brain circuit\u2014the mPFC (medial prefrontal cortex) and its glutamate chemistry\u2014rather than older theories about opioid receptors. This shift reflects cleaner scientific evidence and simpler explanations that drug companies prefer, though the field changes slowly." }, { "date": "2026-05-04", "title": "FDA will issue formal guidance specifically addressing cardiac monitoring requirements for ibogaine and ibogaine analog trials by Q2 2027.", "confidence": 52, "category": "regulation", "geography": "USA", "resolve_date": "2027-06-30", "tags": [ "ibogaine", "FDA", "cardiac safety" ], "status": "pending", "priority": "high", "plain_title": "FDA publishes heart-safety rules for ibogaine trials", "plain_what": "The FDA (the US drug regulator) will write down specific rules about how companies must monitor people's hearts during ibogaine trials. This matters because ibogaine can affect heart rhythm in ways that could be dangerous, and right now there are no clear federal rules about what doctors have to check." }, { "date": "2026-05-04", "title": "At least three published clinical trial protocol amendments for ongoing psilocybin or MDMA trials will cite SSRI/fluoxetine interaction data as justification for modified washout criteria by Q3 2026.", "confidence": 28, "category": "research", "geography": "Global", "resolve_date": "2026-09-30", "tags": [ "psilocybin", "MDMA", "SSRI", "clinical trial", "protocol amendment" ], "status": "pending", "priority": "high", "plain_title": "Trial protocols cite SSRI drug interaction research in washout rules", "plain_what": "Ongoing psilocybin and MDMA clinical trials will publicly announce changes to their rules about how long people must stop taking SSRIs (common antidepressants like Prozac) before entering the trial. They'll do this because new research shows these drugs interact with psychedelics in ways that matter for safety." }, { "date": "2026-05-04", "title": "SSRI washout protocols will be formally required (via FDA mandate or sponsor-initiated amendments across at least five active trials) for MDMA and psilocybin INDs by August 2026, causing measurable enrollment delays at multiple sites.", "confidence": 14, "category": "regulation", "geography": "Global", "resolve_date": "2026-08-02", "tags": [ "psilocybin", "MDMA", "SSRI", "FDA", "enrollment" ], "status": "pending", "priority": "medium", "plain_title": "SSRI washout rules mandated across multiple trials by mid-2026", "plain_what": "Within 18 months, the FDA (or major drug companies running trials) will require people to stop taking SSRIs for a set period before joining MDMA or psilocybin trials. This will slow down enrollment because fewer people will be eligible, and the waiting period will be longer." }, { "date": "2026-05-04", "title": "A serious adverse event at an unregulated U.S. ketamine or psychedelic clinic will be cited in congressional hearing testimony or trigger a formal federal investigation within 12 months of today.", "confidence": 38, "category": "safety", "geography": "USA", "resolve_date": "2027-05-04", "tags": [ "ketamine", "adverse event", "congressional oversight", "clinic safety" ], "status": "pending", "priority": "high", "plain_title": "Congressional hearing or federal probe triggered by ketamine clinic harm", "plain_what": "Someone will be seriously hurt or die at an unregulated ketamine or psychedelic clinic in the US, the story will get attention, and Congress or a federal agency will hold a public hearing or launch a formal investigation. This matters because ketamine clinics are booming but barely regulated, and one high-profile disaster could reshape the whole industry." }, { "date": "2026-05-04", "title": "FDA will issue formal guidance on QT monitoring requirements for ibogaine by mid-2027, and this guidance will be cited as a primary reason for delay in at least one IND progress report filed before December 2027.", "confidence": 31, "category": "regulation", "geography": "USA", "resolve_date": "2027-06-30", "tags": [ "ibogaine", "FDA", "cardiac safety", "IND" ], "status": "pending", "priority": "medium", "plain_title": "FDA heart-safety guidance delays at least one ibogaine IND approval", "plain_what": "The FDA will publish formal rules about heart monitoring for ibogaine, and at least one company running an ibogaine trial will later tell the FDA that this new guidance is the reason their trial got delayed. This is similar to the first prediction but focuses on whether the new rules actually slow down drug approvals." }, { "date": "2026-05-05", "title": "No standalone federal psychedelic scheduling bill will pass both chambers before the 2026 midterms.", "confidence": 90, "category": "legislation", "geography": "USA", "resolve_date": "2026-11-03", "tags": [ "legislation", "scheduling", "psychedelics" ], "status": "pending", "priority": "high", "plain_title": "Congress won't pass a standalone psychedelic bill before mid-2026", "plain_what": "Right now, Congress has no psychedelic scheduling bills scheduled for a real hearing. The DEA (Drug Enforcement Administration) opposes them. With fewer than 15 weeks of actual legislative time left before the November 2026 elections, a standalone bill has almost no chance\u2014the only realistic path would be sneaking it into a larger military spending bill or budget bill." }, { "date": "2026-05-05", "title": "FDA will issue formal written guidance requiring mandatory cardiac screening (ECG, QTc baseline) for any ibogaine IND submitted or amended in 2026.", "confidence": 62, "category": "regulation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "ibogaine", "FDA", "cardiac", "IND" ], "status": "pending", "priority": "high", "plain_title": "FDA will require heart screening before testing ibogaine in humans", "plain_what": "Ibogaine (a plant-derived drug being tested for addiction) can damage the heart in serious ways\u2014the data is public and clear. The FDA (US drug regulator) will almost certainly demand that any company testing ibogaine in humans first does heart screening tests (an ECG baseline and QTc measurement) before those humans start the drug. This protects patients and shields the FDA from liability." }, { "date": "2026-05-05", "title": "DEA will submit formal written opposition to any NDAA provision creating ibogaine veteran access that bypasses Schedule I review, before December 31 2026.", "confidence": 72, "category": "legislation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "ibogaine", "DEA", "Schedule I", "veteran", "NDAA" ], "status": "pending", "priority": "high", "plain_title": "DEA will formally oppose any law letting veterans skip ibogaine review", "plain_what": "Some in Congress want to create a fast track for military veterans to access ibogaine without waiting for Schedule I review (the formal drug classification process). The DEA has legal standing and institutional reasons to block this\u2014they will write an official letter or Congressional statement opposing any law that lets ibogaine bypass the normal review process." }, { "date": "2026-05-05", "title": "By November 2026, at least one major ibogaine clinical-stage company or academic program will publicly announce a pivot toward non-cardiotoxic ibogaine analogs (e.g., oxa-noribogaine) as their primary development candidate.", "confidence": 58, "category": "research", "geography": "Global", "resolve_date": "2026-11-05", "tags": [ "ibogaine", "oxa-noribogaine", "analogs", "cardiac", "drug-development" ], "status": "pending", "priority": "high", "plain_title": "Ibogaine companies will publicly switch to safer chemical alternatives", "plain_what": "Ibogaine works for some addictions but harms the heart. Companies and researchers testing ibogaine know this. By November 2026, at least one major company or academic lab will publicly announce they're shifting their main focus to safer versions\u2014like oxa-noribogaine, a chemical cousin without the heart damage. They'll say this out loud in a press release or research announcement because the cardiac risk makes ibogaine hard to sell to regulators and patients." }, { "date": "2026-05-05", "title": "At least two additional U.S. states will formally introduce legislation establishing veteran-specific psychedelic therapy access programs in calendar year 2026.", "confidence": 78, "category": "legislation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "veteran", "state-legislation", "psychedelics", "psilocybin", "ketamine" ], "status": "pending", "priority": "high", "plain_title": "Two more states will propose veteran psychedelic therapy access laws in 2026", "plain_what": "States like Texas, Colorado, Oregon, and Arizona are already moving ahead with their own psychedelic therapy programs\u2014they don't wait for the federal government. By the end of 2026, at least two additional states will formally introduce (file) new bills creating veteran-only psychedelic therapy programs. This counts bills filed, even if they don't pass, because state-level momentum is real and separate from federal drug scheduling." }, { "date": "2026-05-06", "title": "At least one psychedelic compound \u2014 most likely COMPASS Pathways COMP360 \u2014 will receive FDA approval or formal approval recommendation before end of 2027.", "confidence": 87, "category": "regulation", "geography": "USA", "resolve_date": "2027-12-31", "tags": [ "FDA", "COMPASS", "COMP360", "psilocybin", "TRD", "approval" ], "status": "pending", "priority": "critical", "plain_title": "First psychedelic drug approved by FDA by end of 2027", "plain_what": "COMPASS Pathways' psilocybin compound COMP360 is on track to become the first psychedelic drug approved by the FDA, likely for treatment-resistant depression \u2014 meaning millions of people who don't respond to antidepressants would have a new legal option." }, { "date": "2026-05-06", "title": "Trump EO Right to Try pathway will produce at least one operational psychedelic patient access program before January 2027.", "confidence": 79, "category": "regulation", "geography": "USA", "resolve_date": "2027-01-01", "tags": [ "Right_to_Try", "ibogaine", "psilocybin", "Texas", "patient_access", "EO" ], "status": "pending", "priority": "high", "plain_title": "Legal psychedelic therapy access program opens in the US before 2027", "plain_what": "The Trump executive order created a pathway for seriously ill patients to access investigational psychedelic drugs \u2014 and Texas is moving fastest to build the first operational program." }, { "date": "2026-05-06", "title": "DEA will formally initiate rescheduling review for at least one psychedelic compound before April 2027.", "confidence": 71, "category": "legislation", "geography": "USA", "resolve_date": "2027-04-18", "tags": [ "DEA", "rescheduling", "Schedule_I", "psilocybin", "EO" ], "status": "pending", "priority": "high", "plain_title": "DEA begins formal process to move psilocybin out of Schedule I", "plain_what": "The DEA will start the legal process to reclassify psilocybin from Schedule I (most dangerous, no accepted medical use) to a lower schedule \u2014 a historic step that would make it legal to prescribe and manufacture." }, { "date": "2026-05-06", "title": "Psychedelic biotech sector will trade higher 6 months post-EO (October 2026) versus pre-EO (April 17, 2026).", "confidence": 83, "category": "market", "geography": "Global", "resolve_date": "2026-10-18", "tags": [ "CMPS", "ATAI", "stocks", "market", "investors", "sector" ], "status": "pending", "priority": "high", "plain_title": "Psychedelic stocks will be higher in October than they were before Trump's order", "plain_what": "The cluster of psychedelic drug companies \u2014 COMPASS Pathways, AtaiBeckley, Mind Medicine, others \u2014 has already surged on the executive order and will likely be trading even higher by October as FDA decision timelines approach." }, { "date": "2026-05-06", "title": "Major pharma company will announce licensing, acquisition or partnership with psychedelic biotech before January 2027.", "confidence": 62, "category": "market", "geography": "Global", "resolve_date": "2027-01-01", "tags": [ "BigPharma", "acquisition", "licensing", "partnership", "consolidation" ], "status": "pending", "priority": "medium", "plain_title": "A major drug company will buy or partner with a psychedelic biotech this year", "plain_what": "One of the world's largest pharmaceutical companies \u2014 Pfizer, J&J, Eli Lilly, Roche, or similar \u2014 will likely announce a deal with a psychedelic drug company before the year is out, following the same playbook used with gene therapy and GLP-1 drugs." }, { "date": "2026-05-06", "title": "Microdosing will see at least 5 new FDA-approved IND applications filed before December 2026.", "confidence": 91, "category": "research", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "microdosing", "IND", "clinical_trials", "FDA", "scalability" ], "status": "pending", "priority": "medium", "plain_title": "Microdosing becomes the fastest-growing psychedelic research area in 2026", "plain_what": "Small, sub-perceptual doses of psychedelics (microdosing) are becoming the next big clinical research area because they don't require expensive therapist sessions \u2014 making them easier to prescribe and scale." }, { "date": "2026-05-06", "title": "UC system (UCSF, UCLA, UCSD) will publish statistically significant psilocybin results in a non-psychiatric indication before December 2027.", "confidence": 76, "category": "research", "geography": "USA", "resolve_date": "2027-12-31", "tags": [ "UCSF", "UCLA", "UCSD", "psilocybin", "chronic_pain", "burnout", "expansion" ], "status": "pending", "priority": "medium", "plain_title": "Psilocybin shown to work for something beyond depression or PTSD", "plain_what": "University of California researchers are testing psilocybin for chronic back pain, eating disorders, and doctor burnout \u2014 and one of these trials is expected to show significant positive results before 2028." }, { "date": "2026-05-06", "title": "Psychedelic-assisted therapy will be standard in psychiatric training programs by January 2028.", "confidence": 94, "category": "culture", "geography": "USA", "resolve_date": "2028-01-01", "tags": [ "psychiatry", "training", "curriculum", "mainstream", "culture_shift" ], "status": "pending", "priority": "medium", "plain_title": "Medical schools will teach psychedelic therapy as standard psychiatry by 2028", "plain_what": "Within the next 18 months, psychiatry residents, nurses, and mental health practitioners will be studying psychedelic-assisted therapy as a required part of their medical training \u2014 not a fringe elective." }, { "date": "2026-05-06", "title": "Psychedelic field will achieve formal bipartisan Congressional recognition before end of 2026.", "confidence": 88, "category": "legislation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "Congress", "bipartisan", "veterans", "legislation", "hearings" ], "status": "pending", "priority": "medium", "plain_title": "Both parties in Congress will formally acknowledge psychedelic therapy as legitimate medicine by end of 2026", "plain_what": "Congress will hold a formal hearing or pass resolution language officially recognizing psychedelic therapy \u2014 ending the political stigma that has blocked legislation for decades." }, { "date": "2026-05-07", "title": "No federal rescheduling of any classical psychedelic \u2014 psilocybin, MDMA, LSD, DMT \u2014 will occur before 2028.", "confidence": 85, "category": "legislation", "geography": "USA", "resolve_date": "2028-01-01", "tags": [ "psilocybin", "MDMA", "DMT", "LSD", "rescheduling" ], "status": "pending", "priority": "high", "plain_title": "No psychedelic rescheduling at federal level before 2028", "plain_what": "The federal government won't move psilocybin, MDMA, LSD, or DMT from Schedule I (the strictest category) to a lower schedule before 2028. This matters because rescheduling is the only legal path that lets doctors prescribe these drugs widely \u2014 and it requires the FDA to first approve one as a medicine, which hasn't happened yet." }, { "date": "2026-05-07", "title": "Federal psilocybin scheduling reform will not receive a floor vote in the 119th Congress (ending January 3, 2027).", "confidence": 87, "category": "legislation", "geography": "USA", "resolve_date": "2027-01-03", "tags": [ "psilocybin", "rescheduling", "Congress" ], "status": "pending", "priority": "high", "plain_title": "Psilocybin rescheduling won't get a Congressional vote by January 2027", "plain_what": "Congress (specifically the House or Senate) won't vote on a psilocybin rescheduling bill before January 3, 2027, when the current Congress ends. No bill has made it out of committee, and party leaders aren't pushing it as a priority. A small bipartisan group of members supports it, but they don't have the votes or the political machinery to force a floor vote." }, { "date": "2026-05-07", "title": "FDA will issue a formal clinical hold or safety guidance on at least one ibogaine IND citing QT prolongation before end of 2026.", "confidence": 72, "category": "regulatory", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "ibogaine", "FDA", "clinical-hold", "cardiac" ], "status": "pending", "priority": "high", "plain_title": "FDA will warn about ibogaine heart rhythm dangers by end of 2026", "plain_what": "The FDA will formally halt or restrict at least one ibogaine drug trial (called a clinical hold) or issue safety guidance because of a cardiac problem called QT prolongation \u2014 a heartbeat irregularity that can cause sudden death. Ibogaine is known to affect the heart's electrical system, and researchers have already documented this risk in peer-reviewed studies. The FDA uses this evidence to trigger safety holds." }, { "date": "2026-05-07", "title": "Ibogaine cardiac safety will remain the primary regulatory gating factor for all FDA and Congressional ibogaine progress through at least mid-2027.", "confidence": 78, "category": "regulatory", "geography": "USA", "resolve_date": "2027-07-01", "tags": [ "ibogaine", "FDA", "cardiac", "regulation" ], "status": "pending", "priority": "high", "plain_title": "Ibogaine heart safety will block FDA progress through mid-2027", "plain_what": "The cardiac (heart) safety problem with ibogaine \u2014 specifically QT prolongation \u2014 will be the main reason the FDA doesn't approve ibogaine or clear new trials for at least 18 more months. No new research has emerged to prove the heart risk is safe or manageable, so the safety concern stays locked in place as the blocking point. Ibogaine advocates are pushing, but the FDA won't move until the heart problem is resolved." }, { "date": "2026-05-07", "title": "FDA will not publish a formal guidance document on SSRI-psychedelic washout protocols before November 2027.", "confidence": 70, "category": "regulatory", "geography": "USA", "resolve_date": "2027-11-07", "tags": [ "FDA", "SSRI", "psilocybin", "MDMA", "trial-design" ], "status": "pending", "priority": "medium", "plain_title": "FDA won't publish SSRI-psychedelic interaction guidance by November 2027", "plain_what": "The FDA won't issue official written instructions for doctors on how long patients taking SSRI antidepressants need to wait before using psychedelic medicines. Animal studies hint at an interaction risk, but the FDA needs human trial data to write guidance \u2014 and that data doesn't exist. FDA guidance documents take 12\u201324 months to write and approve internally, plus they need public comment periods. Official guidance won't land before November 2027." }, { "date": "2026-05-08", "title": "DEA will initiate formal scheduling review proceedings for psilocybin within 6 months of any FDA approval recommendation, extending access timelines by minimum 18 months", "confidence": 78, "category": "regulation", "geography": "USA", "resolve_date": "2028-06-01", "tags": [ "psilocybin", "FDA", "DEA" ], "status": "pending", "priority": "high", "plain_title": "DEA delays psilocybin access by 18+ months after any FDA approval", "plain_what": "The DEA (Drug Enforcement Administration\u2014the federal agency that classifies illegal drugs) has its own separate legal power to review and approve drugs, independent of the FDA (the US drug regulator). If the FDA approves psilocybin for medical use, the DEA will launch its own formal review that typically takes 18+ months to complete. This matters because patients and researchers have to wait even after the FDA says yes." }, { "date": "2026-05-08", "title": "FDA will issue a formal ibogaine cardiac safety guidance document requiring mandatory QT monitoring protocols before any IND expansion, slowing veteran access trials by 12-18 months", "confidence": 75, "category": "regulation", "geography": "USA", "resolve_date": "2027-03-01", "tags": [ "ibogaine", "FDA", "veteran" ], "status": "pending", "priority": "high", "plain_title": "FDA mandates heart monitoring for ibogaine, delaying veteran therapy access", "plain_what": "Ibogaine (a plant-derived compound) causes a known heart rhythm problem called QT prolongation\u2014the time it takes your heart's electrical system to reset after each beat. The FDA has documented adverse events and will require mandatory EKG (heart monitoring) before patients can receive ibogaine in clinical trials. This adds 12\u201318 months to the timeline because the FDA has to write new safety rules, and study teams have to redesign their protocols to include the monitoring." }, { "date": "2026-05-08", "title": "Federal rescheduling of any classical psychedelic will not occur before 2028, due to DEA independent scheduling process adding 18-24 months beyond any FDA action", "confidence": 80, "category": "regulation", "geography": "USA", "resolve_date": "2028-01-01", "tags": [ "FDA", "DEA", "psilocybin", "rescheduling" ], "status": "pending", "priority": "high", "plain_title": "No classical psychedelic will be rescheduled federally before 2028", "plain_what": "Classical psychedelics like psilocybin, LSD, and mescaline are illegal Schedule I drugs (meaning the DEA says they have no medical use). Rescheduling means moving them to a lower schedule so doctors can prescribe them. The FDA and DEA both have to approve this, and the whole process\u2014from an FDA recommendation to final DEA approval\u2014takes 18\u201324 months. No psychedelic company has filed the paperwork for FDA approval yet, so the earliest an FDA recommendation could come is 2026\u20132027, making 2028 the earliest possible rescheduling date." }, { "date": "2026-05-08", "title": "A documented serious adverse event at a commercial psychedelic retreat will receive major national media coverage before end of 2026, triggering emergency state-level regulatory review in Oregon or Colorado", "confidence": 62, "category": "regulation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "Oregon", "Colorado", "retreat", "safety" ], "status": "pending", "priority": "high", "plain_title": "A serious retreat injury will trigger state-level safety crackdowns by 2026", "plain_what": "Oregon and Colorado now allow licensed psychedelic retreat centers to operate legally. These programs are expanding fast, but safety standards vary widely between operators. A documented serious injury or death at one of these commercial retreats is likely to get major newspaper and TV coverage. When that happens, state regulators will launch emergency reviews and probably create stricter safety rules. This matters because it could slow down the entire industry's growth and change how these businesses operate." }, { "date": "2026-05-08", "title": "Ibogaine cardiac safety documentation will drive regulatory and investment bifurcation between natural ibogaine (restricted, mandatory monitoring) and synthetic analogs (accelerated development), with distinct treatment pathways formalized in FDA guidance or legislation by end of 2027", "confidence": 55, "category": "regulation", "geography": "USA", "resolve_date": "2027-12-31", "tags": [ "ibogaine", "FDA", "legislation", "analogs" ], "status": "pending", "priority": "high", "plain_title": "Ibogaine splits into two paths: natural (restricted) and synthetic (faster approval)", "plain_what": "Ibogaine causes heart rhythm problems that synthetic versions of the same molecule (or chemically similar compounds) may not cause. The FDA and investment companies are noticing this and moving toward a two-track approach: natural ibogaine gets heavy restrictions and mandatory heart monitoring, while new synthetic versions developed in labs get faster approval because they don't carry the same cardiac risk. By 2027, this split will probably be formalized in FDA guidance or new laws. This matters because it means natural ibogaine stays harder to access, while synthetic alternatives move faster toward patients." }, { "date": "2026-05-09", "title": "FDA will issue a formal Safety Communication or draft guidance specifically addressing ibogaine cardiac monitoring requirements before December 31, 2026.", "confidence": 62, "category": "regulation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "ibogaine", "FDA", "cardiac-safety" ], "status": "pending", "priority": "high", "plain_title": "FDA issues formal safety alert on ibogaine heart monitoring by end of 2026", "plain_what": "The FDA (US drug regulator) will publish an official warning or guidance document about heart safety risks from ibogaine, a psychedelic compound being tested as a treatment. Two recent scientific papers documented heart rhythm problems in ibogaine users, which triggers an FDA obligation to communicate these risks publicly to doctors and patients." }, { "date": "2026-05-09", "title": "Ibogaine cardiac safety will become a formal regulatory bottleneck \u2014 via FDA IND hold letters, draft guidance, or DEA opposition \u2014 before December 31, 2026, forcing sponsors toward analog development or stricter protocol constraints.", "confidence": 71, "category": "regulation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "ibogaine", "FDA", "DEA", "cardiac-safety" ], "status": "pending", "priority": "high", "plain_title": "Ibogaine development stalls due to cardiac safety concerns and regulatory blocks", "plain_what": "Ibogaine drug trials will hit regulatory roadblocks \u2014 either the FDA (US drug regulator) will freeze trials pending better heart safety data, or the DEA (US drug enforcement agency) will block rescheduling efforts \u2014 before the end of 2026. These aren't obstacles that can be ignored; they force companies to redesign trials or develop chemically similar alternatives." }, { "date": "2026-05-09", "title": "DEA will formally oppose or delay any pending ibogaine rescheduling petition before December 31, 2026, citing cardiovascular adverse event literature published in 2026.", "confidence": 41, "category": "regulation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "ibogaine", "DEA", "Schedule-I", "rescheduling" ], "status": "pending", "priority": "medium", "plain_title": "DEA blocks ibogaine rescheduling using new cardiac safety evidence by 2026", "plain_what": "If someone files an official petition to move ibogaine from Schedule I (banned) to a looser category, the DEA (US drug enforcement agency) will reject it by citing the new heart safety papers published in 2026. This prediction only matters if a petition actually gets filed first \u2014 as of now, none is publicly confirmed." }, { "date": "2026-05-09", "title": "At least two pharmaceutical sponsors will file new INDs or major trial amendments targeting psilocybin for cocaine use disorder before December 31, 2026.", "confidence": 52, "category": "research", "geography": "Global", "resolve_date": "2026-12-31", "tags": [ "psilocybin", "cocaine-use-disorder", "IND", "clinical-trials" ], "status": "pending", "priority": "high", "plain_title": "Two major companies file new psilocybin trials for cocaine addiction by 2026", "plain_what": "A successful clinical trial published in a major scientific journal will show psilocybin helps people quit cocaine. This result will prompt at least two pharmaceutical companies (like COMPASS Pathways or ATAI Life Sciences) to file new Investigational New Drug applications (INDs \u2014 official permission to run human trials) or expand their existing trials. This matters because it opens a new market for psychedelic treatments beyond depression and anxiety." }, { "date": "2026-05-09", "title": "Psilocybin for cocaine use disorder will emerge as a named pipeline indication with at least two new IND filings or primary-endpoint trial amendments documented before August 7, 2026.", "confidence": 18, "category": "research", "geography": "Global", "resolve_date": "2026-08-07", "tags": [ "psilocybin", "cocaine-use-disorder", "IND" ], "status": "pending", "priority": "medium", "plain_title": "Two psilocybin cocaine addiction trials launch within three months", "plain_what": "This prediction says the same thing as the previous one but demands it happens within just 90 days (by August 7, 2026). That's an unrealistically tight timeline: preparing an IND application typically takes 6 months on its own. Even if a major trial publishes tomorrow, companies won't have filed two new INDs in three months." }, { "date": "2026-05-10", "title": "FDA will issue a formal ibogaine safety communication or guidance document citing cardiac risk before issuing any IND pathway expansion, effectively adding 12-18 months to regulatory timeline.", "confidence": 72, "category": "regulatory", "geography": "USA", "resolve_date": "2027-03-01", "tags": [ "ibogaine", "FDA", "cardiac", "IND" ], "status": "pending", "priority": "high", "plain_title": "FDA issues cardiac safety warning on ibogaine, delaying approval 12\u201318 months", "plain_what": "The FDA (the US drug regulator) will publicly release a formal safety alert about ibogaine's risk of irregular heartbeats before allowing clinical trials to expand. This happens because the drug causes a measurable change in heart electrical activity called QT prolongation. The delay matters because it pushes any potential approval years further away." }, { "date": "2026-05-10", "title": "Any viable ibogaine NDA pathway will formally require a mandatory cardiac monitoring protocol, making 2028 the earliest realistic federal approval date.", "confidence": 74, "category": "regulatory", "geography": "USA", "resolve_date": "2028-12-31", "tags": [ "ibogaine", "FDA", "NDA", "cardiac monitoring" ], "status": "pending", "priority": "high", "plain_title": "Any approved ibogaine treatment will require mandatory heart monitoring, approval by 2028", "plain_what": "If ibogaine ever gets approved by the FDA for medical use, the agency will require mandatory cardiac monitoring (likely EKGs and blood work) as part of its Risk Evaluation and Mitigation Strategy (REMS) \u2014 a framework the FDA uses to manage drugs with serious safety risks. This requirement will mean the earliest realistic approval date is late 2028." }, { "date": "2026-05-10", "title": "At least one U.S. state (most likely California) will operationalize a regulated psilocybin access framework with licensed facilitators before any federal scheduling change, creating a de facto two-tier system.", "confidence": 78, "category": "legislation", "geography": "USA", "resolve_date": "2026-11-06", "tags": [ "psilocybin", "legislation", "California", "state policy", "two-tier system" ], "status": "pending", "priority": "high", "plain_title": "States will open legal psilocybin therapy programs before federal law changes", "plain_what": "At least one US state\u2014probably California\u2014will create a legal, regulated system for psilocybin therapy with trained facilitators before the federal government reclassifies psilocybin (which takes years and faces opposition). This means people in those states can access psilocybin legally while it remains illegal federally, creating a two-tier system: some states allow it, the federal government doesn't." }, { "date": "2026-05-10", "title": "FDA will require at least one independent replication of psilocybin RCT data for cocaine use disorder before considering it label-worthy, making 2029 the earliest realistic approval date for that indication.", "confidence": 76, "category": "regulatory", "geography": "USA", "resolve_date": "2029-01-01", "tags": [ "psilocybin", "FDA", "cocaine use disorder", "RCT", "replication" ], "status": "pending", "priority": "high", "plain_title": "FDA will demand repeat studies of psilocybin for cocaine addiction, approval by 2029", "plain_what": "The FDA (the US drug regulator) will not approve psilocybin for treating cocaine addiction based on a single clinical trial. Instead, the agency will require independent researchers to replicate the results in a second study before it considers the drug effective enough. No completed Phase 3 trials (the gold-standard final stage) exist yet, so this means approval can't happen before 2029 at the earliest." }, { "date": "2026-05-10", "title": "California will enact legislation establishing a regulated psilocybin therapy framework with a licensed facilitator model before end of 2026.", "confidence": 52, "category": "legislation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "psilocybin", "California", "legislation", "facilitator model" ], "status": "pending", "priority": "high", "plain_title": "California passes legal psilocybin therapy law before end of 2026", "plain_what": "California will pass legislation that allows licensed therapists or facilitators to legally administer psilocybin in a regulated, medically supervised setting before December 2026. Similar programs already exist in Oregon and Colorado. California has active bills pending, though the governor vetoed a related psilocybin bill in 2023, creating some uncertainty about whether this specific law passes soon." }, { "date": "2026-05-10", "title": "A veteran death in an unregulated foreign ibogaine setting, with documented prior VA system contact, will trigger a formal U.S. Congressional hearing on ibogaine safety and access before end of 2026.", "confidence": 48, "category": "legislation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "ibogaine", "veterans", "Congress", "safety", "hearing" ], "status": "pending", "priority": "high", "plain_title": "Congressional hearing triggered by veteran death in unregulated ibogaine treatment", "plain_what": "A veteran (someone who served in the military) who died in an unsafe, unregulated ibogaine treatment facility abroad will create a news story that forces Congress to hold a public hearing about ibogaine safety and access. Thousands of veterans are traveling to foreign countries for ibogaine treatment annually because it's not available or illegal in the US, and deaths in unregulated settings do occur. The delay here is that this needs to happen in the next ~7 months with enough media attention to trigger congressional action." }, { "date": "2026-05-11", "title": "Veteran-led psychedelic retreat networks will serve over 5,000 veterans in informal settings by end of 2026.", "confidence": 55, "category": "culture", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "veteran", "psychedelics", "informal-access" ], "status": "pending", "priority": "medium", "plain_title": "Veterans will access psychedelic retreats outside the US by 5,000 by late 2026", "plain_what": "Groups like Heroic Hearts already run informal psychedelic retreats for military veterans in countries where these substances are legal or tolerated. The prediction says 5,000 veterans total will have used these retreats by the end of 2026. This matters because veterans struggle with PTSD and trauma, and some find relief through these retreats \u2014 but they happen in legal gray zones with no oversight." }, { "date": "2026-05-11", "title": "FDA will issue a formal safety communication specifically on ibogaine cardiac risks by 2027-02-11.", "confidence": 52, "category": "regulatory", "geography": "USA", "resolve_date": "2027-02-11", "tags": [ "ibogaine", "FDA", "cardiac-safety" ], "status": "pending", "priority": "high", "plain_title": "FDA will formally warn about ibogaine heart rhythm dangers by February 2027", "plain_what": "Ibogaine is a powerful plant medicine used to treat addiction, but it can disrupt your heart's electrical system and cause dangerous arrhythmias (irregular heartbeats). The FDA (the US drug regulator) publishes formal safety warnings when enough bad cases pile up. This prediction says they'll do that for ibogaine by early 2027. If they do, it will make any legal access to ibogaine much harder and signal serious risk." }, { "date": "2026-05-11", "title": "Ibogaine will face a formal FDA or DEA safety communication within 12 months (by 2026-08-09) that materially constrains any U.S. access expansion before 2028.", "confidence": 28, "category": "regulatory", "geography": "USA", "resolve_date": "2026-08-09", "tags": [ "ibogaine", "FDA", "DEA", "regulatory-barrier" ], "status": "pending", "priority": "high", "plain_title": "FDA or DEA will restrict ibogaine access before it expands in the US", "plain_what": "This is a shorter deadline version of the previous prediction \u2014 it asks whether regulators will formally constrain ibogaine before the end of summer 2026 (only three months away). The logic is the same: cardiac risks are piling up, but a formal warning this fast is unlikely unless something bad happens suddenly. Most federal agencies move slower than this." }, { "date": "2026-05-11", "title": "The extinction-without-relapse dissociation observed in psilocybin-cocaine studies will generate at least 3 competing mechanistic hypotheses in peer-reviewed literature within 12 months.", "confidence": 72, "category": "research", "geography": "Global", "resolve_date": "2027-05-11", "tags": [ "psilocybin", "cocaine", "mechanistic-debate", "addiction" ], "status": "pending", "priority": "high", "plain_title": "Psilocybin research will spawn three competing theories about extinction without relapse", "plain_what": "Recent studies show psilocybin can help people quit cocaine by actually changing how the brain processes memory and reward \u2014 specifically, it breaks the link between cues and craving while leaving extinction memory intact. This is a weird dissociation that doesn't match current theory. The prediction says scientists will propose at least three different mechanistic explanations for this in peer-reviewed papers within a year. This matters because whoever figures it out right could design better addiction treatments." }, { "date": "2026-05-11", "title": "At least 4 new U.S. state bills legalizing or decriminalizing psychedelic therapy will pass by 2026-11-07, while no federal psychedelic therapy legislation advances past committee.", "confidence": 70, "category": "legislation", "geography": "USA", "resolve_date": "2026-11-07", "tags": [ "legislation", "state-policy", "psychedelics", "federal-stall" ], "status": "pending", "priority": "high", "plain_title": "US states will pass four new psychedelic therapy laws while Congress stays frozen", "plain_what": "Colorado and Oregon already have legal psychedelic therapy programs running. Minnesota, Massachusetts, California, Vermont and others are actively writing new bills right now. The prediction says at least four more states will pass laws legalizing or decriminalizing psychedelic-assisted therapy by November 2026, while Congress (the federal government) does nothing. This matters because it creates a patchwork of legal access across the country while the FDA and DEA remain unchanged." }, { "date": "2026-05-12", "title": "The psilocybin cocaine RCT will be widely misreported as a 'cure for addiction' in at least 3 major mainstream outlets, followed by a published correction or debunking piece within 60 days of initial coverage.", "confidence": 72, "category": "culture", "geography": "Global", "resolve_date": "2026-07-12", "tags": [ "psilocybin", "addiction", "media" ], "status": "pending", "priority": "high", "plain_title": "Media will hype psilocybin cocaine study as 'cure,' then print corrections", "plain_what": "When researchers publish findings on psilocybin helping people quit cocaine, news outlets will simplify the story into a flashy 'miracle cure' headline. Scientists and journalists will then have to publish corrections explaining the actual nuances. This happens because headlines need to be short and exciting, while the real science is complicated." }, { "date": "2026-05-12", "title": "FDA will issue a formal Safety Communication specifically on ibogaine-associated cardiac risks (QT prolongation/arrhythmia) before December 31, 2026.", "confidence": 38, "category": "regulation", "geography": "USA", "resolve_date": "2026-11-30", "tags": [ "ibogaine", "FDA", "cardiac" ], "status": "pending", "priority": "high", "plain_title": "FDA warns the public about ibogaine heart rhythm dangers", "plain_what": "The FDA (the U.S. drug regulator) will publish an official warning about ibogaine's documented risk of causing dangerous heart rhythm problems. This matters because people are seeking ibogaine treatment overseas for PTSD and addiction, but the FDA hasn't yet formally warned Americans about the specific cardiac danger, even though deaths have been documented." }, { "date": "2026-05-12", "title": "FDA will issue a formal Safety Communication on ibogaine cardiac risks before August 10, 2026, and this will create a measurable regulatory divergence in IND approval timelines between natural ibogaine and synthetic analogue (e.g., tabernanthalog, TBG) applications.", "confidence": 28, "category": "regulation", "geography": "USA", "resolve_date": "2026-08-10", "tags": [ "ibogaine", "FDA", "synthetic", "IND" ], "status": "pending", "priority": "high", "plain_title": "FDA cardiac warning on ibogaine causes split in synthetic drug approval", "plain_what": "The FDA will issue a cardiac safety warning about natural ibogaine, and this will push regulators to treat synthetic versions (engineered in labs to remove cardiac risk) differently\u2014approving or moving faster on the engineered versions while slowing natural ibogaine development. This creates a two-track system where the natural compound and its engineered cousins follow different FDA pathways." }, { "date": "2026-05-12", "title": "At least one U.S. Congressional committee will hold a public hearing specifically addressing FDA policy on ibogaine (including access, scheduling, or clinical trial pathways) before March 31, 2027.", "confidence": 55, "category": "legislation", "geography": "USA", "resolve_date": "2027-03-31", "tags": [ "ibogaine", "FDA", "veteran", "Congress" ], "status": "pending", "priority": "high", "plain_title": "Congress holds public hearing on FDA's ibogaine policy and access", "plain_what": "A U.S. Congressional committee will hold a public hearing asking the FDA to defend why Americans can't easily access ibogaine treatment, especially for veterans with PTSD and addiction. This matters because veterans are dying while accessing ibogaine overseas, creating political pressure for Congress to investigate regulatory roadblocks." }, { "date": "2026-05-12", "title": "At least one pre-registered multi-site replication trial of psilocybin's extinction-without-relapse-prevention mechanism in substance use disorder will be launched (registered on ClinicalTrials.gov or equivalent) before June 30, 2027.", "confidence": 52, "category": "research", "geography": "Global", "resolve_date": "2027-06-30", "tags": [ "psilocybin", "addiction", "clinical-trial", "replication" ], "status": "pending", "priority": "high", "plain_title": "Research team launches new psilocybin addiction study with clear science", "plain_what": "Scientists will register a new multi-site research study (publicly announced on ClinicalTrials.gov, the official trial registry) focused on understanding exactly how psilocybin helps people stop using cocaine or opioids. They'll pre-register their methods to prevent researchers from changing their approach after seeing results. This matters because it builds solid science on the mechanism (the actual biological how) rather than just whether it works." }, { "date": "2026-05-13", "title": "DEA will formally oppose any rescheduling petition for ibogaine before 2028, citing cardiac liability literature as sufficient scientific basis for continued Schedule I classification.", "confidence": 68, "category": "regulation", "geography": "USA", "resolve_date": "2028-01-01", "tags": [ "ibogaine", "DEA", "Schedule I" ], "status": "pending", "priority": "high", "plain_title": "DEA will formally reject any ibogaine rescheduling request by 2028", "plain_what": "The DEA (the US agency that controls which drugs are legal) will write an official letter saying no to any attempt to move ibogaine to a less restricted category. They'll point to medical studies showing the drug can damage the heart as their reason. This matters because it locks ibogaine out of legal medical use for years." }, { "date": "2026-05-13", "title": "No federal psychedelic scheduling reform legislation will reach a floor vote in either the House or Senate before November 2028.", "confidence": 78, "category": "legislation", "geography": "USA", "resolve_date": "2028-11-01", "tags": [ "ibogaine", "psychedelics", "scheduling reform" ], "status": "pending", "priority": "high", "plain_title": "No federal psychedelic law reform will reach a floor vote by end of 2028", "plain_what": "Congress won't bring any bill that loosens psychedelic drug rules to a formal floor vote in either the House or Senate before November 2028. Bills die quietly in committee because lawmakers and leadership haven't prioritized the issue, and new heart-safety data gives opponents ammunition to block progress." }, { "date": "2026-05-13", "title": "FDA will issue a formal safety communication or guidance document specifically addressing ibogaine cardiac risk before end of 2026.", "confidence": 42, "category": "regulation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "ibogaine", "FDA", "cardiac safety" ], "status": "pending", "priority": "high", "plain_title": "FDA will issue a cardiac safety warning on ibogaine by end of 2026", "plain_what": "The FDA (the US drug regulator) will publish a formal safety alert or guidance document specifically warning doctors and patients about ibogaine's risk of heart damage\u2014QT prolongation and abnormal heart rhythms. This matters because it's the federal signal that ibogaine is officially unsafe, making it even harder for researchers to run trials or for companies to develop it." }, { "date": "2026-05-13", "title": "Ibogaine will not achieve federal NDA approval or Schedule I rescheduling before January 1, 2028.", "confidence": 88, "category": "regulation", "geography": "USA", "resolve_date": "2028-01-01", "tags": [ "ibogaine", "NDA", "rescheduling" ], "status": "pending", "priority": "high", "plain_title": "Ibogaine won't get federal approval or rescheduling by early 2028", "plain_what": "Ibogaine will remain federally illegal and unapproved as a medicine through the start of 2028. The FDA doesn't approve drugs without successful large-scale trials, which don't exist for ibogaine. The DEA won't reschedule it without FDA approval or a solid legal petition. The timeline is simply too short." }, { "date": "2026-05-13", "title": "A noribogaine or ibogaine-analogue biotech will announce a financing round above $30M (Series A or B) before end of Q1 2027, with communications explicitly referencing ibogaine cardiac liability as validating the safer-analogue development thesis.", "confidence": 38, "category": "market", "geography": "Global", "resolve_date": "2027-03-31", "tags": [ "ibogaine", "noribogaine", "biotech", "venture capital" ], "status": "pending", "priority": "high", "plain_title": "A safer ibogaine alternative will raise over $30M by spring 2027", "plain_what": "A biotech company will announce a major funding round\u2014Series A or B, more than $30 million\u2014for a drug that's designed to be a safer version of ibogaine. The company will publicly explain that they're building this alternative because of new research showing ibogaine damages the heart. This matters because it shows investors believe the problem is real and the safer-drug solution is worth betting on." }, { "date": "2026-05-14", "title": "Ibogaine neuroplasticity mechanism generates at least 5 major peer-reviewed mechanistic studies AND 2 dedicated research consortia by end of 2027, independent of clinical regulatory outcomes.", "confidence": 62, "category": "research", "geography": "Global", "resolve_date": "2027-12-31", "tags": [ "ibogaine", "neuroplasticity", "basic-science" ], "status": "pending", "priority": "high", "plain_title": "Ibogaine plasticity research spawns 5+ studies and 2 consortia by 2027", "plain_what": "Scientists discover ibogaine resets the brain's ability to form new connections like a juvenile brain does. This finding is so interesting that researchers and funders will support at least 5 major published studies and create 2 dedicated research groups to explore it \u2014 even if the FDA never approves ibogaine as medicine. This matters because it opens a whole new way to think about how ibogaine works, separate from whether it's actually safe to use as treatment." }, { "date": "2026-05-14", "title": "FDA issues a formal Drug Safety Communication on ibogaine cardiac risk (QT prolongation, ventricular arrhythmia) by Q4 2026.", "confidence": 44, "category": "regulation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "ibogaine", "FDA", "cardiac-safety" ], "status": "pending", "priority": "high", "plain_title": "FDA issues formal cardiac safety warning on ibogaine by late 2026", "plain_what": "Three separate peer-reviewed studies have now identified that ibogaine can cause dangerous heart rhythm problems (QT prolongation and ventricular arrhythmia). When FDA (the US drug regulator) sees this kind of signal in published research, it typically issues a formal Drug Safety Communication warning doctors and the public. However, because ibogaine is currently Schedule I (completely illegal under federal law with no approved medical use), the FDA might decide it doesn't have to issue a formal warning \u2014 it's already illegal anyway. This matters because a formal warning carries legal weight and could influence state-level decisions about whether to allow ibogaine access." }, { "date": "2026-05-14", "title": "Ibogaine cardiac safety concerns produce a formal regulatory OR legislative response \u2014 FDA Safety Communication or congressional cardiac monitoring mandate \u2014 by end of 2026.", "confidence": 52, "category": "regulation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "ibogaine", "FDA", "cardiac-safety", "legislation" ], "status": "pending", "priority": "high", "plain_title": "Federal regulators or Congress formally address ibogaine cardiac safety by 2026", "plain_what": "Ibogaine's cardiac risks are real and documented in peer-reviewed research. A formal response could come from either the FDA (a safety warning), or from Congress (a new law requiring cardiac monitoring for ibogaine access), or from another federal health agency. This broader framing makes formal action more likely than an FDA-specific warning, because if cardiac risks keep accumulating in the research, Congress \u2014 especially veterans' advocates who want ibogaine access for addiction treatment \u2014 might step in and say \"we need cardiac monitoring requirements.\" This matters because it signals the US government is taking the safety issue seriously, which influences what states do." }, { "date": "2026-05-14", "title": "State-level psychedelic access legislation remains the primary U.S. policy vector through end of 2027, with at least one state (California most likely) enacting a regulated access framework ahead of any federal scheduling or approval action.", "confidence": 72, "category": "legislation", "geography": "USA", "resolve_date": "2027-12-31", "tags": [ "legislation", "California", "psychedelics", "state-policy" ], "status": "pending", "priority": "high", "plain_title": "States lead U.S. psychedelic policy ahead of federal action through 2027", "plain_what": "The federal government (the FDA and DEA) move slowly on approving new drugs \u2014 it takes 2+ years minimum, usually longer. Congress is gridlocked and doesn't move fast on drug policy. But individual states can act quickly. Oregon, Colorado, and especially California have bills moving through their legislatures right now to let people access psychedelics like psilocybin and MDMA under controlled, supervised conditions. It's very likely that at least one major state \u2014 probably California \u2014 will pass and implement a regulated psychedelic access framework before the FDA approves any psychedelic as medicine or before Congress changes federal drug law. This matters because it creates a real-world proof-of-concept that voters and other states will copy." }, { "date": "2026-05-15", "title": "FDA publishes formal guidance requiring cardiac monitoring infrastructure as prerequisite for ibogaine IND expansion or rescheduling petition before end of 2026", "confidence": 41, "category": "regulation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "ibogaine", "FDA", "cardiac-safety" ], "status": "pending", "priority": "high", "plain_title": "FDA publishes cardiac monitoring rules for ibogaine trials by end of 2026", "plain_what": "The FDA (the US drug regulator) will likely publish formal written guidance saying that anyone running clinical trials with ibogaine must have hospital-grade heart monitoring equipment. This matters because ibogaine can cause dangerous heart rhythm problems, and the FDA needs to document the safety rules before more people can test it." }, { "date": "2026-05-15", "title": "Formal federal regulatory or legislative language codifying hospital-grade cardiac monitoring as a prerequisite for any ibogaine access pathway is published before 2026-08-13", "confidence": 7, "category": "regulation", "geography": "USA", "resolve_date": "2026-08-13", "tags": [ "ibogaine", "cardiac-safety", "legislation" ], "status": "pending", "priority": "high", "plain_title": "Federal ibogaine cardiac monitoring rules written into law by August 2026", "plain_what": "Congress or a federal agency will write ibogaine heart-monitoring requirements into actual legal language by mid-August 2026. This is much less likely than FDA guidance alone because Congress moves slowly and there's no emergency forcing the issue." }, { "date": "2026-05-15", "title": "The dissociation between extinction and relapse-prevention in the cocaine psilocybin RCT becomes a primary mechanistic research focus, generating an identifiable sub-literature of at least 10 peer-reviewed papers on consolidation vs. extinction within 24 months of publication", "confidence": 62, "category": "research", "geography": "Global", "resolve_date": "2028-05-15", "tags": [ "psilocybin", "cocaine", "extinction", "consolidation", "mechanistic-research" ], "status": "pending", "priority": "high", "plain_title": "Psilocybin-cocaine study sparks 10+ papers on brain mechanisms within 2 years", "plain_what": "A clinical trial combining psilocybin with cocaine addiction treatment will show an unusual result: people's brains learn to stop craving cocaine, but they also don't relapse the way brain science predicts. This contradiction will be so interesting that scientists will publish at least 10 peer-reviewed papers in the next two years trying to explain which parts of the brain are really responsible." }, { "date": "2026-05-15", "title": "Ibogaine remains Schedule I through 2028 with no rescheduling petition advancing past initial DEA review", "confidence": 72, "category": "regulation", "geography": "USA", "resolve_date": "2028-12-31", "tags": [ "ibogaine", "DEA", "Schedule I", "rescheduling" ], "status": "pending", "priority": "high", "plain_title": "Ibogaine stays illegal Schedule I drug through 2028", "plain_what": "Ibogaine will remain a Schedule I controlled substance (the strictest category, meaning no approved medical use) through 2028 because the US government almost never moves drugs down from Schedule I. Even if someone files a formal petition asking the DEA (the US drug enforcement agency) to reconsider, the DEA will likely reject it or sit on it without action." }, { "date": "2026-05-15", "title": "At least $50M in new NIH and DARPA grant awards targeting ibogaine analog development and neuroplasticity mechanism characterization is announced within 18 months of 2026-05-15", "confidence": 38, "category": "research", "geography": "USA", "resolve_date": "2027-11-15", "tags": [ "ibogaine", "NIH", "DARPA", "neuroplasticity", "funding" ], "status": "pending", "priority": "high", "plain_title": "US government funds $50M+ ibogaine research and plasticity studies by late 2027", "plain_what": "The US government\u2014through the NIH (National Institutes of Health) or DARPA (the Defense Department's research agency)\u2014will announce at least $50 million in new research grants for ibogaine and brain plasticity studies by late 2027. This matters because government funding signals that ibogaine is moving from fringe to mainstream science, and the money enables labs to do expensive mechanistic research." }, { "date": "2026-05-16", "title": "FDA will issue formal ibogaine cardiac safety guidance requiring mandatory cardiac screening protocols before any IND expansion, delaying veteran-focused trials by 12-18 months", "confidence": 62, "category": "regulatory", "geography": "USA", "resolve_date": "2027-03-01", "tags": [ "ibogaine", "FDA", "veteran" ], "status": "pending", "priority": "high", "plain_title": "FDA demands heart screening before ibogaine trials expand", "plain_what": "The FDA (US drug regulator) will require companies to do cardiac screening tests before expanding ibogaine studies, because recent research shows ibogaine can affect heart rhythm. This slows down trials \u2014 especially ones for veterans \u2014 by over a year." }, { "date": "2026-05-16", "title": "At least three non-hallucinogenic structural ibogaine analogues will enter preclinical development within 36 months, driven by neuroplasticity mechanism findings", "confidence": 61, "category": "research", "geography": "Global", "resolve_date": "2029-05-01", "tags": [ "ibogaine", "neuroplasticity", "drug-development" ], "status": "pending", "priority": "high", "plain_title": "Three non-psychedelic ibogaine drugs will start lab testing", "plain_what": "Researchers will start developing versions of ibogaine that don't make you hallucinate but keep the healing effects by targeting brain plasticity. Companies will invest in these because they're easier to regulate and market." }, { "date": "2026-05-16", "title": "At least two sponsors will submit accelerated approval pathway applications to FDA for psilocybin-based therapies by November 2027", "confidence": 38, "category": "regulatory", "geography": "USA", "resolve_date": "2027-11-01", "tags": [ "psilocybin", "FDA", "clinical-trials" ], "status": "pending", "priority": "high", "plain_title": "Two companies will ask FDA for fast-track psilocybin approval", "plain_what": "Psilocybin therapy companies have good clinical trial data on depression and suicidal thoughts. Two of them will ask the FDA (US drug regulator) for an expedited approval process called 'accelerated approval,' which is faster than normal. But the FDA may say no because of how hard it is to run psilocybin trials fairly." }, { "date": "2026-05-16", "title": "A formal congressional study commission on psychedelic medicine will be established via NDAA or standalone legislation before end of 2026, but no scheduling or prescribing legislation will pass before 2028", "confidence": 58, "category": "legislation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "legislation", "NDAA", "psychedelics" ], "status": "pending", "priority": "high", "plain_title": "Congress forms psychedelic study group before 2027, no laws until 2028", "plain_what": "Congress will create an official commission to study psychedelic medicine\u2014likely tucked into the National Defense Authorization Act (NDAA), which funds the military\u2014because both parties like supporting veterans. But nobody will actually change drug laws or let doctors prescribe psychedelics before 2028." }, { "date": "2026-05-17", "title": "At least 5 NIH-funded mechanistic follow-up studies on ibogaine's neural plasticity mechanism will be awarded within 2 years, with at least one study explicitly targeting non-hallucinogenic analogue development.", "confidence": 55, "category": "research", "geography": "USA", "resolve_date": "2028-05-17", "tags": [ "ibogaine", "NIH", "plasticity" ], "status": "pending", "priority": "high", "plain_title": "NIH funds 5+ ibogaine brain studies within 2 years, including non-hallucinogenic versions", "plain_what": "The US government's National Institutes of Health (NIH) will award at least 5 research grants studying how ibogaine changes the brain and how scientists might create similar drugs without the psychedelic effects. This matters because it signals that federal science institutions see real promise in ibogaine as a medicine, not just a drug of abuse." }, { "date": "2026-05-17", "title": "The cocaine-psilocybin 'extinction without relapse prevention' finding will be cited by name in at least 3 pieces of formal anti-psychedelic congressional testimony or submitted written statements within 12 months of publication.", "confidence": 28, "category": "legislation", "geography": "USA", "resolve_date": "2027-05-17", "tags": [ "psilocybin", "cocaine", "congress" ], "status": "pending", "priority": "medium", "plain_title": "Anti-drug politicians cite psilocybin-cocaine study in congressional testimony within 12 months", "plain_what": "A recent study found that psilocybin might help people with cocaine addiction by erasing addiction memories without preventing relapse\u2014a genuine finding that critics of psychedelics could use in Congress. The prediction is that at least 3 formal pieces of congressional testimony or written statements will specifically name and cite this study to argue against psychedelic legalization within one year of publication." }, { "date": "2026-05-17", "title": "FDA will issue formal written cardiac safety guidance or a mandatory cardiac screening requirement specifically for ibogaine INDs before June 2027, materially delaying at least one active veteran access program.", "confidence": 52, "category": "regulatory", "geography": "USA", "resolve_date": "2027-06-01", "tags": [ "ibogaine", "FDA", "cardiac", "veteran" ], "status": "pending", "priority": "high", "plain_title": "FDA requires heart screening for ibogaine before therapeutic programs start", "plain_what": "Ibogaine can affect the heart's electrical rhythm, which worries regulators. The FDA may issue formal written safety requirements that anyone using ibogaine in a clinical program must have their heart tested first. This would slow down at least one current ibogaine program by at least 18 months because they'd have to add new testing requirements and get FDA approval for the changes." }, { "date": "2026-05-17", "title": "Mandatory federal cardiac safety protocols for ibogaine will be required before any regulated U.S. therapeutic access program launches, causing delays of at least 18 months beyond currently projected timelines.", "confidence": 18, "category": "regulatory", "geography": "USA", "resolve_date": "2026-08-15", "tags": [ "ibogaine", "cardiac", "FDA" ], "status": "pending", "priority": "high", "plain_title": "Federal ibogaine cardiac safety rules delay therapeutic access by 18+ months", "plain_what": "Before the FDA allows any legal therapeutic ibogaine program in the US, federal regulators may require mandatory cardiac safety protocols (heart tests and screening). This prediction says such rules will exist and will push back timelines for at least one active program trying to help veterans get access to ibogaine by at least 18 months from current projections." }, { "date": "2026-05-17", "title": "No psychedelic substance (psilocybin, MDMA, ibogaine, ketamine analogues, or LSD) will be federally rescheduled from Schedule I in the United States before January 1, 2028.", "confidence": 82, "category": "regulatory", "geography": "USA", "resolve_date": "2028-01-01", "tags": [ "rescheduling", "DEA", "FDA", "psilocybin", "MDMA", "ibogaine" ], "status": "pending", "priority": "high", "plain_title": "No psychedelic drug becomes legal medicine in US before 2028", "plain_what": "Psilocybin, MDMA, ibogaine, ketamine-like drugs, or LSD will not be moved from Schedule I (the DEA's most restrictive category for illegal drugs with no medical use) to a lower schedule by the US government before January 1, 2028. This matters because as long as they stay Schedule I, doctors cannot prescribe them legally, even in clinical trials, even if they work." }, { "date": "2026-05-17", "title": "Psychedelic biotech sector equities (as measured by a basket of publicly traded psychedelic companies) will show negative or flat returns through Q4 2026 absent a concrete FDA approval or positive advisory committee vote for a psychedelic compound.", "confidence": 68, "category": "market", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "biotech", "equities", "FDA", "psychedelics" ], "status": "pending", "priority": "high", "plain_title": "Psychedelic company stocks stay flat or lose money through 2026", "plain_what": "Publicly traded companies that develop psychedelic medicines will have negative or flat stock returns through the end of 2026 unless the FDA approves a psychedelic medicine or an FDA advisory committee votes to recommend approval. This matters because it signals whether investors believe these companies will succeed or whether the FDA rejection of MDMA has killed momentum." }, { "date": "2026-05-18", "title": "FDA will issue formal ibogaine cardiac safety guidance requiring mandatory cardiac screening protocols before any IND approval proceeds, by Q1 2027.", "confidence": 82, "category": "regulation", "geography": "USA", "resolve_date": "2027-03-31", "tags": [ "ibogaine", "FDA" ], "status": "pending", "priority": "high", "plain_title": "FDA will require heart screening before approving ibogaine studies", "plain_what": "The FDA (the US drug regulator) will write formal rules saying anyone testing ibogaine must get heart tests first, because recent research shows ibogaine can cause dangerous heart rhythms. This matters because it slows down ibogaine research but protects people from cardiac injury." }, { "date": "2026-05-18", "title": "Psilocybin cocaine RCT extinction-without-relapse-prevention finding will generate 3+ follow-up mechanistic studies within 18 months investigating default mode network suppression during extinction learning.", "confidence": 79, "category": "research", "geography": "Global", "resolve_date": "2027-11-18", "tags": [ "psilocybin" ], "status": "pending", "priority": "high", "plain_title": "Researchers will study why psilocybin blocks cocaine relapse so effectively", "plain_what": "Scientists just found that psilocybin (the active compound in magic mushrooms) helps people learn to stop craving cocaine without needing the usual relapse prevention therapy. Neuroscientists will now run 3+ new studies to figure out exactly which brain circuits make this work, because it's a genuinely novel mechanism that could unlock new addiction treatments." }, { "date": "2026-05-18", "title": "Senate Veterans Affairs Committee will hold ibogaine-specific hearings with Stanford researchers testifying before September 2026.", "confidence": 78, "category": "legislation", "geography": "USA", "resolve_date": "2026-09-30", "tags": [ "ibogaine", "veteran" ], "status": "pending", "priority": "high", "plain_title": "Senate will hold ibogaine hearings with Stanford researchers by September 2026", "plain_what": "The US Senate Committee that oversees veterans healthcare will hold public hearings specifically about ibogaine for addiction treatment, with Stanford researchers presenting evidence. This happens because veterans are advocating for ibogaine access and senators need to understand both the promise and the recent cardiac safety concerns before they act." }, { "date": "2026-05-18", "title": "A major investigative piece linking ibogaine cardiac deaths specifically to veteran treatment programs will publish in a top-tier outlet before August 2026.", "confidence": 76, "category": "culture", "geography": "USA", "resolve_date": "2026-08-01", "tags": [ "ibogaine", "DEA", "veteran" ], "status": "pending", "priority": "high", "plain_title": "Major news outlet will expose ibogaine cardiac deaths in veteran programs", "plain_what": "A major investigative journalist will publish a detailed story in a top-tier news outlet linking deaths from ibogaine-related heart problems specifically to veteran treatment programs. This story will combine new research on QT prolongation (heart rhythm danger) with opioid interaction risks, creating enough concrete evidence that editors will green-light the investigation." }, { "date": "2026-05-18", "title": "CMPS will outperform MMED by at least 15% on a 6-month basis as psilocybin depression RCT data is absorbed by institutional allocators.", "confidence": 74, "category": "market", "geography": "Global", "resolve_date": "2026-11-18", "tags": [ "psilocybin", "depression" ], "status": "pending", "priority": "medium", "plain_title": "Compass stock outperforms MindMed on psilocybin depression data", "plain_what": "Compass Pathways' stock will perform better than MindMed's stock (by at least 15% over 6 months) because Compass just published strong depression trial results, while MindMed has weaker clinical data. Institutional money managers follow randomized controlled trial results, not hype\u2014and Compass has cleaner evidence in a validated indication (depression)." }, { "date": "2026-05-18", "title": "Psilocybin will receive Breakthrough Therapy Designation for cocaine use disorder within 12 months based on today's RCT data.", "confidence": 71, "category": "regulation", "geography": "Global", "resolve_date": "2027-05-18", "tags": [ "psilocybin" ], "status": "pending", "priority": "medium", "plain_title": "", "plain_what": "" }, { "date": "2026-05-18", "title": "California will enact a regulated psilocybin therapy framework by end of 2027, becoming the largest state-sanctioned psychedelic therapy market.", "confidence": 70, "category": "legislation", "geography": "Global", "resolve_date": "2027-12-31", "tags": [ "psilocybin", "California", "market" ], "status": "pending", "priority": "medium", "plain_title": "", "plain_what": "" }, { "date": "2026-05-19", "title": "The psilocybin cocaine RCT will be significantly misrepresented in at least three major mainstream media outlets within 72 hours of publication, and a researcher-led public correction effort will itself generate coverage framing psychedelic science as prone to hype cycles", "confidence": 62, "category": "culture", "geography": "Global", "resolve_date": "2026-05-22", "tags": [ "psilocybin", "media", "cocaine", "RCT", "science-communication" ], "status": "pending", "priority": "high", "plain_title": "Psilocybin-cocaine study gets mangled in 72 hours, then correction itself becomes a credibility scandal", "plain_what": "When researchers publish a surprising finding about psilocybin and cocaine addiction, mainstream news outlets will oversimplify or misrepresent the actual results within three days. When scientists try to publicly correct these errors, journalists will frame the whole situation as evidence that psychedelic science hypes itself up\u2014turning the correction effort into another credibility problem instead of fixing the original one." }, { "date": "2026-05-19", "title": "Ibogaine will remain Schedule I through December 31, 2029, with DEA's 8-factor analysis citing cardiac liability as sufficient procedural basis to deny rescheduling despite active IND filings and veteran advocacy pressure", "confidence": 71, "category": "regulation", "geography": "USA", "resolve_date": "2029-12-31", "tags": [ "ibogaine", "DEA", "Schedule I", "cardiac", "veteran", "rescheduling" ], "status": "pending", "priority": "high", "plain_title": "Ibogaine stays illegal through 2029 because of heart risks, despite veteran pressure", "plain_what": "Ibogaine\u2014a West African plant used by some to treat addiction\u2014will remain a Schedule I controlled substance (meaning illegal with no accepted medical use) through the end of 2029. The DEA (the US drug enforcement agency) will cite documented cardiac (heart) dangers as their reason to reject rescheduling, even though veterans and activists push hard for legal access and companies are already running FDA (US drug regulator) approved clinical trials." }, { "date": "2026-05-19", "title": "CMPS (Compass Pathways) will not recover above $12.50 by August 19, 2026, confirming that publication volume is not an investable catalyst and only binary FDA events or M&A signals move institutional psychedelic capital", "confidence": 67, "category": "market", "geography": "USA", "resolve_date": "2026-08-19", "tags": [ "CMPS", "Compass Pathways", "psychedelic", "biotech", "FDA", "institutional-capital" ], "status": "pending", "priority": "high", "plain_title": "Compass Pathways stock won't bounce back above $12.50 by August 2026", "plain_what": "Compass Pathways (CMPS)\u2014a company developing psilocybin therapy\u2014will not see its stock price climb back above $12.50 by mid-August 2026. This matters because it shows that publishing research papers and positive clinical results alone don't move stock prices anymore. Only big announcements (FDA approval meetings, or one company buying another) actually make institutional investors (the big money players) move." }, { "date": "2026-05-20", "title": "Psilocybin will remain Schedule I through end of 2027, as no NDA has been filed and DEA rescheduling requires completion of a formal administrative process that FDA approval would trigger but publication volume cannot accelerate.", "confidence": 88, "category": "regulatory", "geography": "USA", "resolve_date": "2027-12-31", "tags": [ "psilocybin", "DEA", "Schedule I", "rescheduling" ], "status": "pending", "priority": "high", "plain_title": "Psilocybin stays illegal until at least end of 2027", "plain_what": "Psilocybin will almost certainly remain a Schedule I drug (illegal with no accepted medical use) through 2027 because no company has yet filed an NDA (the FDA application required to approve a new drug). Even after an NDA is approved, the DEA (the federal agency that controls drug legality) needs 12-24+ months to formally change psilocybin's legal status. Since the clock hasn't even started, rescheduling by 2028 is unlikely." }, { "date": "2026-05-20", "title": "At least one major mainstream US news outlet will publish a headline characterizing the cocaine use disorder psilocybin RCT results as evidence that 'psychedelics cure addiction' within 30 days of publication, followed by a correction cycle that complicates congressional messaging.", "confidence": 78, "category": "culture", "geography": "USA", "resolve_date": "2026-06-20", "tags": [ "psilocybin", "addiction", "media", "cocaine use disorder" ], "status": "pending", "priority": "high", "plain_title": "Major news will hype psilocybin addiction cure, then quietly correct", "plain_what": "When researchers announce that psilocybin helped people quit cocaine, major news outlets will publish headlines saying psychedelics 'cure addiction'\u2014even though the actual finding is much narrower (psilocybin reduced cravings in one study). Within 2-4 weeks, scientists and careful reporters will publish corrections and pushback. This cycle confuses the public and makes Congress skeptical of psychedelic funding." }, { "date": "2026-05-20", "title": "A psilocybin NDA for treatment-resistant MDD will be filed with the FDA by COMPASS Pathways or a direct competitor by November 2027, citing recent RCT data as supportive evidence alongside existing Phase 3 results.", "confidence": 62, "category": "regulatory", "geography": "USA", "resolve_date": "2027-11-30", "tags": [ "psilocybin", "COMPASS", "NDA", "treatment-resistant MDD", "Phase 3" ], "status": "pending", "priority": "high", "plain_title": "Psilocybin NDA filed for depression treatment by late 2027", "plain_what": "COMPASS Pathways or a competitor will likely submit an NDA (formal approval application) to the FDA by November 2027 for psilocybin as a treatment for severe depression that doesn't respond to other drugs. They have completed Phase 3 trials (the final human testing stage) and have publicly said they're preparing the application. This doesn't mean psilocybin will be approved or legal yet\u2014just that the formal FDA review process will begin." }, { "date": "2026-05-20", "title": "The ibogaine juvenile plasticity finding will generate at least 3 NIH R01 grant awards (not merely applications) specifically targeting critical period plasticity mechanisms within 18 months of May 2026.", "confidence": 38, "category": "research", "geography": "USA", "resolve_date": "2027-11-20", "tags": [ "ibogaine", "NIH", "critical period plasticity", "R01", "neuroscience funding" ], "status": "pending", "priority": "high", "plain_title": "Ibogaine brain plasticity finding sparks three NIH grants", "plain_what": "A recent discovery that ibogaine (a psychedelic) can reopen brain plasticity windows in adults is so important that the NIH (US medical research agency) will likely fund at least three R01 grants (major research awards) specifically to study how this works. This is aggressive because NIH typically funds only 1 in 5 grant proposals, and the finding needs time to get recognized and peer-reviewed. Within 18 months of May 2026 (by late 2027) is the deadline." }, { "date": "2026-05-21", "title": "FDA will formally require prospective cardiac monitoring REMS as a non-negotiable precondition for any ibogaine IND approval in veteran-access programs by Q1 2027", "confidence": 72, "category": "regulation", "geography": "USA", "resolve_date": "2027-03-01", "tags": [ "ibogaine", "FDA", "REMS", "veteran", "cardiac" ], "status": "pending", "priority": "high", "plain_title": "FDA will require heart monitoring for ibogaine veteran programs by early 2027", "plain_what": "The FDA (the US drug regulator) will make cardiac monitoring a non-negotiable requirement before approving ibogaine for veterans. Recent safety studies show ibogaine can cause heart problems, so the FDA will use formal risk management agreements to ensure hospitals monitor patients' hearts. This matters because it affects whether veterans can legally access ibogaine for PTSD and addiction through approved channels." }, { "date": "2026-05-21", "title": "The number of identifiable US-based or Mexico/Caribbean-based retreats explicitly marketing to US veterans for ibogaine treatment will be at least 40% higher than current baseline by 2027-05-21", "confidence": 63, "category": "market", "geography": "USA", "resolve_date": "2027-05-21", "tags": [ "ibogaine", "veteran", "gray-market", "retreats", "demand" ], "status": "pending", "priority": "high", "plain_title": "US ibogaine retreats marketing to veterans will grow 40% by mid-2027", "plain_what": "The number of treatment retreats in the US and nearby countries (Mexico, Caribbean islands) that explicitly market ibogaine to US veterans will jump by at least 40%. Veterans hear about positive results from other vets through social media and informal networks, and many don't want to wait for the slow FDA approval process. This matters because unregulated retreats have no safety oversight." }, { "date": "2026-05-21", "title": "A documented fatality at a US-based or US-citizen-attended gray-market ibogaine retreat will receive national mainstream media coverage and prompt at least one congressional hearing within 12 months", "confidence": 61, "category": "regulation", "geography": "USA", "resolve_date": "2026-05-21", "tags": [ "ibogaine", "gray-market", "fatality", "congress", "veteran" ], "status": "pending", "priority": "high", "plain_title": "A death at an unregulated ibogaine retreat will trigger congressional investigation", "plain_what": "Someone will die at an ibogaine retreat that operates without FDA oversight, and that death will make national news and spark a congressional hearing. Ibogaine can cause serious heart problems, and many retreats don't have cardiac monitoring. Veterans seeking treatment have additional heart risks from injuries and medication use. When a high-profile death occurs, Congress will demand answers about why this treatment isn't regulated." }, { "date": "2026-05-21", "title": "At least one major pharmaceutical company (top-20 by revenue) will announce a psilocybin licensing deal or acquisition of COMPASS Pathways or ATAI Life Sciences by 2027-02-21", "confidence": 52, "category": "market", "geography": "USA", "resolve_date": "2027-02-21", "tags": [ "psilocybin", "pharma", "COMPASS", "ATAI", "acquisition" ], "status": "pending", "priority": "medium", "plain_title": "A major pharmaceutical company will acquire a psilocybin psychedelic firm by early 2027", "plain_what": "One of the world's twenty largest drug companies will buy or license psilocybin (the active compound in magic mushrooms) from COMPASS Pathways or ATAI Life Sciences, the two main public companies developing it. These companies have successful clinical trial results that prove psilocybin works for depression and other conditions. Big pharma sees that their old product lines are running out of patent protection, so they're buying new breakthrough treatments. This matters because it means psilocybin could become a mainstream medicine." }, { "date": "2026-05-21", "title": "At least three NIH R01 or equivalent grant applications explicitly targeting ibogaine's cortical plasticity mechanism in non-addiction CNS indications (amblyopia, stroke, TBI) will be funded within 18 months", "confidence": 48, "category": "research", "geography": "USA", "resolve_date": "2026-11-21", "tags": [ "ibogaine", "NIH", "plasticity", "TBI", "stroke", "amblyopia" ], "status": "pending", "priority": "medium", "plain_title": "NIH will fund at least three ibogaine plasticity research grants within 18 months", "plain_what": "The National Institutes of Health (NIH, the US government's medical research agency) will award at least three major research grants focused on how ibogaine helps the brain rebuild neural connections in conditions like amblyopia (lazy eye), stroke, and traumatic brain injury. These studies are scientifically straightforward and don't involve addiction treatment, which makes them less politically controversial. This matters because government funding legitimizes the research and could open new medical uses." }, { "date": "2026-05-22", "title": "FDA will issue formal guidance requiring mandatory cardiac monitoring protocols for ibogaine INDs before end of 2026", "confidence": 72, "category": "regulation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "ibogaine", "FDA", "cardiac", "IND" ], "status": "pending", "priority": "high", "plain_title": "FDA requires heart monitoring for ibogaine clinical trials by end of 2026", "plain_what": "The FDA (the US drug regulator) will publish formal written guidance saying that any scientist testing ibogaine must monitor patients' hearts for dangerous rhythm problems. This matters because ibogaine can affect heart electrical activity, and the FDA has the data to back up this requirement\u2014it just needs to publish the rule." }, { "date": "2026-05-22", "title": "Veterans will be the named beneficiary population in the majority of psychedelic access bills introduced in US state legislatures in 2026, with ibogaine bills outnumbering psilocybin or MDMA bills", "confidence": 68, "category": "legislation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "ibogaine", "psilocybin", "MDMA", "legislation", "veteran" ], "status": "pending", "priority": "high", "plain_title": "Most new state psychedelic bills in 2026 target veterans with ibogaine", "plain_what": "When state lawmakers introduce new bills about psychedelic access in 2026, most will specifically name veterans with PTSD or traumatic brain injury as the target group\u2014and more will mention ibogaine than psilocybin or MDMA. This matters because it shows where political energy is moving: away from broad public access and toward a narrow, bipartisan coalition around veteran treatment." }, { "date": "2026-05-22", "title": "DEA will initiate at least two publicly announced enforcement actions against unlicensed psychedelic clinic operators before end of 2026", "confidence": 65, "category": "regulation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "psilocybin", "ketamine", "DEA", "enforcement", "Schedule I" ], "status": "pending", "priority": "high", "plain_title": "DEA will publicly charge at least two unlicensed psychedelic clinics by end of 2026", "plain_what": "The DEA (US drug enforcement agency) will announce at least two enforcement actions against clinics operating without proper registration or licenses to give psychedelic drugs. This matters because as states create new psilocybin and ketamine clinics, many operators skip DEA paperwork, and the agency needs to show it's still relevant and enforcing rules." }, { "date": "2026-05-22", "title": "No new psychedelic compound will receive FDA Breakthrough Therapy Designation in 2026", "confidence": 61, "category": "regulation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "FDA", "breakthrough therapy", "psilocybin", "MDMA", "ibogaine" ], "status": "pending", "priority": "medium", "plain_title": "No new psychedelic will get FDA fast-track approval status in 2026", "plain_what": "No psychedelic drug will earn Breakthrough Therapy Designation (a special FDA fast-track label) in 2026. This matters because it shows that the FDA's skepticism is real and growing\u2014the agency is now scrutinizing whether trial results are actually solid or just reflect placebo effects and experimenter bias." }, { "date": "2026-05-22", "title": "At least two US states will enact Right-to-Try or expanded access legislation explicitly naming ibogaine for veteran PTSD or TBI treatment before 2027-07-01", "confidence": 52, "category": "legislation", "geography": "USA", "resolve_date": "2027-06-30", "tags": [ "ibogaine", "right-to-try", "veteran", "state legislation" ], "status": "pending", "priority": "high", "plain_title": "Two states will pass ibogaine access laws for veterans before July 2027", "plain_what": "At least two US states will pass laws allowing veterans with PTSD or traumatic brain injury to access ibogaine outside normal FDA clinical trial rules (called right-to-try or expanded access). This matters because state legislatures can move faster than federal agencies, and the veteran community has real political power\u2014both conservative and liberal lawmakers support veteran access to new treatments." }, { "date": "2026-05-23", "title": "Mainstream media will materially misrepresent at least one psilocybin RCT finding published in May 2026 within 60 days, with a named researcher publicly issuing a correction request by August 21, 2026.", "confidence": 78, "category": "culture", "geography": "Global", "resolve_date": "2026-07-22", "tags": [ "psilocybin", "media", "research-communication" ], "status": "pending", "priority": "high", "plain_title": "News outlet will badly distort a psilocybin study finding by August 2026", "plain_what": "A major news organization will publish a misleading headline or story about a psilocybin research study released in May 2026. A scientist involved in the research will publicly ask for a correction. This happens because journalists often oversimplify complicated study results to meet deadlines, and the science here involves tricky distinctions that are easy to flatten into false claims." }, { "date": "2026-05-23", "title": "DEA will submit formal written opposition to any NDAA ibogaine veteran access amendment before the Senate Armed Services Committee markup, citing cardiac safety data and Schedule I diversion risk.", "confidence": 76, "category": "legislation", "geography": "USA", "resolve_date": "2026-09-01", "tags": [ "ibogaine", "DEA", "veteran", "NDAA" ], "status": "pending", "priority": "high", "plain_title": "DEA will formally oppose letting military veterans access ibogaine", "plain_what": "Congress may try to let military veterans use ibogaine (an illegal plant medicine) to treat addiction or PTSD through a special amendment. The DEA (the US drug enforcement agency) will file official written testimony against this, citing two concerns: ibogaine can cause dangerous heart rhythm changes, and people might illegally sell it. The DEA does this routinely when Congress tries to bypass normal drug approval channels." }, { "date": "2026-05-23", "title": "Ibogaine cardiac safety will remain the primary stated regulatory bottleneck blocking IND expansion in the US through June 30, 2027, with no FDA formal guidance issued permitting expanded ibogaine trials without mandatory cardiac monitoring protocols.", "confidence": 74, "category": "regulatory", "geography": "USA", "resolve_date": "2027-06-30", "tags": [ "ibogaine", "FDA", "cardiac-safety", "regulatory" ], "status": "pending", "priority": "high", "plain_title": "FDA will keep requiring heart monitoring for ibogaine trials through mid-2027", "plain_what": "Ibogaine is a powerful plant medicine that can affect heart rhythm (a condition called QTc prolongation that can cause sudden cardiac death). The FDA (the US drug regulator) requires anyone running an ibogaine clinical trial to monitor patients' hearts carefully. Until June 30, 2027, the FDA will not issue new written guidance that lets researchers skip or reduce heart monitoring, even though heart monitoring makes trials expensive and hard to run at scale." }, { "date": "2026-05-23", "title": "The ibogaine visual cortex plasticity finding will be cited by at least 5 peer-reviewed mechanistic studies at independent institutions by May 23, 2027, expanding ibogaine's scientific framing beyond addiction.", "confidence": 62, "category": "research", "geography": "Global", "resolve_date": "2027-05-23", "tags": [ "ibogaine", "neuroplasticity", "research" ], "status": "pending", "priority": "medium", "plain_title": "Scientists will cite ibogaine brain plasticity finding in five new studies by May 2027", "plain_what": "A recent study found that ibogaine can make the adult brain behave like a young brain (increasing neuroplasticity, or the brain's ability to rewire itself). Over the next 18 months, at least five independent research groups at different institutions will publish their own studies citing this finding. They'll explore whether this brain-rewiring effect could help with other conditions like lazy eye (amblyopia), PTSD, or stroke recovery \u2014 not just addiction." }, { "date": "2026-05-23", "title": "A major mainstream outlet (top-50 US or UK publication by traffic) will publish a feature conflating psilocybin cocaine use disorder trial findings with recreational microdosing trends by July 7, 2026, generating at least one named researcher publicly objecting within 14 days of publication.", "confidence": 48, "category": "culture", "geography": "Global", "resolve_date": "2026-07-07", "tags": [ "psilocybin", "microdosing", "media" ], "status": "pending", "priority": "medium", "plain_title": "Major news outlet will confuse psilocybin addiction research with recreational microdosing by July 2026", "plain_what": "A major news organization will publish a feature story that mixes up two completely different things: (1) a clinical trial using psilocybin to treat cocaine addiction through a specific mechanism called extinction learning, and (2) people taking tiny doses of psilocybin recreationally. The outlet will imply they work the same way because both involve psilocybin and 'brain change.' A named researcher will publicly object within two weeks." }, { "date": "2026-05-24", "title": "Psilocybin remains federally Schedule I in the USA through December 31, 2028.", "confidence": 85, "category": "regulation", "geography": "USA", "resolve_date": "2028-12-31", "tags": [ "psilocybin", "Schedule I", "DEA", "rescheduling" ], "status": "pending", "priority": "high", "plain_title": "Psilocybin stays illegal at federal level through 2028", "plain_what": "The U.S. federal government will keep psilocybin classified as Schedule I (most dangerous, no medical use) through the end of 2028. This matters because even if your state allows it, federal law still applies \u2014 you can still face federal charges, and banks won't touch businesses selling it. Moving psilocybin to a lower schedule requires the FDA (the U.S. drug regulator) to approve it as medicine first, then the DEA (the federal drug enforcement agency) to officially change its category, a process that takes years even after FDA approval." }, { "date": "2026-05-24", "title": "No U.S. state beyond Oregon and Colorado enacts a legal therapeutic psilocybin access framework (not just decriminalization) signed into law before January 1, 2028.", "confidence": 72, "category": "regulation", "geography": "USA", "resolve_date": "2027-12-31", "tags": [ "psilocybin", "state law", "therapeutic access", "legalization" ], "status": "pending", "priority": "high", "plain_title": "Only Oregon and Colorado approve legal psilocybin therapy by 2028", "plain_what": "No other U.S. state will pass a law creating a legal framework for people to access psilocybin therapy (not just decriminalization, but an actual licensed system) before January 2028. This matters because it determines whether your state offers any legal route to the treatment. Oregon and Colorado are moving slowly and hitting real problems setting up their systems, which is cooling other states' enthusiasm. Most states are in a 'let's wait and see how this goes' mode rather than drafting their own laws." }, { "date": "2026-05-24", "title": "At least three peer-reviewed papers on psychedelic neuroplasticity mechanisms are published in Nature-family or Cell-family journals in calendar year 2026.", "confidence": 65, "category": "research", "geography": "Global", "resolve_date": "2026-12-31", "tags": [ "neuroplasticity", "psilocybin", "peer-reviewed", "Nature", "Cell", "basic science" ], "status": "pending", "priority": "medium", "plain_title": "Three major science journals publish psychedelic brain research in 2026", "plain_what": "Three or more papers explaining exactly how psychedelics change the brain will appear in the world's most prestigious science journals (Nature Neuroscience, Nature Medicine, Cell, or Neuron) in calendar year 2026. This matters because these papers establish the biological mechanism \u2014 the proof that these drugs actually rewire brain circuits in real, measurable ways. This evidence builds the case for medical use and attracts serious research funding." }, { "date": "2026-05-24", "title": "At least one Phase 3 psychedelic trial (psilocybin for MDD or a supplemental MDMA-PTSD study) reports a statistically significant primary endpoint result by December 31, 2026.", "confidence": 62, "category": "research", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "psilocybin", "MDMA", "Phase 3", "clinical trial", "MDD", "PTSD" ], "status": "pending", "priority": "high", "plain_title": "A Phase 3 psychedelic trial hits its main goal by late 2026", "plain_what": "At least one large final-stage clinical trial testing psilocybin for depression or MDMA (a related psychedelic) for PTSD will report that the drug actually works as hoped by the end of 2026. This matters because Phase 3 trials are the final hurdle before the FDA decides whether to approve a drug for doctors to prescribe. If one succeeds, it proves the drug works, brings approval closer, and validates the whole industry's approach." }, { "date": "2026-05-24", "title": "Psychedelic therapy research provisions are included in the FY2027 NDAA or a VA appropriations bill passed by December 15, 2026.", "confidence": 58, "category": "legislation", "geography": "USA", "resolve_date": "2026-12-15", "tags": [ "legislation", "veteran", "NDAA", "VA", "psychedelic research" ], "status": "pending", "priority": "medium", "plain_title": "Congress funds psychedelic research for veterans by late 2026", "plain_what": "The U.S. Congress will approve money to fund psychedelic research for veterans \u2014 likely by tucking it into a must-pass military spending bill (the National Defense Authorization Act, or NDAA) or a Veterans Administration budget bill by mid-December 2026. This matters because Congress has already done this twice (in 2022 and 2023), showing veteran psychedelic research has real legislative support. Money means trials start, evidence accumulates, and veterans get earlier access to potential treatments." }, { "date": "2026-05-25", "title": "FDA issues a Complete Response Letter for MDMA-assisted therapy, citing inadequate blinding controls and therapist fidelity data, requiring at least one additional trial before resubmission.", "confidence": 74, "category": "regulatory", "geography": "USA", "resolve_date": "2026-09-30", "tags": [ "MDMA", "FDA", "MDMA-AT", "CRL" ], "status": "pending", "priority": "high", "plain_title": "FDA rejects MDMA therapy, demands another trial on blinding", "plain_what": "The FDA (the US drug regulator) will send back Lykos's MDMA-assisted therapy application with a Complete Response Letter \u2014 a formal rejection. The FDA will specifically cite two problems: the study wasn't properly blinded (meaning patients and therapists might have known who got real MDMA vs. placebo), and they don't have enough data on whether therapists followed the protocol consistently. This matters because it delays MDMA therapy by 3-5 years and signals the FDA is tightening its standards after the messy Lykos approval fight last year." }, { "date": "2026-05-25", "title": "Stanford's DOD-funded ibogaine veteran trial will publicly release preliminary outcomes data by Q3 2026, directly cited in at least one congressional hearing or formal Senate briefing.", "confidence": 72, "category": "research", "geography": "USA", "resolve_date": "2026-09-30", "tags": [ "ibogaine", "veteran", "Stanford", "Congress" ], "status": "pending", "priority": "high", "plain_title": "Stanford's ibogaine study releases veteran outcomes by mid-2026", "plain_what": "Stanford University, funded by the US Department of Defense (DOD), is running a trial of ibogaine for military veterans with PTSD and substance use disorder. By Q3 2026 (summer/fall), they will publish early results showing whether ibogaine actually helps these veterans. This matters because veterans' groups and their congressional allies are waiting for this data to push for policy change \u2014 ibogaine is currently illegal in the US." }, { "date": "2026-05-25", "title": "A named veteran will deliver live or recorded congressional testimony specifically about personal ibogaine treatment outcomes before September 2026, constituting the highest-profile psychedelic policy moment of the year.", "confidence": 68, "category": "culture", "geography": "USA", "resolve_date": "2026-08-31", "tags": [ "ibogaine", "veteran", "Congress", "testimony" ], "status": "pending", "priority": "high", "plain_title": "A veteran testifies to Congress about their ibogaine treatment", "plain_what": "A named veteran will go to Capitol Hill \u2014 either in person or via recorded video testimony \u2014 and tell members of Congress that ibogaine treated their PTSD, substance use, or both. Congress will hold a formal hearing or briefing. This will be the biggest psychedelic moment in politics that year because veteran testimony is extremely powerful in Congress, and it will come right after Stanford releases their data (see above), giving the story scientific weight." }, { "date": "2026-05-25", "title": "A peer-reviewed meta-analysis formally quantifying blinding failure rates across MDMA-AT randomized controlled trials will be published in a journal with impact factor >5 by Q1 2027.", "confidence": 65, "category": "research", "geography": "Global", "resolve_date": "2027-03-31", "tags": [ "MDMA", "blinding", "meta-analysis", "methodology" ], "status": "pending", "priority": "medium", "plain_title": "Study published: MDMA blinding doesn't work in most trials", "plain_what": "Scientists will publish a formal research review in a major journal (impact factor above 5 \u2014 meaning it's in the top tier of prestigious publications) that examines all the MDMA-assisted therapy trials and measures exactly how badly the blinding failed. Blinding failure means patients could tell whether they got real MDMA or placebo, which inflates how good the drug looks. This study will quantify the problem across multiple trials and show it's systematic, not a one-off mistake." }, { "date": "2026-05-25", "title": "A major investigative piece exposing financial conflicts of interest between named Republican political figures and venture-backed psychedelic companies will be published by a top-10 U.S. outlet before September 2026.", "confidence": 62, "category": "culture", "geography": "USA", "resolve_date": "2026-09-01", "tags": [ "politics", "Republican", "psychedelics", "venture capital", "investigative" ], "status": "pending", "priority": "medium", "plain_title": "Major news outlet exposes Republican ties to psychedelic companies", "plain_what": "A top-tier US news outlet \u2014 think New York Times, Washington Post, Wall Street Journal, or The Atlantic \u2014 will publish an investigative piece about named Republican politicians or operatives who have financial stakes in psychedelic startups. The piece will document conflicts of interest: these politicians push psychedelic policy or funding while their allies or allies' companies stand to profit. This matters because it exposes how money shapes drug policy and could derail the Republican push to legalize psychedelics." }, { "date": "2026-05-26", "title": "Veteran suicide rate data will be cited in at least three major floor speeches during FY2027 appropriations debate, directly linking ibogaine access to DoD mental health funding.", "confidence": 81, "category": "legislation", "geography": "Global", "resolve_date": "2026-08-31", "tags": [ "ibogaine", "veteran" ], "status": "pending", "priority": "high", "plain_title": "Veteran suicide data will feature in three major congressional budget speeches, linking ibogaine access to military mental health funding.", "plain_what": "Members of Congress will cite suicide statistics affecting veterans during 2027 budget debates and explicitly connect ibogaine (a psychedelic drug) as a potential solution. This matters because it signals mainstream political support for psychedelic research as a real mental health tool, not fringe medicine." }, { "date": "2026-05-26", "title": "MDMA NDA will not receive an approval decision in 2026; FDA will request additional safety data on cardiovascular and abuse potential, pushing decision to mid-2027 at earliest.", "confidence": 79, "category": "regulation", "geography": "USA", "resolve_date": "2027-06-30", "tags": [ "MDMA", "FDA" ], "status": "pending", "priority": "high", "plain_title": "FDA will delay MDMA drug approval decision until mid-2027, requesting more cardiovascular safety data.", "plain_what": "The FDA (the US drug regulator) will not approve the MDMA drug application in 2026. Instead, reviewers will ask the company to run more tests on heart safety and addiction risk. This delays the drug by 12-18 months, pushing approval into the middle of 2027 at the earliest." }, { "date": "2026-05-26", "title": "MDMA NDA approval decision will not occur in 2026, with mid-2027 as the earliest realistic timeline under current review trajectory.", "confidence": 77, "category": "regulation", "geography": "Global", "resolve_date": "2026-08-24", "tags": [ "MDMA" ], "status": "pending", "priority": "high", "plain_title": "MDMA approval decision will slip to mid-2027 at earliest; 2026 approval unlikely.", "plain_what": "The FDA will not approve MDMA as a prescription medicine in 2026. The agency's current review pace and the company's clinical data package suggest regulators won't make a final decision until the middle of 2027. This is a real delay that affects when patients can actually access the treatment." }, { "date": "2026-05-26", "title": "A major investigative piece exposing ketamine clinic safety culture failures \u2014 including undisclosed adverse events and inadequate screening \u2014 will publish in a top-tier outlet before Q4 2026.", "confidence": 77, "category": "culture", "geography": "Global", "resolve_date": "2026-09-30", "tags": [ "ketamine" ], "status": "pending", "priority": "high", "plain_title": "Major news outlet will expose ketamine clinic safety failures before end of 2026.", "plain_what": "A major newspaper or magazine will publish a detailed investigation revealing that ketamine clinics are not tracking adverse events properly, aren't screening patients carefully enough, and are hiding safety problems. This story will come out before Q4 2026 and will damage the reputation of the ketamine clinic industry." }, { "date": "2026-05-26", "title": "Ketamine clinic sector will face combined regulatory pressure \u2014 DEA investigations and FDA safety communication \u2014 before Q1 2027, creating significant sector turbulence.", "confidence": 76, "category": "regulation", "geography": "USA", "resolve_date": "2026-08-24", "tags": [ "ketamine", "FDA", "DEA" ], "status": "pending", "priority": "high", "plain_title": "DEA and FDA will pressure ketamine clinics with enforcement actions before early 2027.", "plain_what": "The DEA (the US drug enforcement agency) and the FDA will both take action against ketamine clinics\u2014DEA through investigations, FDA through safety communications\u2014before Q1 2027. This creates real legal and business risk for clinic operators and may force some clinics to close or change how they operate." }, { "date": "2026-05-27", "title": "MDMA-assisted therapy will not receive FDA approval in 2026; any NDA re-engagement will result in a resubmission pathway requiring additional safety data.", "confidence": 82, "category": "regulatory", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "MDMA", "FDA", "psychedelic-therapy" ], "status": "pending", "priority": "high", "plain_title": "MDMA therapy won't get FDA approval in 2026; company must start over", "plain_what": "The FDA rejected MDMA-assisted therapy in 2024 because the research had serious problems\u2014like therapists knowing who got the real drug. The company would need to run a new, better-designed study to reapply. Without that work already underway, approval this year is extremely unlikely." }, { "date": "2026-05-27", "title": "DEA will initiate at least 2 publicly documented enforcement actions against unregulated psychedelic retreat operators in the US before end of September 2026.", "confidence": 72, "category": "policy", "geography": "USA", "resolve_date": "2026-09-30", "tags": [ "DEA", "enforcement", "retreats", "5-MeO-DMT" ], "status": "pending", "priority": "high", "plain_title": "DEA will shut down at least two unregulated psychedelic retreat operators before September 2026", "plain_what": "Someone has already died at an unregulated retreat using toad venom (a powerful psychedelic extracted from toads). This death gives the DEA (Drug Enforcement Administration) both a public safety reason and political cover to arrest operators running illegal psychedelic retreats, especially in cities where psilocybin has been decriminalized but not legalized." }, { "date": "2026-05-27", "title": "At least one psychedelic biotech company trading below $15/share as of May 2026 will publicly announce a strategic review, merger exploration, or distressed partnership by Q3 2026.", "confidence": 71, "category": "market", "geography": "Global", "resolve_date": "2026-09-30", "tags": [ "biotech", "M&A", "psychedelic-stocks", "CMPS", "MMED" ], "status": "pending", "priority": "medium", "plain_title": "At least one struggling psychedelic company will explore mergers before end of Q3 2026", "plain_what": "Two major psychedelic biotech companies (COMPASS and Mind Medicine) trade at rock-bottom stock prices with no approval in sight and shrinking cash. When boards see money running out and no good news coming, they typically announce they're 'exploring strategic options'\u2014which usually means merger talks, asset sales, or shutdown. This is the standard corporate signal for desperation." }, { "date": "2026-05-27", "title": "Congressional testimony specifically addressing safety standards at unregulated psychedelic retreat operations will occur before end of 2026, triggered by at least one publicized participant death.", "confidence": 68, "category": "policy", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "Congress", "retreats", "DEA", "public-safety", "oversight" ], "status": "pending", "priority": "high", "plain_title": "Congress will hold hearings on unregulated retreat safety after a publicized death", "plain_what": "A fatality at an illegal psychedelic retreat will force Congressional committees to hold a public hearing demanding answers about why unregulated operations can operate openly. Both lawmakers worried about veteran access and those focused on public safety will use the death as a reason to demand action\u2014one side pushing for legal access, the other for stricter enforcement." }, { "date": "2026-05-27", "title": "FDA will issue a formal REMS update or Dear Healthcare Provider letter for esketamine (Spravato) citing ED suicidality utilization safety signals by February 2027.", "confidence": 64, "category": "regulatory", "geography": "USA", "resolve_date": "2027-02-27", "tags": [ "ketamine", "esketamine", "Spravato", "FDA", "REMS" ], "status": "pending", "priority": "high", "plain_title": "FDA will update ketamine therapy safety warnings or instructions for doctors by February 2027", "plain_what": "Esketamine (Spravato) is a ketamine-based drug the FDA approved for depression, but doctors are now using it off-label (not as approved) to treat suicidal crises in emergency departments without the careful monitoring the FDA required. The FDA monitors real-world safety and will eventually issue a warning letter or instruction update telling doctors how to use it safely, or warning them not to use it in emergency settings where monitoring isn't possible." }, { "date": "2026-05-28", "title": "MDMA will not receive FDA approval in calendar year 2026 and will receive a second Complete Response Letter citing safety and abuse potential gaps.", "confidence": 73, "category": "regulation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "MDMA", "FDA", "CRL", "MAPS" ], "status": "pending", "priority": "high", "plain_title": "MDMA won't get FDA approval in 2026, gets rejection letter instead", "plain_what": "The FDA (the US drug regulator) will reject MDMA as a treatment for PTSD in 2026 with a formal Complete Response Letter \u2014 a rejection that cites incomplete data on heart safety and addiction risk. This matters because MDMA's approval has been delayed repeatedly, and this prediction says the delays continue through all of next year." }, { "date": "2026-05-28", "title": "FDA will issue a formal safety communication on ketamine/esketamine and suicidality before October 2026, including updated REMS requirements for Spravato.", "confidence": 72, "category": "regulation", "geography": "USA", "resolve_date": "2026-09-30", "tags": [ "ketamine", "FDA", "REMS", "Spravato" ], "status": "pending", "priority": "high", "plain_title": "FDA will warn doctors about ketamine and suicidality risk before October 2026", "plain_what": "The FDA will issue a formal safety communication warning doctors and hospitals about suicidality (suicide risk) linked to ketamine and its cousin esketamine (sold as Spravato) before October 2026. The agency will also tighten how these drugs can be prescribed (called REMS \u2014 Risk Evaluation and Mitigation Strategy). This matters because hospitals are increasingly using ketamine in emergency departments, and the FDA has spotted a signal that suicides are going up among people using it." }, { "date": "2026-05-28", "title": "At least three U.S. states will introduce ibogaine-specific veteran access legislation before December 31, 2026.", "confidence": 68, "category": "legislation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "ibogaine", "legislation", "veterans", "state-level" ], "status": "pending", "priority": "medium", "plain_title": "At least three states introduce ibogaine access bills for veterans by end of 2026", "plain_what": "Before December 31, 2026, at least three US states will introduce (but not necessarily pass) new laws letting veterans access ibogaine \u2014 a plant-based psychedelic \u2014 outside the normal federal drug rules. This matters because the federal DEA (US drug enforcement agency) classifies ibogaine as illegal, but states can sometimes work around that. Veteran groups are pushing this hard because early evidence suggests ibogaine helps with PTSD and addiction." }, { "date": "2026-05-28", "title": "Peer-reviewed Phase 3 data on MDMA-assisted massed exposure therapy for PTSD will be published in a indexed journal by September 15, 2026.", "confidence": 62, "category": "research", "geography": "Global", "resolve_date": "2026-09-15", "tags": [ "MDMA", "Phase 3", "PTSD", "publication" ], "status": "pending", "priority": "high", "plain_title": "MDMA PTSD study results published in major journal by September 2026", "plain_what": "A peer-reviewed scientific journal will publish the full results of a large Phase 3 clinical trial (the final stage before approval) testing MDMA with a new compressed treatment schedule for PTSD by September 15, 2026. This matters because it shows whether the new, faster way of delivering MDMA therapy actually works \u2014 which could influence whether the FDA approves it." }, { "date": "2026-05-28", "title": "A Tier 1 outlet (NYT, WaPo, New Yorker, ProPublica, or equivalent) will publish an investigative piece on adverse events at unregulated psychedelic retreats \u2014 including at least one documented death \u2014 before September 2026.", "confidence": 62, "category": "media", "geography": "USA", "resolve_date": "2026-08-31", "tags": [ "ayahuasca", "retreat safety", "harm", "investigative journalism" ], "status": "pending", "priority": "medium", "plain_title": "Major news outlet investigates deaths at unregulated psychedelic retreats by September 2026", "plain_what": "A top-tier news organization like the New York Times, Washington Post, or ProPublica will publish a deep-dive investigation of harm and deaths at illegal or unregulated psychedelic retreat centers before September 2026. This matters because psychedelic retreats are booming in places like Costa Rica and Jamaica, but there's almost no safety oversight, and people are dying \u2014 but the story hasn't hit mainstream media yet." }, { "date": "2026-05-29", "title": "No U.S. state that has not already passed psychedelic decriminalization or regulated access legislation will enact such a law via state legislature (not ballot initiative) before December 31, 2026.", "confidence": 85, "category": "legislation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "psychedelics", "state legislation", "decriminalization", "ballot initiative" ], "status": "pending", "priority": "high", "plain_title": "No new state legislatures will legalize psychedelics by end of 2026", "plain_what": "States that want to let people use psychedelics have done it through ballot measures (where voters decide directly), not through their legislatures (where politicians decide). Politicians are reluctant to vote for this without voters pushing them to. This matters because it means psychedelic access will stay limited to the few states that already changed their laws." }, { "date": "2026-05-29", "title": "Federal psychedelic legislation will not reach a floor vote in either the House or Senate before the 2026 midterm elections (November 3, 2026).", "confidence": 82, "category": "legislation", "geography": "USA", "resolve_date": "2026-11-03", "tags": [ "psychedelics", "legislation", "midterms", "Congress" ], "status": "pending", "priority": "high", "plain_title": "Congress won't vote on federal psychedelic bills before November 2026", "plain_what": "Congress has a packed calendar before the midterm elections, and psychedelics aren't a top priority for leadership. Even though some lawmakers support change, the people who control what gets voted on haven't pushed it forward. This means federal legalization stays off the table for at least another year." }, { "date": "2026-05-29", "title": "Federal rescheduling of psilocybin will not occur before January 1, 2029, due to DEA mandatory comment periods and interagency review requirements.", "confidence": 81, "category": "regulation", "geography": "USA", "resolve_date": "2029-01-01", "tags": [ "psilocybin", "DEA", "rescheduling", "FDA", "CSA" ], "status": "pending", "priority": "high", "plain_title": "DEA won't reschedule psilocybin before 2029 due to bureaucratic rules", "plain_what": "The federal government has a specific legal process to move drugs between legal categories. Even if the FDA (the drug-approving agency) recommends psilocybin for rescheduling, the DEA (the drug-enforcement agency) must wait 60+ days for public comments, coordinate with other agencies, and publish a final decision. This takes 2\u20133 years minimum. Since the FDA hasn't made a recommendation yet, you're looking at 2029 earliest." }, { "date": "2026-05-29", "title": "CMS will not establish reimbursement coverage for psilocybin-assisted therapy under Medicare or Medicaid by December 31, 2028.", "confidence": 78, "category": "market", "geography": "USA", "resolve_date": "2028-12-31", "tags": [ "psilocybin", "CMS", "Medicare", "reimbursement", "coverage" ], "status": "pending", "priority": "high", "plain_title": "Medicare won't pay for psilocybin therapy by end of 2028", "plain_what": "For the government health insurance for people over 65 to pay for psilocybin therapy, three things need to happen: the FDA approves it, someone assigns a billing code, and Medicare decides it's worth the cost. Medicare is skeptical of expensive, therapy-heavy treatments, and this whole process takes years. Even if everything moves fast, you're past 2028." }, { "date": "2026-05-29", "title": "CMPS (Compass Pathways) stock will retrace below $12.00 within 15 trading days of its most recent 8%+ single-day spike, absent a confirmed Phase 3 data readout or major partnership announcement.", "confidence": 76, "category": "market", "geography": "Global", "resolve_date": "2026-06-20", "tags": [ "CMPS", "Compass Pathways", "biotech", "equity", "psilocybin" ], "status": "pending", "priority": "high", "plain_title": "Compass Pathways stock will drop below $12 within 15 trading days", "plain_what": "When a small biotech stock jumps 8% or more in one day without real news, retail traders are usually driving the move. Big institutional investors use these jumps as a chance to sell and get out. Without actual drug approval or a partnership announcement, the stock typically falls back down within 2\u20133 weeks. This prediction tracks one specific stock spike." }, { "date": "2026-05-30", "title": "Federal rescheduling of psilocybin will not occur before January 2028, as no completed Phase 3 NDA submission exists and DEA scheduling timelines preclude earlier action.", "confidence": 82, "category": "regulation", "geography": "USA", "resolve_date": "2028-01-01", "tags": [ "psilocybin", "FDA", "DEA", "rescheduling", "Schedule-I", "NDA" ], "status": "pending", "priority": "high", "plain_title": "Psilocybin won't get rescheduled federally before January 2028", "plain_what": "Psilocybin (the active ingredient in magic mushrooms) is currently a Schedule I drug, meaning the US government says it has no medical use. For that to change, a drug company has to finish late-stage human trials, submit the results to the FDA (the US drug regulator), the FDA has to approve it, and then the DEA (the drug enforcement agency) has to officially move it to a less restricted category. Right now, no company has finished those trials yet, so the earliest this could realistically happen is 2028." }, { "date": "2026-05-30", "title": "Federal rescheduling of MDMA will not occur before January 2028, with DEA statutory process and FDA cardiac safety review creating compounding delays beyond VA political pressure.", "confidence": 79, "category": "regulation", "geography": "USA", "resolve_date": "2028-01-01", "tags": [ "MDMA", "FDA", "DEA", "rescheduling", "Schedule-I" ], "status": "pending", "priority": "high", "plain_title": "MDMA won't get rescheduled federally before January 2028", "plain_what": "MDMA (also called ecstasy) is also Schedule I right now. The FDA has already rejected the approval application twice because of safety concerns, especially heart problems. Even though veterans and their supporters in Congress are pushing hard for faster approval, the FDA has to complete its safety review and the DEA has its own independent legal authority to make scheduling decisions. That means political pressure doesn't override scientific review, and the process will take longer than optimists expect." }, { "date": "2026-05-30", "title": "CMPS will retrace at least 60% of its May 30 gains within 10 trading days, absent a confirmed Phase 3 data readout or partnership announcement.", "confidence": 77, "category": "markets", "geography": "USA", "resolve_date": "2026-06-13", "tags": [ "CMPS", "biotech", "psychedelic-stocks", "technical-reversion" ], "status": "pending", "priority": "high", "plain_title": "Compass Pathways stock will drop sharply after its recent spike", "plain_what": "Compass Pathways (ticker CMPS) had its stock price jump on May 30, but there was no obvious news reason for it\u2014just retail trader enthusiasm. History shows that small biotech stocks that spike on no real catalyst usually come crashing back down within days or weeks. This prediction says the stock will lose at least 60% of those gains within two weeks unless the company announces actual trial results or a major partnership deal." }, { "date": "2026-05-30", "title": "DEA will formally object to any VA appropriations language authorizing psychedelic research that bypasses Schedule I administrative review, triggering a DOJ OLC referral before December 2026.", "confidence": 72, "category": "legislation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "DEA", "DOJ", "OLC", "Schedule-I", "VA", "appropriations" ], "status": "pending", "priority": "high", "plain_title": "DEA will block Congress from bypassing psilocybin scheduling rules", "plain_what": "Some people in Congress might try to pass a law saying the VA (Veterans Affairs) can run psilocybin research without waiting for FDA approval or DEA rescheduling\u2014basically trying to work around the normal drug approval system through appropriations language. The DEA has independent legal authority under drug scheduling law and has blocked this kind of workaround before. When that clash happens, the Department of Justice will have to step in as referee, and that will probably happen before the end of 2026." }, { "date": "2026-05-30", "title": "At least one FDA IND approval for psilocybin targeting non-treatment-resistant MDD (rather than TRD only) will be granted before December 2026.", "confidence": 68, "category": "research", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "psilocybin", "FDA", "IND", "MDD", "clinical-trials" ], "status": "pending", "priority": "medium", "plain_title": "FDA will approve psilocybin research for broader depression, not just severe cases", "plain_what": "Right now, all the focus is on psilocybin for treatment-resistant depression\u2014that's severe depression that doesn't respond to normal antidepressants. But new trial data suggests psilocybin might also work for regular depression that hasn't been treated yet. An Investigational New Drug (IND) application is the FDA's permission slip for a drug company to start human trials. This prediction says that before the end of 2026, at least one company will get FDA permission to test psilocybin on regular depression patients, not just the most severe cases." }, { "date": "2026-05-31", "title": "DEA will not initiate rescheduling proceedings for psilocybin or MDMA independent of FDA action before 2026-12-31.", "confidence": 88, "category": "regulation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "psilocybin", "MDMA", "DEA", "FDA", "rescheduling" ], "status": "pending", "priority": "high", "plain_title": "DEA won't move on psilocybin or MDMA without FDA approval by end of 2026", "plain_what": "The DEA (the US drug enforcement agency) will wait for the FDA (the US medicine regulator) to act first before it reclassifies psilocybin or MDMA. This matters because DEA action could unlock medical use and research, but the DEA has no track record of moving independently on drugs \u2014 it watches for FDA approval first to avoid legal and political risk." }, { "date": "2026-05-31", "title": "No standalone federal psychedelic scheduling reform bill will receive a floor vote in the 119th Congress (concluding January 2027).", "confidence": 85, "category": "legislation", "geography": "USA", "resolve_date": "2027-01-03", "tags": [ "psilocybin", "MDMA", "scheduling", "Congress", "119th" ], "status": "pending", "priority": "high", "plain_title": "Congress won't vote on a psychedelic scheduling reform bill by end of 2026", "plain_what": "No stand-alone federal bill that removes or loosens restrictions on psychedelic drugs will reach a floor vote in Congress before January 2027. This matters because Congress controls federal drug law, and a floor vote is the only real test of political support \u2014 and law enforcement groups are lobbying hard to keep these drugs restricted." }, { "date": "2026-05-31", "title": "At least 3 U.S. states will introduce veteran-specific psychedelic therapy access bills before 2026-12-31.", "confidence": 81, "category": "legislation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "veteran", "psilocybin", "MDMA", "state-legislation", "therapy" ], "status": "pending", "priority": "high", "plain_title": "Three or more US states will propose veteran psychedelic therapy bills by end of 2026", "plain_what": "At least three US states will introduce bills (not necessarily pass them) that let veterans access psychedelic-assisted therapy before the end of 2026. This matters because veterans are a politically sympathetic group, and states are already moving on this \u2014 Colorado and Texas have already done it \u2014 so more will follow." }, { "date": "2026-05-31", "title": "CMPS stock will retrace at least 5% from its 2026-05-31 closing price within 10 trading days, absent a confirmatory catalyst (FDA meeting date announcement or partnership deal).", "confidence": 79, "category": "market", "geography": "USA", "resolve_date": "2026-06-16", "tags": [ "CMPS", "biotech", "psychedelic", "equity", "FDA" ], "status": "pending", "priority": "high", "plain_title": "Compass Pathways stock will drop 5% within two weeks of May 31, 2026", "plain_what": "If Compass Pathways (a psilocybin biotech company) stock jumps up by early summer 2026 without real news like an FDA meeting announcement or a business deal, it will likely fall back down 5% or more within ten trading days. This matters because small biotech stocks move on hype, and when the hype fades, sellers take profits and the stock falls back." }, { "date": "2026-05-31", "title": "A major investigative piece exposing ketamine clinic safety failures or financial conflicts of interest will be published in a top-tier U.S. or UK outlet before 2026-09-30.", "confidence": 72, "category": "culture", "geography": "USA", "resolve_date": "2026-09-30", "tags": [ "ketamine", "clinic-safety", "investigative-journalism", "regulation" ], "status": "pending", "priority": "medium", "plain_title": "Major news outlet will expose ketamine clinic safety or financial problems by fall 2026", "plain_what": "A major newspaper or news organization (like the New York Times, Washington Post, or The Guardian) will publish a detailed investigation into problems at ketamine clinics \u2014 either patients getting hurt due to poor safety practices or companies making money in sketchy ways. This matters because ketamine clinics operate in a legal gray zone with minimal oversight, and the Matthew Perry overdose death put pressure on journalists to dig into the industry." }, { "date": "2026-06-01", "title": "Federal psilocybin rescheduling will not occur before 2028-01-01 regardless of 2026 legislative or clinical developments.", "confidence": 82, "category": "regulation", "geography": "USA", "resolve_date": "2028-01-01", "tags": [ "psilocybin", "DEA", "rescheduling", "federal" ], "status": "pending", "priority": "high", "plain_title": "Psilocybin won't be rescheduled federally before 2028", "plain_what": "The federal government won't move psilocybin to a less restricted category before January 2028, even if Congress pushes hard or new research comes out. The actual rescheduling process takes 18\u201324 months minimum and involves the DEA (Drug Enforcement Administration), HHS (Department of Health and Human Services), a public comment period, and final paperwork \u2014 and nobody has even formally started yet." }, { "date": "2026-06-01", "title": "At least three additional U.S. states will introduce psilocybin decriminalization or therapeutic access legislation before 2026-12-31.", "confidence": 77, "category": "legislation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "psilocybin", "legislation", "state-level", "Oregon", "Colorado" ], "status": "pending", "priority": "high", "plain_title": "Three more states legalize psilocybin therapy or decriminalize before 2026 ends", "plain_what": "At least three more U.S. states will introduce bills to either let therapists use psilocybin legally or decriminalize small amounts before December 31, 2026. Oregon and Colorado already did this, and other states like California and Washington have activist groups pushing hard. When the federal government can't agree on something, states usually try it first \u2014 that's what happened with cannabis, and it's happening with psychedelics now." }, { "date": "2026-06-01", "title": "CMPS will retrace to between $12.80 and $13.40 within 7 trading days absent a formal FDA or partnership announcement.", "confidence": 74, "category": "market", "geography": "USA", "resolve_date": "2026-06-10", "tags": [ "CMPS", "biotech", "market", "mean-reversion", "FDA" ], "status": "pending", "priority": "medium", "plain_title": "Compass stock drops back to $12.80\u2013$13.40 within one week", "plain_what": "A psychedelic company's stock (CMPS) went up 11% in one day with no actual news. That's a classic sign that retail traders jumped in fast. When that happens, the stock almost always comes back down within a week or two because professional investors don't chase moves like that without real company developments \u2014 new FDA (Food and Drug Administration) approval, a partnership, something concrete." }, { "date": "2026-06-01", "title": "DEA will initiate at least two publicly announced enforcement actions against unregulated psychedelic retreat operators in the U.S. before 2026-09-01.", "confidence": 73, "category": "enforcement", "geography": "USA", "resolve_date": "2026-09-01", "tags": [ "DEA", "enforcement", "retreats", "psilocybin", "Schedule I" ], "status": "pending", "priority": "medium", "plain_title": "DEA will publicly prosecute unlicensed retreat operators before September 2026", "plain_what": "The DEA (Drug Enforcement Administration) will announce at least two enforcement actions \u2014 arrests, indictments, or raids \u2014 against illegal psilocybin retreat operators running in the U.S. before September 1, 2026. When federal drug laws face challenges, enforcement agencies fight back by cracking down visibly. Recent deaths at unregulated retreats give the DEA a legitimate public-safety reason to act." }, { "date": "2026-06-01", "title": "Veterans will remain the dominant political framing for U.S. psychedelic reform legislation introduced or advanced in 2026, appearing in the primary title or stated purpose of the majority of federal bills.", "confidence": 72, "category": "politics", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "legislation", "veterans", "framing", "federal", "bipartisan" ], "status": "pending", "priority": "medium", "plain_title": "U.S. lawmakers will frame psychedelic reform around veterans", "plain_what": "When Congress introduces bills about psychedelics in 2026, most of them will emphasize helping military veterans with PTSD (post-traumatic stress disorder) and other service-related trauma. This framing works because it sidesteps culture-war arguments \u2014 nobody wants to deny veterans new medical options. Advocacy groups like MAPS (Multidisciplinary Association for Psychedelic Studies) have deliberately chosen this angle, and it attracts both Democratic and Republican support." }, { "date": "2026-06-02", "title": "No DEA Schedule I rescheduling of any psychedelic substance will take effect before March 31, 2027, regardless of executive orders or White House pressure.", "confidence": 85, "category": "regulation", "geography": "USA", "resolve_date": "2027-03-31", "tags": [ "DEA", "Schedule I", "rescheduling", "executive order", "administrative law" ], "status": "pending", "priority": "high", "plain_title": "No psychedelic drug will be rescheduled before March 2027", "plain_what": "Even if the president orders it, the DEA (Drug Enforcement Administration) must follow a specific law that requires an 8-step review and approval from the health department before it can reschedule any drug. This process takes at least 18 months and no executive order can skip it. You won't see MDMA or psilocybin moved off Schedule I before spring 2027." }, { "date": "2026-06-02", "title": "Any Trump administration psychedelic 'fast-track' executive action announced before Q3 2026 will produce no binding rescheduling, no federal prescribing pathway, and no FDA approval acceleration before October 2026 \u2014 measurable as zero regulatory docket changes at DEA or FDA.", "confidence": 80, "category": "legislation", "geography": "USA", "resolve_date": "2026-10-01", "tags": [ "DEA", "FDA", "executive order", "Trump", "political signaling" ], "status": "pending", "priority": "high", "plain_title": "Trump psychedelic fast-track order will produce zero regulatory changes by October 2026", "plain_what": "If the Trump administration announces a fast-track executive order for psychedelics before mid-2026, nothing will actually happen at the DEA (Drug Enforcement Administration) or FDA (Food and Drug Administration) by October 2026. Political announcements routinely run 12\u201324 months ahead of real regulatory action. You can measure this yourself: there will be no new documents filed in the public federal register or FDA docket." }, { "date": "2026-06-02", "title": "FDA issues a Complete Response Letter for MDMA-PTSD NDA before December 31, 2026, citing unresolved cardiovascular monitoring and therapist-misconduct safety signals.", "confidence": 78, "category": "regulation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "MDMA", "FDA", "PTSD", "CRL", "Lykos" ], "status": "pending", "priority": "high", "plain_title": "FDA rejects MDMA-PTSD approval, citing safety concerns by end of 2026", "plain_what": "The FDA (Food and Drug Administration) will likely issue a Complete Response Letter (a rejection requiring major changes) for Lykos Therapeutics' MDMA-PTSD application before the end of 2026. The FDA already flagged problems in 2024: heart safety isn't being monitored well enough, the trial wasn't truly blinded (both patients and therapists knew who got the real drug), and there's potential for therapist misconduct. These are serious enough that a rejection is the most likely outcome." }, { "date": "2026-06-02", "title": "Lykos Therapeutics (MDMA-AT developer) will either cease operations, be acquired, or publicly announce a pivot away from MDMA-PTSD as primary program before December 31, 2026.", "confidence": 74, "category": "investment", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "Lykos", "MDMA", "FDA", "CRL", "biotech", "acquisition" ], "status": "pending", "priority": "high", "plain_title": "Lykos Therapeutics shuts down, gets bought, or abandons MDMA program by 2026", "plain_what": "Lykos Therapeutics (the company developing MDMA for PTSD) already received a rejection from the FDA in August 2024 and fired 75% of its staff. Fixing the problems requires running a brand-new Phase 3 trial that will cost $50\u2013100 million and take 3\u20135 years. The company has no approved drugs, no revenue, and limited cash left. By the end of 2026, Lykos will either shut down, be bought by another company, or publicly announce they're switching away from MDMA as their main focus." }, { "date": "2026-06-02", "title": "At least 3 additional U.S. states will enact veteran-specific psychedelic therapy access legislation (signed into law or passed both chambers) before January 1, 2027.", "confidence": 72, "category": "legislation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "legislation", "veteran", "state law", "psychedelics", "access" ], "status": "pending", "priority": "high", "plain_title": "Three more states legalize psychedelics for veterans before 2027", "plain_what": "By the end of 2026, at least three additional U.S. states will pass laws letting veterans access psychedelic therapy. Texas, Colorado, and Oregon have already done this. Arizona, Florida, Missouri, and Virginia have bills in committee right now with support from both Republicans and Democrats, because both parties back veterans' health. States can create these exemptions without touching federal drug law, making it easier politically. You'll see at least three more states pass similar laws by January 2027." }, { "date": "2026-06-03", "title": "MMED will retrace at least 8% of its June 3 closing price within ten trading days absent a confirmed Phase 3 readout or partnership announcement", "confidence": 80, "category": "market", "geography": "USA", "resolve_date": "2026-06-17", "tags": [ "MMED", "psychedelics", "mean-reversion", "small-cap" ], "status": "pending", "priority": "high", "plain_title": "Mindmed stock will drop 8% within two weeks without major news", "plain_what": "Mindmed (MMED) jumped 14% in a single day on June 3 with no clear reason behind it. This kind of sudden jump in a stock with few shares available to trade usually doesn't stick around\u2014big investors use these moments to sell their shares, which pushes the price back down. History shows this pattern repeats every two weeks or so." }, { "date": "2026-06-03", "title": "Federal psilocybin rescheduling will not advance past DEA petition review stage before January 1, 2028", "confidence": 78, "category": "legislation", "geography": "USA", "resolve_date": "2028-01-01", "tags": [ "psilocybin", "DEA", "scheduling", "federal" ], "status": "pending", "priority": "high", "plain_title": "Federal psilocybin rescheduling will stall through 2027", "plain_what": "Psilocybin (the active compound in magic mushrooms) is currently a Schedule I controlled substance, the most restricted category. Moving it to a less restricted schedule requires the Drug Enforcement Administration (DEA) to officially change its rules, or Congress to pass a law. The DEA has built-in institutional reasons to resist this change, and Congress has not scheduled floor time to debate it. Meanwhile, states like Oregon and Colorado are moving ahead on their own." }, { "date": "2026-06-03", "title": "DEA will initiate formal enforcement action (criminal referral, civil penalty, or license revocation) against at least two ketamine clinic operators for off-label prescribing or diversion violations before 2026-12-31", "confidence": 72, "category": "regulation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "ketamine", "DEA", "enforcement", "diversion" ], "status": "pending", "priority": "medium", "plain_title": "DEA will prosecute two ketamine clinics for illegal prescribing by 2026", "plain_what": "Ketamine clinics have multiplied across America faster than the DEA (Drug Enforcement Administration) can monitor them. Many operate through telehealth, bill insurance in questionable ways, and prescribe ketamine off-label (for uses the FDA hasn't officially approved). The DEA's databases already flag suspicious billing patterns. Congress is paying attention to fraud in behavioral health. When the DEA acts, it usually files criminal charges, imposes fines, or revokes a clinic's license to prescribe." }, { "date": "2026-06-03", "title": "An ibogaine veteran treatment provision will be included in the FY2027 NDAA with documented co-sponsorship from at least 40 House members before 2026-12-01", "confidence": 65, "category": "legislation", "geography": "USA", "resolve_date": "2026-12-01", "tags": [ "ibogaine", "veteran", "NDAA", "Congress" ], "status": "pending", "priority": "medium", "plain_title": "Ibogaine veteran treatment will enter defense bill by end of 2026", "plain_what": "Ibogaine is a hallucinogen from West Africa that some researchers believe could treat opioid addiction and PTSD (post-traumatic stress disorder) in veterans. The National Defense Authorization Act (NDAA) is Congress's annual defense spending bill\u2014it passes every year with bipartisan support and often includes health research provisions. A provision to study ibogaine for veterans could slip into this bill because: (1) veteran suicide is a bipartisan concern both parties care about, (2) the Trump administration has signaled openness to psychedelic research, and (3) the NDAA is a reliable vehicle for getting things through Congress." }, { "date": "2026-06-03", "title": "At least three academic medical centers will register Phase 2 clinical trials combining ketamine with a named adjunct agent (e.g., lithium, rapamycin, or a BDNF modulator) on ClinicalTrials.gov before 2027-01-01", "confidence": 62, "category": "research", "geography": "USA", "resolve_date": "2027-01-01", "tags": [ "ketamine", "clinical-trials", "combination-therapy", "BDNF" ], "status": "pending", "priority": "medium", "plain_title": "Three medical schools will test ketamine plus add-on drugs by 2027", "plain_what": "Researchers at academic medical centers are starting to test ketamine combined with other drugs\u2014like lithium, rapamycin, or compounds that boost BDNF (brain-derived neurotrophic factor), a protein that helps neurons grow. This approach makes scientific sense: ketamine works fast but doesn't always stick; adding something else might make the effect last longer or work better. Academic hospitals have ethics boards (IRBs) that approve these studies, and the National Institutes of Health (NIH) is funding this kind of research." }, { "date": "2026-06-04", "title": "Ketamine/esketamine accounts for more billable psychedelic-adjacent clinical encounters in U.S. healthcare settings than all other psychedelic compounds combined through Q3 2027, per published utilization data.", "confidence": 82, "category": "research", "geography": "USA", "resolve_date": "2027-09-30", "tags": [ "ketamine", "esketamine", "clinical utilization", "market dominance" ], "status": "pending", "priority": "high", "plain_title": "Ketamine becomes the dominant billable psychedelic treatment by 2027", "plain_what": "Ketamine and esketamine (a variant) will account for more patient visits and insurance billing than all other psychedelic treatments combined through mid-2027. This matters because esketamine already has FDA (the U.S. drug regulator) approval and insurance coverage, while MDMA approval is stalled and psilocybin has no federal approval yet. Thousands of IV ketamine clinics already operate across the U.S., giving ketamine an enormous head start." }, { "date": "2026-06-04", "title": "DEA files formal public comment opposing any NDAA 2027 ibogaine scheduling waiver language, citing diversion risk and insufficient Schedule I exception precedent.", "confidence": 74, "category": "regulatory", "geography": "USA", "resolve_date": "2026-10-01", "tags": [ "ibogaine", "DEA", "Schedule I", "NDAA" ], "status": "pending", "priority": "high", "plain_title": "DEA formally opposes ibogaine legal exemption in Congress", "plain_what": "The DEA (U.S. Drug Enforcement Administration) will file an official public objection if Congress tries to carve out ibogaine as a legal exception to Schedule I drug rules in the 2027 defense bill. This matters because ibogaine is a Schedule I drug with abuse risk, and the DEA has a legal duty to oppose scheduling exemptions. The agency opposed similar exemptions for kratom and will likely do the same here." }, { "date": "2026-06-04", "title": "At least 2 peer-reviewed publications in journals with impact factor \u226510 report novel neuroplasticity biomarkers associated with psilocybin's antidepressant effect, published before 2027-01-01.", "confidence": 73, "category": "research", "geography": "Global", "resolve_date": "2026-12-31", "tags": [ "psilocybin", "neuroplasticity", "biomarkers", "depression" ], "status": "pending", "priority": "high", "plain_title": "Scientists publish psilocybin brain-healing findings in top journals", "plain_what": "At least two high-impact scientific journals (Nature Medicine, JAMA Psychiatry, or similar tier-1 publications) will publish peer-reviewed studies showing how psilocybin physically reshapes the brain in ways that reduce depression. These studies will measure specific brain markers like growth factors and brain cell connections that demonstrate psilocybin's healing mechanism. This matters because concrete biological proof moves psilocybin from anecdotal to scientifically grounded treatment." }, { "date": "2026-06-04", "title": "FDA issues formal Complete Response Letter on MDMA NDA resubmission by Q4 2026, citing therapist fidelity data gaps \u2014 approval pushed to 2028 at earliest.", "confidence": 72, "category": "regulatory", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "MDMA", "FDA", "CRL", "PTSD" ], "status": "pending", "priority": "high", "plain_title": "FDA rejects MDMA therapy approval again in late 2026", "plain_what": "The FDA will issue a second rejection letter (called a Complete Response Letter) to the company seeking MDMA approval, likely by the end of 2026. The FDA's concern will focus on whether therapists actually stuck to the treatment protocol and whether patients could tell they were receiving real MDMA versus placebo. This delays MDMA approval to at least 2028. This matters because it signals the FDA's bar for approval is higher than initially thought\u2014the agency wants ironclad proof of proper therapist conduct." }, { "date": "2026-06-04", "title": "At least 3 new IRB-approved clinical trials studying ketamine for pediatric suicidal ideation or treatment-resistant depression open enrollment at U.S. academic medical centers before 2027-01-01.", "confidence": 71, "category": "research", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "ketamine", "pediatric", "clinical trials", "suicidal ideation" ], "status": "pending", "priority": "high", "plain_title": "U.S. medical centers launch ketamine trials for suicidal youth", "plain_what": "At least three major U.S. academic hospitals will start FDA (U.S. drug regulator) approved clinical trials testing ketamine for young people who are suicidal or resistant to antidepressants by the end of 2026. This matters because ketamine already has FDA approval for adults, which makes it far easier for hospitals to test in children. Suicidal youth represent a genuine emergency that has bipartisan political support, so hospitals have strong incentive to move fast." }, { "date": "2026-06-05", "title": "No psychedelic compound will receive FDA approval in calendar year 2026.", "confidence": 93, "category": "regulation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "FDA", "psilocybin", "MDMA", "approval" ], "status": "pending", "priority": "high", "plain_title": "No psychedelic drug gets FDA approval in 2026", "plain_what": "The FDA (the US drug regulator) won't approve any psychedelic compound for medical use during 2026. This matters because it means patients looking for legal, regulated psychedelic therapy still won't have that option, and companies betting on 2026 approvals will face delays." }, { "date": "2026-06-05", "title": "Psilocybin will not receive FDA approval for any indication before 2028-09-30.", "confidence": 81, "category": "regulation", "geography": "USA", "resolve_date": "2028-09-30", "tags": [ "psilocybin", "FDA", "approval", "timeline" ], "status": "pending", "priority": "high", "plain_title": "Psilocybin won't get FDA approval before September 2028", "plain_what": "Psilocybin (the active compound in magic mushrooms) won't receive FDA approval until at least late 2028. This matters because it extends the wait for people with treatment-resistant depression or other conditions who are counting on legal medical access." }, { "date": "2026-06-05", "title": "DEA will file formal written opposition to psilocybin administrative rescheduling by 2027-06-30, explicitly citing longitudinal safety data gaps or diversion risk.", "confidence": 78, "category": "regulation", "geography": "USA", "resolve_date": "2027-06-30", "tags": [ "psilocybin", "DEA", "rescheduling" ], "status": "pending", "priority": "high", "plain_title": "DEA will formally oppose psilocybin rescheduling by mid-2027", "plain_what": "The DEA (the US drug enforcement agency) will file an official written statement against moving psilocybin out of Schedule I (the strictest legal category) before June 2027. This matters because it's a powerful legal barrier that will slow or block any congressional or administrative push to reschedule the drug." }, { "date": "2026-06-05", "title": "A federally funded veteran psychedelic therapy program will be publicly announced but will have zero patients enrolled or treated by 2026-12-31.", "confidence": 74, "category": "legislation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "veteran", "VA", "pilot program", "psilocybin" ], "status": "pending", "priority": "high", "plain_title": "Announced veteran psychedelic program enrolls zero patients by end-2026", "plain_what": "A federal program offering psychedelic therapy to veterans will be announced (likely with media fanfare) but won't actually treat any patients before the end of 2026. This matters because it shows the gap between political promises and the hard regulatory and logistical work needed to actually deliver treatment." }, { "date": "2026-06-05", "title": "At least 3 major national outlet investigations (NYT, WaPo, ProPublica, The Atlantic, or equivalent) will publish pieces specifically documenting the gap between federal veteran psychedelic rhetoric and actual patient access, before 2026-12-31.", "confidence": 62, "category": "culture", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "veteran", "journalism", "access gap", "media" ], "status": "pending", "priority": "medium", "plain_title": "Major media outlets expose gap between veteran psychedelic promises and real access by end-2026", "plain_what": "At least three major news organizations (New York Times, Washington Post, ProPublica, The Atlantic, or similar) will publish investigations specifically about the mismatch between what politicians promise veterans about psychedelic therapy and what actually gets delivered. This matters because it highlights a real access problem and applies public pressure on agencies and politicians to follow through." }, { "date": "2026-06-06", "title": "No major US anesthesiology or psychiatry society will issue clinical guidance restricting adult psychiatric ketamine use based on juvenile rodent neurotoxicity data before October 31, 2026", "confidence": 78, "category": "research", "geography": "Global", "resolve_date": "2026-10-31", "tags": [ "ketamine", "neurotoxicity", "FDA", "clinical guidance", "ASA", "APA" ], "status": "pending", "priority": "high", "plain_title": "Major US medical groups won't restrict ketamine for psychiatry based on rat studies by Oct 2026", "plain_what": "Scientists have shown that ketamine damages young rats' brains at very high doses, but doctors in the US \u2014 including the American Society of Anesthesiologists and American Psychiatric Association \u2014 typically only change their clinical guidelines when they see harm in actual humans. Since nobody has documented that harm in humans receiving ketamine for depression or PTSD, these groups are unlikely to issue new warnings against the treatment." }, { "date": "2026-06-06", "title": "DEA will formally oppose any psilocybin rescheduling petition before June 30, 2027, citing insufficient abuse liability and pharmacodependence data, maintaining Schedule I status", "confidence": 75, "category": "enforcement", "geography": "USA", "resolve_date": "2027-06-30", "tags": [ "psilocybin", "DEA", "Schedule I", "rescheduling" ], "status": "pending", "priority": "high", "plain_title": "DEA will formally oppose psilocybin rescheduling before mid-2027, keeping it illegal", "plain_what": "The DEA (Drug Enforcement Administration) has the legal power to say no to rescheduling psilocybin \u2014 moving it from Schedule I (illegal with no accepted medical use) to a lower schedule \u2014 regardless of what the FDA (Food and Drug Administration) recommends. The DEA will likely use the fact that no psilocybin drug has been officially approved yet, and will cite concerns about abuse and dependence, as reasons to block rescheduling." }, { "date": "2026-06-06", "title": "FDA will issue a Complete Response Letter for MDMA-PTSD NDA by September 30, 2026, requiring additional long-term safety data rather than granting approval or outright rejection", "confidence": 74, "category": "regulation", "geography": "USA", "resolve_date": "2026-09-30", "tags": [ "MDMA", "FDA", "PTSD", "CRL", "NDA" ], "status": "pending", "priority": "high", "plain_title": "FDA will ask Mindmed for more MDMA-PTSD safety data, not approve or reject outright", "plain_what": "The FDA's advisory committee voted against approving MDMA (the active ingredient in Ecstasy) for PTSD in June 2024, citing concerns about trial design flaws and whether patients' function really improved. Rather than simply rejecting the application, the FDA will most likely issue a Complete Response Letter \u2014 a formal request for more data. This is the safest middle ground: it avoids the political fallout of approving a Schedule I drug while also avoiding the optics of rejecting a potential PTSD treatment supported by veterans' groups." }, { "date": "2026-06-06", "title": "MMED will outperform both ATAI and CMPS on total return through September 30, 2026, as institutional capital rotates toward revenue-generating or partnered assets", "confidence": 72, "category": "market", "geography": "Global", "resolve_date": "2026-09-30", "tags": [ "MMED", "ATAI", "CMPS", "psychedelic biotech", "equity" ], "status": "pending", "priority": "high", "plain_title": "Mindmed stock will beat ATAI and Compass on returns through September 2026", "plain_what": "Mindmed (MMED) has a more stable stock price than two competitors \u2014 ATAI Life Sciences (ATAI) and Compass Pathways (CMPS) \u2014 which have both lost significant value. Institutional investors (big money managers) are rotating away from pure research-stage biotech companies that depend entirely on one or two clinical trial results, and moving toward companies that either generate revenue or have partnerships with established pharma companies. Mindmed's stock is likely to outperform because it's already survived the worst of the downturn." }, { "date": "2026-06-06", "title": "ATAI and CMPS will both underperform the XBI (SPDR S&P Biotech ETF) on total return from June 6 to September 30, 2026, absent a positive Phase 2b or Phase 3 data readout", "confidence": 71, "category": "market", "geography": "Global", "resolve_date": "2026-09-30", "tags": [ "ATAI", "CMPS", "XBI", "biotech", "psychedelic equity" ], "status": "pending", "priority": "medium", "plain_title": "ATAI and Compass will underperform the broader biotech sector through September 2026", "plain_what": "ATAI and Compass are pure psychedelic research companies with no drugs sold yet \u2014 they only make money if their clinical trials succeed. The XBI (SPDR S&P Biotech ETF) tracks the entire biotech sector, which includes many companies that already sell drugs and generate revenue. After the hype around psychedelics cooled (especially after the MDMA regulatory setback), these two stocks will likely fall in value relative to the broader biotech industry unless they announce positive results from late-stage clinical trials." }, { "date": "2026-06-07", "title": "Neither psilocybin nor MDMA is rescheduled under the Controlled Substances Act before December 31, 2026.", "confidence": 84, "category": "regulation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "psilocybin", "MDMA", "DEA", "rescheduling", "CSA" ], "status": "pending", "priority": "high", "plain_title": "Psilocybin and MDMA stay illegal under federal law through 2026", "plain_what": "The U.S. government will not officially move psilocybin or MDMA to a less-restricted legal category before the end of 2026. This matters because it means people can't legally use these drugs for therapy anywhere in America, and companies can't sell them, no matter what state you live in." }, { "date": "2026-06-07", "title": "No federal psychedelic therapy legislation reaches a floor vote in either chamber of Congress before November 3, 2026 midterms.", "confidence": 83, "category": "legislation", "geography": "USA", "resolve_date": "2026-11-03", "tags": [ "psychedelics", "legislation", "congress", "midterms" ], "status": "pending", "priority": "high", "plain_title": "Congress won't vote on psychedelic therapy bills before 2026 elections", "plain_what": "No bill specifically creating legal pathways for psychedelic-assisted therapy will reach a floor vote (where all members vote) in the House or Senate before the November 2026 midterm elections. This matters because it means Congress won't formally debate or decide whether these therapies should be legal." }, { "date": "2026-06-07", "title": "FDA does not approve any MDMA-assisted therapy NDA in 2026, issuing a Complete Response Letter or requesting additional clinical data by December 31, 2026.", "confidence": 81, "category": "regulation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "MDMA", "FDA", "PTSD", "NDA", "CRL" ], "status": "pending", "priority": "high", "plain_title": "FDA rejects MDMA-assisted therapy application, requests more data", "plain_what": "The FDA (the U.S. drug regulator) will not approve MDMA-assisted therapy for use as a medicine by the end of 2026. Instead, the FDA will send back a Complete Response Letter\u2014official rejection asking the company to submit more clinical trial data. This matters because it delays MDMA therapy access by years and signals the FDA isn't confident the therapy is safe or effective enough yet." }, { "date": "2026-06-07", "title": "DEA executes publicly announced enforcement actions against at least three ketamine clinic operators in distinct U.S. states before October 1, 2026.", "confidence": 72, "category": "regulation", "geography": "USA", "resolve_date": "2026-09-30", "tags": [ "ketamine", "DEA", "enforcement", "clinics" ], "status": "pending", "priority": "high", "plain_title": "DEA raids at least three ketamine clinics across different states", "plain_what": "The DEA (the U.S. drug enforcement agency) will publicly announce at least three separate enforcement actions (raids, arrests, or clinic closures) against ketamine clinics in three different U.S. states before October 2026. Ketamine clinics operate in a legal gray zone\u2014they prescribe ketamine (a legal but controlled anesthetic) for depression and pain, often via telemedicine. The DEA will likely target these clinics because the current political environment favors aggressive drug enforcement." }, { "date": "2026-06-07", "title": "At least two additional U.S. states pass ballot measures or legislation creating regulated psilocybin therapy access frameworks by November 30, 2026.", "confidence": 61, "category": "legislation", "geography": "USA", "resolve_date": "2026-11-30", "tags": [ "psilocybin", "state-law", "ballot-measure", "therapy" ], "status": "pending", "priority": "medium", "plain_title": "Two more states legalize psilocybin therapy by end of 2026", "plain_what": "At least two additional U.S. states will pass laws or ballot measures creating legal pathways for psilocybin-assisted therapy by November 30, 2026. Oregon and Colorado already did this. Other states like California, Washington, and Michigan have active ballot initiatives or legislative proposals. This matters because state-level action moves faster than federal action, so people in those states will get legal access even while the federal government hasn't approved it." }, { "date": "2026-06-08", "title": "No psychedelic substance is rescheduled from Schedule I by DEA in calendar year 2026.", "confidence": 80, "category": "regulation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "DEA", "Schedule I", "rescheduling", "MDMA", "psilocybin" ], "status": "pending", "priority": "high", "plain_title": "No psychedelic drug moves out of Schedule I by end of 2026", "plain_what": "The DEA (US Drug Enforcement Administration) controls whether drugs stay illegal or get reclassified\u2014and they operate separately from the FDA (the US drug regulator) that approves medicines. Even if the FDA says a psychedelic medicine is safe and works, the DEA has to independently decide to move it to a lower schedule, a process that takes months or years. This matters because it means legal prescription use stays blocked even if the FDA green-lights it." }, { "date": "2026-06-08", "title": "If FDA approves any psychedelic therapeutic in 2026, the approval will include a REMS program requiring certified treatment centers AND a minimum supervised observation period of at least 6 hours post-administration.", "confidence": 76, "category": "regulation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "FDA", "REMS", "ketamine", "esketamine", "approval", "MDMA" ], "status": "pending", "priority": "high", "plain_title": "FDA-approved psychedelics require treatment centers and 6-hour monitoring", "plain_what": "If the FDA approves a psychedelic medicine in 2026, it will come with a REMS program (a set of safety rules) requiring you to receive it only at certified treatment centers, not at home, and you'll have to stay under medical observation for at least 6 hours after you take it. The FDA learned this from esketamine (Spravato), where they required 2-hour monitoring, and they won't loosen those rules for a Schedule I drug because a bad headline about someone misusing it could sink the whole program." }, { "date": "2026-06-08", "title": "No peer-reviewed controlled trial (Phase II or higher) replicating psilocybin efficacy in Alzheimer's disease or dementia publishes results before 2027-12-31.", "confidence": 73, "category": "research", "geography": "Global", "resolve_date": "2027-12-31", "tags": [ "psilocybin", "Alzheimer's", "dementia", "clinical trial", "replication" ], "status": "pending", "priority": "high", "plain_title": "No published study proves psilocybin works for Alzheimer's before 2027", "plain_what": "There are promising early hints that psilocybin might help Alzheimer's and dementia patients, but no rigorous controlled trial (the gold standard for proof) has been completed and published yet. Running these trials is brutally hard: people with dementia can't reliably consent, recruiting enough patients takes years, and following them safely for months after treatment is medically complex. Even well-funded trials starting now won't finish, analyze, and publish results by the end of 2026." }, { "date": "2026-06-08", "title": "Any White House or federal executive-branch psychedelic research initiative announced before 2026-08-01 will be explicitly framed around veteran opioid/addiction recovery and will not name MDMA as a target compound.", "confidence": 72, "category": "policy", "geography": "USA", "resolve_date": "2026-08-01", "tags": [ "veteran", "opioid", "MDMA", "ibogaine", "Trump", "federal policy" ], "status": "pending", "priority": "medium", "plain_title": "Federal psychedelic research plan focuses on veterans and avoids MDMA", "plain_what": "If the White House announces a psychedelic research initiative before August 2026, it will be framed around helping veterans with opioid addiction and PTSD, not recreational drug legalization. It will probably mention psilocybin or ibogaine but avoid naming MDMA (the party drug), because that association polls badly across party lines. This framing lets politicians claim interest in psychedelic medicine as helping veterans while avoiding 'rave drug' attacks." }, { "date": "2026-06-08", "title": "At least one pharma company with >$1B market cap announces a licensing deal, acquisition, or formal partnership targeting ketamine or esketamine clinic infrastructure by 2026-09-30.", "confidence": 68, "category": "market", "geography": "USA", "resolve_date": "2026-09-30", "tags": [ "ketamine", "esketamine", "pharma", "M&A", "clinic", "market" ], "status": "pending", "priority": "medium", "plain_title": "A large pharma company buys ketamine clinic infrastructure by September 2026", "plain_what": "A big pharmaceutical company (market value over $1 billion) will announce a deal to buy, partner with, or license a ketamine clinic operator\u2014outfits like Field Trip or Ketamine Wellness Centers. Ketamine is already legal (Schedule III, less restricted), generates real clinic revenue, and poses no Schedule I legal risk, so pharma companies view clinic infrastructure as a safer way to enter the psychedelic space without the regulatory chaos of Schedule I compounds. This could happen by September 2026." }, { "date": "2026-06-09", "title": "Patient Choice and Access Act will not pass in its current form before January 2027", "confidence": 81, "category": "legislation", "geography": "USA", "resolve_date": "2027-01-15", "tags": [ "PCAA", "psychedelic-legislation", "FDA", "DEA" ], "status": "pending", "priority": "high", "plain_title": "Patient Choice Act won't pass Congress before January 2027", "plain_what": "Congress is considering a bill that would let patients access psychedelic treatments outside of FDA (the US drug regulator) oversight. It probably won't become law in the next two years because it lacks safety rules that FDA needs, and Congress has too many other priorities. This matters because it affects whether patients can legally get these treatments soon." }, { "date": "2026-06-09", "title": "Any NDAA ibogaine research exemption enacted in 2026 will include DEA scheduling review requirements delaying implementation by at least 12 months post-enactment", "confidence": 77, "category": "regulation", "geography": "USA", "resolve_date": "2028-06-01", "tags": [ "ibogaine", "DEA", "NDAA", "scheduling" ], "status": "pending", "priority": "high", "plain_title": "DEA will delay any ibogaine research rule by at least 12 months", "plain_what": "If Congress passes a law letting researchers study ibogaine (a plant alkaloid with addiction-treatment potential), the DEA (the US drug enforcement agency) controls when it actually happens. The DEA will take at least a year to implement it, even after Congress acts, because that's how the agency has always handled cannabis research exemptions. This delays actual research." }, { "date": "2026-06-09", "title": "CMPS (Compass Pathways) closes below $9.50 on at least one trading day before September 30, 2026, absent Phase 3 data release", "confidence": 74, "category": "market", "geography": "USA", "resolve_date": "2026-09-30", "tags": [ "CMPS", "Compass-Pathways", "psychedelic-biotech", "Phase-3" ], "status": "pending", "priority": "high", "plain_title": "Compass Pathways stock drops below $9.50 before September 2026", "plain_what": "Compass Pathways, a company developing psilocybin therapy, is showing signs of institutional investors selling off shares. Without major positive news (like successful late-stage trial results), the stock will probably dip below $9.50 at some point in the next nine months. This matters because it signals investor confidence is fragile." }, { "date": "2026-06-09", "title": "Ketamine infrastructure equities will outperform the XBI (SPDR S&P Biotech ETF) on a total return basis through Q4 2026", "confidence": 73, "category": "market", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "ketamine", "biotech", "XBI", "psychedelic-equities" ], "status": "pending", "priority": "high", "plain_title": "Ketamine clinics will outperform biotech index through end of 2026", "plain_what": "Ketamine is already approved and clinics are already operating profitably. Newer psychedelic companies are still waiting for FDA approval and burning cash on trials. Because ketamine has proven revenue and low regulatory risk, investors should get better returns from ketamine-focused companies than from the broader biotech sector. This matters because it shows where smart money is moving." }, { "date": "2026-06-09", "title": "FDA will issue a formal public communication cautioning against extrapolating single-case psilocybin reports to clinical practice by Q1 2027", "confidence": 72, "category": "regulation", "geography": "USA", "resolve_date": "2027-02-28", "tags": [ "psilocybin", "FDA", "Alzheimer's", "case-report" ], "status": "pending", "priority": "high", "plain_title": "FDA warns against using single anecdotes as proof of psilocybin cures", "plain_what": "A few viral stories online claim psilocybin cured someone's Alzheimer's disease. When enough people see these stories, patients and doctors start asking for the treatment, even though one person getting better doesn't prove it works. The FDA (the US drug regulator) will probably issue a formal warning telling doctors and patients not to believe these individual stories. This matters because it protects people from trying unproven treatments." }, { "date": "2026-06-10", "title": "No federal rescheduling (final rule or interim final rule) of psilocybin, MDMA, or ibogaine occurs in calendar year 2026", "confidence": 91, "category": "regulation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "psilocybin", "MDMA", "ibogaine", "DEA", "FDA" ], "status": "pending", "priority": "high", "plain_title": "Psilocybin, MDMA, and ibogaine stay fully illegal federally in 2026", "plain_what": "The US government will not change the legal status of these three drugs in 2026. For this to happen, the FDA (the US drug regulator) would first need to approve one of them as a medicine \u2014 and none are approved yet. The bureaucratic process alone takes well over a year even after someone kicks it off, and nobody has." }, { "date": "2026-06-10", "title": "No standalone federal psychedelic rescheduling or legalization bill passes a floor vote in either chamber of Congress in calendar year 2026", "confidence": 86, "category": "legislation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "Congress", "psilocybin", "MDMA", "ibogaine" ], "status": "pending", "priority": "high", "plain_title": "Congress will not vote on any bill to legalize or reschedule psychedelics in 2026", "plain_what": "No bill whose main goal is changing the legal status of psychedelics will get a formal vote on the floor of the US House or Senate in 2026. Congress has a packed schedule of budget fights and election-year politics, and historically any psychedelic policy wins have been slipped into bigger bills \u2014 not pushed as standalone laws." }, { "date": "2026-06-10", "title": "A major national outlet (NYT, WaPo, WSJ, ProPublica, New Yorker, Bloomberg, or equivalent) publishes an investigative expos\u00e9 on ketamine clinic deaths, telehealth prescribing practices, or clinic-chain financial misconduct by Q1 2027", "confidence": 78, "category": "culture", "geography": "USA", "resolve_date": "2027-03-31", "tags": [ "ketamine", "media", "telehealth" ], "status": "pending", "priority": "high", "plain_title": "A major news outlet will publish a hard-hitting investigation into ketamine clinics by early 2027", "plain_what": "A well-known national news organization \u2014 think the New York Times, Washington Post, or similar \u2014 will publish a deep investigative piece on ketamine clinics before the end of March 2027. Reporters are already working on it, the death of actor Matthew Perry showed editors this story has public appetite, and the ketamine clinic industry has expanded fast with very little oversight." }, { "date": "2026-06-10", "title": "FDA or DEA initiates formal regulatory or enforcement action targeting compounded ketamine telehealth prescribing by Q1 2027", "confidence": 74, "category": "regulation", "geography": "USA", "resolve_date": "2027-03-31", "tags": [ "ketamine", "FDA", "DEA", "telehealth", "compounding" ], "status": "pending", "priority": "high", "plain_title": "US regulators will crack down on ketamine prescribing via telehealth by early 2027", "plain_what": "The FDA (the US drug regulator) or the DEA (the US drug enforcement agency) will take formal action \u2014 think new rules, warning letters, or enforcement cases \u2014 targeting the booming business of prescribing ketamine through online video appointments. Ketamine clinics have multiplied rapidly with loose oversight, and regulators already have a track record of flagging these practices." }, { "date": "2026-06-10", "title": "DEA issues at least one official public statement in 2026 asserting Controlled Substances Act supremacy over state-authorized ibogaine programs", "confidence": 70, "category": "regulation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "ibogaine", "DEA", "states" ], "status": "pending", "priority": "high", "plain_title": "The DEA will publicly warn that federal drug law overrides state ibogaine programs in 2026", "plain_what": "The DEA (the US drug enforcement agency) will likely put out an official public statement in 2026 making clear that ibogaine \u2014 a powerful psychedelic being explored as an addiction treatment \u2014 is still illegal under federal law, regardless of what individual states allow. States like Texas are starting to authorize ibogaine programs, and the DEA has historically pushed back when states get too far ahead of federal law." }, { "date": "2026-06-11", "title": "No standalone psychedelic reform bill receives a floor vote in the U.S. House or Senate in calendar year 2026; any federal psychedelic policy advancement occurs only via riders or amendments attached to must-pass vehicles (NDAA, appropriations, VA funding).", "confidence": 80, "category": "legislation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "legislation", "veteran" ], "status": "pending", "priority": "high", "plain_title": "Psychedelic drug reform bills won't get a real vote in 2026", "plain_what": "No standalone bill to change federal psychedelic drug laws will get a full vote in the US Congress in 2026. Instead, any small wins will be hidden inside giant must-pass bills like the military budget or veterans' funding. This matters because it means sweeping federal change stays off the table for at least another year." }, { "date": "2026-06-11", "title": "A major national outlet (NYT, WaPo, WSJ, ProPublica, STAT, Bloomberg, or The Atlantic) publishes an investigative piece on licensed ketamine clinic chains \u2014 covering adverse events, prescribing practices, or investor pressure on clinical decisions \u2014 by 2026-12-11.", "confidence": 74, "category": "culture", "geography": "USA", "resolve_date": "2026-12-11", "tags": [ "ketamine", "media" ], "status": "pending", "priority": "medium", "plain_title": "A major news outlet will expose ketamine clinic bad practices", "plain_what": "A top-tier news organization like the New York Times, Wall Street Journal, or ProPublica is likely to publish a deep investigative story about ketamine clinic chains by end of 2026. The story will probably focus on patient safety incidents, sloppy prescribing, or business pressure overriding medical judgment. This matters because ketamine is currently the only legal psychedelic-style treatment widely available, and millions of people are using it." }, { "date": "2026-06-11", "title": "An ibogaine-for-veterans provision \u2014 research funding, a pilot program, or state-program authorization language \u2014 is attached to the FY2027 NDAA or VA/MilCon appropriations bill as reported out of committee or passed by either chamber.", "confidence": 68, "category": "legislation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "ibogaine", "veteran", "legislation" ], "status": "pending", "priority": "high", "plain_title": "Veterans may get ibogaine treatment funding tucked into military bill", "plain_what": "There's a decent chance that a provision allowing research into or piloting ibogaine treatment for veterans gets attached to the 2027 US military budget or veterans' funding bill. Ibogaine is a powerful psychedelic being studied for addiction and trauma, and veterans are the most politically safe group to fund it for. If this passes, it would be the first time the federal government puts real money behind ibogaine." }, { "date": "2026-06-11", "title": "DEA announces at least one public enforcement action (registration revocation, settlement, indictment, or formal order to show cause) against a licensed ketamine clinic chain or telehealth ketamine prescriber by 2027-03-11.", "confidence": 65, "category": "regulatory", "geography": "USA", "resolve_date": "2027-03-11", "tags": [ "ketamine", "DEA", "enforcement" ], "status": "pending", "priority": "medium", "plain_title": "The DEA will crack down on at least one ketamine provider", "plain_what": "The DEA (the US Drug Enforcement Administration, which polices drug distribution) is likely to publicly punish at least one licensed ketamine clinic or online ketamine prescriber before early 2027 \u2014 through a license revocation, a formal legal order, or a settlement. Ketamine is a controlled substance, and the DEA has been watching the rapid expansion of ketamine telehealth with growing concern. This would send a clear warning shot to the whole industry." }, { "date": "2026-06-11", "title": "At least two additional VA medical centers (beyond Chicago) publicly announce or begin enrolling patients in psilocybin-assisted therapy programs by 2027-06-11.", "confidence": 60, "category": "research", "geography": "USA", "resolve_date": "2027-06-11", "tags": [ "psilocybin", "VA", "veteran" ], "status": "pending", "priority": "medium", "plain_title": "Two more VA hospitals may launch psilocybin therapy programs", "plain_what": "Beyond the VA (Department of Veterans Affairs) hospital in Chicago that already has a psilocybin program, there's a reasonable chance at least two more VA facilities will announce or start enrolling veterans in psilocybin-assisted therapy by mid-2027. This would mark a real expansion of psychedelic therapy within the largest healthcare system in the country. Veterans with PTSD (post-traumatic stress disorder) and depression would be the first to benefit." }, { "date": "2026-06-12", "title": "No federal rescheduling of psilocybin or MDMA occurs before December 31, 2026; any CSA scheduling change in this cycle happens only via the mandatory review triggered by an FDA approval, not congressional action.", "confidence": 80, "category": "legislation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "psilocybin", "MDMA", "FDA", "CSA" ], "status": "pending", "priority": "high", "plain_title": "Congress won't change psilocybin or MDMA drug laws by 2026", "plain_what": "Right now, psilocybin and MDMA sit in the strictest category of controlled substances. The only realistic path to changing that is if the US drug regulator (FDA (the US Food and Drug Administration)) first approves one of them as a medicine \u2014 which would then force a legal reclassification automatically. Politicians won't touch this issue before that happens because the political risk is too high." }, { "date": "2026-06-12", "title": "The psilocybin-dementia case study produces a hype-then-correction cycle by August 11, 2026: at least two mainstream outlets (top-50 circulation/traffic) publish coverage overstating the n=1 findings, followed by at least one published expert rebuttal, fact-check, or scientist-authored corrective op-ed.", "confidence": 72, "category": "culture", "geography": "Global", "resolve_date": "2026-08-11", "tags": [ "psilocybin", "media", "dementia" ], "status": "pending", "priority": "high", "plain_title": "Psilocybin and dementia headlines will mislead \u2014 then get corrected", "plain_what": "A single case study (meaning one patient, not a proper trial) about psilocybin possibly helping someone with dementia is likely to get picked up by major news outlets and reported as much bigger news than it actually is. Then experts will push back publicly and explain why one patient's story doesn't prove anything. This cycle \u2014 hype, then correction \u2014 has happened before with psychedelics research." }, { "date": "2026-06-12", "title": "DEA publicly announces enforcement actions (orders to show cause, registrant revocations, immediate suspension orders, or settlements) against at least two distinct ketamine telehealth platforms or high-volume ketamine prescribers by March 31, 2027.", "confidence": 62, "category": "enforcement", "geography": "USA", "resolve_date": "2027-03-31", "tags": [ "ketamine", "DEA", "telehealth" ], "status": "pending", "priority": "medium", "plain_title": "US drug cops will crack down on at least two ketamine telehealth companies", "plain_what": "The DEA (Drug Enforcement Administration, the US agency that enforces drug laws) has been investigating online ketamine prescription services that mail ketamine to patients at home. By early 2027, at least two of those companies or high-volume prescribers are expected to face formal legal or administrative action \u2014 meaning license threats, suspensions, or settlements. This matters because it signals the era of loosely regulated at-home ketamine is ending." }, { "date": "2026-06-12", "title": "FDA issues a formal safety communication, drug safety alert, or compounding risk alert specifically addressing compounded or at-home ketamine use by March 31, 2027.", "confidence": 58, "category": "regulation", "geography": "USA", "resolve_date": "2027-03-31", "tags": [ "ketamine", "FDA", "safety-communication" ], "status": "pending", "priority": "medium", "plain_title": "FDA will issue an official warning about at-home and compounded ketamine", "plain_what": "The FDA (the US drug regulator) already warned about compounded ketamine in 2023 \u2014 meaning ketamine mixed or repackaged by pharmacies outside of normal manufacturing standards. Based on growing evidence of unsafe practices in telehealth ketamine prescribing, a new or updated safety alert is expected by early 2027. This would be the government officially telling the public: this specific form of ketamine use carries real risks." }, { "date": "2026-06-13", "title": "DEA will maintain Schedule I status for psilocybin and MDMA throughout 2026.", "confidence": 85, "category": "regulatory", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "psilocybin", "MDMA", "DEA", "Schedule I" ], "status": "pending", "priority": "high", "plain_title": "Psilocybin and MDMA stay in the most restricted drug category through 2026", "plain_what": "The DEA (the US agency that controls which drugs are legal and how strictly) keeps psilocybin and MDMA on its most-restricted list, Schedule I, meaning they're treated the same as heroin \u2014 no accepted medical use, no prescriptions. This matters because until the FDA (the US drug regulator) approves a specific drug product, the DEA has no legal trigger to move these substances off that list. Real people hoping to access these treatments through normal healthcare channels will have to wait longer." }, { "date": "2026-06-13", "title": "No psychedelic NDA will receive FDA approval in 2026; any reviewed application will face demands for confirmatory durability data and functional-unblinding mitigation.", "confidence": 76, "category": "regulatory", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "FDA", "NDA", "psychedelics" ], "status": "pending", "priority": "high", "plain_title": "No psychedelic drug gets full FDA approval in 2026", "plain_what": "The FDA will not fully approve any psychedelic-based medicine this year. The main reason: drug companies haven't solved two big problems \u2014 first, their studies are hard to run fairly because people almost always know whether they got the real drug (you can tell when you're tripping), and second, we don't yet know how long the benefits last. The FDA won't approve something when those gaps exist, because its job is to protect patients from treatments that might not work as advertised." }, { "date": "2026-06-13", "title": "No federal psychedelic legalization or rescheduling will advance in 2026; only research-access and veteran-focused measures will progress.", "confidence": 75, "category": "legislation", "geography": "USA", "resolve_date": "2026-12-10", "tags": [ "veteran", "legalization", "federal" ], "status": "pending", "priority": "high", "plain_title": "Congress won't broadly legalize psychedelics in 2026 \u2014 only veterans get traction", "plain_what": "There will be no big federal move to legalize or reclassify psychedelics for general use in 2026. The only psychedelic-related laws that actually move forward will be narrow ones focused on giving military veterans access to these treatments. This matters because it means the path to broader access stays blocked for most people, while veterans \u2014 a politically protected group \u2014 may get a limited early door opened for them." }, { "date": "2026-06-13", "title": "At least two high-impact peer-reviewed publications on psilocybin's mechanism (e.g., 5-HT2A signaling, microglial density) will appear by September 2026.", "confidence": 74, "category": "research", "geography": "Global", "resolve_date": "2026-09-11", "tags": [ "psilocybin", "5-HT2A", "neuroscience" ], "status": "pending", "priority": "medium", "plain_title": "Scientists publish major new findings on exactly how psilocybin works in the brain", "plain_what": "By September 2026, at least two serious, peer-reviewed scientific papers will explain the specific brain mechanics behind psilocybin \u2014 things like which receptors it activates and how it affects immune cells in the brain. This matters because understanding the 'why' behind psilocybin's effects helps researchers design better treatments, predict side effects, and eventually build new drugs that work similarly but might be easier to control." }, { "date": "2026-06-13", "title": "Veteran-framed access will be the only psychedelic policy category to gain measurable legislative momentum (bill introduction, hearing, or pilot funding) by June 2027.", "confidence": 70, "category": "policy", "geography": "USA", "resolve_date": "2027-06-13", "tags": [ "veteran", "policy" ], "status": "pending", "priority": "medium", "plain_title": "Veterans will be the only group to win new psychedelic access laws by mid-2027", "plain_what": "By June 2027, the only psychedelic policy that actually moves through any government body \u2014 a bill introduced, a hearing held, or real money allocated \u2014 will be specifically framed around helping veterans. This matters because politicians across party lines find it very hard to vote against veterans, which gives those bills a unique political advantage that general psychedelic reform simply doesn't have right now." }, { "date": "2026-06-14", "title": "FDA issues no psychedelic approval decision in 2026, requiring additional confirmatory data first.", "confidence": 74, "category": "regulation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "FDA" ], "status": "pending", "priority": "medium", "plain_title": "US drug regulator won't approve any psychedelic medicine in 2026", "plain_what": "The FDA (the US drug regulator) looks set to ask companies for more proof before greenlighting any psychedelic as an official medicine in 2026. This means no psychedelic drug will become a standard, insurance-covered prescription treatment next year. People hoping for a legal medical option will need to wait longer." }, { "date": "2026-06-14", "title": "No federal psychedelic rescheduling passes in 2026.", "confidence": 72, "category": "legislation", "geography": "USA", "resolve_date": "2026-12-11", "tags": [], "status": "pending", "priority": "medium", "plain_title": "Federal law on psychedelics will not change in 2026", "plain_what": "Congress is not expected to pass any law that changes how the US federal government classifies psychedelics in 2026. Right now psychedelics like psilocybin and MDMA sit in the strictest category of controlled substances, meaning they're treated like drugs with no medical value and high abuse risk. That legal status looks set to stay the same." }, { "date": "2026-06-14", "title": "No federal psychedelic rescheduling legislation passes in 2026.", "confidence": 72, "category": "legislation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "legislation" ], "status": "pending", "priority": "medium", "plain_title": "Congress will not pass any psychedelic law reform in 2026", "plain_what": "Lawmakers in Washington are focused on other priorities and don't have the votes to change federal psychedelic laws in 2026. The political conditions simply aren't there yet. This matters because without a federal law change, psychedelics remain fully illegal across the whole country regardless of state rules." }, { "date": "2026-06-14", "title": "Mechanistic/preclinical findings outpace validated clinical translation throughout 2026.", "confidence": 72, "category": "research", "geography": "Global", "resolve_date": "2026-12-31", "tags": [], "status": "pending", "priority": "medium", "plain_title": "Lab discoveries about psychedelics will race ahead of real-world clinical proof in 2026", "plain_what": "Scientists in labs will keep making exciting discoveries about how psychedelics affect the brain in 2026, mostly using animal studies and new research tools. But turning those discoveries into treatments proven to work safely in humans takes much longer. This gap between 'what we're finding in the lab' and 'what we can actually offer patients' will stay wide." }, { "date": "2026-06-14", "title": "Mechanistic research outpaces validated clinical translation in 2026.", "confidence": 70, "category": "research", "geography": "Global", "resolve_date": "2026-09-12", "tags": [], "status": "pending", "priority": "medium", "plain_title": "Brain science on psychedelics will outrun human clinical proof in 2026", "plain_what": "Researchers will learn a lot more about what psychedelics do inside the brain in 2026, but that knowledge will move faster than large, rigorous human trials can confirm. This matters because understanding a mechanism doesn't mean a treatment is ready \u2014 you still need proof it works safely in thousands of real patients over time." }, { "date": "2026-06-15", "title": "No federal rescheduling of any classic psychedelic (psilocybin, LSD, DMT, mescaline) occurs before 2027-06-15.", "confidence": 85, "category": "regulatory", "geography": "USA", "resolve_date": "2027-06-15", "tags": [ "DEA", "rescheduling" ], "status": "pending", "priority": "high", "plain_title": "Psychedelics stay in the most restricted drug category until at least mid-2027", "plain_what": "Right now, classic psychedelics like psilocybin and LSD sit in Schedule I \u2014 the US government's most restricted drug category, meaning they're treated as having no medical use. Moving them to a less restricted category requires the DEA (the Drug Enforcement Administration, which controls which drugs are legal) to act, and the DEA only does that after the FDA (the US drug regulator) approves a drug for medical use. Since no FDA approval is coming soon, the legal status of these substances won't change before June 2027. This matters because Schedule I status is what makes research hard, keeps therapists from legally offering these treatments, and blocks insurance coverage." }, { "date": "2026-06-15", "title": "No FDA psychedelic approval or advisory committee action occurs before Q4 2026.", "confidence": 80, "category": "regulatory", "geography": "USA", "resolve_date": "2026-10-01", "tags": [ "FDA" ], "status": "pending", "priority": "high", "plain_title": "No psychedelic drug will get FDA approval or a formal review meeting before late 2026", "plain_what": "Before the FDA approves any drug, it usually holds a public advisory committee meeting \u2014 basically a panel of outside experts who debate whether the evidence is strong enough. Right now, no such meeting is scheduled for any psychedelic drug, and the FDA's calendar is empty on this front. The most recent attempt, MDMA for PTSD, was rejected partly because of problems with how the clinical trials were run. Until those problems are solved, nothing moves forward. This matters because FDA approval is the gateway to legal prescriptions, insurance coverage, and wider access." }, { "date": "2026-06-15", "title": "No psychedelic-specific federal bill reaches a floor vote in either chamber of Congress before 2026-09-15.", "confidence": 80, "category": "legislation", "geography": "USA", "resolve_date": "2026-09-15", "tags": [ "legislation" ], "status": "pending", "priority": "high", "plain_title": "Congress won't hold a full floor vote on any psychedelic-focused bill before fall 2026", "plain_what": "A few psychedelic-related bills exist in Congress, but they're stuck in committee \u2014 meaning a small group of lawmakers haven't even agreed to send them to the full House or Senate for a vote yet. Congress is currently focused on defense spending and energy policy, and psychedelic mental health bills aren't anywhere near the top of the priority list. Without a floor vote, no new federal law on psychedelics can pass. This matters because federal law is what would create a nationwide framework for legal psychedelic therapy." }, { "date": "2026-06-15", "title": "FDA does not approve MDMA-assisted therapy for PTSD before 2026-09-13.", "confidence": 78, "category": "regulatory", "geography": "USA", "resolve_date": "2026-09-13", "tags": [ "MDMA", "FDA", "PTSD" ], "status": "pending", "priority": "high", "plain_title": "The FDA will not approve MDMA as a PTSD treatment before September 2026", "plain_what": "MDMA-assisted therapy for PTSD (post-traumatic stress disorder) was the closest any psychedelic had come to FDA approval, but in 2024 the FDA sent it back and asked for more evidence. The main problems were that trial participants could easily tell whether they got the real drug or a placebo, which compromises the reliability of the results, and that the data overall wasn't convincing enough. Fixing those issues and running new studies takes years. This matters because approval would have been a historic moment \u2014 the first legal psychedelic therapy in the US \u2014 and its delay pushes back everything else in the field." }, { "date": "2026-06-15", "title": "No first-in-human clinical trial of psilocybin for TBI/neuroplasticity indications registers or dosing-initiates before 2027-06-15.", "confidence": 72, "category": "research", "geography": "Global", "resolve_date": "2027-06-15", "tags": [ "psilocybin", "TBI", "preclinical" ], "status": "pending", "priority": "medium", "plain_title": "No human trial of psilocybin for brain injury recovery will start before mid-2027", "plain_what": "Some animal studies suggest psilocybin might help the brain rewire itself after injury \u2014 a property called neuroplasticity. But animal results and human trials are very different things. Before researchers can give psilocybin to a human with a brain injury, they need to figure out the right dose, prove it's safe for that specific condition, and get government permission (called an IND, or Investigational New Drug application) from the FDA. That groundwork simply hasn't been done yet for traumatic brain injury. This matters because if the animal findings do translate to humans, it could open a completely new use for psilocybin beyond mental health." }, { "date": "2026-06-16", "title": "DEA maintains Schedule I status for non-FDA-approved psychedelics (MDMA, psilocybin) through end of 2027", "confidence": 78, "category": "regulation", "geography": "USA", "resolve_date": "2027-12-31", "tags": [ "DEA", "Schedule I" ], "status": "pending", "priority": "high", "plain_title": "MDMA and psilocybin stay federally illegal through 2027", "plain_what": "The DEA (the US agency that controls which drugs are legal) won't change the status of MDMA or psilocybin until the FDA (the US drug regulator) officially approves one of them as a medicine \u2014 and that approval hasn't happened yet. Until it does, both substances remain in the strictest legal category, meaning possession and use are federal crimes. This affects millions of people who might benefit from these treatments but can't access them legally." }, { "date": "2026-06-16", "title": "FDA will require at least one additional confirmatory MDMA-PTSD trial before granting any approval", "confidence": 72, "category": "regulation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "MDMA", "FDA", "PTSD" ], "status": "pending", "priority": "high", "plain_title": "FDA will demand another full MDMA trial before approving it", "plain_what": "In 2024, the FDA rejected the first application to approve MDMA-assisted therapy for PTSD (post-traumatic stress disorder), raising concerns about how the studies were run and whether participants could tell if they got the drug or a fake pill \u2014 which can skew results. The FDA is now expected to require a brand-new, large-scale clinical trial before it will reconsider approval. This means patients hoping for a legal MDMA therapy option are likely years away from getting one." }, { "date": "2026-06-16", "title": "No validated, FDA-recognized predictive neuroimaging or molecular biomarker for psychedelic therapy response is established by end of 2027", "confidence": 70, "category": "research", "geography": "Global", "resolve_date": "2027-12-31", "tags": [ "biomarkers", "neuroscience" ], "status": "pending", "priority": "medium", "plain_title": "No reliable biological test for predicting psychedelic therapy success by 2027", "plain_what": "Scientists are studying brain scans and biological markers trying to figure out in advance which patients will respond best to psychedelic therapy \u2014 the same way a blood test can predict how someone will respond to certain cancer drugs. Despite lots of promising research, nobody will have a test that's actually validated and ready for real clinical use by the end of 2027. This matters because without such a test, doctors can't reliably match patients to treatments." }, { "date": "2026-06-16", "title": "At least one additional US state enacts or operationalizes a psychedelic access/therapy program by mid-2027", "confidence": 65, "category": "legislation", "geography": "USA", "resolve_date": "2027-06-30", "tags": [ "state policy", "psilocybin" ], "status": "pending", "priority": "medium", "plain_title": "At least one more US state will open a legal psychedelic therapy program by mid-2027", "plain_what": "Oregon and Colorado have already created legal, regulated programs where trained facilitators can guide people through psilocybin (the active ingredient in magic mushrooms) sessions. Several other states are moving similar bills through their legislatures, and at least one is expected to pass and begin operating by mid-2027. This gradually expands where Americans can legally access this kind of therapy without traveling abroad." }, { "date": "2026-06-17", "title": "No classic psychedelic (psilocybin, LSD, DMT, mescaline) is rescheduled out of Schedule I by the DEA in 2026.", "confidence": 85, "category": "regulation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "Schedule I", "DEA" ], "status": "pending", "priority": "high", "plain_title": "Psychedelics stay illegal at the federal level through 2026", "plain_what": "The DEA (the US agency that controls which drugs are legal) can only move a drug out of its most restricted category after the FDA (the US drug regulator) approves it as medicine. Since no psychedelic drug is close to FDA approval, nothing changes in 2026. People caught with psilocybin, LSD, DMT, or mescaline still face full federal criminal penalties." }, { "date": "2026-06-17", "title": "No standalone federal psychedelic legalization or rescheduling bill is enacted into law in 2026; any movement is limited to research-funding or veteran-treatment riders.", "confidence": 82, "category": "legislation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "legislation" ], "status": "pending", "priority": "high", "plain_title": "Congress won't pass a broad psychedelics law in 2026", "plain_what": "A handful of lawmakers support spending money on psychedelic research or giving military veterans access to experimental treatments, but there is no serious political appetite to legalize or broadly reschedule these drugs at the national level. Any psychedelic-related measures that do pass will be small add-ons tucked inside larger bills \u2014 not landmark legislation." }, { "date": "2026-06-17", "title": "No psychedelic NDA receives FDA approval in 2026; FDA activity remains limited to guidance documents and adcomm scheduling.", "confidence": 80, "category": "regulation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "FDA", "NDA" ], "status": "pending", "priority": "high", "plain_title": "No psychedelic drug gets FDA approval in 2026", "plain_what": "For the FDA to approve a psychedelic as medicine, companies must prove in large clinical trials that the drug works better than a placebo \u2014 and that's genuinely hard to do with psychedelics because participants almost always know whether they got the real drug. That unsolved problem, plus the slow pace of trials, means no psychedelic medicine lands on pharmacy shelves in 2026." }, { "date": "2026-06-17", "title": "CMPS retraces at least 50% of its 2026-06-17 single-day gain within three weeks absent a Phase 3 or adcomm catalyst.", "confidence": 70, "category": "market", "geography": "Global", "resolve_date": "2026-07-08", "tags": [ "CMPS" ], "status": "pending", "priority": "high", "plain_title": "A psychedelic stock's big one-day spike likely fades fast", "plain_what": "CMPS is a psychedelic drug company whose stock jumped sharply on a single day in mid-June 2026. When a stock pops on a headline rather than a major clinical result \u2014 like a successful large trial or a key regulatory meeting \u2014 it usually falls back toward where it started within a few weeks. Other companies in the same space didn't rise at the same time, suggesting this was hype around one piece of news, not a real shift in the sector." }, { "date": "2026-06-17", "title": "The 2026-06-17 single-patient Alzheimer's-psilocybin reversal claim is publicly walked back, contextualized, or corrected by the originating party or major coverage within four weeks.", "confidence": 68, "category": "culture", "geography": "Global", "resolve_date": "2026-07-15", "tags": [ "psilocybin", "Alzheimers" ], "status": "pending", "priority": "medium", "plain_title": "The dramatic Alzheimer's-psilocybin claim will likely get walked back", "plain_what": "A report from mid-June 2026 claimed one single patient with Alzheimer's appeared to dramatically improve after psilocybin treatment. One patient is not enough to draw any real conclusions \u2014 it could be coincidence, a good day, or a measurement fluke. Claims like this almost always get quietly corrected or heavily qualified once scientists and journalists look more carefully, usually within a month." }, { "date": "2026-06-18", "title": "Any psilocybin or MDMA approval this cycle ships with a mandatory REMS requiring certified sites and trained monitors.", "confidence": 82, "category": "regulation", "geography": "Global", "resolve_date": "2026-12-31", "tags": [ "psilocybin", "MDMA" ], "status": "pending", "priority": "high", "plain_title": "Approved psychedelic drugs will only be available at licensed, supervised clinics", "plain_what": "If the FDA (the US drug regulator) approves psilocybin or MDMA for medical use, it will attach a strict safety program called a REMS (Risk Evaluation and Mitigation Strategy). This means you could only get the treatment at specially certified locations with trained staff watching over you \u2014 not at a regular doctor's office or at home. This limits how many people can actually access the treatment, at least at first." }, { "date": "2026-06-18", "title": "No full federal rescheduling of psilocybin passes this year; FDA and DEA tracks stay separate.", "confidence": 80, "category": "legislation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "psilocybin", "FDA", "DEA" ], "status": "pending", "priority": "high", "plain_title": "Magic mushrooms will stay federally illegal all year, no matter what", "plain_what": "Even though some states have loosened their rules around psilocybin (the active ingredient in 'magic mushrooms'), the federal government won't change its nationwide rules this year. The FDA (the US drug regulator) and the DEA (the federal drug enforcement agency) each have their own separate, slow-moving processes \u2014 and neither is ready to act. This means psilocybin remains a Schedule I drug federally, the same legal category as heroin." }, { "date": "2026-06-18", "title": "No full federal rescheduling of psilocybin this year; FDA approval and DEA scheduling remain separate, slower tracks.", "confidence": 79, "category": "legislation", "geography": "USA", "resolve_date": "2026-12-15", "tags": [ "psilocybin", "FDA", "DEA" ], "status": "pending", "priority": "high", "plain_title": "Psilocybin remains federally illegal this year; federal approval and scheduling are separate slow processes", "plain_what": "Multiple experts \u2014 a lawmaker, a DEA (federal drug enforcement) officer, and an FDA (drug regulator) reviewer \u2014 all broadly agree: federal rules on psilocybin won't change this year. Getting a drug approved for medicine and changing its legal scheduling are two different government processes that move at different speeds, and neither is finishing this year. One expert disagreed, but the strong consensus says status quo holds." }, { "date": "2026-06-18", "title": "DEA does not reschedule psilocybin this year even if FDA approves; scheduling review lags approval substantially.", "confidence": 78, "category": "regulation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "psilocybin", "FDA", "DEA" ], "status": "pending", "priority": "high", "plain_title": "DEA won't change psilocybin's legal status even if the FDA approves it for medicine", "plain_what": "Here's something surprising: even if the FDA (the US drug regulator) officially approves psilocybin as a medicine, that doesn't automatically make it legal to prescribe or use. The DEA (the federal drug enforcement agency) runs a completely separate review process to decide what 'schedule' \u2014 meaning legal category \u2014 a drug belongs to, and that process is slow and cautious. So there could be a gap where psilocybin is technically FDA-approved but still federally illegal to distribute." }, { "date": "2026-06-18", "title": "Any near-term approval carries restrictive REMS with certified sites, limiting real-world access.", "confidence": 75, "category": "regulation", "geography": "Global", "resolve_date": "2026-09-16", "tags": [], "status": "pending", "priority": "high", "plain_title": "If approved, psychedelic treatments will only reach a small fraction of patients at first", "plain_what": "A group of experts \u2014 including an FDA (drug regulator) reviewer, a veterans' advocate, and a journalist \u2014 mostly agree that any first approval will come wrapped in tight restrictions on who can offer the treatment and where. These restrictions exist to protect patients, but they also mean that only a small number of clinics will be allowed to offer the therapy. For people who need it most \u2014 like veterans with PTSD \u2014 getting access could still require jumping through major hoops." }, { "date": "2026-06-19", "title": "Approval is gated by restrictive REMS plus a DEA scheduling lag, creating an access bottleneck.", "confidence": 74, "category": "regulatory", "geography": "USA", "resolve_date": "2026-09-17", "tags": [ "DEA" ], "status": "pending", "priority": "medium", "plain_title": "Drug approval rules and scheduling delays will limit who gets access", "plain_what": "Even after the US drug regulator approves a psychedelic medicine, a second government agency \u2014 the DEA (Drug Enforcement Administration) \u2014 must separately reclassify the drug before doctors can legally prescribe it. On top of that, strict safety rules called REMS (Risk Evaluation and Mitigation Strategies) will limit which clinics and providers can offer treatment. This means approval on paper does not equal treatment available in the real world." }, { "date": "2026-06-19", "title": "FDA approval arrives within 8 months and access scales faster than skeptics claim.", "confidence": 74, "category": "regulatory", "geography": "USA", "resolve_date": "2027-02-19", "tags": [ "FDA" ], "status": "pending", "priority": "medium", "plain_title": "A psychedelic drug could get approved and reach patients faster than expected", "plain_what": "Some experts believe the US drug regulator could approve a psychedelic medicine within eight months, and that treatment centers are already hiring and training staff in anticipation. The argument is that critics are underestimating how ready the system actually is. If true, people who need these treatments could get legal access sooner than most predictions suggest." }, { "date": "2026-06-19", "title": "DEA rescheduling lags FDA approval by 6+ months, creating a hard access bottleneck.", "confidence": 74, "category": "regulatory", "geography": "USA", "resolve_date": "2027-12-19", "tags": [ "FDA", "DEA" ], "status": "pending", "priority": "medium", "plain_title": "The DEA's separate drug reclassification will delay real patient access by at least six months", "plain_what": "Even after the US drug regulator approves a psychedelic medicine, the DEA must go through its own formal legal process to reclassify the drug \u2014 and that process cannot be rushed. This creates a hard stop between 'approved' and 'available.' Communities, especially vulnerable ones, could bear the cost if this step gets skipped or shortcut." }, { "date": "2026-06-19", "title": "An FDA psychedelic approval arrives within 9-12 months.", "confidence": 72, "category": "regulatory", "geography": "USA", "resolve_date": "2026-09-17", "tags": [ "FDA" ], "status": "pending", "priority": "medium", "plain_title": "A psychedelic medicine will likely get FDA approval within the next year", "plain_what": "A strong group of analysts and researchers believe the US drug regulator will formally approve a psychedelic-based medicine within nine to twelve months. This would be a historic milestone \u2014 the first time a psychedelic has been legally recognized as a medicine in the US. It would open the door to insurance coverage debates, clinical training programs, and a wave of follow-on research." }, { "date": "2026-06-19", "title": "An FDA psychedelic approval arrives within 9-12 months, unlocking bipartisan legislative movement.", "confidence": 72, "category": "regulatory", "geography": "USA", "resolve_date": "2027-04-19", "tags": [ "FDA" ], "status": "pending", "priority": "medium", "plain_title": "FDA approval of a psychedelic could spark real political action in Congress", "plain_what": "When the US drug regulator officially approves a psychedelic medicine, it may give politicians on both sides of the aisle the cover they need to push related laws \u2014 especially around access for veterans. Right now, many lawmakers support psychedelic therapy privately but won't act without the FDA's seal of legitimacy. An approval could break that logjam." }, { "date": "2026-06-20", "title": "DEA remains decoupled from any FDA action and does not reschedule within 12 months.", "confidence": 72, "category": "regulatory", "geography": "USA", "resolve_date": "2027-06-22", "tags": [ "FDA", "DEA" ], "status": "pending", "priority": "medium", "plain_title": "The DEA will not change psilocybin or MDMA's illegal status this year", "plain_what": "Even if the FDA (the US drug regulator) approves a psychedelic medicine, a completely separate agency \u2014 the DEA (the Drug Enforcement Administration) \u2014 controls whether it stays classified as a dangerous, restricted substance. These two agencies move independently, and the DEA is expected to hold its position for at least another 12 months. This matters because DEA classification determines who can legally prescribe, possess, and use a drug." }, { "date": "2026-06-20", "title": "Federal rescheduling does not reach a floor vote within 12 months; DEA stays decoupled from FDA approval.", "confidence": 71, "category": "legislation", "geography": "USA", "resolve_date": "2026-12-19", "tags": [ "FDA", "DEA" ], "status": "pending", "priority": "medium", "plain_title": "Congress will not vote on rescheduling psychedelics within 12 months", "plain_what": "For a drug's legal status to change at the federal level through Congress, lawmakers have to actually bring a bill to a full vote \u2014 and that's not expected to happen in the next year. The DEA will also continue operating independently from whatever the FDA decides. This matters because without a congressional vote or DEA action, the legal landscape for psychedelic medicines stays frozen." }, { "date": "2026-06-20", "title": "FDA requires a confirmatory MDMA trial or REMS-heavy conditional approval before broad market access.", "confidence": 70, "category": "regulatory", "geography": "USA", "resolve_date": "2027-03-31", "tags": [ "MDMA", "FDA", "market" ], "status": "pending", "priority": "medium", "plain_title": "The FDA will add major conditions before approving MDMA as a medicine", "plain_what": "The FDA is likely to either demand an additional round of clinical trials before approving MDMA-assisted therapy, or grant a very narrow, heavily restricted approval with strict safety monitoring requirements. This is because trial results had problems \u2014 participants could usually tell whether they got the real drug or a placebo, which muddies the data, and long-term effectiveness hasn't been proven. For patients with PTSD (post-traumatic stress disorder), this could mean approval is delayed or access is very limited." }, { "date": "2026-06-20", "title": "Psychedelic biotech swings >20% intraday on the next binary clinical or FDA catalyst within 9 months.", "confidence": 70, "category": "markets", "geography": "USA", "resolve_date": "2027-03-22", "tags": [ "FDA", "biotech" ], "status": "pending", "priority": "medium", "plain_title": "A psychedelic company's stock will jump or crash more than 20% in a single day", "plain_what": "Psychedelic biotech stocks are currently riding a wave of excitement and speculation, but that excitement isn't backed by solid, proven business results. When a major event happens \u2014 like an FDA decision or clinical trial results \u2014 the stock price tends to react violently, swinging wildly up or down in a single trading day. This kind of volatility can mean big gains or devastating losses for investors very quickly." }, { "date": "2026-06-20", "title": "Mechanistic research outpaces standardized clinical protocols, yielding heterogeneous real-world outcomes.", "confidence": 68, "category": "research", "geography": "Global", "resolve_date": "2027-06-22", "tags": [], "status": "pending", "priority": "medium", "plain_title": "Science is advancing faster than clinics can safely standardize psychedelic treatments", "plain_what": "Researchers are rapidly learning how psychedelics work in the brain, but that knowledge is moving faster than the ability to turn it into consistent, safe treatment guidelines for clinics. In the real world \u2014 especially with ketamine, which is already legally prescribed \u2014 outcomes vary wildly depending on who's giving the treatment and how. This gap between what scientists know and what clinicians reliably do is getting wider, not smaller." }, { "date": "2026-06-21", "title": "FDA will not approve any psychedelic NDA in 2026 absent a complete resubmission addressing functional unblinding.", "confidence": 74, "category": "regulation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "FDA", "psychedelics" ], "status": "pending", "priority": "high", "plain_title": "No psychedelic drug will get US approval in 2026", "plain_what": "The FDA (the US drug regulator) won't approve any psychedelic medicine next year unless companies completely redo their applications to fix a specific problem: participants in trials can usually tell whether they got the real drug or a placebo, which muddies the results. No company has fixed this yet, so approval is off the table for now. This delays access to potentially life-changing treatments for people with depression, PTSD, and addiction." }, { "date": "2026-06-21", "title": "No federal rescheduling of any Schedule I psychedelic will occur before FDA approval, through 2026.", "confidence": 74, "category": "legislation", "geography": "USA", "resolve_date": "2026-12-19", "tags": [ "DEA", "FDA", "rescheduling" ], "status": "pending", "priority": "high", "plain_title": "Psychedelics will stay in the most restricted drug category through 2026", "plain_what": "In the US, psychedelics like psilocybin and MDMA sit in Schedule I \u2014 the government's most restricted drug category, meaning they're treated as having no accepted medical use and high abuse potential. The DEA (the agency that enforces drug laws) almost always waits for the FDA to approve a drug before loosening those restrictions. Since no FDA approval is coming in 2026, the scheduling won't change either." }, { "date": "2026-06-21", "title": "Congress will not pass standalone federal psychedelic rescheduling legislation before FDA approval; any advancing measure will be veteran-focused pilot programs.", "confidence": 70, "category": "legislation", "geography": "USA", "resolve_date": "2027-06-22", "tags": [ "Congress", "veteran", "rescheduling" ], "status": "pending", "priority": "medium", "plain_title": "Congress will only fund small veteran-focused psychedelic pilot programs", "plain_what": "Rather than passing a broad law to change how psychedelics are classified, Congress will focus any psychedelic action narrowly on military veterans \u2014 a group with strong political sympathy on both sides of the aisle. Full rescheduling legislation has almost no political momentum, but small pilot programs for veterans with PTSD (post-traumatic stress disorder) give politicians a safe, popular thing to support. This shapes who gets early access \u2014 mostly veterans, not the general public." }, { "date": "2026-06-21", "title": "No psychedelic therapy will receive FDA approval based primarily on real-world evidence or case series by 2027-06-22.", "confidence": 69, "category": "research", "geography": "USA", "resolve_date": "2027-06-22", "tags": [ "FDA", "clinical-translation", "RWE" ], "status": "pending", "priority": "medium", "plain_title": "No psychedelic treatment approved using only real-world patient data by mid-2027", "plain_what": "Some advocates argue that real-world reports \u2014 stories from patients and clinicians, observational data \u2014 should be enough to get psychedelic therapies approved. The FDA disagrees: it requires carefully controlled studies where you compare a treatment group to a placebo group under strict conditions. No psychedelic therapy will clear that bar using only real-world evidence by June 2027. This matters because it means approval takes longer and costs much more." }, { "date": "2026-06-21", "title": "DEA will maintain Schedule I classification for psychedelics and issue at least one scrutiny action on telehealth ketamine prescribing by 2027-06-22.", "confidence": 68, "category": "regulation", "geography": "USA", "resolve_date": "2027-06-22", "tags": [ "ketamine", "DEA", "telehealth" ], "status": "pending", "priority": "high", "plain_title": "DEA will crack down on at-home ketamine prescribed over video call", "plain_what": "Ketamine is a legal anesthetic that doctors can prescribe off-label for depression, and a wave of telehealth companies now ship it to patients' homes after a video call. The DEA (the drug enforcement agency) has flagged this as a serious diversion risk \u2014 meaning the drug could end up misused or sold. By mid-2027, expect the DEA to issue at least one formal warning, rule, or enforcement action specifically targeting this kind of at-home ketamine prescribing." }, { "date": "2026-06-22", "title": "DEA does not reschedule psilocybin or MDMA out of Schedule I before 2026-12-31.", "confidence": 85, "category": "regulatory", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "psilocybin", "MDMA", "DEA", "FDA" ], "status": "pending", "priority": "high", "plain_title": "Psilocybin and MDMA stay on the US banned list through 2025", "plain_what": "The DEA (Drug Enforcement Administration, the US agency that controls which drugs are legal) cannot move psilocybin or MDMA off the most restricted category unless the FDA (the US drug regulator) first approves them as medicine. Since no FDA approval exists yet, the legal status stays frozen. This means anyone caught with these substances still faces serious federal criminal consequences." }, { "date": "2026-06-22", "title": "No federal legislation rescheduling psilocybin or MDMA is enacted in the 119th Congress before 2026-12-31.", "confidence": 80, "category": "legislation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "psilocybin", "MDMA", "legislation" ], "status": "pending", "priority": "high", "plain_title": "US Congress will not pass a law legalizing these drugs by 2025", "plain_what": "For Congress to reschedule psilocybin or MDMA, politicians would need to vote for it openly, without FDA approval giving them political cover. With midterm elections looming, most lawmakers see that vote as too risky. The result is that no new federal law changing the status of these drugs is likely to pass." }, { "date": "2026-06-22", "title": "Functional unblinding is cited as an unresolved limitation in at least one FDA advisory committee or major peer-reviewed publication on psychedelic trials before 2027-06-30.", "confidence": 80, "category": "research", "geography": "Global", "resolve_date": "2027-06-30", "tags": [ "unblinding", "trial-design" ], "status": "pending", "priority": "medium", "plain_title": "A key flaw in psychedelic drug trials will keep making headlines", "plain_what": "In psychedelic studies, participants almost always know whether they got the real drug or a placebo because the experience is so powerful and obvious. This is called 'functional unblinding,' and it makes it hard to know if the benefits come from the drug or from people simply expecting to feel better. Regulators and scientists are increasingly calling this out as a problem that no one has solved yet." }, { "date": "2026-06-22", "title": "No FDA approval of MDMA-assisted therapy for PTSD occurs before 2026-12-31.", "confidence": 78, "category": "regulatory", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "MDMA", "PTSD", "FDA" ], "status": "pending", "priority": "high", "plain_title": "MDMA therapy for trauma will not get US approval by end of 2025", "plain_what": "In August 2024, the FDA (the US drug regulator) rejected the first application to approve MDMA as a treatment for PTSD (post-traumatic stress disorder). The agency had concerns about participants knowing they were on the real drug, the potential for abuse, and problems with how the trials were run. To reapply, the company needs to run new large-scale trials, which will take years." }, { "date": "2026-06-22", "title": "Any FDA approval of an MDMA or psilocybin therapy through 2027-12-31 includes a REMS mandating monitored in-clinic dosing sessions.", "confidence": 74, "category": "regulatory", "geography": "USA", "resolve_date": "2027-12-31", "tags": [ "MDMA", "psilocybin", "REMS" ], "status": "pending", "priority": "medium", "plain_title": "Any approved psychedelic therapy must happen in a monitored clinic", "plain_what": "If MDMA or psilocybin ever gets FDA approval, the agency will almost certainly attach strict rules requiring patients to take the drug inside a licensed clinic while staff watch over them the whole time. These rules, called a REMS (Risk Evaluation and Mitigation Strategy), are how the FDA manages especially risky medicines. You would not be able to take an approved psychedelic therapy at home." }, { "date": "2026-06-23", "title": "DEA maintains Schedule I classification through 2026 even if FDA approves MDMA.", "confidence": 78, "category": "regulatory", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "MDMA", "FDA", "DEA", "Schedule I" ], "status": "pending", "priority": "high", "plain_title": "MDMA stays illegal federally even if the FDA approves it", "plain_what": "Even if the FDA (the US drug regulator) approves MDMA as a medicine, a separate government agency called the DEA (the Drug Enforcement Administration) controls which drugs are legal to possess. That rescheduling review takes at least a year, so MDMA will almost certainly stay in the most restricted legal category through 2026. This means patients can't just walk into a pharmacy to get it \u2014 the two approval processes don't move in sync." }, { "date": "2026-06-23", "title": "DEA maintains Schedule I status through 2026 even if FDA acts.", "confidence": 76, "category": "regulatory", "geography": "USA", "resolve_date": "2026-09-21", "tags": [ "FDA", "DEA", "Schedule I" ], "status": "pending", "priority": "high", "plain_title": "MDMA stays in the most restricted drug category through 2026", "plain_what": "Multiple independent experts agree that MDMA will remain a Schedule I drug (the same legal category as heroin \u2014 meaning no accepted medical use, according to the government) through 2026, even if the FDA approves it as a medicine. The DEA runs its own separate review, and that process takes time. Real people trying to access MDMA-assisted therapy legally will face continued barriers." }, { "date": "2026-06-23", "title": "No standalone federal psychedelic legalization passes in 2026; progress comes via riders and state action.", "confidence": 75, "category": "legislation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [], "status": "pending", "priority": "high", "plain_title": "No federal law legalizing psychedelics in 2026 \u2014 states lead the way", "plain_what": "Congress won't pass a stand-alone law legalizing psychedelics in 2026. The closest thing to federal movement will be small provisions tucked into larger bills \u2014 especially ones framed around helping military veterans. Meanwhile, states like Oregon and Colorado will keep pushing ahead on their own. This matters because your access to legal psychedelic therapy in 2026 will almost entirely depend on where you live." }, { "date": "2026-06-23", "title": "Any MDMA approval will carry a REMS with confirmatory-trial postmarketing requirements rather than clean approval.", "confidence": 74, "category": "regulatory", "geography": "Global", "resolve_date": "2026-12-31", "tags": [ "MDMA", "market" ], "status": "pending", "priority": "medium", "plain_title": "FDA will attach strict conditions to any MDMA approval \u2014 not a free pass", "plain_what": "If the FDA approves MDMA, it will come with a tight rulebook called a REMS (Risk Evaluation and Mitigation Strategy) \u2014 a set of safety guardrails that controls exactly who can prescribe it, where, and how. On top of that, drug makers will have to run more clinical trials after approval to keep proving it works and is safe. This is not unusual for risky drugs, but it means MDMA therapy won't spread quickly or cheaply even after approval." }, { "date": "2026-06-23", "title": "MDMA approval, if granted, arrives with REMS and confirmatory-trial conditions \u2014 not clean approval.", "confidence": 72, "category": "regulatory", "geography": "Global", "resolve_date": "2026-09-21", "tags": [ "MDMA" ], "status": "pending", "priority": "medium", "plain_title": "Any MDMA approval comes with tight restrictions and required follow-up studies", "plain_what": "A group of four experts \u2014 including regulators, investors, and lawmakers \u2014 agree that if MDMA gets FDA approval, it will come bundled with a REMS (a formal safety management program) and a requirement to keep running clinical trials after it's on the market. No one with FDA experience expects a clean, unrestricted approval for a psychedelic drug. This means slower rollout and higher costs for everyone in the system." }, { "date": "2026-06-24", "title": "No DEA rescheduling of psilocybin or MDMA occurs in 2026; any movement is FDA-driven and follows formal approval.", "confidence": 78, "category": "regulation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "psilocybin", "MDMA", "FDA", "DEA" ], "status": "pending", "priority": "high", "plain_title": "The DEA won't change psilocybin or MDMA's legal status in 2026", "plain_what": "The DEA (Drug Enforcement Administration, the agency that controls which drugs are legal and how strictly) won't downgrade psilocybin or MDMA from their current 'most dangerous, no accepted use' category in 2026. That can only happen after the FDA (the US drug safety regulator) formally approves one of these substances as a medicine \u2014 and no approval is close enough to trigger that process this year. This matters because reclassification is what would make these drugs legally accessible beyond tightly controlled research settings." }, { "date": "2026-06-24", "title": "No standalone federal psychedelic rescheduling bill or floor vote passes in 2026; veteran-access provisions are the only vehicle to advance.", "confidence": 76, "category": "legislation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "veteran", "legislation" ], "status": "pending", "priority": "high", "plain_title": "Congress won't pass a federal psychedelic drug reform law in 2026", "plain_what": "No bill making psychedelics broadly more legal at the federal level will pass Congress in 2026. The legislative calendar is packed, and there's only one angle that gets enough cross-party support to move at all: measures that give military veterans access to psychedelic treatments. Everything else is stuck. This matters because without federal action, the patchwork of state-by-state rules continues, creating confusion about what's legal where." }, { "date": "2026-06-24", "title": "Any MDMA-PTSD regulatory action by 2027-06-24 carries REMS, restricted distribution, or a post-marketing data requirement rather than clean approval.", "confidence": 74, "category": "regulation", "geography": "USA", "resolve_date": "2027-06-24", "tags": [ "MDMA", "PTSD", "FDA", "market" ], "status": "pending", "priority": "high", "plain_title": "If MDMA gets approved for PTSD treatment, it will come with strict conditions attached", "plain_what": "If the FDA approves MDMA (also known as ecstasy) as a treatment for PTSD (post-traumatic stress disorder) by mid-2027, it won't be a clean, straightforward approval. The agency will attach strict controls \u2014 things like a special safety program limiting which doctors can prescribe it, requirements on who can distribute it, or mandatory follow-up studies to collect more data. This matters because those restrictions would limit how many patients could actually access the treatment, even after approval." }, { "date": "2026-06-24", "title": "No FDA approval of psilocybin in any indication occurs in 2026; advanced-cancer and grief Phase 3 durability data remain too thin.", "confidence": 73, "category": "regulation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "psilocybin", "FDA" ], "status": "pending", "priority": "high", "plain_title": "Psilocybin won't get FDA approval as a medicine in 2026", "plain_what": "The FDA won't approve psilocybin (the active compound in 'magic mushrooms') as a treatment for any medical condition in 2026. The most promising research areas \u2014 helping people with terminal cancer anxiety or grief \u2014 don't yet have long-term study results showing the effects hold up over time. Without that evidence, the FDA won't approve it. This matters because approval is what would allow doctors to legally prescribe it and insurers to potentially cover it." }, { "date": "2026-06-24", "title": "At least one peer-reviewed publication or major-journal commentary by 2027-06-24 criticizes psychedelic indication expansion for outpacing durability and mechanistic evidence.", "confidence": 70, "category": "research", "geography": "Global", "resolve_date": "2027-06-24", "tags": [ "research", "durability" ], "status": "pending", "priority": "medium", "plain_title": "Scientists will publicly push back on overhyped psychedelic treatment claims", "plain_what": "By mid-2027, at least one serious scientific journal will publish a prominent critique arguing that enthusiasm for psychedelics as treatments has raced ahead of the actual evidence. Researchers will point out that most studies are small, short-term, and don't prove that benefits last. This matters because overpromising can mislead patients, distort investment decisions, and ultimately set the field back if results don't hold up." }, { "date": "2026-06-25", "title": "Any near-term FDA psychedelic action will favor ketamine-class agents with established blinding over MDMA/psilocybin.", "confidence": 74, "category": "research", "geography": "USA", "resolve_date": "2027-06-30", "tags": [ "psilocybin", "MDMA", "ketamine", "FDA" ], "status": "pending", "priority": "medium", "plain_title": "Ketamine drugs will get US approval before MDMA or psilocybin", "plain_what": "The FDA (the US drug regulator) is more likely to approve new ketamine-based medicines than MDMA or magic mushroom treatments in the near future. The problem with MDMA and psilocybin studies is that participants usually know whether they got the real drug or a placebo \u2014 which makes the results harder to trust. Ketamine studies don't have that problem as badly, so they're easier for regulators to evaluate." }, { "date": "2026-06-25", "title": "No federal psilocybin rescheduling this Congress; only narrow veteran/research provisions advance.", "confidence": 72, "category": "legislation", "geography": "USA", "resolve_date": "2026-12-22", "tags": [ "psilocybin", "veteran" ], "status": "pending", "priority": "medium", "plain_title": "Magic mushrooms will stay federally illegal for at least two more years", "plain_what": "The US Congress is very unlikely to remove psilocybin (the active ingredient in magic mushrooms) from the federal list of banned substances during its current session. The only realistic small wins are narrow bills that let military veterans access treatment or expand research \u2014 not broad legalization or rescheduling for the general public." }, { "date": "2026-06-25", "title": "No federal psilocybin rescheduling passes this Congress; only veteran/research carve-outs advance.", "confidence": 72, "category": "legislation", "geography": "USA", "resolve_date": "2027-01-03", "tags": [ "psilocybin", "veteran" ], "status": "pending", "priority": "medium", "plain_title": "Congress won't legalize magic mushrooms \u2014 small veteran bills are the best case", "plain_what": "There simply aren't enough votes in Congress right now to move psilocybin off the federal banned substances list. The one area where politicians across parties can agree is using it carefully for military veterans with conditions like PTSD (post-traumatic stress disorder). That narrow focus is what's actually achievable." }, { "date": "2026-06-25", "title": "Any psychedelic approval carries restrictive Schedule II-style REMS and DEA controls.", "confidence": 72, "category": "regulation", "geography": "USA", "resolve_date": "2028-06-25", "tags": [ "DEA", "Schedule I" ], "status": "pending", "priority": "medium", "plain_title": "Any approved psychedelic drug will come with very strict safety controls", "plain_what": "If a psychedelic drug does get FDA approval, it won't come with easy or open access. It will almost certainly require a special safety program \u2014 called a REMS (Risk Evaluation and Mitigation Strategy) \u2014 that limits who can prescribe it, where it can be given, and who can receive it. The DEA (the US agency that controls dangerous drugs) will also keep tight oversight. A patient death linked to an unsupervised session has made regulators more cautious, not less." }, { "date": "2026-06-25", "title": "Any psychedelic approval carries restrictive REMS/DEA controls, not loosened access.", "confidence": 70, "category": "regulation", "geography": "USA", "resolve_date": "2026-09-23", "tags": [ "DEA" ], "status": "pending", "priority": "medium", "plain_title": "Approved psychedelics will face tight government controls, not open access", "plain_what": "Multiple regulators and officials agree: if any psychedelic gets approved as a medicine, it will come wrapped in strict rules. These include a REMS (a formal safety program that restricts who can prescribe and dispense a drug) and continued DEA (the US drug enforcement agency) oversight. This isn't about blocking treatment \u2014 it's about preventing misuse and harm outside supervised settings." }, { "date": "2026-06-26", "title": "No rescheduling of psilocybin or MDMA in 2026; Schedule I status holds.", "confidence": 80, "category": "regulation", "geography": "Global", "resolve_date": "2026-12-31", "tags": [ "psilocybin", "MDMA", "Schedule I" ], "status": "pending", "priority": "high", "plain_title": "Psilocybin and MDMA stay illegal at the federal level in 2026", "plain_what": "The US federal government will keep psilocybin (the active ingredient in magic mushrooms) and MDMA (ecstasy) in the strictest drug category, meaning no legal medical use nationwide. Politicians are nervous about loosening drug laws and prefer to fund research quietly rather than make a big public move. This matters because millions of people who might benefit from these treatments still can't access them legally." }, { "date": "2026-06-26", "title": "No federal rescheduling of psilocybin or MDMA in 2026; research and veterans-access bills advance instead.", "confidence": 79, "category": "legislation", "geography": "USA", "resolve_date": "2026-12-23", "tags": [ "psilocybin", "MDMA", "veteran" ], "status": "pending", "priority": "high", "plain_title": "Federal drug law won't change, but veterans may get easier research access", "plain_what": "Congress is unlikely to move psilocybin or MDMA out of the most restricted drug category in 2026, but smaller bills focused on research and helping veterans access these treatments are gaining ground. This is a politically easier move \u2014 lawmakers can say they support helping veterans without fully endorsing psychedelics for everyone. For patients, it means slow, incremental progress rather than a big policy shift." }, { "date": "2026-06-26", "title": "Neuroimmune and synaptic-plasticity mechanisms dominate 2026 psychedelic research output.", "confidence": 75, "category": "research", "geography": "Global", "resolve_date": "2026-12-31", "tags": [], "status": "pending", "priority": "high", "plain_title": "Scientists will zero in on how psychedelics reduce brain inflammation and rewire connections", "plain_what": "In 2026, most psychedelic research will focus on two big questions: do these drugs calm harmful brain inflammation, and do they physically rebuild broken connections between brain cells? These aren't just academic questions \u2014 they could explain why psychedelics seem to help with depression, PTSD, and addiction in ways that standard drugs don't. Understanding the 'why' is a crucial step toward making treatments safer and more predictable." }, { "date": "2026-06-26", "title": "FDA will not approve any new psychedelic NDA in 2026; at least one REMS-heavy conditional pathway is proposed instead.", "confidence": 70, "category": "regulation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "FDA" ], "status": "pending", "priority": "medium", "plain_title": "No psychedelic drug will get full FDA approval in 2026, but a strict conditional path may be proposed", "plain_what": "The FDA (the US drug regulator) won't fully approve any psychedelic medicine in 2026 \u2014 too many scientific questions remain unanswered. Instead, the FDA may propose a special framework that would allow limited, heavily supervised use while gathering more safety data. Think of it like a provisional driver's license with lots of restrictions. This matters because it would give patients some access while keeping tight guardrails in place." }, { "date": "2026-06-26", "title": "CMPS or ATAI gives back the majority of June gains within 90 days absent a Phase 3 readout.", "confidence": 66, "category": "markets", "geography": "Global", "resolve_date": "2026-09-30", "tags": [ "atai", "Phase 3" ], "status": "pending", "priority": "medium", "plain_title": "Psychedelic stock gains will likely reverse fast without hard clinical trial data", "plain_what": "Two psychedelic companies \u2014 CMPS (Compass Pathways) and ATAI Life Sciences \u2014 may see their stock prices rise sharply in June 2026, but that rise will probably collapse within three months if they don't release results from a large, late-stage clinical trial. Stock markets often reward exciting news stories before the science catches up, and when the hype fades, prices drop back down. This cycle has happened repeatedly in the psychedelic investment space." }, { "date": "2026-06-27", "title": "No FDA approval of psilocybin or MDMA-based therapy issued in 2026", "confidence": 85, "category": "regulatory", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "FDA", "psilocybin", "MDMA" ], "status": "pending", "priority": "high", "plain_title": "No psychedelic therapy will get US government approval in 2026", "plain_what": "The US drug regulator (FDA) won't officially approve psilocybin (the active compound in magic mushrooms) or MDMA-assisted therapy this year. Getting approval requires completing a massive paperwork package, a months-long government review, and a public expert panel \u2014 there simply isn't enough time in 2026 for all of that to happen. So people hoping to access these treatments through traditional clinics or insurance will keep waiting." }, { "date": "2026-06-27", "title": "No DEA rescheduling of psilocybin or MDMA in 2026", "confidence": 82, "category": "regulatory", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "psilocybin", "MDMA", "DEA" ], "status": "pending", "priority": "high", "plain_title": "The US government won't reclassify mushrooms or MDMA in 2026", "plain_what": "Rescheduling means changing how strictly the government controls a drug \u2014 moving psilocybin or MDMA out of the most tightly locked-down category (Schedule I, reserved for substances with 'no medical use'). But by law, the DEA (the Drug Enforcement Administration, which polices controlled substances) can only do this after the FDA finishes its own review first. Since the FDA won't finish in 2026, the DEA can't act either. This matters because rescheduling would dramatically affect who can research, prescribe, and access these drugs." }, { "date": "2026-06-27", "title": "CMPS psilocybin Phase 3 topline triggers a >25% single-day stock move in 2026", "confidence": 76, "category": "market", "geography": "Global", "resolve_date": "2026-12-31", "tags": [ "psilocybin", "CMPS", "stock" ], "status": "pending", "priority": "high", "plain_title": "One company's mushroom drug trial results will cause a massive stock swing", "plain_what": "A company called Compass Pathways (ticker: CMPS) is running a large late-stage clinical trial on a psilocybin-based treatment, and the results are expected in 2026. When a speculative biotech company releases make-or-break trial data, its stock price tends to jump or crash dramatically in a single day. Good news could send the stock soaring; bad news could wipe out a quarter or more of its value overnight." }, { "date": "2026-06-27", "title": "Psilocybin Phase 3 topline hits its primary endpoint in 2026", "confidence": 70, "category": "research", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "psilocybin", "Phase 3" ], "status": "pending", "priority": "medium", "plain_title": "The big psilocybin trial will likely show the drug actually works", "plain_what": "Compass Pathways' large clinical trial is testing whether a synthetic psilocybin pill can treat depression, and it's expected to hit its main goal \u2014 showing the drug works better than a placebo. The trial is nearly finished, the treatment already got a special 'promising' flag from the FDA, and earlier smaller studies showed positive results. If it succeeds, it's a major milestone for turning a psychedelic into a legitimate medicine." }, { "date": "2026-06-27", "title": "FDA or independent reviewers publicly flag durability/unblinding concerns about the 2026 psilocybin Phase 3 result", "confidence": 68, "category": "research", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "psilocybin", "FDA", "unblinding" ], "status": "pending", "priority": "medium", "plain_title": "Experts will publicly question whether the trial results are trustworthy", "plain_what": "Even if the big psilocybin trial shows positive results, scientists and the FDA will likely raise specific concerns. The two main worries: first, people in the trial can usually tell whether they got the real drug (because of the obvious effects), which can skew results. Second, researchers don't yet know how long the benefits last. These are real, unresolved problems with psychedelic research, and a positive result will almost certainly spark a public debate about whether the findings hold up." }, { "date": "2026-06-28", "title": "A positive psychedelic depression Phase 3 topline reports in 2026.", "confidence": 80, "category": "research", "geography": "Global", "resolve_date": "2026-12-31", "tags": [ "Phase 3", "depression" ], "status": "pending", "priority": "high", "plain_title": "A major depression drug trial posts promising results in 2026", "plain_what": "A late-stage clinical trial testing a psychedelic treatment for depression is expected to share its headline results this year. This is the final hurdle before a company can ask regulators to approve the drug. If results are good, it could mean a new treatment option for people who haven't responded to antidepressants." }, { "date": "2026-06-28", "title": "Any 2026 psychedelic approval will carry a REMS with mandated durability and responder follow-up.", "confidence": 78, "category": "regulation", "geography": "Global", "resolve_date": "2026-12-31", "tags": [], "status": "pending", "priority": "high", "plain_title": "Any approved psychedelic drug will come with strict ongoing safety rules", "plain_what": "If the US drug regulator (FDA) approves a psychedelic medicine, it will almost certainly attach a special safety program called a REMS (Risk Evaluation and Mitigation Strategy). This means patients and doctors can't just get a prescription like a normal drug \u2014 there are extra steps, check-ins, and tracking requirements. The FDA wants to make sure the drug keeps working safely over time and understand why it helps some people more than others." }, { "date": "2026-06-28", "title": "No federal rescheduling within 12 months; Schedule I posture holds.", "confidence": 75, "category": "legislation", "geography": "USA", "resolve_date": "2027-06-28", "tags": [ "Schedule I" ], "status": "pending", "priority": "high", "plain_title": "Psychedelics stay in the most restricted drug category for at least another year", "plain_what": "Right now, most psychedelics sit in Schedule I \u2014 the US government's strictest drug category, reserved for substances it considers to have no accepted medical use and high abuse potential. Despite growing research interest, there's a 75% chance this doesn't change in the next 12 months. Approving a single drug doesn't automatically change the rules for the whole category." }, { "date": "2026-06-28", "title": "A positive psychedelic depression Phase 3 topline lands in 2026, but with response heterogeneity.", "confidence": 74, "category": "research", "geography": "Global", "resolve_date": "2026-09-26", "tags": [ "Phase 3", "depression" ], "status": "pending", "priority": "medium", "plain_title": "Depression trial results look promising but work better for some patients than others", "plain_what": "Four independent expert perspectives broadly agree: a major psychedelic depression trial will report positive results in 2026, but the drug won't work equally well for everyone. Some patients will respond dramatically; others won't respond much at all. Understanding who benefits most \u2014 and why \u2014 is the next big scientific challenge." }, { "date": "2026-06-28", "title": "Federal rescheduling will NOT pass within 12 months.", "confidence": 74, "category": "legislation", "geography": "USA", "resolve_date": "2026-12-25", "tags": [], "status": "pending", "priority": "medium", "plain_title": "Federal law on psychedelics will not change in the next 12 months", "plain_what": "Three separate expert perspectives \u2014 a policy analyst, a drug enforcement official, and a regulatory reviewer \u2014 all agree that federal law won't loosen its grip on psychedelics in the near future. There's no active legislation close to passing, and enforcement agencies are still dealing with diversion and misuse cases. The legal landscape stays frozen for now." }, { "date": "2026-06-29", "title": "DEA maintains Schedule I status for psilocybin and MDMA through 2026 regardless of FDA review progress.", "confidence": 78, "category": "regulatory", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "psilocybin", "MDMA", "FDA", "DEA", "Schedule I" ], "status": "pending", "priority": "high", "plain_title": "Psilocybin and MDMA stay illegal federally through 2026", "plain_what": "The DEA (the US agency that controls which drugs are legal) will keep psilocybin and MDMA in the most restricted category \u2014 Schedule I \u2014 through 2026. This means no doctor can legally prescribe them anywhere in the US under federal law. That stays true even if the FDA (the US drug regulator) makes progress reviewing them as medicines." }, { "date": "2026-06-29", "title": "No federal rescheduling of psilocybin or MDMA in 2026; change stays incremental and FDA-dependent.", "confidence": 77, "category": "regulatory", "geography": "USA", "resolve_date": "2026-09-27", "tags": [ "psilocybin", "MDMA", "FDA" ], "status": "pending", "priority": "high", "plain_title": "No federal legalization change for psychedelics in 2026", "plain_what": "The federal government will not move psilocybin or MDMA out of the most restricted drug category in 2026. Any small steps forward will depend entirely on the FDA's slow review process. Real change, if it comes, will be gradual \u2014 not a sudden policy shift." }, { "date": "2026-06-29", "title": "No standalone federal psilocybin rescheduling bill passes in 2026; progress comes via research funding and veteran pilots.", "confidence": 75, "category": "legislation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "psilocybin", "veteran" ], "status": "pending", "priority": "high", "plain_title": "Congress won't legalize psilocybin in 2026, but may fund veteran programs", "plain_what": "No bill making psilocybin broadly legal will pass through Congress in 2026. However, lawmakers from both parties do agree on helping veterans and funding more research \u2014 so smaller wins in those specific areas are possible. The big legal change simply does not have enough votes yet." }, { "date": "2026-06-29", "title": "FDA issues no psilocybin approval in 2026; any MDMA action requires additional confirmatory data or REMS conditions.", "confidence": 74, "category": "regulatory", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "psilocybin", "MDMA", "FDA" ], "status": "pending", "priority": "medium", "plain_title": "FDA will not approve psilocybin in 2026; MDMA needs more proof first", "plain_what": "The FDA will not give psilocybin the green light as a medicine in 2026. For MDMA, the FDA already raised serious concerns after reviewing trial data \u2014 patients and therapists both knew who got the real drug, which may have skewed results. Before any approval, the FDA wants stronger, cleaner evidence that the treatment actually works." }, { "date": "2026-06-29", "title": "Psychedelic biotech equities stay rangebound through Q3 2026 absent a Phase 3 readout or FDA decision.", "confidence": 72, "category": "markets", "geography": "USA", "resolve_date": "2026-09-30", "tags": [ "FDA", "Phase 3", "biotech" ], "status": "pending", "priority": "medium", "plain_title": "Psychedelic company stock prices will stay flat through mid-2026", "plain_what": "Shares in psychedelic biotech companies will mostly trade sideways \u2014 neither crashing nor surging \u2014 through the third quarter of 2026. Without a major clinical trial result or an FDA decision, there is no big event to drive prices up. Big institutional investors are waiting on the sidelines until something concrete happens." }, { "date": "2026-06-30", "title": "No full FDA approval of psilocybin or MDMA for any indication during calendar year 2026.", "confidence": 76, "category": "regulatory", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "psilocybin", "MDMA", "FDA" ], "status": "pending", "priority": "high", "plain_title": "No psychedelic drug gets full US approval in 2026", "plain_what": "The FDA (the US drug regulator) will not fully approve psilocybin (magic mushroom compound) or MDMA (the active ingredient in ecstasy) as a medicine in 2026. Approval requires years of safety reviews, and the FDA still has unresolved questions about how to monitor patients using these drugs safely. This means no one will be able to get a prescription for these substances at a regular pharmacy in 2026." }, { "date": "2026-06-30", "title": "DEA keeps classic psychedelics (psilocybin, LSD, DMT) on Schedule I through 2026 with no rescheduling action.", "confidence": 72, "category": "regulatory", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "DEA", "Schedule I" ], "status": "pending", "priority": "medium", "plain_title": "Magic mushrooms and LSD stay fully illegal federally through 2026", "plain_what": "The DEA (the US agency that classifies drugs and enforces drug laws) will keep psilocybin, LSD, and DMT in Schedule I \u2014 the strictest category, reserved for substances the government says have no accepted medical use and high abuse potential. The DEA can only reschedule these drugs after the FDA approves one of them as medicine, and that approval isn't happening in 2026. So the federal ban stays in place by default." }, { "date": "2026-06-30", "title": "Psychedelic sector equities remain range-bound (no major index member sustains a >30% move) through Q3 2026 absent a Phase 3 readout or M&A.", "confidence": 71, "category": "market", "geography": "Global", "resolve_date": "2026-09-30", "tags": [ "Phase 3", "equities" ], "status": "pending", "priority": "medium", "plain_title": "Psychedelic company stocks mostly stay flat through mid-2026", "plain_what": "Shares in psychedelic medicine companies are unlikely to swing up or down by more than 30% in a sustained way through the third quarter of 2026. The optimistic story about these drugs changing mental healthcare is already reflected in current stock prices. Only a major event \u2014 like a big clinical trial result or one company buying another \u2014 would move the needle significantly, and neither looks imminent." }, { "date": "2026-06-30", "title": "Positive Phase 2 or Phase 3 psilocybin data for a substance-use disorder indication (AUD or TUD) publishes or is presented by 2027-06-30.", "confidence": 68, "category": "research", "geography": "Global", "resolve_date": "2027-06-30", "tags": [ "psilocybin", "substance-use disorder" ], "status": "pending", "priority": "medium", "plain_title": "Strong trial results for psilocybin treating addiction published by mid-2027", "plain_what": "By June 30, 2027, we'll likely see solid clinical trial results showing that psilocybin helps people quit alcohol (AUD, or alcohol use disorder) or tobacco (TUD, or tobacco use disorder). Several trials are already running and approaching the point where researchers will have enough data to report findings. If the results are positive, it would be the first strong scientific evidence that a psychedelic can treat addiction at the level regulators take seriously." }, { "date": "2026-07-01", "title": "Federal rescheduling of psilocybin does NOT occur within 18 months; Schedule I remains intact.", "confidence": 78, "category": "regulation", "geography": "USA", "resolve_date": "2028-01-01", "tags": [ "psilocybin", "Schedule I" ], "status": "pending", "priority": "high", "plain_title": "Psilocybin stays on the most restricted drug list for now", "plain_what": "The US government will not move psilocybin off its most restricted drug category (Schedule I \u2014 meaning 'no accepted medical use, high abuse potential') within the next 18 months. This matters because Schedule I status makes research harder, keeps criminal penalties in place, and means no legal medical use at the federal level." }, { "date": "2026-07-01", "title": "Federal rescheduling of psilocybin will NOT occur within 18 months; Schedule I holds broadly.", "confidence": 75, "category": "regulation", "geography": "USA", "resolve_date": "2026-09-29", "tags": [ "psilocybin", "Schedule I" ], "status": "pending", "priority": "high", "plain_title": "Psilocybin stays on the most restricted drug list for now", "plain_what": "Multiple independent expert perspectives \u2014 including a law enforcement officer, a drug regulator, and a lawmaker \u2014 all agree that psilocybin will stay in the most restricted drug category (Schedule I) for at least 18 months. One expert disagreed, but the majority view is that no federal reclassification is coming soon." }, { "date": "2026-07-01", "title": "No FDA psilocybin approval decision occurs within 18 months.", "confidence": 75, "category": "regulation", "geography": "USA", "resolve_date": "2028-01-01", "tags": [ "psilocybin", "FDA" ], "status": "pending", "priority": "high", "plain_title": "The FDA won't approve a psilocybin drug within 18 months", "plain_what": "The FDA (the US drug regulator) will not approve any psilocybin-based medicine in the next 18 months. Most studies are still in early or mid stages \u2014 researchers haven't yet run the large, definitive trials the FDA requires before it will say a drug is safe and effective enough to prescribe." }, { "date": "2026-07-01", "title": "The MDMA FDA decision triggers a \u00b125% sector-wide repricing regardless of direction.", "confidence": 72, "category": "market", "geography": "USA", "resolve_date": "2027-07-01", "tags": [ "MDMA", "FDA" ], "status": "pending", "priority": "medium", "plain_title": "MDMA's FDA decision will swing the whole psychedelic market 25% either way", "plain_what": "When the FDA (the US drug regulator) makes its decision on MDMA (commonly known as ecstasy) as a therapy for PTSD (post-traumatic stress disorder), the entire psychedelic investment sector will jump or drop by roughly 25%. It doesn't matter which way the decision goes \u2014 a yes or a no will both force big investors to rapidly reprice every company in this space." }, { "date": "2026-07-01", "title": "Psilocybin mechanistic/imaging findings replicate robustly while disease-specific claims require correction.", "confidence": 72, "category": "research", "geography": "Global", "resolve_date": "2028-01-01", "tags": [ "psilocybin" ], "status": "pending", "priority": "medium", "plain_title": "Brain scan findings hold up, but specific disease cure claims need fixing", "plain_what": "Scientists are finding solid, repeatable evidence about how psilocybin physically changes brain activity and connectivity \u2014 those findings are holding up. But specific claims like 'psilocybin cures depression' or 'it treats addiction' are being overstated and will need to be walked back as more rigorous studies come in." }, { "date": "2026-07-02", "title": "Any 2026-2027 psychedelic approval will carry a mandatory REMS with certified-site and monitored-dosing requirements.", "confidence": 82, "category": "regulatory", "geography": "Global", "resolve_date": "2027-06-30", "tags": [], "status": "pending", "priority": "high", "plain_title": "Any approved psychedelic drug will require special certified clinics", "plain_what": "If a psychedelic gets approved as a medicine in 2026 or 2027, patients won't be able to pick it up at a regular pharmacy. Instead, they'll have to go to a specially approved clinic where trained staff supervise the experience. This exists because regulators want to make sure people are safe and fully understand what they're taking." }, { "date": "2026-07-02", "title": "Any rescheduling remains Schedule I outside approved medical use; DEA resists broad descheduling through 2026.", "confidence": 78, "category": "regulatory", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "DEA", "Schedule I" ], "status": "pending", "priority": "high", "plain_title": "Psychedelics stay illegal federally except in approved medical settings", "plain_what": "The DEA (the US agency that controls which drugs are legal and illegal) is expected to keep psychedelics on the most restricted list of substances through 2026, except in very narrow medical situations. This means that even as some states loosen their own rules, federal law stays tight, and the DEA keeps enforcing it." }, { "date": "2026-07-02", "title": "Any near-term psychedelic approval arrives with heavy REMS/certified-site constraints, not open access.", "confidence": 76, "category": "regulatory", "geography": "Global", "resolve_date": "2026-09-30", "tags": [], "status": "pending", "priority": "high", "plain_title": "Approved psychedelics will require supervised clinics, not free access", "plain_what": "Multiple independent expert perspectives agree: if any psychedelic gets approved as a medicine soon, it will come with strict rules requiring patients to receive it at certified locations under supervision. This is not a controversial prediction \u2014 almost everyone looking at the regulatory landscape sees this coming." }, { "date": "2026-07-02", "title": "No broad federal psychedelic rescheduling bill passes or reaches a floor vote in 2026.", "confidence": 75, "category": "legislation", "geography": "USA", "resolve_date": "2026-12-29", "tags": [], "status": "pending", "priority": "high", "plain_title": "No law to loosen federal psychedelic restrictions will pass in 2026", "plain_what": "Even though there's growing public and political interest in psychedelics as medicine, no bill to federally relax psychedelic laws is expected to actually reach a full congressional vote in 2026. The political and law enforcement resistance is simply too strong right now, even among some supporters." }, { "date": "2026-07-02", "title": "Continued small-cap M&A: at least two more psychedelic microcap acquisitions/reverse-mergers close by Q1 2027.", "confidence": 75, "category": "market", "geography": "Global", "resolve_date": "2027-03-31", "tags": [], "status": "pending", "priority": "high", "plain_title": "At least two small psychedelic companies will merge or get bought out by early 2027", "plain_what": "Many small psychedelic companies are running low on cash and have no major near-term milestones to excite investors. Rather than go under, at least two of them are expected to merge with or get absorbed by other companies before early 2027. This is already happening \u2014 one recent deal between XTL and Psyga set the pattern." }, { "date": "2026-07-03", "title": "No FDA final approval of any psychedelic-assisted therapy (psilocybin, MDMA) will occur before 2026-08-02.", "confidence": 97, "category": "regulatory", "geography": "USA", "resolve_date": "2026-08-02", "tags": [ "FDA" ], "status": "pending", "priority": "high", "plain_title": "No psychedelic therapy will get US drug approval before August 2026", "plain_what": "The FDA (the US drug regulator) has not approved any therapy using psilocybin (the active ingredient in magic mushrooms) or MDMA (ecstasy) as a medicine. The FDA already rejected MDMA-assisted therapy in 2024 and asked the company to do more work. Psilocybin is still in earlier stages of review. Neither drug will clear the full approval process in the next few weeks." }, { "date": "2026-07-03", "title": "Full federal rescheduling of psilocybin/MDMA out of Schedule I will not occur in 2026.", "confidence": 90, "category": "legislation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [], "status": "pending", "priority": "high", "plain_title": "Psilocybin and MDMA will stay in the most restricted drug category all of 2026", "plain_what": "In the US, psilocybin and MDMA sit in Schedule I \u2014 the government's most restrictive drug category, reserved for substances it says have no accepted medical use and high abuse potential. Moving a drug out of that category requires a lengthy scientific review by two federal agencies. That process hasn't even started for these drugs, so it can't finish by the end of 2026." }, { "date": "2026-07-03", "title": "A ketamine or psychedelic clinic safety, consent, or diversion incident will surface in major US media before 2026-08-02.", "confidence": 65, "category": "culture", "geography": "USA", "resolve_date": "2026-08-02", "tags": [ "ketamine" ], "status": "pending", "priority": "medium", "plain_title": "A ketamine or psychedelic clinic scandal will make national US news by August 2026", "plain_what": "Ketamine clinics have expanded rapidly across the US with little oversight, and stories about patient harm, sexual misconduct, or shady business practices have been appearing regularly in major outlets. Given how often these stories surface, there's a decent chance at least one named incident lands in a big national publication \u2014 like the New York Times or Washington Post \u2014 within the next month." }, { "date": "2026-07-03", "title": "A binary Phase 3/pivotal readout will drive a >25% single-day move in a leading psychedelic-focused public company before 2027-01-31.", "confidence": 62, "category": "market", "geography": "Global", "resolve_date": "2027-01-31", "tags": [ "Phase 3" ], "status": "pending", "priority": "medium", "plain_title": "A key clinical trial result will send a psychedelic company's stock up or down 25% in one day", "plain_what": "Several publicly traded psychedelic drug companies \u2014 Compass Pathways, MindMed, and atai Life Sciences \u2014 are waiting on results from large, late-stage clinical trials. When a company announces whether its drug worked or failed, investors react fast. These stocks are thinly traded and highly sensitive to news, which means a single announcement can cause a massive price swing in either direction." }, { "date": "2026-07-03", "title": "FDA will take a formal action (advisory committee meeting, PDUFA action, or Complete Response Letter) on a psilocybin-for-MDD NDA by 2027-07-01.", "confidence": 55, "category": "regulatory", "geography": "USA", "resolve_date": "2027-07-01", "tags": [ "psilocybin", "FDA" ], "status": "pending", "priority": "medium", "plain_title": "The FDA will formally act on a psilocybin-for-depression drug application by mid-2027", "plain_what": "Compass Pathways is running a large late-stage trial testing psilocybin as a treatment for major depression. If the results look good, they'll submit a formal drug application to the FDA. The FDA would then have to respond \u2014 either by approving it, rejecting it, or calling an expert panel meeting to debate it. That full sequence happening by July 2027 is plausible but not certain." }, { "date": "2026-07-04", "title": "No FDA approval of an ibogaine-based product by August 2026; cardiac risk keeps parent compound unapproved.", "confidence": 98, "category": "research", "geography": "USA", "resolve_date": "2026-08-03", "tags": [ "ibogaine", "FDA" ], "status": "pending", "priority": "medium", "plain_title": "Ibogaine will not get US drug approval by August 2026", "plain_what": "Ibogaine is a powerful plant-based drug being studied for addiction treatment, but it can cause dangerous heart rhythm problems. The FDA (the US drug regulator) won't approve any drug it considers too risky without strong safety evidence, and that evidence doesn't exist yet. This means people cannot legally access ibogaine as an approved medicine in the US anytime soon." }, { "date": "2026-07-04", "title": "No DEA rescheduling final rule for psilocybin, MDMA, or ibogaine published by early August 2026.", "confidence": 97, "category": "legislation", "geography": "USA", "resolve_date": "2026-08-03", "tags": [ "Schedule I", "DEA" ], "status": "pending", "priority": "high", "plain_title": "US government won't officially loosen drug rules for psilocybin, MDMA, or ibogaine by August 2026", "plain_what": "Psilocybin (the active ingredient in magic mushrooms), MDMA (ecstasy), and ibogaine are all classified as Schedule I \u2014 the most restricted category of drugs under US federal law. Moving a drug out of that category requires a long chain of government steps that takes years, and none of those steps are currently in motion. Nothing will change in the next 30 days." }, { "date": "2026-07-04", "title": "Ibogaine remains without full FDA approval through Q3 2026 due to cardiac safety; only derivative/research advances.", "confidence": 95, "category": "research", "geography": "USA", "resolve_date": "2026-10-02", "tags": [ "ibogaine", "FDA" ], "status": "pending", "priority": "medium", "plain_title": "Ibogaine stays unapproved in the US through fall 2026; safer versions are being studied", "plain_what": "Ibogaine can stop the drug cravings cycle in remarkable ways, but it can also cause fatal heart problems, and the FDA won't approve a drug with that profile without completed large-scale safety trials \u2014 which don't exist yet. Scientists are working on chemically modified versions of ibogaine that aim to keep the benefits and remove the heart danger. Regular patients won't have legal access to standard ibogaine through official US medical channels this year." }, { "date": "2026-07-04", "title": "No federal psychedelic rescheduling in 2026; Schedule I posture and incrementalism hold.", "confidence": 85, "category": "legislation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "Schedule I" ], "status": "pending", "priority": "high", "plain_title": "Psilocybin, MDMA, and ibogaine stay federally illegal through all of 2026", "plain_what": "At the federal level, these three substances will remain in the most restricted drug category through the end of 2026. Neither Congress nor the DEA is actively moving to change this. States like Oregon and Colorado have made their own rules, but federal law \u2014 which affects things like banking, insurance, and interstate commerce \u2014 stays the same." }, { "date": "2026-07-04", "title": "A US veteran-access pathway for psilocybin or ibogaine (state pilot, VA study, or cross-border clinic referral) becomes publicly documented before any federal approval.", "confidence": 70, "category": "policy", "geography": "USA", "resolve_date": "2027-07-04", "tags": [ "psilocybin", "ibogaine", "veteran" ], "status": "pending", "priority": "medium", "plain_title": "US veterans will get documented access to psychedelic treatment before federal laws change", "plain_what": "Military veterans dealing with PTSD (post-traumatic stress disorder) and addiction have become a powerful political force pushing for access to psilocybin and ibogaine. States like Texas have already funded ibogaine research for veterans, and Oregon and Colorado have legal frameworks in place. It's likely that before the federal government officially changes any laws, there will be at least one formally announced, publicly documented program \u2014 through a state, the VA (Veterans Affairs), or an organized clinic referral system \u2014 giving veterans a legal or semi-legal pathway to these treatments." }, { "date": "2026-07-05", "title": "No FDA approval of any psychedelic-assisted therapy (psilocybin, MDMA, or ibogaine) is announced by 2026-08-04.", "confidence": 97, "category": "regulation", "geography": "USA", "resolve_date": "2026-08-04", "tags": [ "psilocybin", "MDMA", "ibogaine" ], "status": "pending", "priority": "high", "plain_title": "No psychedelic therapy gets US government approval before August 2026", "plain_what": "The US Food and Drug Administration (FDA, the agency that decides which medicines are legal to prescribe) will not give the green light to any therapy using psilocybin (the active ingredient in magic mushrooms), MDMA (ecstasy), or ibogaine before August 4, 2026. This matters because without that approval, these treatments stay out of mainstream hospitals and clinics, and most insurance companies won't cover them." }, { "date": "2026-07-05", "title": "No federal psychedelic rescheduling legislation is enacted into law by Congress in 2026.", "confidence": 85, "category": "legislation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "psilocybin", "MDMA" ], "status": "pending", "priority": "medium", "plain_title": "US Congress will not pass a law changing psychedelic drug status in 2026", "plain_what": "Congress, the body that writes and passes US federal laws, will not vote a bill into law that moves psilocybin or MDMA out of Schedule I \u2014 the strictest legal category, reserved for substances the government considers highly dangerous and medically useless. Right now, both substances sit in that category alongside heroin. Changing that through Congress requires enough votes and enough scientific proof, and neither exists yet." }, { "date": "2026-07-05", "title": "No federal rescheduling of psilocybin or MDMA occurs in 2026.", "confidence": 82, "category": "legislation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "psilocybin", "MDMA" ], "status": "pending", "priority": "high", "plain_title": "The US drug enforcement agency won't reclassify psychedelics in 2026", "plain_what": "The DEA (Drug Enforcement Administration, the federal agency that enforces drug laws) has the power to move a drug out of Schedule I without Congress acting \u2014 but it almost always waits for the FDA to approve a medical use first. Since no approval is coming in 2026, the DEA almost certainly won't act either. That means psilocybin and MDMA remain in the same legal bucket as heroin through the end of 2026." }, { "date": "2026-07-05", "title": "A bipartisan veterans-focused psychedelic research measure advances in Congress within 12 months.", "confidence": 60, "category": "legislation", "geography": "USA", "resolve_date": "2027-07-05", "tags": [ "veteran" ], "status": "pending", "priority": "medium", "plain_title": "A veterans-focused psychedelic research bill gets a meaningful vote in Congress within a year", "plain_what": "Military veterans are a cause that politicians from both parties tend to support. Some lawmakers have already tucked funding for psychedelic research into big defense spending bills. This prediction says that within 12 months, a bill or amendment specifically aimed at studying psychedelics as a treatment for veterans \u2014 think PTSD (post-traumatic stress disorder) or traumatic brain injury \u2014 will pass through at least one committee or get a floor vote in the House or Senate." }, { "date": "2026-07-05", "title": "A new US clinical trial studying ibogaine or an ibogaine analogue registers on ClinicalTrials.gov by 2026-08-04.", "confidence": 40, "category": "research", "geography": "USA", "resolve_date": "2026-08-04", "tags": [ "ibogaine" ], "status": "pending", "priority": "medium", "plain_title": "A new US study on ibogaine or a related compound registers publicly by August 2026", "plain_what": "Ibogaine is a powerful psychedelic derived from an African plant, and early research suggests it may help with opioid addiction and brain injuries. Before any study can recruit patients, researchers must register it on ClinicalTrials.gov, a public US government database. This prediction says at least one new study testing ibogaine or a chemically similar compound will appear on that database between now and August 4, 2026. The catch: ibogaine can cause dangerous heart rhythms, which slows down research." }, { "date": "2026-07-06", "title": "Psilocybin and ibogaine remain Schedule I federally throughout the next 12 months.", "confidence": 85, "category": "regulatory", "geography": "USA", "resolve_date": "2027-07-06", "tags": [ "psilocybin", "ibogaine", "Schedule I" ], "status": "pending", "priority": "high", "plain_title": "Psilocybin and ibogaine stay in the most restricted drug category", "plain_what": "The US federal government keeps psilocybin (magic mushrooms) and ibogaine (a plant-based psychedelic) in Schedule I \u2014 the same legal bucket as heroin \u2014 for at least another year. This means no doctor can prescribe them, and researchers need special government permission just to study them. Nothing on the horizon is likely to change that." }, { "date": "2026-07-06", "title": "No federal rescheduling of psilocybin or ibogaine within 12 months.", "confidence": 82, "category": "regulatory", "geography": "USA", "resolve_date": "2026-10-04", "tags": [ "psilocybin", "ibogaine" ], "status": "pending", "priority": "high", "plain_title": "Federal government won't reclassify psychedelics anytime soon", "plain_what": "Experts across law enforcement, lawmaking, and drug regulation all agree: the federal government won't move psychedelics out of their current most-restricted category within the next year. One expert disagreed, but the strong consensus says the legal status stays frozen. This matters because reclassification would unlock research, insurance coverage, and potentially legal medical use." }, { "date": "2026-07-06", "title": "Psychedelic biotech names (CMPS, ATAI) remain range-bound to lower through Q1 2027 absent a Phase 3 readout.", "confidence": 80, "category": "market", "geography": "Global", "resolve_date": "2027-01-06", "tags": [ "atai", "Phase 3", "biotech" ], "status": "pending", "priority": "high", "plain_title": "Psychedelic company stock prices stay flat or keep falling through early 2027", "plain_what": "Publicly traded psychedelic companies like Compass Pathways and ATAI Life Sciences are expected to stay stuck in a rut or lose more value until they publish major drug trial results. Big professional investors are sitting out, the excitement that drove prices up earlier has faded, and there's no obvious near-term event to spark a recovery. Real people who own shares in these companies could keep losing money." }, { "date": "2026-07-06", "title": "No FDA approval of any psychedelic beyond esketamine within 12 months; MDMA NDA path requires additional data.", "confidence": 78, "category": "regulatory", "geography": "USA", "resolve_date": "2027-07-06", "tags": [ "MDMA", "ketamine", "FDA" ], "status": "pending", "priority": "high", "plain_title": "No new psychedelic drug gets full federal approval in the next year", "plain_what": "Right now, the only psychedelic-like drug the FDA (the US drug regulator) has fully approved is esketamine, a nasal spray for depression. No other psychedelic will join it in the next 12 months. The company behind MDMA-assisted therapy has to do more research before regulators will consider approving it. This matters because FDA approval is what lets doctors prescribe a drug and insurance companies pay for it." }, { "date": "2026-07-06", "title": "No federal psychedelic rescheduling or access statute enacted within 12 months.", "confidence": 78, "category": "legislation", "geography": "USA", "resolve_date": "2027-07-06", "tags": [], "status": "pending", "priority": "high", "plain_title": "Congress won't pass any law expanding psychedelic access this year", "plain_what": "No federal law making psychedelics easier to access or research will pass in the next 12 months. Politicians in Washington are too focused on taxes and other priorities, and psychedelic reform doesn't have enough political cover to get a vote. This means the patchwork of state laws \u2014 some states allow certain uses, others don't \u2014 stays the only real avenue for change." }, { "date": "2026-07-07", "title": "TAAP Act advances without altering FDA scientific review standards.", "confidence": 70, "category": "legislation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "FDA" ], "status": "pending", "priority": "medium", "plain_title": "New law opens psychedelic access without changing drug approval rules", "plain_what": "A proposed law called the TAAP Act is moving forward in Congress. It would create new ways for people \u2014 especially veterans \u2014 to access psychedelic treatments. Importantly, it wouldn't lower the bar for proving a drug is safe and effective; the FDA (the US drug regulator) would still apply the same rigorous scientific tests." }, { "date": "2026-07-07", "title": "No federal rescheduling of psilocybin or MDMA occurs within 18 months.", "confidence": 70, "category": "legislation", "geography": "USA", "resolve_date": "2028-01-07", "tags": [ "psilocybin", "MDMA" ], "status": "pending", "priority": "medium", "plain_title": "Psilocybin and MDMA stay in the 'most restricted' drug category for now", "plain_what": "Within the next 18 months, the federal government is very unlikely to move psilocybin or MDMA out of Schedule I \u2014 the category reserved for drugs the government considers to have no accepted medical use. This matters because Schedule I status makes research harder and keeps these substances illegal at the federal level regardless of state laws." }, { "date": "2026-07-07", "title": "No federal rescheduling of psilocybin or MDMA within 18 months.", "confidence": 69, "category": "legislation", "geography": "USA", "resolve_date": "2027-01-03", "tags": [ "psilocybin", "MDMA" ], "status": "pending", "priority": "medium", "plain_title": "Federal drug rescheduling for psychedelics won't happen in 18 months", "plain_what": "Multiple independent expert perspectives agree: the federal government won't reclassify psilocybin or MDMA within 18 months. Changing a drug's legal schedule is a slow, politically complex process \u2014 and right now, neither the FDA nor the DEA (the US Drug Enforcement Administration) nor Congress is ready to do it." }, { "date": "2026-07-07", "title": "TAAP Act / veteran-access language advances legislatively without rescheduling or altering FDA scientific standards.", "confidence": 68, "category": "legislation", "geography": "USA", "resolve_date": "2027-01-03", "tags": [ "FDA", "veteran" ], "status": "pending", "priority": "medium", "plain_title": "Veterans may gain special psychedelic access without any rescheduling", "plain_what": "There's strong agreement across regulatory, law enforcement, and legislative perspectives that Congress will advance language allowing veterans to access psychedelic treatments \u2014 without rescheduling the drugs or changing how the FDA evaluates them for safety and effectiveness. This is a targeted workaround, not a broad legal change." }, { "date": "2026-07-07", "title": "AtaiBeckley VLS-01 Phase 2b TRD data reads out positive and triggers Phase 3 initiation.", "confidence": 68, "category": "clinical_trials", "geography": "Global", "resolve_date": "2027-01-31", "tags": [ "atai", "Phase 3" ], "status": "pending", "priority": "medium", "plain_title": "A promising psychedelic depression drug moves to large-scale testing", "plain_what": "A company called Atai Beckley is testing a drug called VLS-01 for people with treatment-resistant depression \u2014 meaning people whose depression hasn't responded to standard antidepressants. The mid-size trial results look likely to come back positive, which would trigger a much larger trial needed before seeking FDA approval. This matters because treatment-resistant depression affects millions of people with very few good options." }, { "date": "2026-07-08", "title": "DEA takes no rescheduling action on any psychedelic in 2026.", "confidence": 80, "category": "regulatory", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "DEA" ], "status": "pending", "priority": "high", "plain_title": "The DEA will not change psychedelic drug rules in 2026", "plain_what": "The DEA (the US agency that controls which drugs are legal and illegal) says it won't move psychedelics into a less restricted category in 2026. The DEA only reshuffles drug categories after the FDA (the US drug regulator) formally approves a drug as medicine \u2014 and that hasn't happened yet. This means psychedelics stay in the most restricted legal category for another year." }, { "date": "2026-07-08", "title": "No FDA approval or DEA rescheduling of psychedelics occurs in 2026.", "confidence": 79, "category": "regulatory", "geography": "USA", "resolve_date": "2026-10-06", "tags": [ "FDA", "DEA" ], "status": "pending", "priority": "high", "plain_title": "No psychedelic drug gets federally approved or reclassified in 2026", "plain_what": "Four independent experts \u2014 a drug reviewer, a drug enforcement officer, and a lawmaker \u2014 agreed that 2026 will pass without any psychedelic getting the green light from the FDA or getting moved to a less restricted legal category by the DEA. One expert disagreed. This matters because federal approval is the key that unlocks widespread legal medical use." }, { "date": "2026-07-08", "title": "No FDA psychedelic NDA approval occurs in 2026; MDMA remains in resubmission/review limbo.", "confidence": 78, "category": "regulatory", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "MDMA", "FDA" ], "status": "pending", "priority": "high", "plain_title": "MDMA therapy will not get FDA approval in 2026", "plain_what": "MDMA-assisted therapy for trauma (PTSD) already got rejected once by the FDA and is going through a second review \u2014 but regulators say they still need better evidence before they'll approve it. Specifically, they want researchers to solve two problems: participants in trials can easily tell whether they got the real drug, which can skew results, and the long-term effects aren't well enough documented. Political pressure won't speed this up." }, { "date": "2026-07-08", "title": "VLS-01 readout is the only 2026 catalyst that materially moves sector valuations.", "confidence": 70, "category": "market", "geography": "Global", "resolve_date": "2026-10-31", "tags": [], "status": "pending", "priority": "medium", "plain_title": "One drug trial result will drive the whole psychedelic sector's value in 2026", "plain_what": "VLS-01 is a psychedelic drug in mid-stage clinical testing. Experts predict its trial results will be the single event that most moves stock prices and investment across the entire psychedelic industry in 2026. Optimism about laws changing or inspiring stories can only do so much \u2014 hard data from a well-run trial is what pulls in serious institutional money." }, { "date": "2026-07-08", "title": "2026 federal action favors research authorization, not access or rescheduling bills.", "confidence": 70, "category": "legislation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [], "status": "pending", "priority": "medium", "plain_title": "Congress will fund psychedelic research in 2026, but not legalize access", "plain_what": "Lawmakers think they can pass bills that let scientists study psychedelics more easily \u2014 that's a safe, bipartisan vote that most politicians can defend to their home districts. But actually letting patients access psychedelic therapy more freely is still too politically risky for most members of Congress to support. So expect research funding to move, but not patient access." }, { "date": "2026-07-09", "title": "No psychedelic is rescheduled out of Schedule I in 2026 absent full FDA approval.", "confidence": 78, "category": "regulation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "FDA", "Schedule I" ], "status": "pending", "priority": "high", "plain_title": "Psychedelics stay illegal federally until a drug gets full approval", "plain_what": "Right now, psychedelics like psilocybin and MDMA sit in the most restricted drug category the US has. The DEA (the agency that enforces drug laws) only moves a drug to a less restricted category after the FDA (the US drug regulator) fully approves it as medicine. Since no psychedelic has full FDA approval yet, nothing changes in 2026." }, { "date": "2026-07-09", "title": "No standalone federal psychedelic legalization passes in 2026; movement stays at state level or narrow veteran riders.", "confidence": 75, "category": "legislation", "geography": "USA", "resolve_date": "2027-01-05", "tags": [ "veteran" ], "status": "pending", "priority": "high", "plain_title": "Congress won't legalize psychedelics in 2026 \u2014 small veteran carve-outs only", "plain_what": "No sweeping federal law making psychedelics legal is coming in 2026. The most likely action is a tiny exception buried in military spending bills that lets veterans access psychedelic therapy in limited situations. Real change is happening one state at a time instead." }, { "date": "2026-07-09", "title": "No standalone federal psychedelic legalization bill passes in 2026; action stays at state level or narrow veteran riders.", "confidence": 74, "category": "legislation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "veteran" ], "status": "pending", "priority": "medium", "plain_title": "No federal psychedelic legalization bill passes in 2026", "plain_what": "Congress has zero serious momentum on psychedelics right now, and politicians don't want to take a risky vote on a still-controversial topic in an election year. Without FDA approval as political cover, most lawmakers won't touch a standalone psychedelic bill." }, { "date": "2026-07-09", "title": "At least two new psychedelic comorbidity trials (AUD, postpartum) launch or report in 2026.", "confidence": 72, "category": "research", "geography": "Global", "resolve_date": "2026-12-31", "tags": [], "status": "pending", "priority": "medium", "plain_title": "Two new psychedelic trials for alcohol addiction or postpartum depression launch in 2026", "plain_what": "Scientists are increasingly testing psychedelics beyond PTSD (post-traumatic stress disorder) and depression. In 2026, expect at least two formal studies to either kick off or share results on using psychedelics to treat alcohol addiction or postpartum depression \u2014 two huge unmet needs." }, { "date": "2026-07-09", "title": "FDA will not fast-track any psilocybin or ibogaine indication ahead of MDMA in 2026.", "confidence": 70, "category": "regulation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "psilocybin", "MDMA", "ibogaine", "FDA" ], "status": "pending", "priority": "medium", "plain_title": "Psilocybin and ibogaine won't leapfrog MDMA in the FDA approval race in 2026", "plain_what": "MDMA has been in large-scale human trials the longest and is the closest any psychedelic has ever gotten to FDA approval. The FDA isn't going to fast-track psilocybin or ibogaine ahead of MDMA \u2014 it takes years of trial data to even get in the queue, and those drugs are further behind." }, { "date": "2026-07-10", "title": "Psychedelic equities stay depressed through Q4 2026 absent a concrete clinical catalyst.", "confidence": 75, "category": "market", "geography": "Global", "resolve_date": "2026-08-09", "tags": [], "status": "pending", "priority": "high", "plain_title": "Psychedelic company stocks will stay low through late 2026", "plain_what": "Psychedelic company stocks have been struggling, and most experts expect that to continue until at least the end of 2026. The main reason: investors are waiting to see a real breakthrough \u2014 like a drug getting approved \u2014 before putting serious money in. Without that, share prices stay flat or keep falling." }, { "date": "2026-07-10", "title": "FDA's next MDMA action will require additional confirmatory data or a REMS before any approval.", "confidence": 74, "category": "regulation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "MDMA", "FDA" ], "status": "pending", "priority": "medium", "plain_title": "The FDA will demand more proof before approving MDMA therapy", "plain_what": "The FDA (the US drug regulator) already rejected MDMA-assisted therapy once, asking for more evidence. Experts now predict the FDA will require either extra studies or strict safety rules before it ever says yes. The core concern: in the trials so far, patients could tell whether they got the real drug or a fake one, which makes the results harder to trust." }, { "date": "2026-07-10", "title": "Any approved psychedelic will carry a REMS-style controlled-distribution framework.", "confidence": 73, "category": "regulation", "geography": "Global", "resolve_date": "2026-10-08", "tags": [], "status": "pending", "priority": "medium", "plain_title": "Any approved psychedelic drug will come with strict access controls", "plain_what": "If a psychedelic drug ever gets approved, the government won't let it be sold like a normal prescription. Instead, it will almost certainly come with a special restricted system \u2014 meaning only certain certified doctors, clinics, or pharmacies can provide it. This keeps the drug from being misused but also limits who can easily get it." }, { "date": "2026-07-10", "title": "No standalone federal psychedelic legislation passes in 2026; reform advances via state and veteran vehicles.", "confidence": 72, "category": "legislation", "geography": "USA", "resolve_date": "2027-01-06", "tags": [ "legislation", "veteran" ], "status": "pending", "priority": "medium", "plain_title": "Congress won't pass a psychedelic law in 2026, but states will keep moving", "plain_what": "In 2026, the US Congress is not expected to pass any major law making psychedelics easier to access medically. But individual states and programs focused on military veterans are likely to keep pushing forward on their own. Progress will happen, just patchwork \u2014 state by state, not nationwide." }, { "date": "2026-07-10", "title": "No standalone federal psychedelic bill passes in 2026.", "confidence": 72, "category": "legislation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [], "status": "pending", "priority": "medium", "plain_title": "No nationwide psychedelic law will pass in 2026", "plain_what": "Congress is too focused on other big issues \u2014 like artificial intelligence rules and budget fights \u2014 to pass a standalone psychedelic reform law in 2026. Psychedelic advocates simply don't have enough political momentum at the federal level right now to push a bill all the way through." }, { "date": "2026-07-11", "title": "No DEA final rule rescheduling psilocybin is published in the Federal Register by 2026-08-10.", "confidence": 97, "category": "legislation", "geography": "USA", "resolve_date": "2026-08-10", "tags": [ "legislation", "psilocybin", "DEA" ], "status": "pending", "priority": "medium", "plain_title": "Psilocybin stays illegal federally through August 2026", "plain_what": "The DEA (the US Drug Enforcement Administration) will not publish any official rule change moving psilocybin off the most restricted drug category before August 10, 2026. This matters because as long as psilocybin stays in that category, doctors can't prescribe it and most research faces steep hurdles. The prediction is almost certain \u2014 the government's rulemaking process alone takes many months, and none is currently underway." }, { "date": "2026-07-11", "title": "Full federal rescheduling of psilocybin does not occur in 2026.", "confidence": 90, "category": "legislation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "legislation", "psilocybin" ], "status": "pending", "priority": "high", "plain_title": "Psilocybin stays a federally banned substance all through 2026", "plain_what": "By the end of 2026, psilocybin will still sit in Schedule I \u2014 the federal government's most restricted drug category, alongside heroin \u2014 with no approved medical use. This matters because Schedule I status blocks insurance coverage, limits research, and means anyone using psilocybin therapeutically is still doing so outside federal law. The political and bureaucratic stars simply aren't aligned for change this year." }, { "date": "2026-07-11", "title": "FDA will require durability/maintenance data as a condition before any psilocybin-depression approval decision.", "confidence": 72, "category": "regulatory", "geography": "USA", "resolve_date": "2027-06-30", "tags": [ "psilocybin", "FDA", "depression" ], "status": "pending", "priority": "high", "plain_title": "FDA will demand proof psilocybin benefits last before approving it", "plain_what": "Before the FDA (the US drug regulator) approves any psilocybin treatment for depression, it will likely require companies to show that patients stay better over time \u2014 not just that they felt better right after a session. This is a significant hurdle because most psilocybin studies so far have only tracked patients for a few weeks or months. Companies will need longer, harder studies to clear this bar." }, { "date": "2026-07-11", "title": "A US state or federal veteran ibogaine/psilocybin access or research program launches or expands within 12 months.", "confidence": 70, "category": "policy", "geography": "USA", "resolve_date": "2027-07-11", "tags": [ "psilocybin", "ibogaine", "veteran" ], "status": "pending", "priority": "medium", "plain_title": "A government-backed psychedelic program for veterans launches within a year", "plain_what": "Within the next 12 months, at least one US state or the federal government will officially start or expand a program giving veterans access to ibogaine or psilocybin for conditions like PTSD or depression. Veterans' groups have built unusually strong bipartisan support for this \u2014 both Republicans and Democrats back it \u2014 and Texas has already funded ibogaine research. This would be a real, concrete policy win, not just a proposal." }, { "date": "2026-07-11", "title": "COMPASS Pathways (CMPS) stock closes above $5.00 on 2026-08-10.", "confidence": 55, "category": "markets", "geography": "USA", "resolve_date": "2026-08-10", "tags": [ "psilocybin", "markets", "COMPASS" ], "status": "pending", "priority": "medium", "plain_title": "COMPASS Pathways stock: will it stay above $5 in August 2026?", "plain_what": "COMPASS Pathways is the leading publicly traded psilocybin drug development company, and its stock currently sits in uncertain territory. Whether it closes above $5.00 on August 10, 2026 is essentially a live read on whether investors still believe in the company's future. At roughly a coin-flip probability, this prediction reflects how genuinely uncertain the psychedelic biotech market is right now." }, { "date": "2026-07-12", "title": "No federal rescheduling of psilocybin or MDMA in 2026; Schedule I holds.", "confidence": 85, "category": "legislation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "psilocybin", "MDMA", "Schedule I" ], "status": "pending", "priority": "high", "plain_title": "Magic mushrooms and MDMA stay federally illegal through 2026", "plain_what": "The US federal government will not move psilocybin (the active compound in 'magic mushrooms') or MDMA (often called 'ecstasy') off the most restricted drug list in 2026. Congress is currently focused on funding for trauma and school safety \u2014 not on changing how these drugs are classified. This means no federally legal access to these substances outside of approved research studies." }, { "date": "2026-07-12", "title": "Schedule I posture on psilocybin and MDMA holds through 2026 with no DEA rescheduling action.", "confidence": 85, "category": "regulatory", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "psilocybin", "MDMA", "DEA", "Schedule I" ], "status": "pending", "priority": "high", "plain_title": "The DEA won't budge on psilocybin or MDMA rules in 2026", "plain_what": "The DEA (US Drug Enforcement Administration) is the agency that decides which drugs sit on which federal restricted list. It won't move psilocybin or MDMA to a less restricted category in 2026 because no drug has been formally approved by the FDA (the US drug regulator) for those compounds \u2014 and that FDA approval is what normally triggers the DEA to reconsider. Without that trigger, nothing moves." }, { "date": "2026-07-12", "title": "No federal rescheduling of psilocybin or MDMA occurs in 2026; Schedule I posture holds.", "confidence": 84, "category": "legislation", "geography": "USA", "resolve_date": "2027-01-08", "tags": [ "psilocybin", "MDMA", "Schedule I" ], "status": "pending", "priority": "high", "plain_title": "Experts agree: no federal drug status change in 2026", "plain_what": "Specialists looking at this from three different angles \u2014 drug regulation, law enforcement, and Congress \u2014 all agree that psilocybin and MDMA will stay in the most restricted federal drug category through 2026. Not one of them sees a realistic path for change this year. This matters because federal classification affects everything from research funding to criminal penalties." }, { "date": "2026-07-12", "title": "No federal rescheduling vote reaches the House floor in 2026.", "confidence": 80, "category": "legislation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [], "status": "pending", "priority": "high", "plain_title": "Congress won't hold a full vote on psychedelic drug rescheduling in 2026", "plain_what": "For a law to pass in the US, it first has to come up for a vote on the floor of the House of Representatives. No bill to change the legal status of psilocybin or MDMA is even in line to get that vote in 2026. Politicians right now prefer funding research rather than taking the politically risky step of loosening drug laws, especially with elections on the horizon." }, { "date": "2026-07-12", "title": "FDA convenes an advisory committee on COMPASS psilocybin before any approval action, centered on durability of remission.", "confidence": 74, "category": "regulatory", "geography": "USA", "resolve_date": "2027-06-30", "tags": [ "psilocybin", "FDA", "COMPASS" ], "status": "pending", "priority": "medium", "plain_title": "FDA likely to call an expert panel review of COMPASS's psilocybin therapy", "plain_what": "COMPASS Pathways is a company developing a psilocybin-based therapy. Their drug works fast \u2014 patients feel better quickly \u2014 but scientists aren't sure yet how long that improvement lasts. The FDA (US drug regulator) will likely respond by convening an advisory committee, which is an independent panel of outside experts who review the evidence and give recommendations before any approval decision is made. This adds a step to the approval process and could slow things down." }, { "date": "2026-07-13", "title": "COMPASS Pathways (CMPS) does not announce FDA marketing approval for psilocybin therapy by 2026-08-12.", "confidence": 95, "category": "regulatory", "geography": "USA", "resolve_date": "2026-08-12", "tags": [ "psilocybin", "FDA", "CMPS", "Phase 3" ], "status": "pending", "priority": "high", "plain_title": "No US government approval for psilocybin therapy before August 2026", "plain_what": "COMPASS Pathways, the leading company trying to turn psilocybin into a legal medicine, has not yet submitted the final paperwork the FDA (the US drug regulator) needs to approve it. Without that submission, approval before August 2026 is simply not possible. This matters because approval would be the moment when psilocybin therapy could legally move into clinics." }, { "date": "2026-07-13", "title": "DEA holds Schedule I for psilocybin/MDMA through 2026-10-11 (near-term checkpoint).", "confidence": 90, "category": "regulatory", "geography": "USA", "resolve_date": "2026-10-11", "tags": [ "FDA", "DEA", "Schedule I" ], "status": "pending", "priority": "high", "plain_title": "Psilocybin and MDMA stay in the most restricted drug category through October 2026", "plain_what": "In the US, drugs are ranked in schedules from 1 to 5 based on how dangerous and useful the government thinks they are. Schedule I (the DEA \u2014 the Drug Enforcement Administration \u2014 drug police) means 'no accepted medical use and high abuse potential.' Both psilocybin and MDMA sit there now. Changing that requires the FDA to approve a drug first, and that hasn't happened, so the DEA can't legally move them." }, { "date": "2026-07-13", "title": "DEA maintains Schedule I for psilocybin/MDMA absent formal FDA approval through 2026.", "confidence": 82, "category": "regulatory", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "psilocybin", "MDMA", "FDA", "DEA", "Schedule I" ], "status": "pending", "priority": "high", "plain_title": "Psilocybin and MDMA remain fully illegal federally through end of 2026", "plain_what": "The process for moving a drug out of the most restricted federal category starts only after the FDA approves it as medicine. Since neither psilocybin nor MDMA has reached that finish line, the DEA (the Drug Enforcement Administration) has no legal mechanism to change their status in 2026. This keeps a hard ceiling on how these substances can be used, studied, and sold across most of the country." }, { "date": "2026-07-13", "title": "No standalone federal psychedelic rescheduling bill is enacted in 2026; advancement flows only through appropriations/veteran research provisions.", "confidence": 80, "category": "legislation", "geography": "USA", "resolve_date": "2027-01-09", "tags": [ "veteran", "appropriations" ], "status": "pending", "priority": "high", "plain_title": "Congress funds psychedelic research for veterans but passes no broad drug law in 2026", "plain_what": "There is a real difference between Congress paying for research (tucking a line item into a big spending bill) and Congress actually changing drug law (passing a standalone bill). In 2026, the most likely path is veterans' research funding slipped into a larger budget package \u2014 not a dedicated new law rescheduling or legalizing any psychedelic. That means progress, but not the kind that changes what's legal." }, { "date": "2026-07-13", "title": "Psychedelic sector equities (ATAI ticker) show no sustained breakout absent a Phase 3 durability catalyst by 2026-08-12.", "confidence": 70, "category": "market", "geography": "Global", "resolve_date": "2026-08-12", "tags": [ "Phase 3", "ATAI" ], "status": "pending", "priority": "medium", "plain_title": "Psychedelic company stock prices stay flat without major clinical trial results by August 2026", "plain_what": "ATAI Life Sciences is a publicly traded company that invests in psychedelic medicine startups. Its stock price has been stuck in a range because the big investors who move markets are waiting for late-stage clinical trial results that prove these drugs work safely at scale. Without that proof, there's no shared reason for the whole sector to surge. Individual stocks might jump or drop on small news, but no broad breakout happens." }, { "date": "2026-07-14", "title": "No FDA approval of any psychedelic-assisted therapy (MDMA, psilocybin) before end of 2026.", "confidence": 82, "category": "regulatory", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "MDMA", "FDA" ], "status": "pending", "priority": "high", "plain_title": "No psychedelic therapy will get US government approval by 2026", "plain_what": "The FDA (the US drug regulator) is unlikely to fully approve MDMA or psilocybin as medicines before the end of 2026. The main problem is that in clinical trials, participants could usually tell whether they got the real drug or a dummy pill \u2014 which makes it hard for regulators to trust the results. Until drug companies fix that problem and submit new data, approval stays on hold." }, { "date": "2026-07-14", "title": "No federal rescheduling or major FDA psychedelic approval before 2027 (near-term checkpoint).", "confidence": 80, "category": "regulatory", "geography": "USA", "resolve_date": "2026-08-12", "tags": [ "FDA", "DEA" ], "status": "pending", "priority": "high", "plain_title": "Psychedelics stay illegal federally through at least mid-2026", "plain_what": "As of August 2026, neither MDMA nor psilocybin will have been moved to a less restricted legal category, and neither will have received FDA approval. This matters because federal law still shapes what doctors, researchers, and businesses can legally do with these substances across all 50 states." }, { "date": "2026-07-14", "title": "No DEA rescheduling of Schedule I psychedelics (psilocybin/MDMA) through 2026.", "confidence": 80, "category": "regulatory", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "DEA", "Schedule I" ], "status": "pending", "priority": "high", "plain_title": "Psilocybin and MDMA will remain in the most restricted drug category through 2026", "plain_what": "Both psilocybin (the active compound in magic mushrooms) and MDMA (also known as ecstasy or molly) are currently in Schedule I \u2014 the US government's most restricted drug category, reserved for substances with no accepted medical use. Moving a drug out of Schedule I requires a formal scientific recommendation from a government health agency, followed by a lengthy public rulemaking process. Neither of those steps has started, so nothing will change before 2027." }, { "date": "2026-07-14", "title": "As of mid-August 2026, no peer-reviewed Phase 3 (randomized, adequately powered) efficacy result for psilocybin in bipolar II or anorexia is published.", "confidence": 75, "category": "research", "geography": "Global", "resolve_date": "2026-08-13", "tags": [ "psilocybin" ], "status": "pending", "priority": "medium", "plain_title": "No solid clinical trial results for psilocybin in bipolar or eating disorders yet", "plain_what": "By mid-August 2026, there will likely be no large, rigorous clinical trial results published showing whether psilocybin actually works for bipolar II disorder or anorexia nervosa. The studies done so far have been small and exploratory \u2014 more like checking whether it's safe and feasible to run a trial, not proving the drug works. Big, definitive trials in these conditions haven't even gotten close to finishing." }, { "date": "2026-07-14", "title": "Congress passes only veteran-focused psychedelic research funding (not broad access or rescheduling) in 2026.", "confidence": 72, "category": "legislation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "veteran", "legislation" ], "status": "pending", "priority": "medium", "plain_title": "Congress will fund only military veteran psychedelic research, nothing broader", "plain_what": "In 2026, the only psychedelic-related law Congress is likely to pass would fund research specifically for military veterans \u2014 not open up psychedelics to the general public or change their legal status. Veterans and PTSD (post-traumatic stress disorder) attract bipartisan political support in a way that broader drug policy reform simply doesn't. So lawmakers will fund studies, not freedom." }, { "date": "2026-07-15", "title": "FDA will not endorse bipolar II psilocybin scale-up without controlled comparator data.", "confidence": 75, "category": "research", "geography": "USA", "resolve_date": "2027-01-31", "tags": [ "psilocybin", "FDA" ], "status": "pending", "priority": "high", "plain_title": "Psilocybin for bipolar II needs much stronger safety data first", "plain_what": "The US drug regulator (FDA) is very unlikely to approve expanding psilocybin treatment for bipolar II disorder based on the current small, loosely structured studies. Bipolar II involves mood swings that can tip into dangerous highs (called mania), and the FDA needs head-to-head comparison studies before it will sign off. Without that evidence, people with bipolar II won't get access through official medical channels anytime soon." }, { "date": "2026-07-15", "title": "Federal psilocybin rescheduling will not reach a floor vote this session.", "confidence": 72, "category": "legislation", "geography": "USA", "resolve_date": "2027-01-11", "tags": [ "psilocybin" ], "status": "pending", "priority": "medium", "plain_title": "Congress won't vote on making psilocybin legal this year", "plain_what": "A bill to change psilocybin's legal status at the federal level is very unlikely to get a full vote in Congress this session. The DEA (the agency that controls which drugs are illegal), the FDA, and most lawmakers aren't aligned enough to push it through. That means psilocybin stays a Schedule I drug federally \u2014 the same category as heroin \u2014 regardless of what individual states do." }, { "date": "2026-07-15", "title": "No psychedelic biotech will see sustained rally absent a Phase 3 readout or FDA decision this year.", "confidence": 72, "category": "market", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "FDA", "Phase 3", "biotech" ], "status": "pending", "priority": "medium", "plain_title": "Psychedelic company stocks won't see a lasting recovery this year", "plain_what": "Stock prices for psychedelic drug companies are unlikely to climb and stay up in 2024 unless one of them publishes strong results from a large late-stage clinical trial or gets a formal decision from the FDA. News about laws or personal healing stories doesn't persuade big institutional investors to move serious money. Only hard clinical proof does." }, { "date": "2026-07-15", "title": "No psychedelic biotech sees sustained rally absent a Phase 3 readout or FDA decision this year.", "confidence": 70, "category": "market", "geography": "USA", "resolve_date": "2026-08-14", "tags": [ "FDA", "Phase 3", "biotech" ], "status": "pending", "priority": "medium", "plain_title": "Psychedelic company stocks won't see a lasting recovery this year", "plain_what": "Stock prices for psychedelic drug companies are unlikely to climb and stay up in 2024 unless one of them publishes strong results from a large late-stage clinical trial or gets a formal decision from the FDA. News about laws or personal healing stories doesn't persuade big institutional investors to move serious money. Only hard clinical proof does." }, { "date": "2026-07-15", "title": "MDMA-PTSD will require a resubmission with new confirmatory data before any approval.", "confidence": 70, "category": "regulatory", "geography": "Global", "resolve_date": "2027-06-30", "tags": [ "MDMA", "PTSD" ], "status": "pending", "priority": "medium", "plain_title": "MDMA therapy for PTSD needs a do-over before the FDA will approve it", "plain_what": "The FDA (the US drug regulator) is likely to reject the current MDMA-assisted therapy application for PTSD (post-traumatic stress disorder) and ask for a brand new confirmatory study. The core problem is that trial participants could usually tell whether they got MDMA or a placebo, which makes the results unreliable. Even though veterans and others are suffering and dying, the regulator's job is to make sure treatments actually work before allowing them." }, { "date": "2026-07-16", "title": "DEA maintains Schedule I on core psychedelics through 2026; no broad rescheduling.", "confidence": 74, "category": "regulatory", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "DEA", "Schedule I" ], "status": "pending", "priority": "medium", "plain_title": "Psilocybin, MDMA, and LSD stay illegal federally through 2026", "plain_what": "The DEA (the US agency that classifies dangerous drugs) is not expected to move psilocybin, MDMA, or LSD out of their current 'Schedule I' status \u2014 the category reserved for substances the government considers highly dangerous with no accepted medical use. This matters because Schedule I status is the main reason these substances are so hard to research, prescribe, or access legally anywhere in the US." }, { "date": "2026-07-16", "title": "Broad federal rescheduling stalls through 2026 with no floor vote.", "confidence": 72, "category": "legislation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "Schedule I" ], "status": "pending", "priority": "medium", "plain_title": "Congress won't hold a vote on legalizing psychedelics federally by 2026", "plain_what": "Even if individual lawmakers support changing how the federal government classifies psychedelics, a full vote on the floor of the House or Senate is extremely unlikely by the end of 2026. Congress's schedule is packed, and the DEA (Drug Enforcement Administration) hasn't signaled support, which makes lawmakers reluctant to push it forward." }, { "date": "2026-07-16", "title": "Durability/effect-longevity questions appear in the FDA advisory committee record for MDMA-PTSD.", "confidence": 70, "category": "research", "geography": "USA", "resolve_date": "2027-03-01", "tags": [ "FDA" ], "status": "pending", "priority": "medium", "plain_title": "Government advisors will officially question how long MDMA therapy effects last", "plain_what": "When the FDA (the US Food and Drug Administration) convenes a panel of outside experts to review MDMA as a therapy for PTSD (post-traumatic stress disorder), those experts are expected to formally raise questions about whether the treatment's benefits hold up over time. This matters because if relief fades quickly after treatment, it changes how useful or cost-effective the therapy really is." }, { "date": "2026-07-16", "title": "MDMA-PTSD reaches a favorable but conditional FDA outcome with a restrictive REMS within ~12 months.", "confidence": 68, "category": "regulatory", "geography": "USA", "resolve_date": "2026-10-14", "tags": [ "MDMA", "FDA", "PTSD" ], "status": "pending", "priority": "high", "plain_title": "FDA may approve MDMA therapy but with tight controls on who can give it", "plain_what": "If the FDA (Food and Drug Administration) approves MDMA as a therapy for PTSD, it would likely come with a REMS \u2014 a Risk Evaluation and Mitigation Strategy, which is essentially a strict rulebook that limits who can prescribe, administer, and monitor the drug. Think of it like approving a powerful painkiller only for certified pain clinics, not general practitioners. This would make access real but narrow." }, { "date": "2026-07-16", "title": "MDMA-PTSD receives FDA approval within 12 months.", "confidence": 55, "category": "regulatory", "geography": "USA", "resolve_date": "2027-07-16", "tags": [ "MDMA", "FDA", "PTSD" ], "status": "pending", "priority": "medium", "plain_title": "MDMA therapy for PTSD could get FDA approval within the next year", "plain_what": "The FDA (Food and Drug Administration) could approve MDMA as a legal, prescribed therapy for PTSD (post-traumatic stress disorder) within the next 12 months. The clinical trial data is in, and there's political interest in helping veterans and trauma survivors. But the FDA could also reject the application \u2014 so this is far from certain." }, { "date": "2026-07-17", "title": "No full FDA approval of any MDMA or psilocybin product occurs by mid-August 2026.", "confidence": 97, "category": "regulation", "geography": "USA", "resolve_date": "2026-08-16", "tags": [ "psilocybin", "MDMA", "FDA" ], "status": "pending", "priority": "high", "plain_title": "No psychedelic drug gets full US approval before August 2026", "plain_what": "The FDA (the US drug regulator) will not give MDMA or psilocybin full legal drug status by mid-August 2026. Neither substance even has a review deadline scheduled in that window. This means doctors still cannot officially prescribe either drug as an approved medicine." }, { "date": "2026-07-17", "title": "DEA maintains Schedule I classification for psilocybin and MDMA through Q3 2026.", "confidence": 90, "category": "regulation", "geography": "USA", "resolve_date": "2026-08-16", "tags": [ "psilocybin", "MDMA", "DEA", "Schedule I" ], "status": "pending", "priority": "high", "plain_title": "MDMA and psilocybin stay in the most restricted drug category through mid-2026", "plain_what": "The DEA (the US drug enforcement agency) places drugs into categories called schedules; Schedule I means a drug is considered to have no accepted medical use and high abuse potential. Both MDMA and psilocybin will stay in that most restrictive category through at least September 2026. No official government paperwork to change that is currently in motion." }, { "date": "2026-07-17", "title": "No full FDA approval of MDMA or psilocybin occurs in 2026; any progress is via REMS-gated pathways or resubmission.", "confidence": 85, "category": "regulation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "psilocybin", "MDMA", "FDA" ], "status": "pending", "priority": "high", "plain_title": "Psilocybin and MDMA won't get full US drug approval in all of 2026", "plain_what": "Even with a full year on the clock, neither MDMA nor psilocybin will earn complete FDA approval as a medicine in 2026. Companies may make some progress \u2014 like resubmitting their applications or navigating special restricted-access programs \u2014 but the finish line is still out of reach. Real patients hoping for an approved prescription option will have to wait longer." }, { "date": "2026-07-17", "title": "No federal descheduling or standalone psychedelic legalization passes Congress in 2026.", "confidence": 83, "category": "legislation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "psilocybin", "MDMA", "Schedule I" ], "status": "pending", "priority": "high", "plain_title": "US Congress won't legalize or federally approve psychedelics in 2026", "plain_what": "Even though some politicians in both parties are interested in psychedelics, interest doesn't equal votes. No bill that would remove psilocybin or MDMA from the federal banned list is close to passing in 2026. Election-year politics make bold drug reform even less likely to get a floor vote." }, { "date": "2026-07-17", "title": "Compass Pathways (CMPS) shares remain below $20 at end of Q3 2026 absent a regulatory de-risking catalyst.", "confidence": 72, "category": "market", "geography": "USA", "resolve_date": "2026-09-30", "tags": [ "CMPS", "psilocybin", "equities" ], "status": "pending", "priority": "medium", "plain_title": "Compass Pathways stock likely stays under $20 through September 2026", "plain_what": "Compass Pathways (ticker: CMPS) is a company developing psilocybin-based treatments. Its stock price tends to move based on excitement and news, not profits. Without a major win \u2014 like an FDA approval or a strong late-stage clinical trial result \u2014 there's no obvious reason the stock would break above $20 before the end of September 2026." }, { "date": "2026-07-18", "title": "FDA will not approve MDMA-PTSD before Q3 2027 absent a new confirmatory trial addressing functional unblinding.", "confidence": 75, "category": "regulatory", "geography": "USA", "resolve_date": "2027-09-30", "tags": [ "MDMA", "FDA", "PTSD" ], "status": "pending", "priority": "high", "plain_title": "MDMA therapy for trauma unlikely to get US approval before mid-2027", "plain_what": "The FDA (the US drug regulator) probably won't approve MDMA as a treatment for PTSD (post-traumatic stress disorder) before mid-2027. The main problem: in the clinical trials, patients could usually tell whether they got the real drug or a placebo, which makes the results harder to trust. Until researchers run a new study that solves this problem, the FDA is likely to say no." }, { "date": "2026-07-18", "title": "No FDA MDMA-PTSD approval before Q3 2027 without new confirmatory data addressing unblinding.", "confidence": 73, "category": "regulatory", "geography": "USA", "resolve_date": "2026-10-18", "tags": [ "MDMA", "FDA", "PTSD" ], "status": "pending", "priority": "medium", "plain_title": "MDMA trauma therapy approval still years away, experts agree", "plain_what": "A group of reviewers \u2014 including someone simulating an FDA perspective, a brain-drug scientist, and an investor \u2014 largely agrees that MDMA won't get approved for PTSD treatment before mid-2027. The sticking point is a flaw in how the trials were run: patients could tell what they took, which muddies the results. One voice disagreed, but the majority view is: not yet." }, { "date": "2026-07-18", "title": "No institutional re-rating of psychedelic biotech before a concrete 2027 FDA or Phase 3 catalyst.", "confidence": 72, "category": "market", "geography": "USA", "resolve_date": "2027-06-30", "tags": [ "FDA", "Phase 3", "biotech" ], "status": "pending", "priority": "medium", "plain_title": "Big investors won't pour money into psychedelic companies until 2027", "plain_what": "Large institutional investors \u2014 think pension funds and big asset managers \u2014 are not going to significantly increase their bets on psychedelic drug companies until something concrete happens, like an FDA approval or strong results from a late-stage clinical trial. The feel-good headlines and political momentum around psychedelics are already baked into stock prices, so investors are waiting for real proof before moving more money in." }, { "date": "2026-07-18", "title": "No FDA MDMA-PTSD approval before Q3 2027 absent confirmatory mechanistic and clinical data.", "confidence": 72, "category": "regulatory", "geography": "USA", "resolve_date": "2027-09-30", "tags": [ "MDMA", "FDA", "PTSD" ], "status": "pending", "priority": "medium", "plain_title": "MDMA trauma treatment needs stronger science before US approval", "plain_what": "Even setting aside the trial design problems, scientists still don't fully understand exactly how MDMA produces its therapeutic effects in the brain. The FDA wants both better clinical evidence and a clearer scientific explanation before it approves the drug. Political pressure and public enthusiasm won't speed up that process." }, { "date": "2026-07-18", "title": "Federal rescheduling stalls this Congress; only study mandates or veteran pilots advance.", "confidence": 70, "category": "legislation", "geography": "USA", "resolve_date": "2027-01-16", "tags": [ "veteran" ], "status": "pending", "priority": "medium", "plain_title": "Psychedelic drug reform stalls in Congress; small veteran programs may survive", "plain_what": "Changing how the federal government classifies psychedelics \u2014 which would make research and treatment much easier \u2014 is not going to happen in this session of Congress. The most that's likely to pass is laws requiring more studies or small pilot programs letting military veterans access psychedelic treatments. The DEA (the US Drug Enforcement Administration) and other agencies are resistant to bigger changes." }, { "date": "2026-07-19", "title": "No rescheduling in 2026; DEA maintains Schedule I posture.", "confidence": 78, "category": "legislation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "DEA", "Schedule I" ], "status": "pending", "priority": "high", "plain_title": "The DEA will keep psychedelics fully illegal in 2026", "plain_what": "The DEA (the US agency that controls which drugs are legal) shows no signs of moving psychedelics out of their most restricted category in 2026. This category, called Schedule I, treats a drug as having no medical use and high abuse risk. As long as psychedelics stay there, doctors can't prescribe them and researchers face mountains of extra paperwork just to study them." }, { "date": "2026-07-19", "title": "No federal rescheduling of psychedelics occurs in 2026.", "confidence": 77, "category": "legislation", "geography": "USA", "resolve_date": "2027-01-16", "tags": [], "status": "pending", "priority": "high", "plain_title": "Federal law on psychedelics stays unchanged through 2026", "plain_what": "Multiple independent experts \u2014 including a drug enforcement specialist, a lawmaker, and a journalist \u2014 all agree that the federal government won't change its stance on psychedelics in 2026. The US federal drug law will treat psychedelics the same way it treats heroin: no accepted medical use, no legal access. Only one voice in the group disagreed." }, { "date": "2026-07-19", "title": "No federal rescheduling passes in 2026; veteran-access provisions advance instead.", "confidence": 76, "category": "legislation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "veteran" ], "status": "pending", "priority": "high", "plain_title": "No broad federal legalization, but veterans may get limited psychedelic access", "plain_what": "Congress is focused on smaller, targeted bills in 2026 \u2014 not sweeping drug law reform. The most realistic win is a pilot program giving military veterans access to psychedelic therapy through the VA (the US government's veterans healthcare system). Full federal legalization needs support from both political parties, and that support simply doesn't exist right now." }, { "date": "2026-07-19", "title": "No federal rescheduling occurs in 2026.", "confidence": 75, "category": "legislation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [], "status": "pending", "priority": "high", "plain_title": "Congress won't touch psychedelic drug laws at all in 2026", "plain_what": "The current Congress is spending its energy on international sanctions and military veteran benefits \u2014 not drug law reform. There's no bill moving, no committee vote scheduled, and no political momentum to change how psychedelics are classified federally. Without those ingredients, nothing changes." }, { "date": "2026-07-19", "title": "MDMA-PTSD approval does not occur in 2026; resubmission requires new confirmatory functional-unblinding data.", "confidence": 74, "category": "regulation", "geography": "Global", "resolve_date": "2026-12-31", "tags": [ "MDMA", "PTSD" ], "status": "pending", "priority": "medium", "plain_title": "MDMA therapy for PTSD won't get FDA approval in 2026", "plain_what": "MDMA-assisted therapy for PTSD (post-traumatic stress disorder) was rejected by the FDA (the US drug regulator) and the company trying to get it approved will need to run new clinical trials before reapplying. The core problem: in the original studies, participants could usually tell whether they got the real drug or a fake pill, which makes the results harder to trust. The FDA won't budge on this concern, even though many veterans and trauma survivors are desperate for new options." }, { "date": "2026-07-20", "title": "DEA does not publish any proposed rescheduling rule for psilocybin or MDMA within 30 days.", "confidence": 85, "category": "regulatory", "geography": "USA", "resolve_date": "2026-08-19", "tags": [ "DEA", "Schedule I" ], "status": "pending", "priority": "medium", "plain_title": "US drug agency won't move to reschedule psilocybin or MDMA soon", "plain_what": "The DEA (Drug Enforcement Administration, the US agency that controls which drugs are legal) is very unlikely to publish any formal paperwork moving psilocybin or MDMA off the most restricted drug list in the next 30 days. This matters because until that paperwork appears, both substances stay fully illegal at the federal level \u2014 no matter what individual states do." }, { "date": "2026-07-20", "title": "No psychedelic ETF/large-cap re-rating event occurs in the next 30 days.", "confidence": 78, "category": "markets", "geography": "USA", "resolve_date": "2026-08-19", "tags": [ "FDA", "biotech", "ETF" ], "status": "pending", "priority": "medium", "plain_title": "Psychedelic stock fund unlikely to swing 25% in either direction", "plain_what": "The main stock fund tracking psychedelic companies (called PSIL) is expected to stay relatively flat \u2014 not jumping or crashing more than 25% \u2014 over the next 30 days. Big price swings in this sector usually need a major trigger, like a drug getting approved or a big clinical trial result, and none of those are expected right now." }, { "date": "2026-07-20", "title": "DEA maintains psilocybin/MDMA as Schedule I; no final administrative rescheduling rule published in 2026.", "confidence": 74, "category": "regulatory", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "DEA", "Schedule I" ], "status": "pending", "priority": "medium", "plain_title": "Psilocybin and MDMA stay fully federally illegal through end of 2026", "plain_what": "By the end of 2026, the DEA is almost certainly not going to publish a final, binding rule moving psilocybin or MDMA off Schedule I \u2014 the most restrictive category of illegal drugs. The process for doing that is slow, complex, and not close to finished. This means federal law continues to treat these substances the same way it treats heroin." }, { "date": "2026-07-20", "title": "Biotech psychedelic sector stays range-bound absent a Phase 3 or FDA de-risking catalyst (through Oct 2026).", "confidence": 72, "category": "markets", "geography": "USA", "resolve_date": "2026-10-18", "tags": [ "FDA", "Phase 3", "biotech" ], "status": "pending", "priority": "medium", "plain_title": "Psychedelic biotech stocks will stay flat without a major trial result", "plain_what": "Through October 2026, psychedelic company stocks are expected to stay in a fairly narrow range \u2014 not making big gains or losses \u2014 unless a large-scale clinical trial produces results or a drug gets approved. The excitement and stories about psychedelics are already baked into current stock prices, and big professional investors are waiting for hard proof before committing serious money." }, { "date": "2026-07-20", "title": "Full federal rescheduling of psilocybin/MDMA does NOT pass Congress this session (by Jan 2027).", "confidence": 71, "category": "legislation", "geography": "USA", "resolve_date": "2027-01-16", "tags": [ "veteran", "rescheduling" ], "status": "pending", "priority": "medium", "plain_title": "Congress will not make psilocybin or MDMA federally legal by early 2027", "plain_what": "Passing a law through Congress to remove psilocybin or MDMA from the federal banned substances list by January 2027 is extremely unlikely. There simply aren't enough votes, and the political energy around psychedelics is focused on much narrower things \u2014 like allowing military veterans to access treatment \u2014 rather than broad legalization. Changing a drug's legal status through Congress requires far more political will than currently exists." }, { "date": "2026-07-21", "title": "No FDA approval of any psychedelic therapy within 30 days.", "confidence": 97, "category": "regulation", "geography": "USA", "resolve_date": "2026-08-20", "tags": [ "FDA" ], "status": "pending", "priority": "high", "plain_title": "No psychedelic drug will get US approval in the next month", "plain_what": "The FDA (the US drug regulator) won't approve any psychedelic-based treatment in the next 30 days. This matters because approval would be the green light for doctors to legally prescribe these treatments \u2014 and that moment is still a while away." }, { "date": "2026-07-21", "title": "No federal rescheduling of any psychedelic out of Schedule I within 3 months.", "confidence": 93, "category": "regulation", "geography": "USA", "resolve_date": "2026-10-19", "tags": [ "Schedule I" ], "status": "pending", "priority": "high", "plain_title": "Federal law on psychedelics won't change in the next three months", "plain_what": "The DEA (the US agency that controls which drugs are legal and illegal) won't move any psychedelic out of Schedule I \u2014 the most restricted category \u2014 in the next 90 days. Rescheduling requires a long chain of government steps, and none of those steps have even started." }, { "date": "2026-07-21", "title": "No standalone federal psychedelic rescheduling bill will pass Congress within 12 months.", "confidence": 85, "category": "legislation", "geography": "USA", "resolve_date": "2027-07-21", "tags": [], "status": "pending", "priority": "medium", "plain_title": "Congress won't pass a standalone law to legalize psychedelic research in a year", "plain_what": "No bill focused specifically on moving psychedelics out of the most restricted legal category will pass through Congress and get signed into law in the next 12 months. Lawmakers lack the votes and political momentum to push through a bill like this on its own." }, { "date": "2026-07-21", "title": "Psychedelic equity sector gains from today will not hold through mid-September absent a hard clinical/M&A catalyst.", "confidence": 60, "category": "market", "geography": "Global", "resolve_date": "2026-09-15", "tags": [ "CMPS" ], "status": "pending", "priority": "medium", "plain_title": "A recent stock rally in psychedelic companies will likely fade by mid-September", "plain_what": "Psychedelic company stocks recently got a boost from general market excitement \u2014 not from any specific breakthrough of their own. Without a real concrete milestone like a successful drug trial or a major acquisition, those gains tend to fade. COMPASS Pathways (ticker: CMPS), a leading publicly traded psychedelic company, is being used here as the measuring stick." }, { "date": "2026-07-21", "title": "At least one Phase 2/3 psilocybin depression trial will report a statistically significant positive primary endpoint by year end.", "confidence": 60, "category": "research", "geography": "Global", "resolve_date": "2026-12-31", "tags": [ "psilocybin", "depression" ], "status": "pending", "priority": "medium", "plain_title": "At least one major psilocybin depression study will show clear positive results this year", "plain_what": "Several large clinical trials testing psilocybin (the active compound in magic mushrooms) as a depression treatment are expected to share results before the end of 2026. At least one of them is likely to show that psilocybin worked significantly better than the comparison treatment. This would be a meaningful step toward eventually getting it approved as a medicine." }, { "date": "2026-07-22", "title": "No federal descheduling of psilocybin or MDMA before 2028; DEA maintains Schedule I posture.", "confidence": 75, "category": "regulatory", "geography": "USA", "resolve_date": "2028-01-01", "tags": [ "psilocybin", "MDMA", "DEA", "Schedule I" ], "status": "pending", "priority": "high", "plain_title": "Psilocybin and MDMA stay federally illegal until at least 2028", "plain_what": "The DEA (the US agency that classifies drugs) keeps psilocybin and MDMA in the most restricted category, meaning no legal use outside approved research. This matters because even if the FDA (the US drug regulator) approves a psychedelic medicine, doctors still can't prescribe it without the DEA agreeing to loosen restrictions. That agreement won't happen quickly." }, { "date": "2026-07-22", "title": "Mechanistic research output outpaces clinical/regulatory approvals through 2027.", "confidence": 74, "category": "research", "geography": "Global", "resolve_date": "2026-10-20", "tags": [], "status": "pending", "priority": "medium", "plain_title": "Scientists learn more about how psychedelics work than patients can legally access", "plain_what": "Labs are publishing a flood of studies explaining what psilocybin and MDMA do to the brain, but that knowledge is racing ahead of actual drug approvals. This means the science is getting rich while sick people still wait for treatments. The gap between understanding a drug and being allowed to prescribe it can take many years to close." }, { "date": "2026-07-22", "title": "FDA will demand at least one confirmatory MDMA trial addressing functional unblinding before any approval.", "confidence": 74, "category": "regulatory", "geography": "USA", "resolve_date": "2027-06-30", "tags": [ "MDMA", "FDA" ], "status": "pending", "priority": "medium", "plain_title": "FDA will require another MDMA study before approving it as a medicine", "plain_what": "The FDA rejected MDMA-assisted therapy in 2024 partly because participants in trials could usually tell whether they got the real drug \u2014 which could skew results. The FDA wants a new study that accounts for this problem before it will approve MDMA as a treatment. This delays relief for people with PTSD (post-traumatic stress disorder) who were hoping for a legal option soon." }, { "date": "2026-07-22", "title": "Mechanistic and preclinical research output continues outpacing clinical/regulatory approvals through 2027.", "confidence": 74, "category": "research", "geography": "Global", "resolve_date": "2027-12-31", "tags": [], "status": "pending", "priority": "medium", "plain_title": "Lab discoveries about psychedelics far outpace actual approved treatments through 2027", "plain_what": "Scientists are uncovering how psychedelics change the brain at a rapid pace, but those discoveries are not turning into approved medicines or legal therapies at the same speed. Think of it like building a detailed map of a country you're not yet allowed to visit. The knowledge is valuable but doesn't help patients until regulators catch up." }, { "date": "2026-07-22", "title": "No federal rescheduling/descheduling of psilocybin or MDMA before 2028.", "confidence": 73, "category": "regulatory", "geography": "USA", "resolve_date": "2026-10-20", "tags": [ "psilocybin", "MDMA" ], "status": "pending", "priority": "medium", "plain_title": "Psilocybin and MDMA remain federally illegal through at least 2028", "plain_what": "Multiple government insiders \u2014 including drug enforcement officers, lawmakers, and FDA reviewers \u2014 agree that neither psilocybin nor MDMA will be moved out of the most restricted drug category at the federal level before 2028. This means no nationwide legal medical use, no insurance coverage, and no standard prescriptions during this period. State-level exceptions exist but don't change federal law." }, { "date": "2026-07-23", "title": "No Schedule I psychedelic is rescheduled or descheduled federally in 2026.", "confidence": 85, "category": "regulatory", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "Schedule I" ], "status": "pending", "priority": "high", "plain_title": "No psychedelic becomes federally legal in 2026", "plain_what": "In the US, making a drug like psilocybin or MDMA legal at the federal level first requires sign-off from the FDA (the US drug regulator). That sign-off isn't coming this year, and there's no other legal path open. So the federal rules stay the same: these substances remain fully illegal under federal law." }, { "date": "2026-07-23", "title": "The 'psilocybin reshapes the brain' story gets amplified well beyond its actual clinical claim within weeks.", "confidence": 82, "category": "culture", "geography": "Global", "resolve_date": "2026-08-31", "tags": [ "psilocybin" ], "status": "pending", "priority": "high", "plain_title": "Brain study headlines will wildly overstate what the science actually shows", "plain_what": "A study finds something interesting about how psychedelics affect brain activity in a lab setting. By the time it travels through news outlets, the headline reads like scientists have proven psychedelics rebuild your brain and cure depression. The actual finding was far narrower and more tentative. This gap between the real science and the public story spreads fast." }, { "date": "2026-07-23", "title": "No federal rescheduling or FDA approval of a classic psychedelic in 2026; change requires FDA approval first and the docket is empty.", "confidence": 81, "category": "regulatory", "geography": "USA", "resolve_date": "2026-10-21", "tags": [ "FDA" ], "status": "pending", "priority": "high", "plain_title": "Federal law on psychedelics won't change at all in 2026", "plain_what": "Multiple independent experts \u2014 a drug regulator, a drug enforcement officer, and a lawmaker \u2014 all agree: there is no realistic path for any classic psychedelic to become federally legal this year. The FDA hasn't approved any, and Congress has no active legislation moving forward. One expert disagreed, but the consensus is firm." }, { "date": "2026-07-23", "title": "No FDA approval decision on any classic psychedelic occurs in 2026; MDMA remains in post-CRL remediation.", "confidence": 80, "category": "regulatory", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "MDMA", "FDA" ], "status": "pending", "priority": "high", "plain_title": "The FDA won't approve any classic psychedelic as a medicine in 2026", "plain_what": "MDMA (the active ingredient in ecstasy, being studied for PTSD) got rejected by the FDA last year and is still fixing the problems the agency flagged. No other psychedelic has even submitted a full application for approval. With no approvals possible, the legal status of these drugs can't change through the medical route either." }, { "date": "2026-07-23", "title": "Psilocybin mechanistic/'brain remodeling' findings get amplified far beyond their clinical meaning.", "confidence": 79, "category": "culture", "geography": "Global", "resolve_date": "2026-09-21", "tags": [ "psilocybin" ], "status": "pending", "priority": "high", "plain_title": "Psilocybin brain research will be hyped beyond what it proved", "plain_what": "Scientists studying how psilocybin (the active compound in magic mushrooms) affects brain signals will publish findings that are genuinely interesting but limited. Journalists, social media, and sometimes even companies will reframe those findings as proof that psilocybin physically restructures the brain or definitively treats mental illness. It doesn't quite say that." }, { "date": "2026-07-24", "title": "No bill named today (H.R.185 et al.) carries psychedelic access/descheduling language before the August recess; federal action waits for fall appropriations/NDAA.", "confidence": 78, "category": "legislation", "geography": "USA", "resolve_date": "2026-08-07", "tags": [], "status": "pending", "priority": "high", "plain_title": "Congress won't touch psychedelic drug laws before summer break", "plain_what": "Several bills currently moving through Congress have nothing to do with psychedelics, and nobody is pushing hard enough to add psychedelic-related language to them before lawmakers leave for August recess. The next realistic chance for any federal psychedelic law change is in the fall, when Congress debates big spending bills and the annual defense bill." }, { "date": "2026-07-24", "title": "No psychedelic-therapy provision is attached to any bill named today before the August recess; the next real window is fall appropriations/NDAA.", "confidence": 75, "category": "legislation", "geography": "USA", "resolve_date": "2026-08-07", "tags": [], "status": "pending", "priority": "medium", "plain_title": "No psychedelic therapy access gets added to any current bill before summer", "plain_what": "Even the specific bills that advocates hoped might carry psychedelic therapy language won't get it added before Congress leaves for summer. Therapy access for psychedelics \u2014 especially for veterans \u2014 is being positioned as a fall push, likely tied to the annual defense spending bill." }, { "date": "2026-07-24", "title": "The esketamine EEG-microstate finding is not independently replicated in a controlled cohort within 12 weeks; claims stay preliminary.", "confidence": 70, "category": "research", "geography": "Global", "resolve_date": "2026-10-16", "tags": [ "ketamine" ], "status": "pending", "priority": "medium", "plain_title": "Brain scan finding from ketamine study won't be confirmed in 12 weeks", "plain_what": "Researchers found that esketamine (a prescription ketamine-based drug) changed specific brain wave patterns within 24 hours in people with severe depression. That's interesting, but confirming it requires other labs running the same test on different patients \u2014 and that kind of independent check takes much longer than 12 weeks to design, run, and publish." }, { "date": "2026-07-24", "title": "The 'mushrooms reshape brain long after trip' plasticity story draws a skeptical or qualifying corrective from a researcher/outlet within 6 weeks.", "confidence": 67, "category": "research", "geography": "Global", "resolve_date": "2026-09-04", "tags": [], "status": "pending", "priority": "medium", "plain_title": "Scientists will publicly push back on 'mushrooms rewire the brain' headlines", "plain_what": "Media coverage claiming that psilocybin mushrooms physically reshape the brain long after the trip has gotten ahead of what the actual research shows. Within six weeks, expect at least one scientist or science journalist to publish a careful correction pointing out the study's limits \u2014 like that it was done in animals, or the follow-up period was short." }, { "date": "2026-07-24", "title": "The intranasal esketamine EEG-microstate paper draws a published methodological critique flagging small-n/paired-design limits within 8 weeks.", "confidence": 66, "category": "research", "geography": "Global", "resolve_date": "2026-09-18", "tags": [ "ketamine" ], "status": "pending", "priority": "medium", "plain_title": "Researchers will publicly criticize the small size of the ketamine brain study", "plain_what": "The esketamine brain-wave study almost certainly used a small number of patients and compared each person to their own earlier results rather than to a separate control group. Studies designed this way reliably attract published criticism \u2014 in the form of letters or commentaries \u2014 pointing out that the results might not hold up in a larger, more rigorous test." }, { "date": "2026-07-25", "title": "The ibogaine fast-track will draw a critical investigative piece questioning cardiac safety or political motives (MAHA angle) in a major outlet before 2026-09-15.", "confidence": 70, "category": "cultural", "geography": "Global", "resolve_date": "2026-09-15", "tags": [ "ibogaine" ], "status": "pending", "priority": "medium", "plain_title": "Major news outlet will question ibogaine's heart risks or political push", "plain_what": "Ibogaine, a powerful psychedelic being fast-tracked by US drug regulators for veteran treatment, has a known risk of causing dangerous heart rhythm problems. A major newspaper or magazine is likely to publish a deep investigation asking whether the political push to approve it is moving too fast and putting people at risk. This matters because fast-tracking a drug with cardiac risks \u2014 especially under political pressure \u2014 could affect patient safety and public trust." }, { "date": "2026-07-25", "title": "A veteran-organized coalition will publicly petition the VA or Congress for ibogaine access citing the fast-track within 8 weeks.", "confidence": 68, "category": "policy", "geography": "USA", "resolve_date": "2026-09-19", "tags": [ "ibogaine", "veteran" ], "status": "pending", "priority": "medium", "plain_title": "Veteran groups will formally demand ibogaine access from VA or Congress", "plain_what": "Veterans' advocacy organizations are expected to use the FDA (the US drug regulator) fast-track designation for ibogaine as a rallying moment to publicly demand access through the VA (the US Department of Veterans Affairs) or through new laws. A petition or open letter is a cheap, fast way for these groups to get attention and pressure lawmakers. This matters because organized veteran pressure has historically moved drug policy faster than almost anything else." }, { "date": "2026-07-25", "title": "The ibogaine fast-track triggers a formal cardiac-safety counterweight (FDA gating, peer-reviewed hERG/QT caution, or new mechanistic data) before 2026-10-15.", "confidence": 63, "category": "regulatory", "geography": "USA", "resolve_date": "2026-10-25", "tags": [ "ibogaine", "FDA" ], "status": "pending", "priority": "medium", "plain_title": "Regulators or scientists will formally flag ibogaine's dangerous heart side effects", "plain_what": "Ibogaine is known to cause a serious heart condition called QT prolongation, which can trigger a life-threatening irregular heartbeat. As the drug moves through the fast-track approval process, regulators, drug safety experts, or scientists are expected to formally raise this concern \u2014 either by publishing new safety data, issuing a warning, or putting conditions on how trials must be run. This matters because formal safety flags can slow or reshape a drug's path to approval." }, { "date": "2026-07-25", "title": "At least one state (likely TX, KY, or AZ) will announce new ibogaine or veteran-psychedelic funding/pilot legislation before 2026-11-01.", "confidence": 60, "category": "policy", "geography": "USA", "resolve_date": "2026-11-01", "tags": [ "ibogaine", "legislation", "veteran" ], "status": "pending", "priority": "medium", "plain_title": "A US state will fund or propose an ibogaine program for veterans", "plain_what": "Texas has already put state money into ibogaine research for veterans, and the new federal fast-track gives other states political cover to follow. States like Texas, Kentucky, or Arizona \u2014 where veteran communities are large and politically powerful \u2014 may announce new funding, a pilot program, or a bill to explore ibogaine or other psychedelics as veteran treatments. This matters because state-level action can happen much faster than federal approval and creates real access for real people." }, { "date": "2026-07-25", "title": "The iPSC-derived neuron rapid-antidepressant study will report time-dependent plasticity differences between TRD and healthy donors in a peer-reviewed journal before 2026-09-30.", "confidence": 55, "category": "research", "geography": "Global", "resolve_date": "2026-09-30", "tags": [], "status": "pending", "priority": "medium", "plain_title": "Lab study will show depression changes how brain cells respond to antidepressants over time", "plain_what": "Scientists are using a technique that turns human skin or blood cells into working brain cells in a dish \u2014 called iPSC (induced pluripotent stem cell)-derived neurons \u2014 to study why some people's depression doesn't respond to normal treatments. A study comparing brain cells from people with treatment-resistant depression (TRD) to cells from healthy people is expected to show that the two groups respond differently to fast-acting antidepressants as time passes. This matters because it could explain why some people don't get better and point toward more personalized treatments." }, { "date": "2026-07-26", "title": "No formal DEA rescheduling movement on ibogaine or any classic psychedelic follows the MAHA fast-track headlines this quarter.", "confidence": 72, "category": "regulation", "geography": "USA", "resolve_date": "2026-10-01", "tags": [ "ibogaine", "DEA" ], "status": "pending", "priority": "medium", "plain_title": "No DEA drug rescheduling for ibogaine or psychedelics this quarter", "plain_what": "The DEA (the US agency that controls which drugs are legal and illegal) is not moving to change ibogaine's status as a banned substance anytime soon. Changing a drug's legal category takes years of scientific review, not political headlines. Ibogaine also carries a real risk of dangerous heart rhythm problems, which makes regulators move even more slowly." }, { "date": "2026-07-26", "title": "No formal FDA breakthrough or fast-track designation for ibogaine is announced this quarter; any admin statement will carry an explicit cardiac safety caveat.", "confidence": 70, "category": "regulation", "geography": "USA", "resolve_date": "2026-10-01", "tags": [ "ibogaine", "FDA" ], "status": "pending", "priority": "medium", "plain_title": "FDA won't give ibogaine a special approval status this quarter", "plain_what": "The FDA (the US drug regulator) has special labels it can give promising medicines to speed up their review \u2014 but ibogaine won't get one this quarter. Ibogaine can cause dangerous changes to heart rhythm, and any serious regulatory agency has to put safety warnings front and center before talking about approval timelines. Political messaging from the White House doesn't override that process." }, { "date": "2026-07-26", "title": "The 'Trump fast-tracks ibogaine' MAHA framing overstates reality; no formal FDA/DEA designation materializes this quarter and a safety-caveated corrective narrative follows.", "confidence": 67, "category": "regulation", "geography": "USA", "resolve_date": "2026-10-25", "tags": [ "ibogaine", "FDA", "DEA" ], "status": "pending", "priority": "medium", "plain_title": "The 'Trump fast-tracks ibogaine' story is hype \u2014 no real action follows", "plain_what": "News coverage has suggested the Trump administration is pushing ibogaine toward fast approval, but no formal step from the FDA or DEA is actually happening this quarter. After the hype fades, more accurate reporting will emerge showing the claims were overstated. The gap between a politician saying something and a regulatory agency doing something is enormous." }, { "date": "2026-07-26", "title": "The intranasal esketamine EEG-microstate paper draws a published methodological critique for lacking placebo control within 5 months.", "confidence": 66, "category": "research", "geography": "Global", "resolve_date": "2026-12-15", "tags": [ "ketamine" ], "status": "pending", "priority": "medium", "plain_title": "Scientists will publicly challenge a key ketamine brain-study paper within five months", "plain_what": "A research paper looked at how a nasal spray version of ketamine (called esketamine, sold as Spravato) affects brain activity patterns \u2014 but the study had a design flaw: it didn't include a fake-treatment comparison group. When you give people a powerful drug and don't compare results to people who got nothing, it's hard to know if the effects are real or just expectations. Other scientists are likely to call this out in writing." }, { "date": "2026-07-26", "title": "The DARPA-NRx SPARC-TMS contract is an NRx-specific TMS-device catalyst, not sector-moving for CMPS/ATAI/MMED.", "confidence": 63, "category": "capital_markets", "geography": "Global", "resolve_date": "2026-10-25", "tags": [ "atai" ], "status": "pending", "priority": "medium", "plain_title": "A government-funded brain-stimulation deal helps one company, not the whole psychedelic sector", "plain_what": "DARPA (the US military's advanced research agency) signed a contract with a company called NRx to explore combining a drug treatment with TMS (transcranial magnetic stimulation \u2014 a device that uses magnetic pulses to stimulate the brain). This is good news for NRx specifically, but it won't lift the stock prices or fortunes of other psychedelic companies like CMPS, ATAI, or MMED. Government contracts are narrow and targeted." }, { "date": "2026-07-27", "title": "Lykos does not resubmit its MDMA NDA before year-end; any refiling requires a new confirmatory trial commitment.", "confidence": 68, "category": "clinical", "geography": "Global", "resolve_date": "2026-12-31", "tags": [ "MDMA" ], "status": "pending", "priority": "medium", "plain_title": "MDMA therapy company won't reapply for approval this year", "plain_what": "Lykos Therapeutics, the company trying to get MDMA-assisted therapy approved in the US, is unlikely to resubmit its application to the FDA (the US drug regulator) before the end of 2025. To even try again, they'd need to commit to running a whole new confirmatory study \u2014 a massive, expensive undertaking. This matters because it means MDMA therapy stays out of legal medical settings for longer." }, { "date": "2026-07-27", "title": "The iPSC rapid-antidepressant paper drives follow-on research/citations within ~12 weeks but changes zero clinical protocols.", "confidence": 62, "category": "research", "geography": "Global", "resolve_date": "2026-10-25", "tags": [], "status": "pending", "priority": "medium", "plain_title": "Exciting stem cell depression study sparks academic buzz but changes nothing for patients", "plain_what": "A new paper using iPSCs (stem cells grown from a patient's own body) to study how fast-acting antidepressants work is generating real scientific excitement. Within about three months, other researchers will likely cite it and build on it. But it won't change how any doctor actually treats patients anytime soon \u2014 it's fascinating lab science, not a clinical tool yet." }, { "date": "2026-07-27", "title": "MMED's divergent +4.5% move front-runs an MM120 corporate/clinical disclosure within 8 weeks.", "confidence": 62, "category": "capital-markets", "geography": "Global", "resolve_date": "2026-10-25", "tags": [], "status": "pending", "priority": "medium", "plain_title": "MindMed stock jump hints at big company news coming soon", "plain_what": "MindMed (ticker: MMED), a company developing a psychedelic-derived drug called MM120 for anxiety, saw its stock jump 4.5% on a day when the rest of the market was quiet. That kind of out-of-nowhere move often means someone knows something is coming. Analysts think a major clinical or business announcement is likely within eight weeks." }, { "date": "2026-07-27", "title": "MindMed (MMED) issues an MM120 clinical or corporate disclosure within 8 weeks that explains today's divergent move.", "confidence": 62, "category": "capital-markets", "geography": "Global", "resolve_date": "2026-09-21", "tags": [ "MindMed" ], "status": "pending", "priority": "medium", "plain_title": "MindMed will announce major news about its anxiety drug within 8 weeks", "plain_what": "MindMed's stock moved up 4.5% on its own, without any broader market reason, which often means insiders or informed traders are buying ahead of news. The company's drug MM120 \u2014 a carefully refined version of LSD being tested for generalized anxiety disorder \u2014 is at a stage in its clinical testing where results could drop soon. An announcement of some kind is expected within about two months." }, { "date": "2026-07-27", "title": "The iPSC time-dependence paper generates \u22653 follow-on preprints/citations emphasizing patient heterogeneity within 12 weeks, changing zero clinical protocols.", "confidence": 62, "category": "research", "geography": "Global", "resolve_date": "2026-10-19", "tags": [], "status": "pending", "priority": "medium", "plain_title": "New depression research sparks follow-up studies but won't change any treatments", "plain_what": "A detailed new study using iPSCs (stem cells engineered from a patient's own blood or skin cells) is revealing exactly why some antidepressants work fast for some people but not others. Scientists will rush to build on it \u2014 expect at least three follow-up papers within three months. But none of this will change how any therapist or doctor actually treats patients yet. It's real progress, just very early-stage." }, { "date": "2026-07-28", "title": "No >$50M psychedelic M&A or licensing deal closes within 8 weeks; CMPS continues underperforming MMED absent a Phase 3 readout.", "confidence": 66, "category": "capital-markets", "geography": "USA", "resolve_date": "2026-09-22", "tags": [ "DEA", "Phase 3" ], "status": "pending", "priority": "medium", "plain_title": "No big psychedelic company buyouts happen in the next two months", "plain_what": "Right now, no major purchase or licensing deal worth more than $50 million looks likely to close in the next eight weeks. Big institutional investors are sitting on their hands, waiting for hard clinical trial results before committing serious money. One company, CMPS, keeps lagging behind its rival MMED in stock performance because neither has announced a big Phase 3 trial result yet." }, { "date": "2026-07-28", "title": "Federal psychedelic-veteran progress advances only as an NDAA/appropriations rider or hearing schedule, not the standalone Turning Point Act, before year-end.", "confidence": 63, "category": "legislation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "veteran" ], "status": "pending", "priority": "medium", "plain_title": "Veteran psychedelic therapy progress sneaks through the defense budget bill", "plain_what": "A bill called the Turning Point Act, which would give veterans access to psychedelic therapies, is unlikely to pass on its own before the end of 2026. Instead, small but real progress will happen when lawmakers quietly attach psychedelic-related language to must-pass defense spending or budget bills \u2014 a common political workaround. Veterans with PTSD (post-traumatic stress disorder) could see funding for psychedelic research or pilot programs this way, just not through a flashy standalone law." }, { "date": "2026-07-28", "title": "Federal psychedelic-veteran progress travels via NDAA/appropriations rider or hearing \u2014 not the standalone Turning Point Act, which lacks operative access provisions.", "confidence": 62, "category": "legislation", "geography": "USA", "resolve_date": "2027-01-24", "tags": [ "veteran" ], "status": "pending", "priority": "medium", "plain_title": "Veteran psychedelic access advances through budget bills, not the Turning Point Act", "plain_what": "Multiple independent analysts agree: the Turning Point Act sounds promising but doesn't actually contain the specific legal language needed to give veterans real access to psychedelic treatments. Progress will instead come as a small add-on to larger must-pass spending bills. This matters because the method of passage affects how strong, permanent, and well-funded any new veteran access program would be." }, { "date": "2026-07-28", "title": "No FDA action tied to today's named bills; veteran-access movement occurs via appropriations rider, not the Turning Point Act, by year-end.", "confidence": 62, "category": "legislation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "FDA", "veteran" ], "status": "pending", "priority": "medium", "plain_title": "Veteran psychedelic access moves via budget bills, not named standalone laws", "plain_what": "Bills currently getting attention in Congress appear to be focused on other topics entirely \u2014 fraud prevention and farm credit \u2014 not psychedelic access. Any real movement on veterans getting access to psychedelic therapies will happen through add-ons to big defense or government funding bills that Congress has to pass. This is the historical pattern and the most realistic path before the end of 2026." }, { "date": "2026-07-28", "title": "The trial-design narrative review's unblinding/expectancy critique becomes a widely-cited methodological reference in FDA discourse and follow-on publications within 12 weeks.", "confidence": 60, "category": "research", "geography": "USA", "resolve_date": "2026-10-26", "tags": [ "FDA" ], "status": "pending", "priority": "medium", "plain_title": "A new research paper on flawed psychedelic trial design becomes widely influential", "plain_what": "A recently published review paper is criticizing a major problem in psychedelic research: patients in trials can usually tell whether they got the real drug or a placebo (fake pill), which skews the results and makes the treatment look more effective than it might actually be. This is called the unblinding and expectancy problem. Within 12 weeks, this paper is expected to become a frequently cited reference in regulatory discussions and follow-up scientific publications." }, { "date": "2026-07-29", "title": "No standalone psychedelic bill reaches House committee markup this quarter; the only federal movement is via an NDAA veteran-research amendment.", "confidence": 68, "category": "legislation", "geography": "USA", "resolve_date": "2026-11-15", "tags": [ "veteran" ], "status": "pending", "priority": "medium", "plain_title": "Congress skips standalone psychedelic bill; veterans bill sneaks through defense budget", "plain_what": "No dedicated psychedelic law will get a formal committee vote this quarter. Instead, the only real federal progress comes as a small add-on tucked inside the giant annual military spending bill, specifically funding psychedelic research for veterans. This matters because it's a slow, side-door approach rather than a bold policy shift." }, { "date": "2026-07-29", "title": "FDA or an FDA-affiliated author will publicly cite functional-unblinding/monitor-variability concerns (per today's narrative review) in guidance commentary or an advisory context before end of Q3.", "confidence": 66, "category": "research", "geography": "USA", "resolve_date": "2026-09-30", "tags": [ "FDA" ], "status": "pending", "priority": "medium", "plain_title": "FDA raises red flags about how psychedelic drug trials are designed", "plain_what": "The FDA (the US drug regulator) or scientists closely connected to it will publicly point out serious problems with how psychedelic studies are run \u2014 specifically that patients can easily tell whether they got the real drug or a placebo, which skews results. They'll also flag inconsistent oversight by trial monitors. This matters because it could force companies to redesign expensive studies." }, { "date": "2026-07-29", "title": "Federal psychedelic movement stays rider/state-based; no standalone bill reaches markup, while \u22652 states advance measures.", "confidence": 65, "category": "state-policy", "geography": "USA", "resolve_date": "2026-10-28", "tags": [], "status": "pending", "priority": "medium", "plain_title": "States keep pushing psychedelic laws while Congress stays on the sidelines", "plain_what": "At least two US states will move meaningful psychedelic policy forward \u2014 think legalization, regulated therapy programs, or decriminalization \u2014 while the federal government does nothing through a standalone law. This is the classic pattern of states acting as testing grounds when Washington won't budge." }, { "date": "2026-07-29", "title": "Today's trial-design narrative review becomes the quarter's methodological flashpoint, generating multiple editorials on blinding and monitor standardization.", "confidence": 64, "category": "research", "geography": "Global", "resolve_date": "2026-10-28", "tags": [], "status": "pending", "priority": "medium", "plain_title": "New research paper on psychedelic trial flaws sparks major scientific debate", "plain_what": "A recently published review paper \u2014 one that lays out problems with how psychedelic drug trials are designed and overseen \u2014 is on track to become a major talking point in the scientific community. Expect multiple published responses and opinion pieces arguing about whether these trials can be trusted. This is the scientific version of a food fight, and it matters because the outcome shapes what future studies have to look like." }, { "date": "2026-07-29", "title": "The psilocybin-assisted OCD feasibility study will report positive tolerability/signal, spawning at least one new registered psilocybin-OCD trial within 12 weeks.", "confidence": 64, "category": "clinical", "geography": "Global", "resolve_date": "2026-10-21", "tags": [ "psilocybin" ], "status": "pending", "priority": "medium", "plain_title": "Early psilocybin OCD study shows promise, triggering a new follow-up trial", "plain_what": "A small early-stage study testing psilocybin (the active compound in magic mushrooms) as a treatment for OCD (obsessive-compulsive disorder, a condition marked by unwanted repetitive thoughts and behaviors) will report that it's safe and shows early signs of working. That positive result will be enough to get at least one new, larger OCD trial officially registered and launched within about three months. This matters because OCD is hard to treat and has few good options." }, { "date": "2026-07-30", "title": "CMPS trades within a \u00b112% band through September absent a named Phase 3 readout; the 1.9% pop fully mean-reverts within 15 trading days.", "confidence": 70, "category": "markets", "geography": "Global", "resolve_date": "2026-08-25", "tags": [ "Phase 3" ], "status": "pending", "priority": "medium", "plain_title": "COMPASS stock stays flat until big trial results arrive", "plain_what": "Shares of COMPASS Pathways (ticker: CMPS), a company developing a synthetic psilocybin pill called COMP360, recently jumped about 2% for no clear reason. That small gain will likely disappear within three weeks, and the stock will drift sideways \u2014 up or down no more than 12% \u2014 until the company releases results from its large Phase 3 trial (the final, decisive round of human testing required before a drug can be approved). Nothing meaningful has changed about the company; the price move was just random market noise." }, { "date": "2026-07-30", "title": "FDA issues no new psychedelic-specific guidance document before Q4 2026; existing 2023 draft remains the operative framework for any Lykos resubmission.", "confidence": 68, "category": "regulatory", "geography": "USA", "resolve_date": "2026-10-31", "tags": [ "FDA" ], "status": "pending", "priority": "medium", "plain_title": "US drug regulators won't publish new psychedelic rules before late 2026", "plain_what": "The FDA (the US drug regulator) published a draft guidance document in 2023 explaining how companies should design clinical trials for psychedelic drugs. As of now, the FDA has not replaced or updated that document, and it almost certainly won't release a new one before the final quarter of 2026. That 2023 draft remains the rulebook any company \u2014 including Lykos Therapeutics, which is trying to resubmit its MDMA-assisted therapy application after the FDA rejected it \u2014 must follow when designing their studies." }, { "date": "2026-07-30", "title": "SYNVEST imaging shows real 5-HT2A synaptic effects but no clean clinical correlation, disappointing simple neuroplasticity narratives.", "confidence": 62, "category": "research", "geography": "Global", "resolve_date": "2026-10-28", "tags": [], "status": "pending", "priority": "medium", "plain_title": "Brain scan study shows drug effect but can't link it to patient improvement", "plain_what": "A study called SYNVEST is using advanced brain imaging to look at whether psychedelics actually change the density of connections between brain cells by acting on a specific receptor called 5-HT2A (a docking point on brain cells that psychedelics latch onto). The scans will likely show that yes, something measurable changes in the brain. But researchers won't be able to clearly show that more brain-connection changes equals more symptom relief in patients \u2014 which is the headline the field was hoping to prove." }, { "date": "2026-07-30", "title": "A veteran ibogaine/psychedelic access provision is formally introduced or offered as an NDAA/VA amendment within 10 weeks, citing Stanford ibogaine data.", "confidence": 62, "category": "legislation", "geography": "Global", "resolve_date": "2026-10-08", "tags": [ "ibogaine", "veteran" ], "status": "pending", "priority": "medium", "plain_title": "Congress will likely try to expand psychedelic access for veterans this fall", "plain_what": "Within the next ten weeks, at least one member of Congress is expected to formally propose adding a provision to a major defense or veterans' affairs bill that would expand veterans' access to ibogaine (a powerful plant-based psychedelic) or other psychedelic therapies. This push is fueled by recent Stanford University research showing ibogaine may help veterans with opioid addiction and PTSD (post-traumatic stress disorder), and by renewed public attention to veterans' mental health. Getting it formally introduced is step one \u2014 passing is a much longer road." }, { "date": "2026-07-30", "title": "SYNVEST shows measurable 5-HT2A-linked synaptic density changes but WITHOUT clean dose-response correlation to clinical improvement, complicating the neuroplasticity narrative.", "confidence": 62, "category": "research", "geography": "Global", "resolve_date": "2026-12-15", "tags": [], "status": "pending", "priority": "medium", "plain_title": "Brain scan study shows drug effect but can't link it to patient improvement", "plain_what": "SYNVEST researchers will use PET scans (a type of brain imaging that measures biological activity) to look for changes in synaptic density \u2014 essentially, how many connection points exist between brain cells \u2014 after people take psychedelics. The scans will very likely show real, measurable changes tied to how psychedelics interact with 5-HT2A receptors (specific docking sites on brain cells). But those brain changes won't line up neatly with who feels better or worse, which pokes a hole in the popular idea that 'more brain rewiring equals more healing.'" }, { "date": "2026-07-31", "title": "The veteran psilocybin PTSD pilot paper generates no FDA advisory committee scheduling or Type B meeting announcement before end of Q3 2026.", "confidence": 80, "category": "regulatory", "geography": "USA", "resolve_date": "2026-09-30", "tags": [ "psilocybin", "FDA", "veteran", "PTSD" ], "status": "pending", "priority": "high", "plain_title": "Veterans' mushroom study won't trigger any FDA review meetings this year", "plain_what": "A small, early-stage study on psilocybin (the active compound in 'magic mushrooms') for veterans with PTSD (post-traumatic stress disorder) won't be enough to get the FDA (the US drug regulator) to schedule formal review meetings by the end of September 2026. Early studies that lack a control group \u2014 meaning no comparison group of patients \u2014 simply don't meet the bar regulators need to take official action. Real people won't see any new treatment options move forward based on this study alone." }, { "date": "2026-07-31", "title": "The open-label veteran psilocybin pilot drives advocacy and citations but no FDA or DEA regulatory movement in 2026.", "confidence": 76, "category": "regulatory", "geography": "USA", "resolve_date": "2026-10-29", "tags": [ "psilocybin", "FDA", "DEA", "veteran" ], "status": "pending", "priority": "high", "plain_title": "Veterans' psilocybin study will inspire advocates but won't move regulators in 2026", "plain_what": "The open-label veteran psilocybin pilot study will get attention \u2014 researchers will cite it, advocates will use it to push for change, and it may influence public opinion. But neither the FDA (the US drug regulator) nor the DEA (the US Drug Enforcement Administration, which controls what substances are legal) will take any concrete regulatory action because of it this year. One early study, even a hopeful one, isn't enough to change official policy." }, { "date": "2026-07-31", "title": "The veteran psilocybin pilot triggers no change in DEA Schedule I research registration policy or bulk manufacturing quota before year-end.", "confidence": 75, "category": "regulatory", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "psilocybin", "DEA", "Schedule I", "veteran" ], "status": "pending", "priority": "high", "plain_title": "Veterans' psilocybin study won't change DEA research rules or drug supply access in 2026", "plain_what": "The DEA (the US Drug Enforcement Administration) controls who can study psilocybin and how much of it can be legally manufactured for research. One small pilot study on veterans won't be enough to get the DEA to loosen those rules or increase the amount of psilocybin researchers are allowed to produce. Changing DEA policy requires strong, repeated evidence from well-controlled studies \u2014 and we're not there yet." }, { "date": "2026-07-31", "title": "CMPS trades within \u00b112% of $11.39 through September 15 absent a COMP360 Phase 3 topline or M&A announcement.", "confidence": 74, "category": "markets", "geography": "Global", "resolve_date": "2026-09-15", "tags": [ "Phase 3" ], "status": "pending", "priority": "medium", "plain_title": "COMPASS Pathways stock price likely stays flat through mid-September 2026", "plain_what": "COMPASS Pathways (ticker: CMPS) is a company developing a synthetic psilocybin drug called COMP360 for depression. Without a major announcement \u2014 like results from their large Phase 3 trial (the final and most rigorous type of drug study) or news of a merger or acquisition \u2014 the stock price is expected to stay within about 12% of $11.39 through September 15, 2026. The veteran pilot study isn't significant enough to move investors." }, { "date": "2026-07-31", "title": "Psychedelic policy movement this session stays confined to veteran-research riders or appropriations amendments, with no standalone psilocybin bill reaching a floor vote by year-end.", "confidence": 72, "category": "legislation", "geography": "Global", "resolve_date": "2026-12-31", "tags": [ "psilocybin", "veteran" ], "status": "pending", "priority": "medium", "plain_title": "No standalone psilocybin bill will get a full congressional vote in 2026", "plain_what": "In the US Congress, psilocybin reform is most likely to advance only as a small add-on to larger bills \u2014 like ones focused on veterans' care or government spending \u2014 rather than as its own standalone law. Getting a dedicated psilocybin bill to a full floor vote requires more political support than currently exists. Small, targeted additions to veteran-focused legislation are the realistic path forward this year." }, { "date": "2026-08-01", "title": "No DEA rescheduling notice or scheduling review for psilocybin is initiated within 12 weeks.", "confidence": 75, "category": "regulatory", "geography": "USA", "resolve_date": "2026-10-24", "tags": [ "psilocybin", "DEA" ], "status": "pending", "priority": "high", "plain_title": "The US drug agency won't review psilocybin's legal status soon", "plain_what": "The DEA (the US Drug Enforcement Administration, which controls what drugs are legal) is very unlikely to start a formal review of psilocybin's status as a banned substance in the next three months. This matters because rescheduling \u2014 moving psilocybin off the most restricted drug list \u2014 is the main legal barrier stopping doctors from prescribing it widely. Without a DEA review, that barrier stays in place." }, { "date": "2026-08-01", "title": "The veteran psilocybin PTSD pilot will be cited in \u22652 congressional statements/amendments but generate no FDA guidance response within 10 weeks.", "confidence": 72, "category": "regulatory", "geography": "USA", "resolve_date": "2026-10-10", "tags": [ "psilocybin", "FDA", "veteran", "PTSD" ], "status": "pending", "priority": "medium", "plain_title": "Veteran psilocybin study gets political buzz but no FDA response", "plain_what": "A small government-funded pilot study giving psilocybin to veterans with PTSD (post-traumatic stress disorder) is likely to get mentioned in at least two speeches or proposed amendments in Congress. But the FDA (the US Food and Drug Administration, which decides what medical treatments are approved) almost certainly won't issue any formal response or new guidance because of it. A single small pilot study \u2014 especially one without a control group \u2014 doesn't carry enough scientific weight to make regulators act." }, { "date": "2026-08-01", "title": "CMPS closes below $12.50 every trading day through 2026-09-30 absent a Phase 3 readout or partnership.", "confidence": 72, "category": "markets", "geography": "Global", "resolve_date": "2026-09-30", "tags": [ "Phase 3" ], "status": "pending", "priority": "medium", "plain_title": "Compass Pathways stock likely stays below $12.50 through September", "plain_what": "CMPS is the stock ticker for Compass Pathways, a company developing a synthetic psilocybin drug called COMP360. With no major trial results or big business deals expected before the end of September 2026, the stock is likely to keep drifting at or below $12.50 per share. Without a concrete reason for large investors to buy in, there's no force pushing the price up." }, { "date": "2026-08-01", "title": "COMPASS Pathways' COMP360 Phase 3 (TRD) will not receive an FDA advisory committee scheduling notice before 2026-10-15.", "confidence": 70, "category": "regulatory", "geography": "USA", "resolve_date": "2026-10-15", "tags": [ "FDA", "COMPASS", "Phase 3" ], "status": "pending", "priority": "medium", "plain_title": "No FDA expert panel meeting for Compass's depression drug before mid-October", "plain_what": "Before the FDA approves a new drug, it often convenes an advisory committee \u2014 a panel of outside experts who publicly review the evidence and vote on whether the drug seems safe and effective. Compass Pathways hasn't yet submitted a full application for COMP360 as a treatment for hard-to-treat depression, and the FDA has many competing priorities. So no scheduling notice for such a panel meeting is expected before October 15, 2026." }, { "date": "2026-08-01", "title": "The veteran psilocybin PTSD pilot drives political citation but is treated as non-pivotal by FDA/DEA/markets; a methodological corrective (control-arm critique) follows within ~6 weeks.", "confidence": 68, "category": "clinical", "geography": "USA", "resolve_date": "2026-10-30", "tags": [ "psilocybin", "FDA", "DEA", "veteran", "PTSD", "market" ], "status": "pending", "priority": "medium", "plain_title": "Veteran psilocybin study will face public scientific criticism within weeks", "plain_what": "Within about six weeks, scientists and journalists are likely to publicly point out a major flaw in the veteran PTSD psilocybin pilot: it didn't use a control group (a comparison group of people who got a placebo or different treatment). Without that, you can't know whether the improvement veterans showed was caused by the psilocybin or by other factors like hope, attention, and care. This kind of critique is standard in science, but it matters here because it will likely limit how seriously the FDA and DEA treat the study." }, { "date": "2026-08-02", "title": "The Rose Hill/Control Z LOI produces no measurable listed-equity move (>3%) in any named psychedelic ticker through August.", "confidence": 72, "category": "markets", "geography": "Global", "resolve_date": "2026-08-31", "tags": [ "LOI" ], "status": "pending", "priority": "medium", "plain_title": "A private deal memo won't budge psychedelic stock prices in August", "plain_what": "Two private companies signed a letter of intent (a non-binding agreement to potentially work together), but because neither company trades on a stock exchange, this news gives public investors nothing concrete to act on. Stock prices for publicly traded psychedelic companies like CMPS and MMED are driven by hard data \u2014 trial results, acquisitions \u2014 not private paperwork between outside firms. This prediction says none of the major listed psychedelic stocks will jump or drop more than 3% on any single day because of this deal memo." }, { "date": "2026-08-02", "title": "CMPS and MMED remain within \u00b18% of today's close through August absent a Phase 3 readout or M&A event.", "confidence": 70, "category": "markets", "geography": "Global", "resolve_date": "2026-08-31", "tags": [ "Phase 3" ], "status": "pending", "priority": "high", "plain_title": "Two key psychedelic stocks will likely stay flat through August", "plain_what": "CMPS and MMED are two companies developing psychedelic medicines that trade on the NASDAQ stock exchange. Without a major announcement \u2014 like final results from a large clinical trial or a buyout deal \u2014 there's no strong reason for their stock prices to swing sharply in either direction. This prediction says both stocks will end August within 8% of where they started, as long as no game-changing news drops." }, { "date": "2026-08-02", "title": "MARA Act gains additional cosponsors but receives no committee markup or hearing before fall recess.", "confidence": 66, "category": "legislation", "geography": "USA", "resolve_date": "2026-10-15", "tags": [ "MARA" ], "status": "pending", "priority": "high", "plain_title": "A psychedelic medicine bill will get more supporters but no vote before fall", "plain_what": "The MARA Act (Medical Alternatives to Reduce Addiction Act) is a proposed US law that would expand access to psychedelic treatments, especially for veterans. More members of Congress are expected to sign on as supporters, but the bill is very unlikely to actually get a formal committee hearing or vote before Congress goes on its fall recess. This is a familiar pattern \u2014 bills gain names on a list but stall before any real action." }, { "date": "2026-08-02", "title": "The veterans psilocybin pilot is cited in at least one congressional statement or VA-access advocacy filing within 8 weeks.", "confidence": 66, "category": "legislation", "geography": "USA", "resolve_date": "2026-09-27", "tags": [ "psilocybin", "veteran" ], "status": "pending", "priority": "high", "plain_title": "Veterans psychedelic pilot results will show up in Congress within 8 weeks", "plain_what": "A pilot program giving psilocybin (the active compound in magic mushrooms) to veterans produced results that advocates and lawmakers find politically powerful. Within the next eight weeks \u2014 by late September 2026 \u2014 at least one member of Congress or a formal advocacy group is expected to publicly reference this pilot in a statement, speech, or official filing. Veterans' health outcomes resonate strongly with politicians across party lines." }, { "date": "2026-08-02", "title": "At least one veterans service organization publicly endorses MARA or cites the psilocybin pilot in an access campaign within 6 weeks.", "confidence": 63, "category": "legislation", "geography": "USA", "resolve_date": "2026-09-13", "tags": [ "psilocybin", "veteran" ], "status": "pending", "priority": "high", "plain_title": "A major veterans group will back psychedelic medicine access within 6 weeks", "plain_what": "Large veterans service organizations \u2014 groups like the VFW (Veterans of Foreign Wars), the American Legion, IAVA (Iraq and Afghanistan Veterans of America), or the DAV (Disabled American Veterans) \u2014 have millions of members and enormous political influence. Within six weeks, at least one of these groups is expected to publicly endorse the MARA Act or specifically cite the veterans psilocybin pilot in a campaign pushing for broader access. When both data and a live bill exist, these organizations tend to move." }, { "date": "2026-08-03", "title": "FDA issues no new psilocybin-specific guidance before year-end; the smokers/cancer/AUD trials read out only feasibility, not efficacy.", "confidence": 70, "category": "clinical", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "psilocybin", "FDA" ], "status": "pending", "priority": "medium", "plain_title": "US drug regulator won't publish special psilocybin rules by year-end", "plain_what": "The FDA (the US drug regulator) is not expected to release any new official guidelines specifically for psilocybin before the end of 2026. The ongoing clinical trials on smoking, cancer distress, and alcohol problems are only testing whether psilocybin is safe enough to study further \u2014 not yet proving it actually works. Until companies run larger, tightly controlled trials showing real results, the FDA has no strong reason to act." }, { "date": "2026-08-03", "title": "Today's early-phase psilocybin studies (cancer, smokers, AUD) yield only feasibility/safety data, no efficacy readouts, this year.", "confidence": 68, "category": "clinical", "geography": "Global", "resolve_date": "2026-12-31", "tags": [ "psilocybin" ], "status": "pending", "priority": "medium", "plain_title": "Early psilocybin trials report safety data only, not proof it works", "plain_what": "Current psilocybin studies focused on cancer patients, smokers, and people with alcohol problems are small and designed mainly to check whether the treatment is safe \u2014 not to prove it's effective. These are early-stage trials, meaning researchers are still figuring out doses and side effects. Solid proof that psilocybin actually treats these conditions is still years away." }, { "date": "2026-08-03", "title": "No psychedelic access language survives to markup on the Rural Veterans Home-Based Care Act; any advance is a study rider or dies at staff level.", "confidence": 66, "category": "legislation", "geography": "Global", "resolve_date": "2026-11-15", "tags": [ "veteran" ], "status": "pending", "priority": "medium", "plain_title": "Veterans bill won't give vets real psychedelic access this year", "plain_what": "A bill called the Rural Veterans Home-Based Care Act is moving through Congress, but any language that would give veterans actual access to psychedelic treatments is expected to be stripped out or blocked before the bill reaches a serious vote. At best, a small provision allowing further study might survive. This matters because veterans are one of the groups most actively seeking psychedelic-assisted therapy for PTSD (post-traumatic stress disorder) and depression." }, { "date": "2026-08-03", "title": "MindMed (MMED) issues a material disclosure \u2014 pipeline update, financing, or partnership \u2014 within 6 weeks explaining today's divergent 4.7% move.", "confidence": 64, "category": "capital-markets", "geography": "Global", "resolve_date": "2026-09-14", "tags": [ "MindMed" ], "status": "pending", "priority": "medium", "plain_title": "MindMed will make a major company announcement within six weeks", "plain_what": "MindMed (ticker: MMED) is a publicly traded psychedelic drug company whose stock recently jumped about 4.7% on a day when most similar stocks fell \u2014 a pattern that often signals that people with inside knowledge are buying ahead of news. Within the next six weeks, the company is expected to announce something significant, such as an update on its drug pipeline, a new funding deal, or a business partnership. This kind of unusual stock movement rarely happens by accident." }, { "date": "2026-08-03", "title": "The retracted psychedelic-therapy paper triggers a formal journal expression of concern or named-institution investigation statement within 8 weeks.", "confidence": 63, "category": "research", "geography": "Global", "resolve_date": "2026-09-28", "tags": [], "status": "pending", "priority": "medium", "plain_title": "Retracted psychedelic study will trigger official misconduct investigation within eight weeks", "plain_what": "A psychedelic therapy research paper was recently pulled from a scientific journal after problems were found with the data. Within the next eight weeks, the journal or the university behind the research is expected to issue a formal public statement flagging concerns, or launch an official investigation into what went wrong. This matters because bad research can mislead patients, therapists, and policymakers \u2014 and the field needs credibility to move forward." }, { "date": "2026-08-04", "title": "The ibogaine ketamine-abstinence case report generates \u22651 new IND inquiry but no FDA-cleared trial start within 12 weeks, blocked by cardiac (QT) toxicology requirements.", "confidence": 72, "category": "clinical", "geography": "USA", "resolve_date": "2026-10-27", "tags": [ "ketamine", "ibogaine", "FDA" ], "status": "pending", "priority": "medium", "plain_title": "Ibogaine heart-risk rules block any new ketamine-addiction trial starting", "plain_what": "A single patient story about ibogaine helping someone quit ketamine caught attention, but turning one case into an official clinical trial takes years of safety groundwork \u2014 especially because ibogaine can cause dangerous heart rhythms. The FDA (the US drug regulator) requires companies to prove a drug won't kill people before testing it on more patients. No new ibogaine trial targeting ketamine addiction will move from idea to actively recruiting patients by late October 2026." }, { "date": "2026-08-04", "title": "COMPASS Pathways' psilocybin-MDD program produces no FDA filing or breakthrough-status update within 10 weeks; CMPS's 4.2% pop is not accompanied by any regulatory milestone.", "confidence": 70, "category": "clinical", "geography": "USA", "resolve_date": "2026-10-13", "tags": [ "psilocybin", "FDA", "COMPASS" ], "status": "pending", "priority": "medium", "plain_title": "COMPASS Pathways' psilocybin drug program hits no major US regulatory milestone", "plain_what": "COMPASS Pathways is testing a synthetic psilocybin pill called COMP360 for people with hard-to-treat depression. A recent jump in their stock price wasn't driven by any real news from regulators \u2014 it was based on general excitement. Between now and October 13, 2026, the company is not expected to submit their drug for official US approval or announce any new special status from the FDA that would fast-track their program." }, { "date": "2026-08-04", "title": "The ibogaine case report yields no DEA scheduling accommodation and no cleared expanded-access pathway within 12 weeks; cardiac-risk framing dominates any official response.", "confidence": 70, "category": "policy", "geography": "USA", "resolve_date": "2026-10-27", "tags": [ "ibogaine", "DEA" ], "status": "pending", "priority": "medium", "plain_title": "One ibogaine case report won't change US drug laws or expand legal access", "plain_what": "Ibogaine is currently a Schedule I substance in the US \u2014 the most restricted category, meaning the government considers it to have no accepted medical use and high abuse potential. One published patient story won't prompt the DEA (the US Drug Enforcement Administration) to loosen that classification, and the FDA won't open a formal compassionate-use program (a special pathway letting seriously ill patients try unapproved drugs) based on a single anecdote. Ibogaine's history of causing fatal heart problems gives regulators every reason to move slowly." }, { "date": "2026-08-04", "title": "The ibogaine-ketamine case report prompts no validated mechanistic study; any follow-up remains observational, not controlled, within 12 weeks.", "confidence": 68, "category": "research", "geography": "Global", "resolve_date": "2026-10-27", "tags": [ "ketamine", "ibogaine" ], "status": "pending", "priority": "medium", "plain_title": "No rigorous science on how ibogaine and ketamine interact will emerge soon", "plain_what": "Scientists don't yet understand the biology of why ibogaine might help someone stop using ketamine \u2014 the one published case offers a story, not an explanation. Properly designed studies that could actually test a mechanism (like a controlled experiment with a comparison group) take months or years to fund, design, and launch. By late October 2026, any follow-up work will almost certainly still be observational \u2014 meaning researchers watching and recording what happens naturally, not running a controlled experiment." }, { "date": "2026-08-04", "title": "CMPS gives back the majority of its 4.2% gain within 15 trading days absent a data or partnership catalyst; no M&A among CMPS/ATAI/MMED/NUMI in 8 weeks.", "confidence": 63, "category": "markets", "geography": "Global", "resolve_date": "2026-08-25", "tags": [ "atai", "CMPS" ], "status": "pending", "priority": "medium", "plain_title": "COMPASS stock likely falls back and no psychedelic company mergers happen soon", "plain_what": "When a stock jumps without a concrete reason \u2014 like a major trial result or a partnership deal \u2014 it usually drifts back down. COMPASS Pathways' recent 4.2% gain fits that pattern. Meanwhile, none of the major publicly traded psychedelic companies (COMPASS, ATAI Life Sciences, Mind Medicine, or Numinus) appear to be in merger or acquisition talks. Without a real catalyst \u2014 new data, a buyout, or a licensing deal \u2014 the pop is expected to erase itself by August 25, 2026." }, { "date": "2026-08-05", "title": "No controlled human replication of the ibogaine ketamine-abstinence finding is published within 12 weeks; follow-up stays at case-series/preclinical level.", "confidence": 70, "category": "research", "geography": "Global", "resolve_date": "2026-10-28", "tags": [ "ketamine", "ibogaine" ], "status": "pending", "priority": "medium", "plain_title": "No solid ibogaine study will confirm ketamine-abstinence finding soon", "plain_what": "Scientists found a surprising result suggesting ibogaine (a powerful psychedelic from an African plant) might help people stay off ketamine (a dissociative drug). But turning one interesting case report into a properly controlled study \u2014 where you have comparison groups, safety screening, and ethics board approval \u2014 takes months to years, not weeks. So for now, this remains a 'promising but unproven' signal." }, { "date": "2026-08-05", "title": "No FDA advisory-committee or Type B meeting is publicly scheduled for TRP-8803 within 12 weeks; the '72-patient commercialisation' claim gets corrected to a designation.", "confidence": 68, "category": "clinical", "geography": "USA", "resolve_date": "2026-10-28", "tags": [ "FDA" ], "status": "pending", "priority": "medium", "plain_title": "No official FDA meeting scheduled for TRP-8803 drug program anytime soon", "plain_what": "A company called Terran Biosciences has a drug program called TRP-8803, and someone described it as being on a path to commercialization after testing in 72 patients. But the FDA (the US drug regulator) requires far more evidence \u2014 typically hundreds or thousands of patients across multiple studies \u2014 before any drug can be sold. What the company likely received is a special designation (a kind of official encouragement), not a green light to sell anything." }, { "date": "2026-08-05", "title": "No standalone psychedelic bill receives a floor vote in 12 weeks; any movement comes via NDAA/VA appropriations rider or a Mental Health Caucus hearing.", "confidence": 66, "category": "legislation", "geography": "Global", "resolve_date": "2026-10-28", "tags": [], "status": "pending", "priority": "medium", "plain_title": "No standalone psychedelic law will get a full Congress vote this fall", "plain_what": "Getting a new law passed in the US Congress requires finding room on a very crowded schedule, and right now lawmakers are focused on other priorities. The most realistic way psychedelic-related policy moves forward in the next few months is as a small add-on tucked inside a big military spending bill (called the NDAA, or National Defense Authorization Act) or a budget bill for veterans' care \u2014 not as its own bill getting a spotlight vote." }, { "date": "2026-08-05", "title": "The ibogaine ketamine-abstinence case spurs new research/state interest but no controlled human replication within 12 weeks; any state action carries cardiac-safety guardrails.", "confidence": 64, "category": "research", "geography": "Global", "resolve_date": "2026-11-03", "tags": [ "ketamine", "ibogaine" ], "status": "pending", "priority": "medium", "plain_title": "Ibogaine case sparks interest but no rigorous human study follows quickly", "plain_what": "A notable case involving ibogaine and ketamine abstinence is getting attention from researchers and some state governments. But running a proper human study \u2014 one where you carefully screen participants for heart problems (ibogaine can be dangerous for the heart), get ethics approval, and have a control group \u2014 takes far longer than a few weeks. Any state that does move forward will almost certainly build in strict cardiac safety requirements." }, { "date": "2026-08-05", "title": "CMPS retraces at least half its 15% gain (below ~$12.65) within 3 weeks absent a disclosed Phase 3 psilocybin catalyst.", "confidence": 64, "category": "capital-markets", "geography": "Global", "resolve_date": "2026-08-26", "tags": [ "psilocybin", "Phase 3" ], "status": "pending", "priority": "medium", "plain_title": "Small psychedelic stock's big price jump will likely fade fast", "plain_what": "A company called Compass Pathways (ticker: CMPS) saw its stock jump about 15%, but other psychedelic companies didn't move alongside it \u2014 which usually means the jump was driven by hype or short-term trading rather than a real change in the company's prospects. When that happens, stocks typically fall back down to where they started within a few weeks, especially if no major news (like strong results from a large Phase 3 trial) comes out to justify the higher price." }, { "date": "2026-08-06", "title": "The psilocybin-in-autism TRD program will publish or present only pilot/feasibility framing \u2014 no efficacy claim \u2014 by end of Q3.", "confidence": 68, "category": "research", "geography": "Global", "resolve_date": "2026-09-30", "tags": [ "psilocybin" ], "status": "pending", "priority": "medium", "plain_title": "Psilocybin autism-depression study will only report early safety data", "plain_what": "A research team studying psilocybin for depression in autistic adults will share findings framed only as 'is this safe and doable?' \u2014 not 'does it work?' This matters because autistic people face unique risks in these studies, and researchers are being cautious before making any big claims. Real proof of effectiveness will have to wait for larger studies." }, { "date": "2026-08-06", "title": "The clinical-stage biotech that appointed a 'proven scaling CEO' pre-Phase-3 announces a capital raise or dilutive financing within 8 weeks, not a partnership.", "confidence": 66, "category": "capital_markets", "geography": "Global", "resolve_date": "2026-10-01", "tags": [ "biotech" ], "status": "pending", "priority": "medium", "plain_title": "New 'growth CEO' hire at psychedelic biotech signals a dilutive fundraise is coming", "plain_what": "A psychedelic drug company that recently brought in a CEO famous for scaling businesses is expected to announce a fundraise \u2014 meaning it will issue new shares and dilute existing shareholders \u2014 within about two months of that hire. Companies hire 'scaling' executives when they need money and want to look confident doing it. Current shareholders end up owning a smaller slice of the company." }, { "date": "2026-08-06", "title": "Any regulatory or agency response to the ibogaine case reiterates cardiac-safety/QT warnings rather than opening an access pathway, within 90 days.", "confidence": 66, "category": "policy", "geography": "Global", "resolve_date": "2026-11-04", "tags": [ "ibogaine" ], "status": "pending", "priority": "medium", "plain_title": "Regulators will warn about ibogaine heart risks, not open a new access path", "plain_what": "Ibogaine, a plant-based psychedelic being studied for addiction treatment, carries a serious risk of causing dangerous heart arrhythmias. When any government agency officially responds to a recent ibogaine case or proposal within the next 90 days, they are expected to repeat that heart-risk warning rather than create a new way for people to access it legally. The drug remains in the most restricted category \u2014 Schedule I \u2014 and one high-profile case won't change that." }, { "date": "2026-08-06", "title": "The 'proven scaling CEO' story precedes a financing/dilution within 8 weeks \u2014 and coverage will retroactively frame the hire as runway management.", "confidence": 63, "category": "capital_markets", "geography": "Global", "resolve_date": "2026-10-01", "tags": [], "status": "pending", "priority": "medium", "plain_title": "Big CEO hire was cover for a dilutive fundraise all along", "plain_what": "When a psychedelic biotech announces a well-known executive joining as CEO, the real purpose is often to generate positive press before raising money by selling new shares. Once the fundraise happens, journalists and analysts will look back and describe the CEO hire as a way to 'manage the cash runway' \u2014 meaning buy time and confidence while the company scrambled for money. The announcement was the setup; the fundraise is the actual news." }, { "date": "2026-08-06", "title": "ACP-211 monotherapy MDD program will report positive interim/topline signal or advance to next-phase dosing within 12 weeks.", "confidence": 62, "category": "clinical", "geography": "Global", "resolve_date": "2026-10-29", "tags": [], "status": "pending", "priority": "medium", "plain_title": "ACP-211 depression drug trial will hit a positive milestone within 12 weeks", "plain_what": "ACP-211 is an experimental drug being tested as a standalone treatment for people whose depression hasn't responded to regular antidepressants. Within about three months \u2014 so by early November 2026 \u2014 the company running the trial is expected to announce either promising early data or that they're moving to the next stage of testing. Companies typically publicize programs only when they're close to good news, so this announcement seems imminent." }, { "date": "2026-08-07", "title": "At least one psilocybin-AUD mechanistic study (neurobehavioral) will publish peer-reviewed findings supporting rapid neuroplasticity by year-end.", "confidence": 72, "category": "research", "geography": "Global", "resolve_date": "2026-12-31", "tags": [ "psilocybin" ], "status": "pending", "priority": "medium", "plain_title": "Scientists publish proof psilocybin rewires the brain fast in alcohol study", "plain_what": "A research team studying psilocybin as a treatment for alcohol use disorder will publish findings in a peer-reviewed journal showing exactly how the drug triggers rapid brain rewiring \u2014 what scientists call neuroplasticity. This matters because it moves psilocybin beyond 'it seems to work' toward 'here's the biological reason why.' That kind of evidence makes regulators, doctors, and insurers take the treatment more seriously." }, { "date": "2026-08-07", "title": "New peer-reviewed mechanistic output (rapid-onset neuroplasticity, psilocybin-AUD) publishes by year-end, extending the evidence base.", "confidence": 71, "category": "research", "geography": "Global", "resolve_date": "2026-11-05", "tags": [ "psilocybin" ], "status": "pending", "priority": "medium", "plain_title": "Scientists publish proof psilocybin rewires the brain fast in alcohol study", "plain_what": "Another research team studying how psilocybin helps people with alcohol use disorder will publish peer-reviewed findings confirming that the drug triggers fast brain rewiring. Multiple independent scientists reviewing the evidence agree this is likely to happen by the end of 2026. Each new paper like this adds another brick to the foundation that could eventually support widespread medical use." }, { "date": "2026-08-07", "title": "A mechanistic paper on why ketamine/psychedelics act rapidly (neuroplasticity/synaptogenesis) will be published in a peer-reviewed journal by year-end, cited widely.", "confidence": 71, "category": "research", "geography": "Global", "resolve_date": "2026-12-31", "tags": [ "ketamine" ], "status": "pending", "priority": "medium", "plain_title": "Scientists will publish a clear explanation for why psychedelics work so fast", "plain_what": "A peer-reviewed journal paper will come out by the end of 2026 explaining the biological reason drugs like ketamine and psilocybin relieve depression or addiction symptoms so quickly \u2014 specifically by growing new connections between brain cells almost immediately after a dose. Most antidepressants take weeks; these drugs seem to work in hours or days, and researchers want to know why. That answer could reshape how we develop mental health treatments entirely." }, { "date": "2026-08-07", "title": "No psilocybin autism-TRD or anorexia study will publish a controlled efficacy readout (only feasibility/safety) before Q1 2027.", "confidence": 70, "category": "clinical", "geography": "Global", "resolve_date": "2027-03-31", "tags": [ "psilocybin" ], "status": "pending", "priority": "medium", "plain_title": "Psilocybin studies for autism and eating disorders won't show full results yet", "plain_what": "Current psilocybin trials looking at autism-related depression and anorexia are still in early stages \u2014 they're testing whether the treatment is safe and doable, not yet whether it definitively works. Publishing a rigorous 'does it work?' result requires a much stricter study design \u2014 with a control group and blinding \u2014 that these trials haven't built yet. So before early 2027, expect only safety and 'we could run this study' reports, not definitive proof of effectiveness." }, { "date": "2026-08-07", "title": "DEA will NOT signal any change to psilocybin quota or research-supply expansion despite the AUD/MDD trial activity this quarter.", "confidence": 68, "category": "policy", "geography": "USA", "resolve_date": "2026-11-07", "tags": [ "psilocybin", "DEA" ], "status": "pending", "priority": "medium", "plain_title": "The DEA will not loosen rules on psilocybin supply for researchers", "plain_what": "The DEA (Drug Enforcement Administration, the US agency that controls which drugs researchers can access) is very unlikely to announce any expansion of how much psilocybin researchers are allowed to use or produce before the end of 2026. Psilocybin is still a Schedule I drug \u2014 the most restricted category \u2014 and the DEA rarely acts on its own without enormous outside pressure. A recent high-profile death connected to psychedelic therapy has made the political environment even more cautious." }, { "date": "2026-08-08", "title": "The public-healthcare-setting psilocybin RCT for TRD reports positive primary endpoint within 8 weeks, strengthening reimbursement arguments.", "confidence": 62, "category": "clinical", "geography": "Global", "resolve_date": "2026-10-03", "tags": [ "psilocybin" ], "status": "pending", "priority": "medium", "plain_title": "Public hospital psilocybin depression trial hits its main goal", "plain_what": "A clinical trial \u2014 a carefully controlled test on real patients \u2014 running psilocybin therapy inside an ordinary public healthcare setting has hit its main success target for treating hard-to-treat depression. This matters because it shows the therapy can work outside fancy research labs, which is the key argument for getting health insurers to pay for it." }, { "date": "2026-08-08", "title": "A veteran-psychedelic NDAA FY2027 amendment secures at least one Republican and one Democratic cosponsor this session.", "confidence": 62, "category": "legislation", "geography": "Global", "resolve_date": "2026-11-30", "tags": [ "veteran" ], "status": "pending", "priority": "medium", "plain_title": "Both parties back a bill giving veterans access to psychedelic therapy", "plain_what": "A proposed change to the US military's annual budget law \u2014 called the NDAA (National Defense Authorization Act) \u2014 specifically aimed at giving veterans access to psychedelic-assisted therapy has picked up at least one supporter from each political party. Because veteran welfare is one of the few things both sides agree on, this kind of bipartisan backing makes the proposal much harder to kill." }, { "date": "2026-08-08", "title": "MindMed (MMED) discloses an idiosyncratic catalyst within 4 weeks explaining today's 6.4% divergence.", "confidence": 60, "category": "capital-markets", "geography": "Global", "resolve_date": "2026-11-06", "tags": [ "MindMed" ], "status": "pending", "priority": "medium", "plain_title": "MindMed announces the specific news behind its sudden stock jump", "plain_what": "MindMed (ticker: MMED), a company developing psychedelic-based medicines, saw its stock price jump about 6.4% for no obvious reason on a day when similar companies did not. Within the next four weeks, the company is expected to publicly reveal what caused that jump \u2014 whether it's a trial result, a new funding deal, or a business partnership." }, { "date": "2026-08-08", "title": "A veteran-psychedelic access provision is formally offered as an NDAA FY2027 amendment with bipartisan cosponsors this session.", "confidence": 60, "category": "legislation", "geography": "Global", "resolve_date": "2026-11-30", "tags": [ "veteran" ], "status": "pending", "priority": "medium", "plain_title": "A formal bipartisan veteran psychedelic amendment enters the defense bill", "plain_what": "A specific legal proposal \u2014 an amendment \u2014 to the US military's annual budget bill has been officially put forward with supporters from both political parties, and it would give veterans access to psychedelic-assisted therapy. Getting formally submitted as an amendment is a concrete step forward, not just talk, because it forces a public vote and puts lawmakers on record." }, { "date": "2026-08-08", "title": "MindMed (MMED) discloses a specific catalyst \u2014 trial milestone, financing, or partnership \u2014 within 4 weeks explaining today's 6.4% divergence.", "confidence": 60, "category": "capital-markets", "geography": "Global", "resolve_date": "2026-09-05", "tags": [ "MindMed" ], "status": "pending", "priority": "medium", "plain_title": "MindMed reveals the real reason behind its mysterious stock surge", "plain_what": "MindMed's stock jumped 6.4% on a day when the rest of the psychedelic sector barely moved, which strongly suggests someone with inside knowledge was buying in advance of good news. Within four weeks, the company is expected to announce what that news is \u2014 likely a milestone in one of their drug trials, a new round of funding, or a partnership with a larger company." }, { "date": "2026-08-09", "title": "No DEA movement toward loosening 5-MeO-DMT controls despite the coverage; posture reaffirmed if pressed.", "confidence": 70, "category": "enforcement", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "DMT", "DEA" ], "status": "pending", "priority": "medium", "plain_title": "US drug cops will keep toad venom tightly banned, full stop", "plain_what": "The DEA (the US agency that enforces drug laws) shows no sign of making 5-MeO-DMT \u2014 the psychedelic compound found in toad venom \u2014 easier to access legally. In fact, high-profile stories about wealthy people misusing it give the DEA more reason to crack down, not loosen up. For people hoping legal access might come soon, this is a dead end for now." }, { "date": "2026-08-09", "title": "COMPASS is the only name that moves materially (\u00b115%) on a catalyst within 10 weeks; peers stay flat absent readouts.", "confidence": 62, "category": "capital_markets", "geography": "Global", "resolve_date": "2026-10-18", "tags": [ "COMPASS" ], "status": "pending", "priority": "medium", "plain_title": "Only one psychedelic company's stock will swing big this year", "plain_what": "Among all publicly traded psychedelic companies, COMPASS Pathways is the only one likely to see its stock price move sharply \u2014 up or down by 15% or more \u2014 based on actual clinical trial results in the next ten weeks. Every other company's stock will mostly stay flat because they don't have major data coming out. Real institutional investors (think pension funds and hedge funds) only move money on hard scientific results, not news stories or cultural buzz." }, { "date": "2026-08-09", "title": "No peer-reviewed mechanistic paper this quarter substantiates the toad-venom (5-MeO-DMT) therapeutic claims underlying the shaman coverage.", "confidence": 62, "category": "research", "geography": "Global", "resolve_date": "2026-11-09", "tags": [ "DMT" ], "status": "pending", "priority": "medium", "plain_title": "Science still can't back up toad venom's big therapeutic claims", "plain_what": "Despite all the media attention on celebrities using toad-venom ceremonies for healing, no rigorous peer-reviewed scientific paper will be published this quarter that actually explains how or why 5-MeO-DMT might work as a medicine. The hype is running way ahead of the evidence. This matters because without solid science, doctors can't recommend it and regulators won't approve it." }, { "date": "2026-08-09", "title": "The 7-day meditation neuroplasticity study draws methodological critique while being borrowed into psychedelic-mechanism discourse.", "confidence": 60, "category": "research", "geography": "Global", "resolve_date": "2026-11-09", "tags": [], "status": "pending", "priority": "medium", "plain_title": "A meditation brain study will spark debate and fuel psychedelic theories", "plain_what": "A study claiming the brain becomes more adaptable and open to change after just seven days of meditation is drawing criticism from scientists who say the methods weren't rigorous enough. At the same time, people in the psychedelic research world are borrowing the study's ideas to explain how psychedelics might work on the brain. This creates a messy situation where a flawed study gets influential anyway." }, { "date": "2026-08-09", "title": "The 'right-wing psychedelics' framing gets cited in \u22652 sell-side or fund commentaries as a TAM-expansion thesis within 8 weeks.", "confidence": 60, "category": "capital_markets", "geography": "Global", "resolve_date": "2026-10-04", "tags": [], "status": "pending", "priority": "medium", "plain_title": "Wall Street will pitch psychedelics as a conservative-friendly market opportunity", "plain_what": "Within the next eight weeks, at least two financial analysts or investment funds will publish reports arguing that conservatives and right-leaning Americans embracing psychedelics is actually good for business \u2014 because it means a bigger potential customer base and less political resistance in Republican-leaning states like Texas. Wall Street finds a way to turn any cultural trend into a market thesis, and this one is easy to write." }, { "date": "2026-08-10", "title": "COMPASS's two-administration COMP360 TRD topline will report a numerically superior durability curve versus single-dose, but disclosure will include a re-emergence/dropout caveat that analysts flag within two weeks of release.", "confidence": 70, "category": "clinical", "geography": "Global", "resolve_date": "2026-10-15", "tags": [ "COMPASS" ], "status": "pending", "priority": "medium", "plain_title": "COMPASS's two-dose psilocybin trial shows better results but with a catch", "plain_what": "COMPASS Pathways is testing a version of its psilocybin treatment where patients get two doses instead of one, hoping the effects last longer for people with treatment-resistant depression \u2014 meaning depression that hasn't improved with standard antidepressants. The results will likely show the two-dose approach works better for lasting relief, but the fine print will reveal that a notable number of patients either dropped out or saw their depression come back. Analysts \u2014 the financial experts who study this company \u2014 will notice and call it out within about two weeks of the announcement." }, { "date": "2026-08-10", "title": "The COMP360 two-administration TRD topline is the sector's defining near-term binary; it will show durability improvement over single-dose but carry a re-emergence/dropout caveat that analysts and reporters flag within weeks.", "confidence": 68, "category": "clinical", "geography": "Global", "resolve_date": "2026-11-09", "tags": [], "status": "pending", "priority": "medium", "plain_title": "Two-dose psilocybin trial result is the biggest near-term test for the whole industry", "plain_what": "This single clinical trial result from COMPASS Pathways \u2014 comparing one versus two doses of their synthetic psilocybin for severe depression \u2014 is the most important near-term event for the entire psychedelic medicine field. It will likely show that two doses produce longer-lasting improvement, but it will also come with a catch: some patients' depression comes back, or they drop out. Reporters and financial analysts will flag that gap quickly." }, { "date": "2026-08-10", "title": "CMPS options-implied volatility will spike ahead of the two-administration COMP360 topline, with a \u226520% single-session move (either direction) on the release.", "confidence": 68, "category": "capital-markets", "geography": "Global", "resolve_date": "2026-10-20", "tags": [], "status": "pending", "priority": "medium", "plain_title": "COMPASS stock will swing wildly \u2014 at least 20% \u2014 on trial results day", "plain_what": "Before COMPASS Pathways releases its two-dose psilocybin trial results, the options market \u2014 where traders buy contracts to bet on big price moves \u2014 will show extreme nervousness. When the results actually drop, the stock price will likely jump or crash by at least 20% in a single trading day. This kind of violent swing is common when a small company's entire future rides on one clinical trial result." }, { "date": "2026-08-10", "title": "The COMP360 topline PR will overstate durability relative to the actual relapse/re-emergence data, and a critical outlet or analyst will document the spin-vs-substance gap within 3 weeks.", "confidence": 66, "category": "culture", "geography": "Global", "resolve_date": "2026-11-01", "tags": [], "status": "pending", "priority": "medium", "plain_title": "COMPASS's press release will oversell the results \u2014 and someone will fact-check it", "plain_what": "When COMPASS announces its two-dose psilocybin trial results, the official press release will likely emphasize the positive findings and downplay how many patients relapsed or left the study. This is a common pattern in pharmaceutical announcements \u2014 companies lead with the best news. But within three weeks, at least one journalist or financial analyst will dig into the actual scientific data and write about the gap between what the press release claimed and what the numbers really show." }, { "date": "2026-08-10", "title": "The COMP360 readout drives a violent CMPS repricing (\u226520% intraday move) with post-readout downgrades if durability disappoints.", "confidence": 62, "category": "capital-markets", "geography": "Global", "resolve_date": "2026-11-09", "tags": [], "status": "pending", "priority": "medium", "plain_title": "Bad trial results will crash COMPASS stock \u2014 possibly 20% or more in one day", "plain_what": "If the two-dose psilocybin trial results disappoint \u2014 meaning the treatment doesn't last as long as hoped \u2014 COMPASS stock could drop by 20% or more in a single trading session. Financial analysts who cover the company would likely downgrade their recommendation, telling investors to reduce or sell their position. For a company whose entire value is built on this one treatment approach, a weak result could be devastating." }, { "date": "2026-08-11", "title": "DEA will not initiate any rescheduling review for psilocybin or ibogaine this quarter despite state ibogaine-veteran momentum.", "confidence": 72, "category": "policy", "geography": "USA", "resolve_date": "2026-11-11", "tags": [ "psilocybin", "ibogaine", "DEA", "veteran" ], "status": "pending", "priority": "medium", "plain_title": "Federal drug agency won't review psilocybin or ibogaine status this quarter", "plain_what": "The DEA (the US agency that controls which drugs are legal and at what level) is very unlikely to start any formal process to reclassify psilocybin (magic mushrooms) or ibogaine (a plant-based psychedelic) before November 11, 2026. Even though several US states have been pushing to make ibogaine available to veterans, that state-level pressure alone isn't enough to force the federal government's hand. Federal review only gets triggered after large-scale clinical trials finish and the health department formally recommends a change." }, { "date": "2026-08-11", "title": "CMPS stays within \u00b112% of $13.37 through mid-October absent a company-specific Phase 3 readout or partnership announcement.", "confidence": 70, "category": "markets", "geography": "Global", "resolve_date": "2026-10-15", "tags": [ "Phase 3", "CMPS" ], "status": "pending", "priority": "high", "plain_title": "COMPASS Pathways stock price likely stays flat through mid-October", "plain_what": "COMPASS Pathways is a company developing psilocybin-based treatments, and its stock (ticker: CMPS) currently trades around $13.37. The prediction is that the price will stay within about 12% of that level \u2014 so roughly between $11.77 and $14.97 \u2014 all the way to October 15, 2026. That's likely because no major news is expected: no big trial results, no major deals. Without a reason to buy or sell in a big way, the stock just drifts." }, { "date": "2026-08-11", "title": "CMPS records no single-day close move exceeding +/-15% before 2026-09-10.", "confidence": 70, "category": "markets", "geography": "Global", "resolve_date": "2026-09-10", "tags": [ "CMPS" ], "status": "pending", "priority": "medium", "plain_title": "COMPASS Pathways stock unlikely to spike or crash before September 10", "plain_what": "In the next month, COMPASS Pathways stock (CMPS) is very unlikely to jump or drop by more than 15% in a single day. Big single-day moves happen when surprising news drops \u2014 a trial result, a regulatory decision, a major deal. None of those are expected before September 10, 2026, so the stock should stay relatively calm." }, { "date": "2026-08-11", "title": "A peer-reviewed letter/editorial will criticize the subcutaneous esketamine KAP pilot's non-randomized design and confounding of psychotherapy vs drug effect.", "confidence": 68, "category": "research", "geography": "Global", "resolve_date": "2026-11-09", "tags": [ "ketamine" ], "status": "pending", "priority": "high", "plain_title": "Scientists will publicly criticize the design of a new ketamine therapy study", "plain_what": "Researchers ran a small pilot study combining esketamine (a nasal spray version of ketamine, given under the skin in this case) with talk therapy, and they didn't randomly assign patients to groups \u2014 a key standard in medical research. Within a few months of publication, other scientists are likely to write formal criticism pointing out that you can't tell whether any improvement came from the drug, the therapy, or both together. This matters because it affects how seriously regulators and doctors will take the results." }, { "date": "2026-08-11", "title": "The subcutaneous esketamine KAP pilots draw published methodological/attribution criticism within ~10 weeks.", "confidence": 66, "category": "research", "geography": "Global", "resolve_date": "2026-09-08", "tags": [ "ketamine" ], "status": "pending", "priority": "medium", "plain_title": "Experts will question a ketamine therapy pilot study's methods within weeks", "plain_what": "A recent small study tested ketamine given under the skin alongside therapy sessions. Within about 10 weeks of publication, at least one expert \u2014 in a published article, a letter, or a public statement \u2014 is expected to raise concerns about how the study was designed. The core criticism: without a proper comparison group, you simply can't know whether it was the ketamine, the therapy, or just the attention from caring professionals that helped patients." }, { "date": "2026-08-12", "title": "The subcutaneous esketamine KAP trial will draw published methodological critique (editorial or letter) demanding randomized/blinded confirmation before any regulatory claim.", "confidence": 74, "category": "research", "geography": "Global", "resolve_date": "2026-10-21", "tags": [ "ketamine" ], "status": "pending", "priority": "medium", "plain_title": "Scientists will publicly criticize esketamine therapy study design", "plain_what": "A study combining esketamine (a nasal-spray anesthetic used as a psychedelic-assisted therapy) with talk therapy didn't randomly assign patients to different groups, which makes it impossible to tell whether the drug, the therapy, or both together caused any improvements. Other scientists are likely to write criticism in medical journals demanding a more rigorous test before anyone claims this works. This matters because weak study designs can lead doctors and patients to trust treatments that haven't really been proven." }, { "date": "2026-08-12", "title": "Today's non-randomized esketamine KAP trial will draw explicit methodological calls for controlled/randomized designs within ~10 weeks.", "confidence": 73, "category": "research", "geography": "Global", "resolve_date": "2026-11-10", "tags": [ "ketamine" ], "status": "pending", "priority": "medium", "plain_title": "Experts will demand better esketamine study controls within 10 weeks", "plain_what": "A current esketamine therapy study didn't randomly split patients into treatment and control groups, which is the gold standard for proving a treatment works. Multiple experts reviewing the study agree that published criticism calling for a properly controlled repeat study will appear by around late October 2026. This is important because regulatory bodies like the FDA (the US drug regulator) won't act on weak evidence." }, { "date": "2026-08-12", "title": "The non-randomized esketamine KAP trial cannot isolate psychotherapy from drug effect, and methodologists will publicly call for controlled designs within 10 weeks.", "confidence": 72, "category": "research", "geography": "Global", "resolve_date": "2026-10-21", "tags": [ "ketamine" ], "status": "pending", "priority": "medium", "plain_title": "Esketamine study can't separate drug from therapy \u2014 critics incoming", "plain_what": "When a study combines a drug with therapy but doesn't include a comparison group (some people getting only the drug, only the therapy, or neither), there's no way to know which part is helping. Neuroscientists and clinical researchers are expected to point this out publicly, calling for a study that properly isolates each element. Without that, no one \u2014 including regulators \u2014 can responsibly recommend the combined treatment." }, { "date": "2026-08-12", "title": "No FDA meeting or breakthrough-therapy update on any psilocybin GAD/AUD program will emerge from today's early-phase trials within 12 weeks.", "confidence": 70, "category": "regulatory", "geography": "USA", "resolve_date": "2026-11-04", "tags": [ "psilocybin", "FDA" ], "status": "pending", "priority": "medium", "plain_title": "Psilocybin for anxiety and alcohol problems won't reach FDA talks soon", "plain_what": "Early-phase clinical trials testing psilocybin (the active compound in 'magic mushrooms') for generalized anxiety disorder and alcohol use disorder are still in the earliest stages \u2014 they're mainly checking whether the drug is safe and tolerable, not whether it works. The FDA (the US drug regulator) doesn't hold formal meetings or grant special fast-track designations based on this kind of preliminary data. Meaningful regulatory conversations are still years away." }, { "date": "2026-08-12", "title": "No DEA rescheduling movement follows today's signals; any ibogaine veteran-access push stays confined to foreign clinics or research exemptions.", "confidence": 70, "category": "regulatory", "geography": "USA", "resolve_date": "2026-11-04", "tags": [ "ibogaine", "DEA", "veteran" ], "status": "pending", "priority": "medium", "plain_title": "Ibogaine stays offshore and out of DEA reach for now", "plain_what": "Ibogaine, a psychedelic derived from an African plant that shows promise for treating opioid addiction and PTSD (post-traumatic stress disorder) in veterans, carries serious heart risks and is classified as a Schedule I drug (meaning the DEA \u2014 the US Drug Enforcement Administration \u2014 considers it to have no accepted medical use and high abuse potential). Despite advocacy efforts and some promising research, the DEA is not moving to reclassify it, and veterans seeking treatment must travel to clinics in Mexico or other countries, or join narrowly approved research programs. That's unlikely to change soon." }, { "date": "2026-08-13", "title": "The subcutaneous esketamine KAP trial, being non-randomized, will publish safety/tolerability-only conclusions with no efficacy claim FDA would accept for a label change by Q4 2026.", "confidence": 74, "category": "clinical", "geography": "USA", "resolve_date": "2026-11-30", "tags": [ "ketamine", "FDA" ], "status": "pending", "priority": "medium", "plain_title": "Under-skin ketamine study will report safety only, no approval impact", "plain_what": "A clinical trial testing esketamine (a ketamine-related drug) injected under the skin \u2014 rather than sprayed in the nose \u2014 ran without random assignment of patients to groups. That design flaw means the results can only tell us the drug seems tolerable, not whether it actually works better than nothing. The US drug regulator (FDA) won't use this kind of study to update the drug's approved uses." }, { "date": "2026-08-13", "title": "The subcutaneous esketamine KAP paper draws methodological critique (confounding, no randomization) in the literature or commentary within 10 weeks.", "confidence": 68, "category": "research", "geography": "Global", "resolve_date": "2026-10-22", "tags": [ "ketamine" ], "status": "pending", "priority": "medium", "plain_title": "Scientists will publicly criticize the under-skin ketamine study's design flaws", "plain_what": "When the under-skin esketamine study gets published, other researchers are likely to write critiques pointing out that it had no random assignment and no control group. Without those safeguards, you can't tell whether patients got better because of the drug or because they expected to feel better. These critiques typically appear as letters or commentary in the same journal within about ten weeks." }, { "date": "2026-08-13", "title": "The psilocybin GAD oral-solution trial reports positive preliminary tolerability and signal of anxiety reduction, prompting a follow-on Phase 2 announcement within 6 months.", "confidence": 66, "category": "clinical", "geography": "Global", "resolve_date": "2027-02-13", "tags": [ "psilocybin" ], "status": "pending", "priority": "medium", "plain_title": "Psilocybin anxiety trial shows promise, triggering a larger follow-up study", "plain_what": "A trial testing liquid psilocybin (the active compound in 'magic mushrooms') for generalized anxiety disorder (GAD) \u2014 a condition where people feel persistent, hard-to-control worry \u2014 is expected to report that the drug was well-tolerated and showed early signs of reducing anxiety. That kind of positive early result typically gives researchers and funders enough confidence to launch a bigger, more rigorous Phase 2 trial." }, { "date": "2026-08-13", "title": "No standalone psychedelic bill reaches a House floor vote this session; the only viable path is a veteran-access provision attached to the FY27 NDAA.", "confidence": 65, "category": "legislation", "geography": "Global", "resolve_date": "2026-12-31", "tags": [ "veteran" ], "status": "pending", "priority": "medium", "plain_title": "No separate psychedelic bill gets a full House vote this year", "plain_what": "Congress isn't going to vote on a standalone law about psychedelics in this session. The only realistic way something passes is if a small provision giving military veterans access to psychedelic treatments gets quietly attached to the giant yearly defense spending bill called the NDAA (National Defense Authorization Act). That bill must pass, so it's a rare vehicle for controversial add-ons." }, { "date": "2026-08-13", "title": "Federal psychedelic action stalls this session; the only viable path is a veteran-access NDAA rider while states lead.", "confidence": 63, "category": "legislation", "geography": "USA", "resolve_date": "2027-02-09", "tags": [ "veteran" ], "status": "pending", "priority": "medium", "plain_title": "Federal psychedelic reform stalls; states and a veterans defense bill are the only hope", "plain_what": "Multiple expert perspectives agree: the federal government is not going to pass meaningful psychedelic reform as its own law this session. States like Oregon and Colorado are moving faster on their own. The one federal opening is a provision for veteran access tucked into the must-pass annual defense spending bill (NDAA \u2014 National Defense Authorization Act), which Congress is required to approve each year." }, { "date": "2026-08-14", "title": "The VA's newly launched psilocybin PTSD/TRD trials will register primary endpoints framed as safety/feasibility, not efficacy, on ClinicalTrials.gov by Q4 2026.", "confidence": 74, "category": "clinical", "geography": "Global", "resolve_date": "2026-11-30", "tags": [ "psilocybin", "PTSD" ], "status": "pending", "priority": "medium", "plain_title": "VA's mushroom therapy trials will track safety, not results, by year-end", "plain_what": "The VA (the US government's veterans healthcare system) is running studies on psilocybin \u2014 the active compound in magic mushrooms \u2014 for veterans with PTSD and stubborn depression. These trials will officially measure whether the treatment is safe and practical to run, not whether it actually works. That's a deliberate choice: asking 'does it work?' too early invites regulatory and political backlash the VA isn't ready to handle." }, { "date": "2026-08-14", "title": "VA psilocybin trials will report feasibility/safety-framed endpoints and enrollment momentum \u2014 not efficacy \u2014 within 12 months, driving political attention without commercial payoff.", "confidence": 71, "category": "clinical", "geography": "Global", "resolve_date": "2026-11-12", "tags": [ "psilocybin" ], "status": "pending", "priority": "medium", "plain_title": "VA mushroom therapy trials will grab headlines but prove nothing yet", "plain_what": "Within the next year, the VA's psilocybin trials will show they can actually enroll veterans and run sessions without serious problems \u2014 but they won't show whether psilocybin is effective. That early momentum will attract political interest from both supporters and critics, but it won't hand pharmaceutical companies anything they can sell." }, { "date": "2026-08-14", "title": "At least one psilocybin comorbidity trial (PsiloStudy PTSD+AUD or the AUD mechanisms study) will report positive preliminary efficacy signals in a conference presentation before Q1 2027.", "confidence": 66, "category": "clinical", "geography": "Global", "resolve_date": "2027-02-28", "tags": [ "psilocybin", "PTSD" ], "status": "pending", "priority": "medium", "plain_title": "Early signs that mushrooms help addiction and PTSD together, coming soon", "plain_what": "Researchers are running trials testing psilocybin on people who have both PTSD and alcohol use disorder at the same time \u2014 two conditions that frequently travel together and are notoriously hard to treat. Before early 2027, at least one of these studies is expected to share early results at a scientific conference suggesting psilocybin is helping. Past research on psilocybin and alcohol alone has already looked promising, so these results would extend that pattern." }, { "date": "2026-08-14", "title": "A major outlet will publish an investigative piece on ibogaine cardiac-safety risks tied to the Trump/political attention before Q4 2026.", "confidence": 65, "category": "culture", "geography": "Global", "resolve_date": "2026-10-31", "tags": [ "ibogaine" ], "status": "pending", "priority": "medium", "plain_title": "A big news outlet will investigate ibogaine's heart risks before year-end", "plain_what": "Ibogaine is a powerful psychedelic from an African plant that has attracted serious political attention \u2014 including from figures connected to the Trump orbit \u2014 for its apparent ability to help veterans with addiction and PTSD. But ibogaine has a known and documented risk: it can cause dangerous, sometimes fatal, heart rhythm problems. With political figures now publicly championing ibogaine, investigative journalists have a clear story to tell about those risks." }, { "date": "2026-08-14", "title": "No psychedelic biotech M&A or big-pharma licensing deal above $100M will be announced before Q4 2026.", "confidence": 64, "category": "corporate", "geography": "USA", "resolve_date": "2026-10-31", "tags": [ "DEA", "biotech" ], "status": "pending", "priority": "medium", "plain_title": "No big pharma will spend $100M or more on a psychedelic company yet", "plain_what": "Despite years of excitement in the psychedelic medicine space, no large pharmaceutical company is expected to buy or sign a major licensing deal with a psychedelic biotech for more than $100 million before late 2026. Big pharma companies are waiting: they want to see larger, more definitive clinical trial results and clearer signals from the FDA (the US drug regulator) before writing enormous checks. Right now, the science is still too early-stage to justify that kind of investment." }, { "date": "2026-08-15", "title": "Presidential ibogaine attention will yield no DEA scheduling action and no dedicated federal appropriation for ibogaine within 90 days \u2014 rhetoric only.", "confidence": 80, "category": "policy", "geography": "USA", "resolve_date": "2026-11-13", "tags": [ "ibogaine", "DEA" ], "status": "pending", "priority": "high", "plain_title": "Presidential ibogaine buzz produces zero real government action", "plain_what": "Despite recent attention from the White House, ibogaine (a plant-derived substance being studied for addiction treatment) will see no formal move by the DEA (the US agency that controls which drugs are legal) to change its banned status, and Congress will not set aside any dedicated money for it \u2014 at least not by mid-November 2026. This matters because without those two things, the excitement stays talk and patients can't access it legally." }, { "date": "2026-08-15", "title": "The VA psilocybin PTSD/TRD trials will publish only enrollment/protocol details \u2014 no efficacy data \u2014 on ClinicalTrials.gov within 10 weeks.", "confidence": 80, "category": "clinical", "geography": "USA", "resolve_date": "2026-10-24", "tags": [ "psilocybin", "PTSD" ], "status": "pending", "priority": "high", "plain_title": "VA psilocybin trials show sign-up info only \u2014 no results yet", "plain_what": "The US Department of Veterans Affairs has started clinical trials testing psilocybin (the active compound in 'magic mushrooms') for PTSD and hard-to-treat depression in veterans. By late October 2026, the public trial registry will only show details about how the study is set up and how many people are enrolling \u2014 not whether the treatment actually works. This is completely normal for new trials, but it means no answers for veterans anytime soon." }, { "date": "2026-08-15", "title": "The chronic-pain psilocybin mechanism paper and cognition systematic review will conclude 'insufficient evidence / more research needed' rather than endorse clinical rollout.", "confidence": 75, "category": "research", "geography": "Global", "resolve_date": "2026-10-10", "tags": [ "psilocybin" ], "status": "pending", "priority": "medium", "plain_title": "New psilocybin research papers will say 'we need more research' not 'use this now'", "plain_what": "Two new scientific works \u2014 one examining how psilocybin might affect chronic pain in the body, and one reviewing what we know about psilocybin and thinking/cognition \u2014 will both stop short of telling doctors to use psilocybin clinically. Instead, they'll call for more studies. This is the standard conclusion in early-stage science, and it signals we're still years away from evidence strong enough to guide treatment." }, { "date": "2026-08-15", "title": "COMPASS Pathways (CMPS) will not announce any new FDA breakthrough-status update, label expansion, or new regulatory guidance tied to the VA psilocybin news within 90 days.", "confidence": 72, "category": "regulatory", "geography": "USA", "resolve_date": "2026-11-13", "tags": [ "FDA", "COMPASS", "CMPS" ], "status": "pending", "priority": "high", "plain_title": "VA psilocybin news won't give COMPASS a new FDA boost", "plain_what": "COMPASS Pathways (a company developing its own psilocybin drug, traded on Nasdaq as CMPS) will not announce any new special FDA (the US drug regulator) status, expanded approval, or new regulatory guidance connected to the VA trial news \u2014 not by mid-November 2026. The VA runs its own government research program; that process is completely separate from what the FDA does for private companies like COMPASS. Headlines often blur this line, but the two pipelines don't help each other." }, { "date": "2026-08-15", "title": "Within 10 weeks, VA psilocybin trial slot counts will be publicly documented at under 200 total nationally, triggering access-gap coverage in veteran or mainstream media.", "confidence": 70, "category": "clinical", "geography": "USA", "resolve_date": "2026-10-24", "tags": [ "psilocybin", "veteran" ], "status": "pending", "priority": "medium", "plain_title": "VA psilocybin trial spots number under 200 \u2014 media highlights the gap", "plain_what": "By late October 2026, public records will show that the total number of veterans who can actually enroll in VA psilocybin trials across the whole country is fewer than 200. Given that millions of veterans live with PTSD or depression, that gap is enormous \u2014 and at least one major news outlet or veteran-focused publication will write about it. This matters because it shows the distance between the political announcement and real-world access." }, { "date": "2026-08-17", "title": "No FDA advisory committee for any psychedelic NDA is scheduled or announced before 2026-11-30.", "confidence": 70, "category": "regulatory", "geography": "USA", "resolve_date": "2026-11-30", "tags": [ "FDA" ], "status": "pending", "priority": "medium", "plain_title": "No psychedelic drug review panel meeting set before December 2026", "plain_what": "The FDA (the US drug regulator) holds public expert panels before approving major new drugs. No psychedelic company has yet submitted the full package of evidence the FDA needs to even schedule one of these panels. This means no psychedelic drug is close to formal federal approval right now." }, { "date": "2026-08-17", "title": "No standalone psychedelic bill receives a House committee markup before the 2026 session recess; movement is confined to California's therapeutic access framework.", "confidence": 68, "category": "legislation", "geography": "Global", "resolve_date": "2026-12-31", "tags": [ "California" ], "status": "pending", "priority": "medium", "plain_title": "Congress won't vote on psychedelic laws this session; California leads instead", "plain_what": "The US Congress is overwhelmed with other urgent issues \u2014 disaster relief, foreign policy crises \u2014 and psychedelic legislation can't get enough attention to move forward at the federal level this year. California is the one place where real legal progress on supervised psychedelic therapy is actually happening." }, { "date": "2026-08-17", "title": "Cybin's CYB003 Phase 3 (APPROACH/EMBRACE) topline in MDD reports a statistically significant MADRS reduction on primary endpoint before year-end, but FDA will still require the second confirmatory study.", "confidence": 66, "category": "clinical", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "FDA", "Phase 3" ], "status": "pending", "priority": "medium", "plain_title": "Cybin's depression drug trial succeeds, but company still needs a second study", "plain_what": "Cybin, a psychedelic drug company, is running a major clinical trial called APPROACH/EMBRACE for their drug CYB003 \u2014 a modified form of psilocin (the active ingredient in magic mushrooms) \u2014 in people with major depression (MDD). The trial is expected to show the drug meaningfully reduces depression symptoms. But even a clear win won't be enough: the FDA requires two separate successful trials before it will approve any drug, so Cybin still has more work to do." }, { "date": "2026-08-17", "title": "No federal psychedelic bill gets committee markup or floor action this session; movement confined to California therapeutic access.", "confidence": 65, "category": "legislation", "geography": "USA", "resolve_date": "2027-02-13", "tags": [ "California" ], "status": "pending", "priority": "medium", "plain_title": "Congress skips psychedelic legislation again; California remains the only mover", "plain_what": "Multiple perspectives \u2014 including lawmakers, veterans' advocates, and drug enforcement officials \u2014 all agree that federal psychedelic legislation won't get a formal committee vote or floor debate this congressional session. The only meaningful legal progress is happening at the state level in California." }, { "date": "2026-08-17", "title": "CYB003 (deuterated psilocin, MDD) topline is the sector's next repricing event, producing a double-digit single-name move before year-end.", "confidence": 62, "category": "capital-markets", "geography": "Global", "resolve_date": "2026-11-15", "tags": [], "status": "pending", "priority": "medium", "plain_title": "Cybin's trial results will sharply move the whole psychedelic stock sector", "plain_what": "When Cybin announces whether their depression drug trial worked, it won't just affect Cybin's own stock \u2014 it's expected to move the entire psychedelic investment sector by double digits (more than 10% up or down). That's because this is the highest-profile clinical result coming in 2026, and investors across the sector will react to what it signals about the future of psychedelic medicine as a whole." } ]